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 THESIS ABSTRACT 
Background 
Hospital admissions with acute exacerbations of chronic obstructive pulmonary 
disease are common and associated with high mortality rates, frequent readmission 
and worse quality of life. An ability to identify patients at risk of subsequent poor 
outcome is lacking and the longitudinal change in quality of life following discharge is 
uncertain. 
Methods 
The study consisted of two parts:  
1) Clinical data were collected on 920 consecutive patients hospitalised with 
exacerbations. The ability of a novel modification of the traditional MRC 
dyspnoea scale (the extended MRC dyspnoea scale, eMRCD) to identify 
patients at risk of poor outcome was assessed. Independent predictors of 
important clinical outcomes were recorded and clinical prediction tools 
derived. 
2)  A subgroup of 183 patients underwent longitudinal assessment of quality of 
life following hospital discharge and predictors of quality of life decline were 
identified. 
Results 
The study population was similar to that reported in UK national audits. 96 (10.4%) 
patients died in-hospital and 37.3% were readmitted to hospital, or died without being 
readmitted, within 90-days of discharge.  
The eMRCD was a better predictor of outcome than the traditional scale and, 
compared to all clinical variables, was the single strongest predictor of mortality and 
readmission  
Strong independent predictors of many important clinical outcomes were identified 
and, notably, the DECAF (dyspnoea, eosinopenia, consolidation, acidaemia, atrial 
iv 
fibrillation) predictive tool was derived and shown to be an excellent, and internally 
valid, mortality predictor (area under ROC curve = 0.858).  
Most patients who survived to discharge reported an improvement in respiratory 
symptoms and quality of life during follow-up. We defined a subgroup of patients who 
experienced poor post-discharge quality of life and identified robust, simple-to-
measure predictors of poor quality of life. 
Conclusions 
Important patient outcomes can be accurately predicted in this population. Application 
of our results may reduce morbidity and mortality in this common and frequently fatal 
condition by improving clinical decision making regarding appropriate level of care, 
location of care and resource allocation.  
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MAR missing at random 
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THESIS OUTLINE 
The ability to identify patients at risk of poor outcomes in patients hospitalised with 
acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is suboptimal 
at present. Previous research has focused on the prediction of outcome in patients 
with stable COPD and, with the exception of mortality prediction (Table 2.1), 
discussion of prognostication in stable disease is not included in this thesis. 
This thesis details a research project whose main aim was to define and predict 
outcomes in a large cohort of patients hospitalised with exacerbations of chronic 
obstructive pulmonary disease. 
The first section thoroughly reviews the published literature on the prediction of 
mortality, readmission and subsequent quality of life in this patient group and 
evidences the assertion that improved prognostication is needed. In the next section, 
the aims and methodology are outlined and explained. 
The results and discussion follow and are separated in two sections: 
Part 1. The prediction of important patient outcomes in a large cohort of 
patients hospitalised with COPD exacerbations (n = 920), including the 
description of a novel modification of the traditional MRC dyspnoea 
score, the extended MRC Dyspnoea score (eMRCD). 
Part 2. The description of longitudinal quality of life change in a subgroup of 183 
patients surviving to discharge following hospitalisation with AECOPD, 
including the identification of predictors of poor subsequent quality of 
life. 
After discussion of the potential clinical impact of this thesis and suggestions for future 
research, the appendices and references are listed. 
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BACKGROUND 
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CHAPTER 1 INTRODUCTION 
1.1 STABLE COPD 
1.1.1 DEFINITION 
Chronic obstructive pulmonary disease (COPD) is a multisystem condition defined as “a 
preventable and treatable disease with some significant extra-pulmonary effects that 
may contribute to the severity in individual patients.”[1] Its pulmonary component is 
characterised by airflow obstruction that is usually progressive and not fully reversible. 
In the western world, COPD is typically caused by long-term exposure to tobacco 
smoke. 
1.1.2 BURDEN OF DISEASE 
1.1.2.1 PREVALENCE 
Estimates of COPD prevalence vary, largely due to differing diagnostic criteria. Surveys 
relying on physician reported diagnosis alone frequently under report the prevalence 
of COPD, and studies of patient-reported symptoms (without lung function 
verification) will overdiagnose COPD.[1] 
Considerable geographic variation in COPD prevalence exists. The estimated UK COPD 
prevalence varies between 2% and 4%,[2] whereas in North-East England, in adults 
between 45 and 69 years old, the prevalence of COPD lies between 10 and 25% 
(depending on diagnostic criteria).[3] Over 900,000 people have been diagnosed with 
COPD in the UK,[4] but it has been estimated that only 30% of patients with COPD 
have been diagnosed.[5, 6]  
The prevalence of COPD is expected to rise due to an ageing population and the long-
term cumulative effects of tobacco smoke. In the UK, between 1990 and 1997, the 
prevalence rate rose by 69% in women and 25% in men.[7] 
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1.1.2.2 SYMPTOM BURDEN 
The worldwide burden of COPD, as expressed by disability life years and compared to 
other conditions, was expected to rise from eighth in men and seven in women in 
1996, to fifth for both sexes in 2020.[8]  
In the general population, symptoms of chronic bronchitis have been found to be 
present in 8.9% of males and 4.1% of females, and symptoms of breathlessness in 
13.6% of males and 16.4% of females.[9] As the severity of COPD worsens, the burden 
of symptoms increases: patients with very severe airflow obstruction (forced 
expiratory volume in 1 second, FEV1 < 30% predicted) usually have disabling 
breathlessness at rest.[10] 
1.1.2.3 HEALTH RESOURCE USE 
Respiratory disease is the commonest reason for an individual to contact their General 
Practitioner, and of all respiratory diseases, COPD is the 2nd most frequent reason for 
contact with the GP.[11] COPD is the second largest cause of emergency hospital 
admissions in the UK, responsible for over 130,000 admissions - 1/5 of all bed days 
used for respiratory disease.[11, 12]  
A telephone survey of 3245 individuals with COPD showed that a quarter of patients 
had reported ever being hospitalised with COPD and 14% had required a hospital 
admission in the preceding 12 months. 12% had attended the hospital emergency 
department for treatment of their COPD in the previous year.[13] Following discharge, 
33% of patients are readmitted to hospital within 3 months,[12] and up to 55% within 
one year following discharge.[14, 15] 
1.1.2.4 MORTALITY 
Due to imprecise diagnostic criteria and significant underreporting, worldwide 
mortality figures for COPD need to be interpreted with caution and are likely to 
underestimate the true mortality burden of COPD. In spite of this, the World Health 
Organisation (WHO) Global Burden of Disease Study identified COPD as the 6th leading 
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cause of death worldwide in 1990, and projected that it would rise to third by 2020.[8]  
The British Thoracic Society Burden of Lung Disease reported in 1999 and 2006 [11, 16] 
and identified COPD as the 5th most common cause of overall mortality in England and 
Wales (in 1999), and the third leading cause of respiratory death (in 2004). The 
mortality rate associated with COPD is increasing in the developed world particularly 
when compared to other common chronic diseases (Figure 1.1) 
Figure 1.1     Percentage change in age-adjusted death rates in the United States, 1965-
1998 
 
CVD – cardiovascular disease. [17] 
1.1.2.5 COST 
Britton [13] calculated that the annual direct per patient cost of COPD in the UK was 
£819.42 (rising substantially in patients with severe disease)[18] and the total direct 
cost to the NHS is estimated to be £810-£930 million per year.[11] A major proportion 
of the costs related to COPD is secondary to the treatment of acute exacerbations, 
particularly if hospitalisation is required (section 1.2.2.2).  
COPD is a major cause of work absence. 38% of patients with COPD reported their 
work being affected by their disease, with a mean number of 12 work days lost per 
patient per year.[13] It has been estimated that COPD results in 24 million lost working 
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days per annum,[19] and this costs the UK economy over £3.8 billion in lost 
productivity.[13] 
1.1.3 COPD DIAGNOSIS 
Traditionally, the terms ‘chronic bronchitis’ and ‘emphysema’ were used to describe 
the condition now classified as COPD. Chronic bronchitis is a symptom based definition 
that refers to the presence of cough and sputum production for at least 3 months in 2 
or more consecutive years. Emphysema is a pathological term referring to 
“permanent, destructive enlargement of airspaces distal to the terminal bronchioles 
without evidence of fibrosis”,[20] but it only refers to one of many pathological 
abnormalities present in COPD. 
The diagnosis of COPD is dependent on: the presence of characteristic symptoms; the 
identification of an appropriate risk factor (principally tobacco smoke); and the 
presence of airflow obstruction,[1] which is best assessed by spirometry (section 
1.1.3.2). An additional characteristic of COPD is that it is accompanied by a high rate of 
comorbidity (section 1.1.3.5). 
1.1.3.1 SYMPTOMS OF COPD 
Although COPD can be considered a systemic disease, the majority of individuals seek 
medical attention because of respiratory symptoms. In its early stages, COPD can be 
asymptomatic, although the commonest symptoms are cough, sputum production, 
dyspnoea and wheeze / chest tightness. These symptoms are highly variable, vastly 
under-reported and not universally present, even in individuals with severe 
disease.[21] 
Several systemic features have been identified in individuals with COPD and they 
appear more prevalent in those with severe disease. The systemic features of COPD 
include: skeletal muscle wasting and loss of free fat mass (resulting in weight loss and 
low body mass index – BMI), anaemia, osteoporosis and fatigue.[1]  
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1.1.3.1.1 DYSPNOEA  
Dyspnoea is usually defined as an uncomfortable awareness of breathing. It is a major 
cause of disability and anxiety, and the reason that most patients with COPD seek 
medical attention.[1] Patients with COPD use a variety of terms to describe the 
symptoms that they experience when breathless and this makes objective, 
reproducible assessment of the degree of dyspnoea difficult. Smith et al [22] identified, 
in patients with COPD, that the best subjective descriptors of individuals’ symptoms on 
exercise was the feeling of ‘air-hunger’, whereas at rest, descriptions with emotional 
connotations (‘suffocating’, ‘fighting for breath’) were most applicable.  
In an attempt to standardise the assessment of dyspnoea, instruments have been 
developed that assess the effects that breathlessness causes on the ability to 
undertake certain activities of daily living (ADL) (discussed below) or on the effect that 
dyspnoea has on an individual’s quality of life (section 4.3). The modified Medical 
Research Council Dyspnoea Scale (MRCD) (Table 1.1) assesses the impact of dyspnoea 
on the ability to perform ADLs and has been shown to be associated with exercise 
capacity, quality of life, mood state and level of disability.[23] However, MRCD and the 
forced expiratory volume in 1 second (FEV1, section 1.1.3.2) are not closely 
associated,[23] and the severity of dyspnoea according to MRCD is a more accurate 
predictor of mortality and readmission than FEV1 (section 2.1).[24-26] The MRCD 
performs equally as well as other clinical dyspnoea rating tools (e.g. Baseline Dyspnoea 
Index, dyspnoea component of Chronic Respiratory Questionnaire (CRQ), and activity 
component of St. George’s Respiratory Questionnaire (SGRQ)) in evaluating dyspnoea 
in individuals with COPD.[27]  
Table 1.1     The modified MRC Dyspnoea Score [23] 
Grade Degree of breathlessness related to exercise 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying or walking up a slight hill 
3 
Walks slower than contemporaries on level ground because of breathlessness, or has to 
stop for breath when walking at own pace 
4 Stops for breath when walking about 100m or after a few minutes on level ground 
7 
5 Too breathless to leave the house 
1.1.3.1.2 NUTRITIONAL DEPLETION IN COPD 
It is well-established that many patients with COPD are underweight, and 
malnourishment becomes more common as COPD severity worsens.[28] This may in 
part be due to a reduction in calorific intake, but the increased work of breathing and 
systemic inflammation that is associated with this condition also contribute.  
Nutritional depletion has a variety of definitions. The WHO defines nutritional status 
according to body mass index (BMI): weight (kg) / height (m)2 (Table 1.2). 
Table 1.2     International classification of adult nutritional status according to BMI [29] 
Classification BMI (kgm-2) 
Underweight <18.5 
Normal 18.5 – 24.99 
Overweight ≥25 
Obese 30 – 39.99 
Morbidly obese ≥40 
Epidemiological studies in individuals with COPD have used various criteria to define 
poor nutrition and hence the prevalence rate varies (Table 1.3). Although fat free mass 
(FFM) appears to be a more accurate marker of undernutrition, and a better 
prognostic indicator, than BMI (section 2.1),[28] its accurate measurement is complex 
and largely confined to specialist centres. BMI is simple to measure and therefore is 
the nutritional index most commonly evaluated in COPD. 
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Table 1.3     Summary of different definitions of undernourishment and their respective 
prevalence rates in patients with COPD. 
Author Definition of undernutrition Prevalence 
Vermeeren et al [30] BMI ≤ 21kgm
-2
 and / or FFMI ≤ 16 kgm
-2 
27% 
Gray-Donald et al [31] 
BMI < 20 kgm
-2
 (males); 
< 18.8 kgm
-2 
(females) 
18% 
Wilson et al [32] < 90% of ideal body weight 24%* 
Schols et al [28] BMI < 21 or FFMI < 16 kgm
-2
 43.7% 
Hallin et al [33] BMI < 20 kgm
-2
 19%
∆
 
Giron et al [34] BMI < 20 kgm
-2
 or FFMI ≤ 16 kgm
-2 
38%
∆
 
IBW – ideal body weight, FFMI – fat free mass index, * 24% in all patients, 50% in patients with FEV1 
<35% predicted, 
∆
in patients hospitalised with acute exacerbations of COPD. 
It is well established that low BMI is associated with increased all-cause and COPD-
related mortality, independent of disease severity.[35] It has also been shown that an 
elevated BMI is protective against mortality, particularly in patients with severe airflow 
obstruction, with the lowest risk of mortality in the overweight population (BMI 25 to 
30 kgm-2).[33] This relationship is in contrast to the general population where 
increased BMI is associated with reduced life expectancy, independent of smoking 
status and comorbidity.[36] This has been termed the ‘obesity paradox’ and has been 
reported in other chronic conditions (for example, end-stage renal disease, cardiac 
failure and rheumatoid arthritis) [37, 38] although the mechanisms of the relationship 
are unknown. 
Nutritional depletion is possibly more common in patients hospitalised with acute 
exacerbations of COPD and is an adverse prognostic indicator in this population 
(section 2.2.4.1). Periods of hospitalisation are associated with weight loss and 
malnutrition,[39] and in acute exacerbations of COPD, weight loss is associated with 
increased risk of readmission following discharge.[34] However, the prevalence of 
undernutrition and weight loss has not been closely examined in patients hospitalised 
with COPD exacerbations. 
The Malnutrition Universal Screening Tool (MUST) is a nutritional assessment 
instrument, which combines both BMI and recent unexplained weight loss into a 
screening tool which aims to improve the recognition and treatment of malnutrition in 
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the hospital setting (Table 5.2). It has excellent reproducibility between users [40] and 
also predicts mortality more reliably than BMI in elderly acute general medical 
admissions.[39, 41] Its use, however, has not been investigated in patients hospitalised 
with acute exacerbations of COPD (AECOPD) although its component variables suggest 
that it may be a prognostically useful tool. 
1.1.3.2 SPIROMETRY 
Spirometry assesses the volume of air that an individual can expel from their lungs in a 
single expiration from maximal inspiration.[42] The two indices measured are: the 
volume of air expelled in one second during a forced expiration (forced expiratory 
volume 1 - FEV1) and the total volume of air expelled during a single expiration (vital 
capacity – VC). The vital capacity can be measured during a forced manoeuvre (FVC) or 
during a relaxed expiration (VC) however, during forced expiration, dynamic collapse 
of the small airways can result in an underestimation of vital capacity.[21] Values are 
measured in litres and compared to ‘normal’ values based on age, sex, height and 
ethnic origin [43] and are expressed as a percentage of predicted. 
The volume of forcibly expelled air during the first second of expiration relative to their 
vital capacity (FEV1 / FVC) provides a simple assessment of airflow limitation, with 
lower values (< 0.70) indicating airflow obstruction and being necessary for the 
diagnosis of COPD to be made.[44] Although recommended by all major expert bodies, 
using a fixed FEV1 / FVC ratio for the diagnosis of COPD has limitations as it 
overestimates the prevalence of airflow obstruction in the elderly.[45] 
At least three acceptable spirograms need to be obtained from the patient by a trained 
professional. The two largest values for VC and FEV1 must be within 150ml of each 
other. Only when these criteria are met can the test be deemed to be acceptable.[46] 
The presence of bronchodilator reversibility may be useful in helping distinguish COPD 
from asthma but this is not routinely recommended for the diagnosis of COPD.[44] 
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1.1.3.3 STAGES OF COPD 
A simple staging system for the severity of COPD is useful both practically, as a general 
indication to the approach to management, and educationally. However, it is very 
difficult to identify easily measurable clinical indices that accurately describe symptom 
severity as well as predicting outcomes. FEV1 is typically used to stage COPD however: 
there is an imperfect relationship between the degree of lung function impairment and 
the severity of an individual’s symptoms;[1, 24] FEV1 does not consistently predict 
outcome; and although low FEV1 is significantly associated with mortality in the 
population as a whole, in individuals with severe disease, where the range of FEV1 
values is narrow, the relationship weakens or disappears.[47, 48] Recent national 
guidelines [44] reflect this difficulty and recommend a comprehensive assessment of 
severity including the degree of airflow obstruction (Table 1.4) and disability, the 
frequency of exacerbations and a number of easily measurable known prognostic 
factors (e.g. BMI, MRCD scale, quality of life). 
Despite the known problems, categorising FEV1 provides a reproducible measure of 
the severity of airflow obstruction which in turn reflects an important component of 
disease severity. Therefore, the following classification describes the severity of airflow 
obstruction and has been endorsed by all the major international specialist advisory 
organisations (GOLD, BTS, ERS and ATS): 
Table 1.4     Classification of severity of airflow obstruction in COPD [44] 
Stage FEV1 / VC ratio FEV1 % predicted 
Stage 1 – mild COPD < 0.70 ≥ 80 
Stage 2 – moderate COPD < 0.70 50 ≤ FEV1 < 80 
Stage 3 – severe COPD < 0.70 30 ≤ FEV1 < 50 
Stage 4 – very severe COPD < 0.70 < 30* 
*or, FEV1 < 50% + presence of chronic respiratory failure 
1.1.3.4 ASTHMA & COPD 
Similarly to COPD, asthma is a chronic condition causing airflow obstruction as a result 
of airway inflammation. A key component of asthma, and one that helps differentiate 
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the condition from COPD, is that the airflow obstruction is variable and often fully 
reversible. However, both conditions may coexist and there is an overlap between the 
two diseases: certain individuals with longstanding asthma can develop fixed, 
irreversible airflow obstruction and clinical symptoms similar to COPD [49] making the 
differentiation between asthma and COPD difficult. Despite a clinical picture similar to 
COPD, individuals with chronic asthma and fixed airflow obstruction have a pattern of 
airway inflammation that is different to those with COPD [1] as well as a more 
favourable prognosis.[50] Individuals with chronic asthma, compared to those with 
COPD, also show greater lung function reversibility to oral prednisolone although their 
response to inhaled bronchodilators may be similar [51]. In clinical practice it can be 
difficult to differentiate between individuals with COPD and individuals with chronic 
asthma, and they may co-exist. A careful history aimed at identifying the presence, or 
absence, of longstanding asthmatic symptoms coupled with demonstrating airflow 
obstruction during disease stability are important to help differentiate COPD from 
asthma. 
1.1.3.5 COMORBIDITY 
Comorbidity is defined as the presence of other chronic medical conditions in an 
individual in addition to the condition of primary interest.[52] Comorbidities are 
common in COPD but their reported prevalence varies significantly between studies. 
Mapel et al [53] reported that only 6% of individuals with COPD did not have another 
chronic medical condition, and van Manen et al [54] showed that 50% of patients with 
COPD had 1-2 comorbidities, 15% had 3-4, and 7% had ≥ 5. 
The strong association between COPD and comorbidity may be because COPD shares a 
common risk factor (i.e. tobacco smoking) with other chronic conditions, or because 
the systemic effects of COPD predispose to certain medical conditions. Irrespective of 
the aetiology, managing an individual’s comorbidity is important when managing their 
COPD. Huiart et al [55] reported that, in individuals with COPD, cardiovascular disease 
is a more frequent reason for hospitalisation and death than COPD. Zvezdin et al [56] 
retrospectively reviewed the autopsy results of 43 patients who had died within 24 
12 
hours of hospitalisation for acute exacerbations of COPD (AECOPD). Cardiac failure was 
the primary cause of death in 37%, pulmonary embolism caused death in 21% and 
respiratory failure secondary to COPD resulted in death in only 14%. Similarly, in 3343 
patients with stable COPD followed up for up to 5 years, 2/3 of the 550 recorded 
deaths were due to non-respiratory disease.[57]  
Furthermore, the overall comorbidity burden is important in the management of 
patients with COPD and is a strong independent predictor of mortality.[58] The 
Charlson Comorbidity Index (CCI, Table 17.1) [59] is a comorbidity assessment tool 
which quantifies an individual’s comorbidity burden. The CCI grades 15 chronic 
diseases according to their severity: mild diseases are assigned lower scores than 
severe diseases, and a higher score indicates a greater comorbidity burden. 
1.1.4 NATURAL HISTORY 
COPD has a variable natural history but generally, there is a gradual decline in lung 
function and it is estimated that approximately 50% of individuals aged over 70, who 
continue to smoke, will develop COPD.[45] Similarly to the decline in lung function, 
patients with all stages of COPD have been shown to experience a progressive linear 
deterioration in quality of life (measured using the SGRQ) and this decline is 
independent of smoking status.[60] 
The rate of decline in lung function is independently predictive of morbidity and 
mortality [61] although the rate of decline varies between individuals and is difficult to 
predict. The observation that different populations (i.e. susceptible smokers, non-
susceptible smokers, ex-smokers and never smokers) experience varying declines in 
lung function was first identified by Fletcher and Peto in a prospective cohort study of 
working men in London.[62] They identified a gradual decline in lung function (FEV1) 
with ageing in individuals who never smoked. The decline was accelerated in 
individuals who smoked regularly, whilst in those who stopped smoking, lung function 
did not improve but the rate of decline in lung function returned to normal. This is an 
oversimplification of the natural history in COPD but provides a useful schematic to 
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depict the harmful effects of tobacco smoke and the progressive decline frequently 
observed in patients (Figure 1.2). 
Figure 1.2     The natural history of lung function decline in COPD 
  
The dashed lines indicate the effects of smoking cessation at different ages.[62] 
As well as the decline in lung function varying between populations of individuals, 
there is considerable variation in individuals within the populations with some 
individuals who continue to smoke experiencing no lung function decline over a 
number of years.[63] COPD is also characterised by a propensity to episodic acute 
deterioration in an individual’s clinical condition. These episodes of sudden 
deterioration are termed acute exacerbations of COPD are the main focus of this thesis 
and are defined in section 1.2. 
1.1.5 MANAGEMENT OF STABLE DISEASE 
The goals of treatment in stable disease are to: improve patient understanding of their 
condition; address patient symptoms and improve individual quality of life; prevent 
exacerbation and hospitalisation; slow disease progression and improve survival. 
Important educational interventions include: smoking cessation advice (and 
treatment) which reduces both lung function decline (Figure 1.2) and mortality;[64] 
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and providing patients with the means to self-manage episodes of AECOPD which 
shortens recovery time [65] and reduces hospital admissions.[66] 
Vaccination plays an important role in the management of stable COPD. Influenza and 
pneumococcal vaccines reduce the risks of hospitalisation, serious illness and death in 
individuals with COPD.[67, 68] 
A number of inhaled medications have been shown to improve symptoms or quality of 
life, or to reduce exacerbation frequency. These include: β2-agonists;[69] 
anticholinergics;[70] and inhaled corticosteroids (ICS) (in combination with long acting 
β2-agonists) in moderate-to-severe disease.[71] Other agents include oral mucolytic 
therapy, long-term anti-inflammatory macrolide therapy and phosphodiasterase-4 
inhibitors which may all reduce exacerbation frequency in selected individuals.[72-75] 
Pulmonary rehabilitation is a non-pharmacological intervention for individuals with 
COPD that can interrupt the vicious cycle of breathlessness, exercise deconditioning, 
immobility, social isolation and depression. It can also address problems of muscle 
wasting and weight loss. Pulmonary rehabilitation is cost effective and has been shown 
to improve exercise capacity, health-related quality of life and reduce 
hospitalisations.[44]  
In individuals with severe chronic hypoxaemia, pulmonary hypertension and cor 
pulmonale can develop. Cor pulmonale is characterised by signs and symptoms of right 
heart failure (peripheral oedema and raised venous pressure) secondary to chronic 
lung disease in patients who have no other cause of ventricular dysfunction.[44] 
Treatment of cor pulmonale is to correct hypoxia and, in all individuals with chronic 
severe hypoxia (with or without cor pulmonale), treatment with long term oxygen 
therapy (LTOT) for at least 15 hours per day has been shown to increase survival.[76] 
This is, in part, through the prevention of pulmonary hypertension [77] although it also 
has benefits on mental state and haemodynamics.[78] In patients whose oxygen 
saturations significantly fall on exertion, supplemental oxygen administered during 
exercise (ambulatory oxygen) may increase the duration of physical activity,[79] and 
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oxygen is sometimes used in short bursts to relieve symptoms of breathlessness,[80] 
although controversy exists regarding the benefits of short burst therapy.[44, 81] 
In carefully selected individuals with COPD, surgical intervention in the form of lung 
volume reduction surgery (LVRS) [82] or lung transplantation [83] can improve quality 
of life, functional status and survival (in the case of LVRS). In a small proportion of 
patients with chronic hypercapnic respiratory failure who are hypercapnic or 
acidaemic on LTOT, long-term non-invasive ventilation (NIV) may be of benefit.[44] 
1.1.5.1 PALLIATIVE CARE IN COPD 
Palliative care involves the care of patients and their families when the individual’s 
disease no longer responds to curative treatment,[44] and is defined by the WHO as 
“patient and family-centred care that optimizes quality of life by anticipating, 
preventing, and treating suffering.”[84] Palliative care and terminal care are not 
synonymous and the main foci of palliative care are: symptom control; maintenance of 
quality of life and independence; improved, open communication; and psychological, 
emotional and spiritual support for patient and carers.[85]  Traditionally, palliative care 
programmes have focused on the needs of patients with cancer. However, given that 
COPD is typically a progressive condition that results in significant morbidity and 
mortality, and that there are few treatments available to alter the natural history of 
the condition, palliative care is an important aspect of the management of patients 
with (severe) COPD.  
In spite of national recommendations that access to palliative care services should be 
available to all with advanced COPD,[44] many patients do not receive such support as 
they approach the end of their life. This is despite evidence that the palliative care 
needs of patients with COPD may exceed those of individuals with lung cancer. Gore et 
al [86] compared the quality of life of a group of 50 patients with severe COPD with 50 
patients with unresectable lung cancer. Patients with COPD had significantly worse 
physical, social and psychological function, as well a greater burden of anxiety or 
depression (90% COPD versus 52% lung cancer). Of those with lung cancer, 30% were 
in receipt of palliative care input and a further 56% had been offered input from, or 
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were aware of the availability of, these services. In contrast, none of the COPD patients 
were in receipt of, or had been offered, palliative care input.  
Also, the care of patients with COPD at the end of their life results in health resource 
use that is not in line with their needs or wishes. Compared to individuals who had 
died of lung cancer, Au et al [87] showed that, in the last six months of life, patients 
who had died of COPD were more likely to be invasively ventilated and were less likely 
to receive symptomatic treatment for dyspnoea and anxiety with benzodiazepines and 
opiates. This is despite evidence that patients with severe COPD experience more 
severe dyspnoea, and are as unwilling to receive life-prolonging treatments with little 
hope of meaningful recovery, as those with lung cancer.[88, 89] 
The palliative care needs of patients with severe COPD remain unmet and there are 
many plausible reasons for this. Perhaps most important is the difficulty in accurately 
predicting prognosis in patients with COPD: in one study,[90] for patients later found 
to be in their last week of life, their physicians had estimated a 40% likelihood of at 
least 6 months survival.  
The pattern of decline as an individual approaches death is termed the ‘illness 
trajectory’. The illness trajectory of individuals who die from cancer characteristically 
follows a predictable pattern: a period of gradual decline (over weeks, months or 
years) is followed by an accelerated decline, once treatment options are exhausted or 
withdrawn, until death (Figure 1.3). COPD, however, does not follow the same pattern. 
Instead, patients are ill for many years with their condition punctuated by occasional 
acute exacerbations. Exacerbations cluster in time,[91] but the interval between 
exacerbations is difficult to predict, and although each exacerbation may result in 
death, the patient usually survives (Figure 1.4). Also, associated comorbidities, such as 
coronary artery disease, may result in sudden death causing the accurate prediction of 
mortality even more problematic.  
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Figure 1.3     Illness trajectory of individuals who die from cancer [92] 
 
Figure 1.4     Illness trajectory of individuals who die from chronic disease (e.g. COPD or 
heart failure)[92] 
 
Although palliative care is not synonymous with end-of-life care, attempts to predict 
the need for palliative care have focused on predicting end of life with no studies 
identifying predictors of poor quality of life. Furthermore, most studies have 
investigated predictors of palliative care need in malignant, rather than non-malignant, 
disease, and very few have examined patients with COPD. 
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Instruments such as the Palliative Performance Scale,[93] the Karnofsky Performance 
Scale,[94] and the Palliative Prognostic Index [95, 96], which are of prognostic use in 
malignant disease, have been infrequently studied in non-malignant disease: two 
studies [97, 98] have suggested they are prognostically useful in non-malignant 
disease, but in both studies only a small proportion of patients had COPD. 
 The Study to Understand Prognoses and Preferences for Outcomes and Risks of 
Treatments (SUPPORT) aimed to predict six-month survival in seriously ill hospitalized 
adults.[99] Attempts to predict six-month mortality, and hence palliative care need, in 
the population of patients with COPD, have largely been unsuccessful,[100, 101] 
although Connors et al [102] derived a prognostic tool which showed promising 
performance, but it has not been validated outside of the study population.  
Given the lack of robust predictors of medium-term prognosis in COPD (which will be 
discussed in greater detail in Chapter 2), perhaps the most pragmatic solution to 
identify those who may benefit from discussing palliative care options is the ‘surprise’ 
question: “Would you be surprised if the patient died in the next 12 months?”:[103] if 
the answer is “No” then a discussion around palliative care should be initiated. 
However, clinicians have difficultly accurately predicting prognosis and that they are 
often overly pessimistic in patients with COPD,[104] and therefore the ‘surprise’ 
question may over or under recognise patients potentially in need of palliative care. 
It is important to recognise that all previous attempts to predict need for palliative 
care have focused solely on end of life with no reference to quality of life. Yet, given 
the difficulties in accurately identifying medium-term prognosis, prognostic markers 
for poor quality of life, or future decline in quality of life, may provide a more robust, 
and more patient-centred approach, to identifying those who may benefit from 
palliative care input. 
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1.2 ACUTE EXACERBATIONS OF COPD 
1.2.1 DEFINITION AND PREVALENCE 
As COPD progresses, it is typically punctuated by acute exacerbations (AECOPD) which 
often cluster in time.[91] There is no consensus definition for an exacerbation since 
they have a variety of causes, but a useful definition is that “an exacerbation consists 
of an acute worsening of the patient’s condition from the stable-state, which is 
sustained and may warrant the patient to seek additional treatment”.[105] This 
definition includes a wide variety of aetiologies and severities of exacerbation. Up to 
50% of exacerbations are self-managed and never come to the attention of medical 
services,[106] whereas other acute exacerbations result in hospitalisation, respiratory 
failure and / or death. Studies suggest patients with COPD experience ≈1 AECOPD per 
annum,[71] and  approximately 19% of AECOPD require hospitalisation for 
treatment.[44]  
1.2.2 IMPACT OF AECOPD 
1.2.2.1 PATIENT-CENTRED OUTCOMES 
Exacerbations are important in the natural history and management of COPD: they 
cause a reduction in lung function and associated symptoms, resulting in deterioration 
in quality of life (QoL) [107-112], an increased need for healthcare interventions (for 
example, emergency hospitalisation), and an increased risk of mortality.[113-115] 
Admission to hospital for treatment of an acute exacerbation of COPD is associated 
with an in-hospital mortality rate of over 7.5% [12] and an annual mortality rate 
following discharge of up to 49%. 
Recovery following AECOPD can be unpredictable and prolonged. In patients managed 
in the community with AECOPD, the recovery of lung function, symptoms and quality 
of life is most rapid during the initial four weeks, however a continued slow 
improvement is still apparent after six months, and some patients never recover to 
their pre-exacerbation level.[106, 116] The recovery of symptoms and lung function is 
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further prolonged in severe exacerbations or if a patient exacerbates during the 
recovery phase and therefore, in patients hospitalised with AECOPD, the median 
recovery time is likely to be significantly longer.[111] In some individuals, complete 
recovery is not achieved and therefore frequent exacerbations result in an accelerated 
decline in lung function,[117] symptoms and quality of life, [118] thus affecting the 
natural history of the disease.  
Recovery following AECOPD managed in the community is well documented,[106, 119] 
but the time course of recovery following hospitalisation for AECOPD has been 
infrequently studied and requires clarification. Connors et al [102] showed that in 
patients with hypercapnia only 26% of patients were both alive and able to report a 
‘good’ quality of life six months following discharge. Only a single study has assessed 
quality of life longitudinally, and this showed that health status continues to recover 
up to nine months following hospital discharge.[120]  
The major risk factor for the development of AECOPD is a history of previous 
exacerbations,[91] and other risk factors include: low FEV1; chronic mucus 
hypersecretion; higher age;[121] low health status; high comorbidity; high dyspnoea 
levels;[122] and a history of reflux or heartburn.[123]  As COPD severity worsens, 
exacerbations become more frequent,[123-125] and those who experience frequent 
episodes of AECOPD are at a significantly increased risk of hospitalisation,[44] 
subsequent death,[113] low quality of life,[126] and a faster decline in lung function 
[117] and quality of life when compared to individuals who exacerbate less 
frequently.[118, 127]  
Episodes of AECOPD, and in particular, episodes of AECOPD requiring hospitalisation, 
are therefore a key event in the natural history of COPD. They not only impact 
dramatically on patients’ lives, but they may also signify a threshold in an individual’s 
disease: following an exacerbation, and its associated slow or incomplete recovery, the 
patient is at risk of further episodes potentially requiring hospitalisation, thus resulting 
in an accelerated decline in their condition. Episodes of AECOPD therefore provide an 
opportunity to identify those patients at risk of subsequent exacerbation and disease 
decline, and to intervene early.  
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1.2.2.2 HEALTH RESOURCE USE AND COST 
Acute exacerbations are the main reason for admission to hospital in COPD and are 
therefore a major reason behind the high financial burden associated with the 
management of COPD. There are variable estimates that unscheduled contact with the 
health service is responsible for between 35 and 63% of the total costs for COPD.[128, 
129] The cost of AECOPD requiring hospitalisation varies from £2041 to £5298,[130] 
and the majority of the expenditure relates to length of stay and bed costs.[129, 131] It 
is estimated a small proportion of patients with COPD (approximately 10%) are 
responsible for over 70% of the costs associated with the disease, through 
unscheduled contact with the healthcare system for treatment of exacerbations.[132]  
1.2.3 PATHOLOGY AND SYMPTOMATOLOGY 
There are various aetiological agents implicated in AECOPD including both infective 
(bacteria and viruses) and non-infective (atmospheric pollution, pulmonary embolism, 
heart failure). It has been estimated that over 70% of AECOPD are due to an infective 
agent,[133] although in clinical practice a causative agent often remains unidentifiable.  
Increased breathlessness is the main symptom of an exacerbation. Other symptoms 
may include wheeze, cough, sputum (either increased volume or purulence) or fever. 
Anthonisen [134] defined the severity of an acute exacerbation according to the 
symptoms at presentation (Table 1.5). Antibiotics are of clinical benefit in type 1 and 
type 2 exacerbations [134] and individuals with type 1 and type 2 exacerbations are at 
increased risk of in-hospital death, compared to type 3.[135]  
Table 1.5     Anthonisen classification of acute exacerbations of COPD 
Anthonisen Criteria Symptoms & signs 
Type 1 Increased dyspnoea, sputum volume and purulence 
Type 2 Two of the above features present 
Type 3 
One of the above features present & at least one of the following: 
fever, increased wheeze, increased cough, or 20% increase in heart rate 
or respiratory rate compared to baseline 
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1.2.4 PNEUMONIA IN AECOPD 
Community acquired pneumonia (CAP) is defined as an acute respiratory tract illness 
associated with radiographic consolidation on an admission chest radiograph 
consistent with infection, which is neither pre-existing nor due to another cause (for 
example, a known carcinoma or foreign body).[136] Pneumonia is a common 
complicating factor in patients hospitalised with AECOPD (termed pneumonic AECOPD, 
pAECOPD), and in patients hospitalised with CAP, COPD is the most common 
comorbidity.[137]  
Estimates of the prevalence of radiographic consolidation in patients hospitalised with 
AECOPD vary considerably with quoted figures ranging from 10% to 70%.[135, 138-
150] The most severe exacerbations (i.e. patients requiring ventilatory assistance) are 
typically associated with a higher prevalence. The varying prevalence rates are, in part, 
secondary to confusion regarding the terminology of patients with pneumonic 
AECOPD. Broadly, there are three approaches to defining the diagnosis in patients with 
AECOPD and complicating pneumonia: 1) AECOPD and CAP are separate entities and 
hence the presence of consolidation precludes the diagnosis of AECOPD; 2) the final 
diagnosis is AECOPD if the primary reason for admission is AECOPD rather than CAP 
and vice versa; and 3) the presence of consolidation is marker of a severe exacerbation 
of COPD, not a separate diagnosis, and if they coexist the diagnosis should be termed a 
pneumonic AECOPD (pAECOPD). 
The approach of considering AECOPD and CAP as separate disease entities that cannot 
coexist is limited by a number of factors. Firstly, chest radiography has limited 
sensitivity for the diagnosis of pneumonia in both the critical care setting [151] and in 
general patients hospitalised with suspected pneumonia where it has been reported 
that up to 25% of patients with an initial negative chest radiograph (CXR) will have 
evidence of consolidation on computer tomography (CT) scanning,[152-154] and, of 
those with an initial negative CXR, over 50% will develop radiographic consolidation in 
the subsequent 48 hours.[154] Secondly, AECOPD is frequently diagnosed and 
managed in the community where chest radiographs are not routinely available: 
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therefore, excluding CAP from the diagnosis of AECOPD is not a reliable option. Lastly, 
including patients with both non-infective processes and infective bronchitis in the 
diagnosis of AECOPD, but excluding patients in whom the infection has progressed 
beyond the bronchial wall to cause pulmonary consolidation does not seem 
pathophysiologically consistent.  
The second approach to diagnosing patients with COPD and CAP is limited on 
pragmatic grounds. In patients with underlying COPD, both an exacerbation of COPD 
and an episode of CAP will present with a similar clinical phenotype (dyspnoea, cough, 
purulent sputum production, wheeze and constitutional symptoms) and in the 
presence of coexistent pneumonia, it is often not possible to determine, using 
examination findings or simple investigations, that the admission episode is 
predominantly due to pneumonia rather than AECOPD, or vice versa. 
Therefore, for this study, we have adopted the third approach listed above, which is 
supported by: most of the prognostic literature in AECOPD where patients with 
complicating pneumonia were not excluded;[139, 155-158] and the UK National COPD 
Audits which reported that pneumonia complicated 16% of all admissions with 
AECOPD [12] and 34.2% of patients with AECOPD requiring NIV.[159] In addition, 
Lieberman et al [141] compared the clinical characteristics of patients admitted with 
pAECOPD and non-pneumonic AECOPD (npAECOPD). They found that, compared to 
those with npAECOPD, patients with complicating pneumonia were similar in terms of 
sociodemographic details and severity of the underlying COPD, although they had 
more abnormal markers of acute clinical and physiological derangement, suggesting 
that consolidation identifies patients with a more severe acute illness, but does not 
signify a different disease process. 
In CAP necessitating hospitalisation, the CURB-65 clinical prediction tool [160] is a six-
point score (one point each for the presence of confusion, urea > 7mmol/L, respiratory 
rate (RR) ≥ 30min-1, hypotension (systolic blood pressure < 90mmHg or diastolic blood 
pressure < 60mmHg) and age ≥ 65 years) which effectively predicts 30-day mortality. 
Although widely used in patients with AECOPD and coexistent pneumonia, its use in 
this cohort has not been specifically investigated. It has been shown that compared to 
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CAP, patients with pAECOPD are older and more breathless,[161, 162] and therefore 
the assessment of risk in patients with pAECOPD may be skewed and hence the 
expected mortality rates (Table 1.6) quoted in CAP may not be applicable in pAECOPD. 
CURB-65 is also sometimes used to guide clinical decisions in npAECOPD but only a 
single prospective study supports this.[163] 
Table 1.6     CURB-65 severity classification for CAP 
CURB score Severity classification Estimated mortality in CAP* 
0 – 1 Low risk 1.5 
2 Moderate risk 9.2 
3 – 5 High risk 22.4 
*from Lim et al [160] 
1.2.5 MANAGEMENT OF ACUTE EXACERBATIONS IN HOSPITAL 
The mainstay of treating acute exacerbations requiring admission to hospital is the 
administration of controlled oxygen therapy (if the patient is hypoxaemic),[164, 165] 
short acting bronchodilators and oral corticosteroids, as well as preventing 
complications of the disease and hospitalisation.[44] As discussed above, if Anthonisen 
criteria (Table 1.5) types 1 or 2 are fulfilled, then antibiotics are of clinical benefit: the 
number of patients needed to treat with antibiotics to prevent an episode of 
treatment failure or mortality is 3 and 8 respectively.[134, 166]  
As part of the initial assessment, it is recommended [44] that all patients hospitalised 
with AECOPD should have arterial blood gases measured on a known, fixed 
concentration of inspired oxygen. Acidaemic respiratory failure (ARF) (pH < 7.35 and 
paCO2 > 6kPa) is a marker of severe AECOPD and corresponds to an estimated in-
hospital mortality rate of approximately 25%.[146] ARF occurs in approximately 20% of 
all hospital admissions with AECOPD,[146] and in these individuals, support with non-
invasive or invasive ventilation is of benefit.[167]  
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1.2.6 NON-INVASIVE VENTILATION 
Non-invasive ventilation (NIV) refers to the provision of ventilatory support without 
placing an endotracheal airway. Positive pressure ventilators are used in COPD and 
force air into the lungs by applying positive pressure to the airway via interfaces such 
as nasal and oro-nasal masks. 
NIV can relieve the strain that the respiratory muscles experience during an 
exacerbation whilst conventional treatments aim to eradicate the acute cause. 
Invasive ventilation via tracheal intubation achieves this outcome but is associated 
with significant morbidity and mortality, and there may be difficulties weaning patients 
off invasive ventilation.[168] Compared to invasive ventilation, NIV avoids the need for 
sedation, can be applied intermittently and allows the patient to eat, drink and talk. 
Also, NIV reduces the risk of nocosomial pneumonia,[169] reduces the need for 
invasive ventilation, reduces mortality and reduces length of stay.[167] NIV can also be 
effectively used outside of the intensive care unit (ICU) [170] therefore relieving the 
burden on ICU beds. 
NIV reduces the risk of treatment failure by more than 50%, when compared to 
conventional therapy, the number of patients needed to be treated with NIV to 
prevent one treatment failure of 5.[167] However, a significant proportion of 
individuals do not respond to treatment with NIV, with failure rates of up to 50% 
reported in some studies,[171] and in these patients escalating treatment to invasive 
ventilation has been shown to be associated with better outcomes than persevering 
with NIV.[172] NIV also has the potential to cause harm: the mask can be 
uncomfortable and can cause facial skin pressure necrosis, it causes gastric distension 
which may lead to vomiting, and bronchial toilet is difficult as the airway is not secured 
by an endotracheal tube.[173] 
It is recommended that patients with mild to moderate respiratory failure (7.26 ≤ pH < 
7.35 and PaCO2 > 6kPa), or those with severe respiratory failure (pH < 7.26 and PaCO2 > 
6kPa) who are deemed not appropriate for invasive ventilation, should receive 
treatment with NIV.[174] For those with severe respiratory failure (pH < 7.26 and 
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PaCO2 > 6kPa) it was previously recommended that invasive ventilation (IPPV) should 
be considered as first line treatment [44] although this is not standard practice in the 
UK.[146]  Although previously recommended, it is not clear whether patients with 
severe acidosis respond better to invasive ventilation than NIV because most 
randomised controlled trials of NIV in AECOPD excluded patients with pH < 7.26. Two 
studies comparing NIV to invasive ventilation in patients with severe acidaemic 
respiratory failure secondary to AECOPD [149, 175] showed that there was no 
difference in risk of mortality between the two groups, and suggested that a trial of 
NIV, even in severe acidosis, may benefit the patient. Furthermore, McLaughlin et al 
[176] reported that managing patients with severe acidaemic respiratory failure (pH < 
7.25) secondary to AECOPD with NIV resulted in 61% of patients surviving to discharge.  
Therefore, recently updated national COPD guidelines [44] have suggested that in 
acidaemic respiratory failure secondary to AECOPD, NIV should be considered the 
initial treatment of choice irrespective of pH.  
Clinical guidelines regarding the use of NIV [174] stipulate certain contraindications to 
its use, including an altered level of consciousness. Avoiding NIV in patients with 
altered consciousness is recommended because NIV is thought to be less effective in 
uncooperative patients and also may increase the risk of pulmonary aspiration, 
however, most randomised trials have excluded such patients. A case-control study 
[148] has shown that NIV can be successfully used in patients with impaired 
consciousness and, furthermore, it has been shown that invasive ventilation does not 
add any further benefits in patients with severe altered consciousness compared to 
NIV.[175] Therefore, more robust predictors of NIV failure are needed because current 
recommendations do not appear to be supported by the published literature.  
National guidelines also state that NIV should be considered if there is “potential for 
recovery to a quality of life acceptable to the patient”.[174] This subjective assessment 
is very difficult to perform in an acutely unwell patient and the difficulties associated 
with interpreting what an ‘acceptable quality of life’ is leads to considerable variability 
in the use of NIV. Furthermore, there are conflicting results from published evidence. 
Connors et al reported that, in patients with a severe exacerbation treated in hospital, 
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only 26% of patients were alive and reported ‘good’ quality of life at six months 
following hospital discharge,[102] however, a more recent study showed that, in 
patients with AECOPD requiring  treatment on ICU, over two thirds of patients felt that 
their health was the same or better than prior to admission.[177] 
A consequence of the uncertainty with regards to survival and quality of life following 
NIV is that clinicians exhibit prognostic pessimism [104] and therefore patients who 
may benefit from ventilatory support might not receive it. In addition, clinicians may 
be failing to identify patients where treatment with NIV has a low chance of short-term 
survival and is not associated with sustained long-term clinical improvements, but 
instead is saving them for a future life of recurrent hospitalisations, a heavy symptom 
burden and a poor quality of life.  
Therefore, simple, objective measurements that help identify patients who are unlikely 
to benefit from treatment with NIV would ensure that they are spared the potential 
discomfort of treatment with NIV, and that they can either be considered for invasive 
ventilation or symptom palliation. There is also a lack of clarity regarding the potential 
for recovery in quality of life following discharge and an inability to accurately identify 
patients at risk of poor recovery. Therefore, further data on the expected recovery 
following treatment with NIV as well as the identification of independent predictors of 
poor outcome, could help patients and clinicians decide on the appropriate use of NIV. 
1.3 CHAPTER SUMMARY 
COPD is a common cause of morbidity and mortality and its prevalence is increasing. 
The treatment of COPD and its complications places an enormous burden on health 
resources and the burden increases as individuals approach end of life. Most of the 
COPD disease burden (morbidity, mortality and economic) relates to hospital 
admissions for treatment of AECOPD and therefore, an ability to identify individuals at 
risk of in-hospital death and readmission following discharge would enable healthcare 
providers to direct resources at those most in need. This might improve the survival, 
reduce readmission and relieve the financial burden of patients with AECOPD. 
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Patients with COPD have significant unmet palliative care needs and this is, in part, due 
to difficulties in identifying individuals either approaching the end of their life or at risk 
of a decline in quality of life unacceptable to the patient who may be in need of 
palliative care input. A simple clinical tool which accurately and reliably predicts poor 
quality of life, and poor short and medium term prognosis, would be useful in helping 
identify which patients could be considered for referral to the palliative care services. 
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CHAPTER 2 PREDICTING MORTALITY IN COPD 
2.1 PREDICTING MORTALITY IN STABLE DISEASE 
There is a considerable and conflicting literature base regarding prognostic indices in 
stable COPD and application of the results to clinical practice is difficult. Typically, each 
study includes a different set of covariates in their regression analyses and therefore, 
the independent predictors identified by one study are not comparable with the 
predictors from other studies, because potential confounders may have been omitted 
in one, or both, studies. Furthermore, very few papers provide detail on the strength 
and validity of regression models, therefore identified predictors can only be said to be 
independent of the other confounders included in the model and it is not possible to 
assess the strength of their relationship with outcome, or to generalise outside the 
study population.  
Therefore, Table 2.1 attempts to summarise extensive published data so that it can be 
interpreted in the context of other studies and some conclusions can be made outside 
the study populations. Table 2.1 shows not only how frequently a variable predicts 
mortality, but also how often has it been investigated and not been found to be a 
prognostic factor. Studies of unselected groups of patients with stable COPD are 
included and for each prognostic index: its relationship with mortality is described; the 
number of studies that have clearly investigated the relationship with mortality is 
shown; the number of studies identifying an association on univariate analysis is 
recorded; and finally, the number of studies identifying an association with mortality 
on multivariate analysis (numerator) is compared with the total number of studies 
which have investigated that index using multivariate methodologies (denominator). 
This table helps illustrate that factors such as higher age, more severe dyspnoea, poor 
quality of life, low FEV1, low BMI, more severe hypoxaemia, high levels of comorbidity, 
and short distances walked in the 6-minute walk test (6MWT) are consistently found to 
be independently predictive of mortality in stable COPD. Many of the other variables 
have been studied infrequently and therefore it is difficult to come to firm conclusions 
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on the prognostic value of these indices in a general population of individuals with 
stable COPD.  
The data regarding the relationship between sex and mortality is contradictory. In 
unselected patients, survival of females is longer than males, independent of 
FEV1.[178] However, in patients requiring LTOT, and therefore with severe COPD, the 
length of survival of females is less than males.[179] Although the selection criteria for 
LTOT are the same for females as males, it is unclear whether there is the same level of 
recognition of the need for LTOT in males and females and therefore this may bias the 
results. However, it has been shown that women are more prone to the systemic 
effects of severe COPD with significantly higher rates of depression [180] and body fat 
depletion,[30] and this may therefore explain an increased risk of death in females 
with severe COPD. 
It is of interest that certain indices, such as low vital capacity and anaemia, are 
associated with mortality on univariate analysis but fail to act as independent 
predictors of death. It is also of interest that low FEV1 is almost universally associated 
with mortality on univariate analysis but it acts less frequently as an independent 
predictor on multivariate analysis. This is mostly due to studies that included detailed 
assessments of lung function or exercise capacity where they have identified complex 
or difficult to measure variables which are stronger predictors of mortality and 
therefore limit the predictive ability of FEV1. It is also because the predictive capacity 
of FEV1 is constrained by the limited range of FEV1 values that are present when this is 
used as the defining criterion for inclusion in the study.  
Not all of the published research on this topic details all of the indices included in data 
analysis and therefore the above table will underestimate the number of times that 
the above listed indices have failed to demonstrate an association with mortality.  
 
 Table 2.1     Summary of prognostic indices associated with mortality in stable COPD – see text for explanation 
Index 
Positive or negative correlation with 
outcome 
Number of studies 
investigating index 
Association identified on 
univariate analysis 
Association identified on 
multivariate analysis 
Sociodemographic details, 
Age Positive 41 25 19/24 
Sex Male sex at increased risk of death 25 7 3/12 
Smoking load Positive 6 1 0/1 
Years of education Negative 2 1 1/2 
Socioeconomic class 
Lower socioeconomic class associated 
with increased death 
5 0 0 
History and examination, 
Mucus hypersecretion Positive 7 4 1/3 
Pedal oedema Positive 1 0 1/1 
Exacerbation frequency in 
past year 
Positive 4 3 2/2 
Previous admissions in 
past year 
Positive 3 1 0/1 
Dyspnoea Positive 18 11 6/10 
Cor pulmonale Positive 2 2 0 
Heart rate at rest Positive 3 2 1/2 
ECG evidence of right 
heart strain 
Positive 4 2 1/1 
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 Index 
Positive or negative correlation with 
outcome 
Number of studies 
investigating index 
Association identified on 
univariate analysis 
Association identified on 
multivariate analysis 
Disability 
Inability to perform ADLs associated with 
increased risk of death 
1 1 1/1 
Health status assessment, 
Quality of life Negative 14 11 6/9 
Cognitive impairment Positive 4 3 2/4 
Depression Positive 4 3 1/3 
Lung Function, 
FEV1 Negative 44 32 13/23 
VC Negative 17 11 0/7 
FEV1/FVC Negative 6 4 0/2 
IC Negative 2 2 1/1 
TLC Positive 4 3 1/3 
IC/TLC Negative 4 4 2/2 
RV Positive 1 1 1/1 
RV/TLC Positive 6 4 0/1 
FRC Negative  1 0  
Gas transfer Negative 9 6 4/4 
Bronchodilator 
reversibility 
Negative 6 3 2/4 
FEV1 rate of decline Positive 2 2 0 
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 Index 
Positive or negative correlation with 
outcome 
Number of studies 
investigating index 
Association identified on 
univariate analysis 
Association identified on 
multivariate analysis 
Arterial blood gas, 
SpO2 Negative 5 4 0/2 
PaO2 Negative 18 13 5/9 
PaO2/FiO2 Negative 2 2 0/2 
PaCO2 Positive 17 12 4/10 
Exercise capacity, 
Self-reported activity level Negative 1 1 1/1 
6MWT Negative 17 16 8/10 
VO2max § Negative 4 2 2/3 
Nutritional assessment, 
BMI Negative 34 19 10/20 
Weight loss Positive 2 2 1/1 
Fat free mass Negative 4 2 2/3 
Mid arm muscle area Negative 1 1 1/1 
Quadriceps strength Negative 1 1 1/1 
Thigh circumference Negative 1 1 0/1 
MTCSA Negative 1 1 1/1 
Blood tests, 
Haemoglobin Negative 6 4 0/3 
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 Index 
Positive or negative correlation with 
outcome 
Number of studies 
investigating index 
Association identified on 
univariate analysis 
Association identified on 
multivariate analysis 
Albumin Negative 4 4 0/1 
CRP Positive 3 1 2/3 
BNP Positive 1 1 1/1 
Comorbidity, 
CCI Positive 13 8 5/8 
Number of comorbidities Positive 1 0 0/1 
Ischaemic heart disease Positive  8 2 1/2 
Cardiac failure Positive 2 1 1/1 
Cerebrovascular disease Positive 2 2 2/2 
Diabetes Positive 2 0 0 
Medication, 
LTOT Positive 7 3 2/4 
Oral corticosteroids Positive 3 1 1/1 
Inhaled corticosteroids Negative 2 1 1/1 
Influenza vaccine Negative 1 1 1/1 
References - [24, 26, 28, 35, 61, 178, 181-234] 
ECG – electrocardiograph; ADL – activities of daily living; QoL – quality of life; IC – inspiratory capacity; TLC – total lung capacity; RV – residual volume; FRC – functional residual 
capacity; SpO2 – transcutaneous oxygen saturation; PaO2 – arterial partial pressure of O2; FiO2 – fraction of inspired oxygen; PaCO2 – arterial partial pressure of CO2; 6MWT – six 
minute walk test; VO2MAX – maximum oxygen consumption per minute per kilogram; BMI – body mass index; MTCSA – midthigh cross-sectional area; CRP – C reactive protein; BNP 
– brain natriuretic peptide; CCI – Charlson comorbidity index; LTOT – long term oxygen therapy; § - on cardiopulmonary exercise testing 
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2.1.1.1 CLINICAL PREDICTION TOOLS IN STABLE COPD 
Many authors have attempted to develop multivariable prediction tools that can help 
clinicians to accurately predict prognosis, however the developed tools are often 
complex and include prognostic variables that are difficult to measure in routine 
clinical practice. Importantly, for the purposes of my study, none of the tools have 
been studied in exacerbations of COPD requiring hospitalisation. 
Celli et al [26] identified four indices that predicted increased mortality risk: BMI; 
airflow Obstruction; MRC Dyspnoea scale; and Exercise capacity (measured by 6MWT). 
Each variable is assigned a score and the total score (out of 10) is termed the BODE 
index (Table 2.2). A high BODE index score is associated with a worse prognosis: a 
BODE index score of 7-10 is associated with a 52-month mortality rate of 80%.[26] This 
instrument has been shown to be a more accurate predictor of mortality than FEV1, 
and has also been shown to accurately predict the risk of AECOPD [235] and 
hospitalisation due to AECOPD.[25] The BODE index score correlates well with 
measures of quality of life [236] and has been shown to be a useful measure of 
assessing response to certain treatments.[237, 238] 
Table 2.2     The BODE index [26]  
Variable 
BODE score 
0 1 2 3 
FEV1 (% predicted) >65 50-65 35-49 <35 
MRCD scale 1-2 3 4 5 
6MWT (metres) >350 250-349 150-249 <149 
BMI >21 <21   
MRCD – MRC Dyspnoea Scale; 6MWT – six minute walk distance; BMI – body mass index 
Briggs et al [199] developed the COPD Prognostic Index (CPI) which aimed to 
accurately predict death, hospitalisation and exacerbation (Table 2.3). High scores 
indicate increased risk of mortality, hospitalisation and exacerbation. The derivation 
study estimated that a CPI score of 90 equates to a 30% three-year mortality rate, a 
60% three-year hospitalisation rate, and 9 expected exacerbations within three 
years.[199] The initial cohort was split with one third reserved for internal validation of 
the developed instrument, but it has not undergone external independent validation.  
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Table 2.3     The COPD Prognostic Index (CPI)[199] 
Prognostic factor Addition to risk score 
Either:            CRQ total <68 68 to <86 86 to <104 ≥104 
Or:                 SGRQ total >64 <47 to 64 <30 to 47 ≥30 
Score 18 13 7 0 
FEV1 % predicted <30 30 to 49 50 to 59 ≥60 
Score 24 15 7 0 
Age, years <55 55 to 64 65 to 74 ≥75 
Score 0 7 14 20 
Sex 
Score 
Male 
0 
Female 
1 
BMI <20 
Score 
No 
0 
Yes 
11 
History of ED visits / exacerbations * 
Score 
No 
0 
Yes 
20 
History of CVD 
Score 
No 
0 
Yes 
7 
CRQ – Chronic Respiratory Disease Questionnaire; SGRQ – St. George’s Respiratory Questionnaire; ED – 
emergency department; CVD – cardiovascular disease. * within past 12 months. 
Using a large outpatient database of patients with COPD, Schembri and colleagues [57] 
developed a risk score that predicted a composite outcome of hospitalisation or death. 
Risk factors within the score were: increased age; low BMI; MRCD; FEV1 % predicted; 
previous healthcare utilisation; and whether the patient had received influenza 
vaccination. The lack of external validation and the complex calculation required to 
calculate an individual’s risk of outcome mean the utility of this instrument in clinical 
practice is uncertain. 
Esteban et al [206] developed a clinical prediction tool using a population of 600 
unselected individuals with stable COPD. Using a subjective assessment of physical 
activity, dyspnoea and health status, as well as measurement of FEV1 % predicted, the 
Health-Activity-Dyspnoea-Obstruction (HADO) score was developed. This score reliably 
and independently predicted the risk of death at three years more accurately than the 
FEV1. This score has not been externally validated. 
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Kostianev et al [234] derived a multidimensional prognostic score (the DOREMI BOX 
score) in 84 young patients with stable COPD and subsequently validated the score in a 
separate population of 68 COPD patients. The DOREMI BOX score had similar 
performance to the BODE score for the prediction of mortality, however the relatively 
small derivation and validation cohorts and the uncertain variable selection 
methodology used mean that this tool has not been investigated further or used in 
routine clinical practice in the United Kingdom.  
2.1.1.2 SUMMARY OF PROGNOSTICATION IN STABLE COPD 
The prognostic tools discussed have been derived using varied methodologies and 
have frequently not undergone external validation and hence their clinical application 
is limited. Furthermore, in spite of frequent poor outcomes, there has been less 
interest in prognostication following admission for AECOPD. Given the different 
pathophysiological processes that occur in stable COPD and AECOPD, many of the 
indices, and predictive tools identified in stable disease may not be relevant during an 
acute exacerbation. They may also be difficult to measure during a hospital stay and 
may therefore be of limited use. The prognostication of AECOPD and stable COPD 
should therefore be treated separately and the evidence surrounding prognostication 
following admission for AECOPD will be discussed in section 2.2. 
2.2 PREDICTING MORTALITY FOLLOWING HOSPITALISATION FOR AECOPD 
Most studies evaluating prognostic indices in COPD refer to assessments performed 
during a stable state (Table 2.1). There is a lack of robust data, using a prospective 
methodology, assessing prognostic indices in AECOPD requiring hospital admission. 
Prognostication in stable COPD was discussed in section 2.1 and I will now review the 
literature relating to hospitalised patients with AECOPD. Many individual prognostic 
factors are closely related (e.g. FEV1 to exercise performance) and therefore it is 
particularly important to differentiate independent predictors of mortality (identified 
using multivariate analysis) from variables associated with mortality on univariate 
analysis alone. If a variable is independently predictive of death then this is mentioned 
in the text, or it is highlighted in italics in the summary tables. 
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It is unlikely that the same indices predict both acute and longer-term mortality. 
Therefore, in the following text, indices predictive of in-hospital mortality, and indices 
predictive of mortality following hospital discharge have been identified and 
distinguished in both the text and tables. 
2.2.1 SOCIODEMOGRAPHIC DETAILS 
2.2.1.1 AGE 
A retrospective analysis of 71,130 patients with a discharge diagnosis, or cause of 
death, of AECOPD showed that increasing age is independently predictive of in-
hospital mortality.[239] This association has been replicated in several other large 
retrospective [114, 240-242] and prospective [135, 156, 243] studies. Increasing age is 
also independently predictive of mortality following hospital discharge.[15, 242, 244-
246] However, disease duration may be a more important predictor of death following 
discharge than chronological age, which may act as a surrogate marker.[247]  
2.2.1.2 SEX 
Most participants in clinical COPD research are male, reflecting the underlying 
demographics of the disease population. Conclusions regarding the role of sex in the 
prediction of in-hospital mortality are conflicting. Although smaller studies 
disagree,[15, 248] large retrospective analyses suggested that male patients have 
higher in-hospital mortality.[239, 240] The effect of male sex on mortality following 
discharge is uncertain with some articles suggesting an increased risk of death,[14, 
246] others finding no association, [233, 242, 247, 249-251] and a single study 
suggesting an increased long-term mortality rate in females.[252] 
2.2.1.3 INCOME AND EDUCATION 
In stable disease, income and years in education typically demonstrate a negative 
relationship with mortality.[253] However, in patients hospitalised with exacerbations, 
Patil et al [239] suggested that high incomes were independently predictive of 
mortality although the authors advise cautious interpretation of this finding and 
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suggest that there may have been different thresholds for admission for individuals 
with different incomes. Faustini et al [240] suggested that a lower level of education (< 
5 years formal education) was predictive of death after discharge on univariate 
analysis but this finding was not confirmed in a prospective analysis of patients with 
AECOPD.[58] 
2.2.1.4 SOCIAL SUPPORT AND MARITAL STATUS 
Greater social support prior to hospitalisation does not independently predict 
mortality,[156, 254] whereas admission from a long-term care facility does.[239] 
Following discharge, a need for social support is associated with long-term mortality 
but only marital status is an independent predictor (unmarried = increased risk of 
death), not the amount of social care required,[58] nor whether the individual lives 
alone.[255] The protective effect of marital status is consistent with research in other 
diseases [256] and it may be due to better compliance with prescribed medication in 
married individuals with COPD.[257] 
2.2.2 CLINICAL HISTORY 
2.2.2.1 PRE-ADMISSION LEVEL OF FUNCTION 
The relationship between functional limitation and in-hospital mortality has most 
frequently been studied in individuals requiring NIV or ICU treatment where functional 
limitation has not been shown to be associated with in-hospital mortality.[147, 248, 
258, 259] However, treatment with NIV or on ICU is frequently not offered to 
individuals with severe functional limitation and therefore these results should be 
interpreted with caution. A single study of a selected population of patients who died 
in-hospital due to AECOPD,[260] which compared indices collected from the admission 
which resulted in death with the patient’s previous admission, has suggested that 
functional limitation (measured using the Performance status, Table 4.1) 
independently predicts in-hospital mortality, but it is uncertain whether this result 
generalises to all patients hospitalised with AECOPD. 
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However, in patients surviving to discharge, the level of functional impairment, at two 
weeks prior to admission, measured informally [246, 254, 258] or formally using 
validated instruments,[58, 102, 249, 250, 254] is predictive of mortality up to 1 year. 
2.2.2.2 QUALITY OF LIFE AND PSYCHOLOGICAL WELLBEING 
Poor quality of life or psychological wellbeing are well established predictors of 
mortality in stable disease.[181, 186, 261]  The impact of depression and impaired 
quality of life on in-hospital mortality in AECOPD has not been described due to 
difficulties performing assessments in acutely unwell patients.  
However, it is estimated that, at discharge following admission for AECOPD, 40% of 
patients are depressed.[262] Following discharge, depression acts as an independent 
predictor of mortality.[58, 249, 262] 
Gudmundsson et al [255] undertook a large prospective multicentre study of AECOPD. 
Health status was assessed at discharge using the St. George’s Respiratory 
Questionnaire. All components of the SGRQ (symptoms, activities, impacts and total 
score) were associated with increased mortality at 2 years, although only the total and 
impacts scores were independent predictors. Almagro et al [58] suggested that only 
the activity component of SGRQ independently predicted mortality and Yohannes et al 
[249] demonstrated that low quality of life (measured using the Breathing Problems 
Questionnaire) was predictive of 1-year mortality.  
2.2.2.3 DYSPNOEA 
The MRCD scale (Table 1.1)  was associated with, but not independently predictive of, 
in-hospital mortality in a prospective cohort of 284 consecutive admissions with 
AECOPD,[157] and was found to be independently predictive of in-hospital mortality in 
a study of 794 patients presenting to the emergency department (ED) with 
AECOPD.[156] Following discharge, the severity of self-reported dyspnoea predicts 
mortality.[58, 233, 263, 264]  
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2.2.2.4 PRIOR HOSPITALISATION AND EXACERBATION 
A previous hospitalisation for AECOPD,[114, 156] particularly if complicated by 
respiratory failure,[240, 248] has been shown by many to be an independent predictor 
of in-hospital mortality. However, Faustini et al [240] suggested a more complex 
relationship. They showed that two or more hospitalisations within the preceding two 
years, for AECOPD without respiratory failure, increased the risk of mortality after 
discharge but not during admission. In fact, in their retrospective review, individuals 
with no prior hospital admissions were at a greater risk of in-hospital death than of 
dying soon after discharge. The reasons for this are unclear. Individuals without 
previous hospitalisations may only seek medical attention during a severe 
exacerbation and hence have greater in-hospital mortality. It may also reflect the 
higher level of post-discharge support that is frequently offered to individuals with a 
past history of frequent admissions.  
Hospital admissions for COPD and for non-COPD, both before and after the index 
admission, have been shown to be independently predictive of short and long-term 
mortality following discharge.[14, 58, 242, 265, 266]  
2.2.2.5 SMOKING STATUS 
A retrospective cohort study of 786 elderly patients (mean age 75 years) admitted with 
AECOPD demonstrated that active smokers (tobacco smoking within the past 6 
months) had significantly higher in-hospital and post-discharge mortality.[242]  In 
individuals requiring admission to ICU, the poor prognostic effects of active smoking do 
not appear to persist.[248] Goel [267] suggested that a smoking history of greater than 
60 cigarette pack years was independently associated with long-term mortality 
following discharge for AECOPD. However, many other studies have failed to replicate 
these findings,[31, 33, 58, 125, 247, 249, 255] and the prognostic value of smoking 
status must therefore be questioned. 
A summary of the significant findings discussed so far is shown in Table 2.4.  
 
 Table 2.4     Summary of main prognostic indices associated with mortality following hospitalisation for AECOPD (Italics indicate - significance persists 
on multivariate analysis) 
Study Designa 
Outcomes & 
mortality 
rateb 
Sociodemographic 
details 
Pre-admission level of 
function 
QoL and 
psychological 
wellbeing 
Stable-
state 
dyspnoea 
Episodes of 
AECOPD 
Patil [239] 
Retrospective. 
n=71,130 
IHM – 2.5% 
Older age, male sex, 
higher income 
Admission from long-term 
care facility 
   
Roche [156] 
Prospective. 
ED attendees with 
AECOPD. n=794 
IHM – 7.4% Older age 
Home support / 
institutionalisation prior to 
admission 
 
More severe 
dyspnoea 
Previous 
hospitalisation  for 
AECOPD  
Ai-Ping [248] Retrospective. 
AECOPD requiring 
ICU. n=57 
IHM – 24.5% Older age    
Previous 
hospitalisation 
requiring IPPV 
Bustamente-
Fermosel [135] 
Retrospective. n=972 IHM – 6.4% Older age     
Murphy [260] 
Retrospective. 
Deaths secondary to 
AECOPD. n=60 
IHM  Poor performance status    
De la Iglesia 
[157] 
Prospective. n=284 IHM – 3.9%    
More severe 
dyspnoea 
 
Dransfield [114] Retrospective. n=825 IHM – 5.2% Older age    
Previous 
hospitalisation for 
AECOPD
>
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 Study Designa 
Outcomes & 
mortality 
rateb 
Sociodemographic 
details 
Pre-admission level of 
function 
QoL and 
psychological 
wellbeing 
Stable-
state 
dyspnoea 
Episodes of 
AECOPD 
Faustini [240] 
Retrospective. 
n=26,039 
IHM – 2.9% 
30-day 
mortality – 
3.6% 
Older age, male sex, 
admission to 
inappropriate ward* 
   
Previous 
hospitalisation for 
AECOPD 
Fruchter [242] 
Retrospective. Elderly 
patients with 
AECOPD. n=786 
IHM – 7.2% 
12-month 
mortality – 
28% 
Older age    
Subsequent 
hospitalisation for 
AECOPD 
Gunen [247] 
Prospective. n=205 
12-month 
mortality – 
33% 
Longer duration of disease 
(years) 
    
Roberts [254] 
Retrospective. 
n=1221 
3-month 
mortality – 
14% 
Older age 
Institutional care prior to 
admission, Worse 
performance status^ 
   
Almagro [58] Prospective. n=135 
12-month 
mortality – 
22% 
Older age, Unmarried 
High functional 
dependenceº / limitation 
in activity˜ 
Increased levels of 
depression 
  
Ranieri [250] 
Prospective. 
n=244 
6-month 
mortality – 
20% 
 
Increased functional 
dependence 
%
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 Study Designa 
Outcomes & 
mortality 
rateb 
Sociodemographic 
details 
Pre-admission level of 
function 
QoL and 
psychological 
wellbeing 
Stable-
state 
dyspnoea 
Episodes of 
AECOPD 
Yohannes [249] 
Prospective. 
Discharged following 
AECOPD. n=100 
12-month 
mortality – 
36% 
 
Increased functional 
dependence 
Depression, low 
quality of life 
 
Subsequent 
hospitalisation for 
AECOPD 
Groenewegen 
[15] 
Prospective. 
Discharged following 
AECOPD. n=171 
12-month 
mortality – 
23% 
Older age     
Gudmundsson 
[255] 
Prospective. 
Discharged following 
AECOPD. n=416 
2-year 
mortality – 
29.3% 
Older age, male sex 
More limitation in physical 
activity˜ 
Low quality of life  
≥ 2 hospitalisations 
in previous 12 
months 
Ng [262] 
Prospective. 
Discharged following 
AECOPD. n=376 
Mortality 
following 
discharge 
  
Increased levels of 
depression
‡
 
  
Chu [264] 
Prospective. AECOPD 
discharged following 
NIV. n=110 
12-month 
mortality – 
49% 
 
Increased functional 
dependenceº 
 
More severe 
dyspnoea 
Previous 
hospitalisations 
Antonelli-Incalzi 
[244] 
Prospective. 
Discharged following 
AECOPD. n=270 
Long-term 
mortality  
Older age     
Wildman [246] 
Prospective. AECOPD 
requiring HDU/ITU. 
n=832 
180-day 
mortality – 
37.9% 
Older age, male sex 
Increased functional 
dependence 
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 Study Designa 
Outcomes & 
mortality 
rateb 
Sociodemographic 
details 
Pre-admission level of 
function 
QoL and 
psychological 
wellbeing 
Stable-
state 
dyspnoea 
Episodes of 
AECOPD 
Tsimogianni 
[263] 
Prospective. 
Discharged following 
AECOPD. n=81 
3-year 
mortality – 
41% 
   
More severe 
dyspnoea 
 
Almagro [233] Prospective. 
Discharged following 
AECOPD. n=316 
3-year 
mortality – 
42.4% 
Older age   
More severe 
dyspnoea 
 
Kim [265] 
Retrospective. ED 
attendees with 
AECOPD. n=482 
60-day 
mortality – 9% 
Older age    
Previous 
hospitalisation for 
AECOPD 
McGhan [14] 
Retrospective. 
Discharged following 
AECOPD. n=51,353 
12-month 
mortality – 
21% 
Older age, male sex, non-
Caucasian ethnicity 
   
Previous 
hospitalisation for 
AECOPD 
a
 Study involves unselected patients admitted with AECOPD unless otherwise stated; 
b
 IHM – in-hospital mortality; † according to Anthonisen criteria; * inappropriate ward – non-
respiratory or non-ICU; ^ Performance status – assessment of ability to mobilise and perform self-care; º measured by Katz index;  measured by Yesavage scale; ˜ measured by 
SGRQ activity subscale; % measured by Barthel index; ~ only predictive of 12-month mortality; ‡ measured by Hospital Anxiety and Depression Scale; > during 7 year study period; 
QoL – quality of life; IHM – in-hospital mortality; ED – emergency department 
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2.2.2.6 MEDICATION AND OXYGEN THERAPY 
A number of authors have investigated the ability of medication taken at admission to 
predict in-hospital mortality with conflicting results (Table 2.5).  
Treatment with long term maintenance corticosteroids independently predicts higher 
in-hospital mortality in patients requiring treatment in ICU,[248] but has no impact on 
outcome in unselected patients with AECOPD.[156] However, in patients surviving to 
discharge, maintenance oral corticosteroid therapy independently predicts subsequent 
mortality.[15, 185, 242] Soyseth et al [245] suggested that treatment with statins 
reduced mortality following AECOPD but this was not a randomised controlled trial so 
the validity of its conclusions are uncertain.  
LTOT has been shown to be associated but not independently predictive of long-term 
mortality.[58, 135, 247] Some authors suggest LTOT may independently predict in-
hospital mortality,[157] whereas others suggest that it is a surrogate marker of disease 
severity.[156] 
2.2.2.7 COMORBIDITY 
In stable COPD, the comorbidity burden (usually measured by the Charlson 
Comorbidity Index (CCI), Table 17.1) is an established predictor of mortality.[194, 195, 
268] In AECOPD requiring hospitalisation, the evidence is less consistent; CCI was an 
independent predictor of death following discharge in one study,[58] but three others 
showed no independent association with either in-hospital [114, 239] or post-
discharge [250] mortality. However, specific comorbidities, most notably ischaemic 
heart disease,[242, 245, 251, 269, 270] congestive cardiac failure,[14, 114, 245, 265] 
chronic liver disease,[114] chronic renal failure [244] and diabetes,[33, 245, 255, 269] 
independently predict in-hospital mortality, post-discharge mortality or both. A 
possible explanation for this apparent paradox is that all the conditions listed above 
are particularly liable to acute decompensation, and hence increased mortality, and 
these more commonly occur during ill-health (such as during AECOPD) than clinical 
stability.  
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Further emphasizing this point, many authors have shown that acute comorbidity (for 
example, shock, pulmonary oedema, arrhythmia, stroke, renal insufficiency) is 
independently associated with a greater risk of in-hospital, and six-month, 
mortality.[135, 147, 161, 271, 272] In one study [259] of patients with AECOPD 
requiring intensive care, it was not the severity of respiratory failure that predicted 
mortality, but the development of non-respiratory organ failure. This association 
appears in a similar study by Seneff [258] where evidence of non-respiratory 
physiological derangement was significantly predictive of in-hospital death whereas 
derangement of respiratory physiology was not. 
The relevant findings are summarised in Table 2.5. 
 
 Table 2.5     Studies of AECOPD identifying an association between comorbidity or medication and mortality (Italics indicate - Significance persists on 
multivariate analysis) 
Study Design & patient groupa Outcomesb Mortality rate Comorbidity Medication  
Patil [239] Retrospective. n=71,130 IHM 2.5% CCI  
Dransfield [114] Retrospective. n=825 IHM 5.2% 
CCI, congestive heart failure, cerebrovascular 
disease, chronic liver disease 
Patients not in receipt of 
B-blockers 
Fruchter [242] 
Retrospective. 
Elderly medical admissions with 
AECOPD. n=786 
IHM and 6-year 
mortality 
7.25% in-
hospital 
Ischaemic heart disease, congestive cardiac 
failure 
Oral maintenance 
corticosteroids 
Bustamente-
Fermosel [135] 
Retrospective. n=972 IHM 6.4% 
Acute complication developed during hospital 
stay* 
LTOT 
Raurich [271] 
Retrospective. AECOPD requiring 
invasive ventilation. n=101 
IHM 25.7% MODS  
Liu [259] 
Retrospective. AECOPD requiring 
invasive ventilation. n=138 
IHM 39.9% MODS  
Scala [147] 
Prospective. AECOPD requiring NIV. 
n=120 
IHM 10% in-hospital Acute non-respiratory comorbidity  
Fuso [243] Retrospective. n=590 IHM 14.4% Previous myocardial infarction Digoxin 
Roche [156] 
Prospective. AECOPD attending 
ED. n=794 
IHM 7.4%  LTOT 
De la Iglesia [157] Prospective. n=284 IHM 3.9%  LTOT 
Ai-Ping [248] 
Retrospective 
AECOPD requiring ICU. n=57 
IHM 24.5% Cardiac disease 
Oral maintenance 
corticosteroids 
4
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 Study Design & patient groupa Outcomesb Mortality rate Comorbidity Medication  
Seneff [258] 
Prospective. AECOPD requiring 
intensive care 
IHM and 1-yr 
mortality 
24% IHM Acute non-respiratory comorbidity  
Faustini [240] Retrospective. n=26,039 30-day mortality 3.6% Total number of comorbidities >1  
Niewoehner [273] Prospective. n=271 30-day mortality 7%  Theophylline 
Molinos [161] 
Prospective. Admissions with 
AECOPD and pneumonia. n=244 
30-day mortality 9% Septic shock, acute renal failure  
Kim [265] 
Retrospective. ED attendees with 
AECOPD. n=482 
Early mortality 
9% 60-day 
mortality 
Congestive cardiac failure, metastatic cancer  
Ranieri [250] 
Prospective. n=244 
6-month 
mortality 
20% CCI  
Groenewegen [15] Prospective. n=171 1-year mortality 23%  
Oral maintenance 
corticosteroids 
McGhan [14] 
Retrospective. Discharged following 
AECOPD. n=51,353 
6-year mortality 21% 1-year 
Malignancy, pulmonary hypertension, heart 
failure 
 
Fruchter [251] 
Retrospective. Admissions with 
AECOPD with troponin measured. 
n=178 
Long-term 
mortality 
46% 3-year 
mortality 
IHD, chronic renal failure  
Almagro [58] 
Prospective. Discharged following 
AECOPD. n=135 
Long term 
mortality 
22% 1-year CCI 
LTOT, total number of 
drugs per day 
Soyseth [245] 
Retrospective. Discharged following 
AECOPD. n=854 
Long term 
mortality 
Not quoted 
IHD, congestive heart failure, atrial fibrillation, 
diabetes, venous thromboembolism, cancer 
Statins and inhaled 
corticosteroids reduce risk 
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 Study Design & patient groupa Outcomesb Mortality rate Comorbidity Medication  
Antonelli- 
Incalzi [244] 
Prospective. Discharged following 
AECOPD. n=288 
Long term 
mortality 
Median survival 
3.1 years 
Chronic renal failure, chronic liver disease, 
previous myocardial infarction 
 
Hallin [33] 
Prospective. Discharged following 
AECOPD. n=261 
2-year mortality 19% Diabetes  
Gudmundsson [255] Prospective. n=416 2-year mortality 29.3% Diabetes  
Brekke [269] 
Retrospective. Admissions with 
AECOPD and pneumonia. n=897 
Long-term 
mortality 
24.4% 1-year IHD, diabetes, malignancy  
a
 Study involves unselected patients hospitalised with AECOPD unless otherwise stated; 
b
 IHM – in-hospital mortality; * ‘acute complication’ undefined in study; CCI – Charlson 
Comorbidity Index; LTOT – long-term oxygen therapy; IHD – ischaemic heart disease; MODS – multi-organ dysfunction syndrome 
 
5
0 
51 
 
2.2.3 CLINICAL FINDINGS ON ADMISSION 
2.2.3.1 HISTORY AND EXAMINATION FINDINGS 
Cor pulmonale is independently associated with long-term mortality in patients 
hospitalised with AECOPD,[102, 270] and the presence of pedal oedema, which can 
imply the presence of cor pulmonale, is similarly independently associated with 
mortality following discharge.[102, 254] A single study [271] has shown cor pulmonale 
to be independently predictive of in-hospital mortality in patients requiring intensive 
care but others have found no association.[156] 
Roche et al [156] showed that, on admission to hospital with AECOPD, the presence of 
neurological impairment and the use of inspiratory accessory muscles both 
independently predicted in-hospital mortality. Neurological impairment (a reduced 
Glasgow Coma Scale, GCS) has repeatedly been found to independently predict in-
hospital mortality in patients requiring treatment on ICU or in those with co-existent 
pneumonia.[139, 150, 161, 274] 
In a prospective cohort study of 972 individuals hospitalised for AECOPD, Bustamante-
Fermosel [135] classified exacerbations using Anthonisen’s criteria (Table 1.5) as 
‘moderate to severe AECOPD’ (type 1 and type 2) and ‘mild AECOPD’ (type 3). This sub-
classification revealed that a moderate to severe exacerbation was independently 
predictive of in-hospital mortality. The mortality rate associated with a mild AECOPD 
was 0.3% compared to 9.3% in moderate and severe exacerbations (p < 0.05).   
2.2.3.2 BEDSIDE OBSERVATIONS  
A number of investigators have attempted to identify simple bedside physiological 
observations that are predictive of in-hospital mortality. Hypotension [150, 158, 161, 
275] and tachycardia [158] (measured within 24 hours of admission) have been shown 
to independently predict in-hospital mortality, whereas tachypnoea is only found to be 
an independent predictor in patients requiring assisted ventilation or in those with co-
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existent pneumonia.[138, 139, 161] Lower transcutaneous arterial oxygen saturation 
(SpO2) has been found to be associated with, but not independently predictive of, in-
hospital [247, 254] and 3 month [254] mortality. Seneff et al [258] showed that in 
patients requiring intensive care, non-respiratory physiological abnormalities (for 
example, heart rate, blood pressure, temperature) were strongly predictive of both in-
hospital and six-month mortality, whereas respiratory physiological abnormalities 
were predictive of six-month mortality alone. Similarly, Høiseth et al [252] showed 
tachycardia to be an independent predictor of long-term mortality following 
hospitalisation for AECOPD.  
Studies that demonstrate an association between clinical signs and mortality are 
summarized in Table 2.6: 
 
 Table 2.6     Clinical signs associated with mortality following admission for AECOPD (Italics indicate - significance persists on multivariate analysis) 
Study Designa Outcomesb 
Mortality 
rate 
Predictors of mortality 
Roche [156] 
Prospective. AECOPD attending ED. 
n=794 
IHM 7.4% 
Central cyanosis, pedal oedema, asterixis, expiratory use of abdominal muscles, 
neurological impairment, use of inspiratory accessory muscles 
Chandra [275] Retrospective. n=94 IHM 12.8% Central cyanosis, elevated JVP, hypotension 
Wildman [158] 
Retrospective. AECOPD or asthma 
requiring ICU. n=8,527 
IHM 35.5% Tachycardia, hypotension 
Confalonieri [139] 
Prospective. AECOPD requiring NIV. 
n=1,033 
Need for IPPV or 
death 
13.7% in-
hospital 
Neurological impairment, tachypnoea 
Chakrabati [138] Prospective. AECOPD requiring NIV. 
n=88 
Need for IPPV or 
death 
17% in-
hospital 
Tachypnoea 
Ucgun [150] 
Prospective. AECOPD requiring ICU. 
n=151 
IHM 33.1% Hypotension, neurological impairment 
Levy [276] 
Prospective. Patients requiring NIV 
with DNACPR order. n=114† 
IHM 57% Weak cough 
De la Iglesia [157] Prospective. n=284 IHM 3.9% Tachypnoea, reduced conscious level 
Bustamente-
Fermosel [135] 
Retrospective. n=972 IHM 6.4% Severity of exacerbation* 
Seneff [258] 
Retrospective. AECOPD requiring 
ICU. n = 362 
IHM and six-
month mortality 
23.8% IHM 
Non-respiratory physiological abnormalities, respiratory physiological 
abnormalities 
Roberts [254] Retrospective. n=1,400 
3-month 
mortality 
14% Pedal oedema, low transcutanoeous oxygen saturation 
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 Study Designa Outcomesb 
Mortality 
rate 
Predictors of mortality 
Terzano [270] 
Prospective. AECOPD surviving to 
discharge. n=288 
Long-term 
mortality 
19.4% 6-year Cor pulmonale 
Connors [102] 
Prospective. 
Admissions with AECOPD and 
hypercapnia. n=1,016 
6-month 
mortality 
33% Cor pulmonale ^, tachycardia 
Wildman [246] 
Prospective. AECOPD requiring ICU. 
n=832 
6-month 
mortality 
37.9% Glasgow Coma Score <8 
Høiseth [252] 
Prospective. n=99 
Long-term 
mortality 
Median 
survival = 2.3 
years 
Tachycardia 
a
 Study involves unselected patients hospitalised with AECOPD unless otherwise stated; 
b
 IHM – in-hospital mortality;  *for classification of severity – see above; ^ presence of ≥2 
of: pedal oedema; jugular venous distension; enlarged pulmonary arteries on CXR; ECG signs of RVH or RAE; ED – emergency department; ICU – intensive care unit; RVH – right 
ventricular hypertrophy; RAE – right atrial enlargement; JVP – jugular venous pressure; NIV – non-invasive ventilation; IPPV – invasive ventilation 
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2.2.3.3 ACUTE PHYSIOLOGY SCORES 
Markers of acute physiological derangement can be combined in to a composite 
measure of acute illness severity. Common examples of acute physiology scores 
include the APACHE II (Acute Physiology and Chronic Health Evaluation), MEWS 
(Modified Early Warning Score), SAPS (Simplified Acute Physiology Score), and CAPS 
(COPD and Asthma Physiology Score). These scores were, in general, developed for use 
in patients admitted to acute medicine or ICU, however their use in AECOPD has also 
been assessed. In various reports of patients with AECOPD requiring NIV or intensive 
care, APACHE II,[138-140, 248, 272] SAPS,[277] modified early warning score 
(MEWS),[260] and CAPS,[158] have been independently associated with in-hospital 
mortality.  
A study [258] of APACHE II in AECOPD requiring admission to ICU showed that 
respiratory physiological variables (respiratory rate, pH, PaCO2, PaO2, and alveolar-
arterial gradient) were not related to in-hospital mortality but did independently 
predict 6-month mortality. Variables related to non-respiratory system function, 
however, were strong independent predictors of both in-hospital and six-month 
mortality. This suggests that the main factor determining in-hospital mortality in the 
ICU setting is the development of dysfunction of other bodily systems, with the 
severity of the underlying respiratory condition more important in relation to long-
term prognosis. This is consistent with the data on comorbidity where non-respiratory 
conditions prone to acute decompensation during hospitalisation are stronger 
predictors of mortality during, rather than after, admission.  
2.2.4 INVESTIGATIONS 
2.2.4.1 NUTRITIONAL STATUS 
In stable COPD, poor nutritional status is associated with increased mortality.[35, 268, 
278] Studies assessing predictors of in-hospital mortality have been less frequently 
studied but have shown similar findings; low BMI [157, 247, 279] and low percentage 
of ideal body weight [280] are negative prognostic indices.  
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Hallin et al [33] prospectively analysed the BMI of 261 individuals discharged following 
AECOPD. They identified a ‘U-shaped curve’ relationship between BMI and mortality, 
whereby low BMI (<20 kgm-2) and obesity (BMI > 30kgm-2) were shown to be 
independently associated with mortality at 2 years, and overweight patients (BMI 25-
30) had the lowest risk of death. The protective effect of mild BMI elevation has been 
termed the ‘obesity paradox’ (section 1.1.3.1.2). The independent association between 
low BMI and post-discharge mortality is strong and has been confirmed in other 
prospective cohort studies.[102, 247, 250] Alternative measures of nutritional 
depletion, such as low mid arm muscle circumference [246] and unplanned weight loss 
[14] have also been shown to independently predict 180-day mortality. 
2.2.4.2 LUNG FUNCTION 
The forced expiratory volume in 1 second is a well established independent predictor 
of mortality in stable disease (low FEV1 = increased mortality).[26] However, in 
AECOPD, many studies are retrospective with a high proportion of missing spirometry 
data, potentially biasing results. For example, Baker et al [281] retrospectively 
identified 348 individuals admitted with AECOPD. Spirometric data (during a period of 
clinical stability up to two years prior to admission) were only available in 34% and low 
FEV1 did not predict in-hospital mortality. Similarly, Bustamente-Fermosel et al [135] 
only obtained spirometric data in a small minority and no association could be shown 
between FEV1 and in-hospital survival.  
The results from one study of patients treated with NIV [147] suggested that low FEV1 
was independently predictive of treatment failure (death or need for invasive 
ventilation), but others have found no such relationship.[145, 248, 282] The lack of 
consistency about the prognostic value of FEV1 is emphasised by one study [283] in 
which, counterintuitively, a higher baseline FEV1 was associated with higher in-hospital 
mortality.  
Studies investigating mortality following discharge typically contain fewer missing 
results. Despite this, there is still disagreement regarding the influence of FEV1 on 
mortality. A number of studies [31, 242, 244, 269, 270] have shown that individuals 
with low FEV1 are at increased risk of death following discharge, but others [15, 58, 
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247] have found no association. Closer analysis of the positive studies suggests that 
FEV1 is predictive of mortality either when very low (FEV1 < 590ml)[244] or when the 
population on average has relatively well preserved lung function (mean FEV1 ≈ 50% 
predicted).[242, 270] It is therefore likely that patients with the most severely 
impaired lung function have a higher likelihood of death, but FEV1 lacks discriminatory 
power because most patients hospitalised with AECOPD have severe COPD and a 
narrow range of FEV1.  
In the acute setting, spirometry is not one of the recommended investigations,[44] and 
it is infrequently performed. This has prompted investigators to investigate potential 
associations between mortality and peak expiratory flow rate (PEFR). De la Iglesia and 
colleagues [157] identified admission PEFR as an independent predictor of in-hospital 
mortality on multivariate analysis. Roberts [254] confirmed this finding but given that 
the majority of patients (54%) had missing PEFR data, this finding should be 
interpreted with caution. 
2.2.4.3 ARTERIAL BLOOD GASES 
2.2.4.3.1 HYPOXAEMIA 
In studies in which FiO2 is not standardised, it is not surprising that no relation between 
low PaO2 and mortality is found.[150, 242, 243, 248] However, hypoxaemia breathing 
air,[161, 247, 270] an increased alveolar-arterial gradient,[243] and a low PaO2 / FiO2 
ratio [102] are all independently associated with in-hospital or six-month mortality.  
2.2.4.3.2 HYPERCAPNIA 
In stable COPD, hypercapnia is a strong independent predictor of mortality.[48, 113, 
195] In all patients hospitalised with AECOPD, however, high PaCO2 values on 
admission have only been shown to predict in-hospital mortality in a single study,[279] 
whereas many other authors have failed to replicate this finding.[157, 243, 247, 258, 
272] In AECOPD requiring NIV, a very high PaCO2 is predictive of a combined outcome 
of treatment failure or death.[139, 284] Hypercapnia is likely to signify severe COPD as 
well as a severe acute exacerbation, and it may therefore appear surprising that it is 
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not consistently related to short term mortality. However, in many studies, the 
participants’ mean PaCO2 is high (often > 7kPa), which is likely to limit its discriminative 
value. A subgroup analysis of hospitalised patients with AECOPD, the majority of whom 
(82%) had PaCO2 < 6.0kPa, showed that hypercapnia independently predicted in-
hospital death,[161] and three further studies [161, 242, 247] with mean PaCO2 closer 
to normal (mean < 6.5kPa) showed an association between hypercapnia and in-
hospital mortality.  
The severity of hypercapnia on admission is more clearly related to long-term 
mortality.[15, 242, 251] Almagro et al,[58] however, suggested that hypercapnia at 
discharge, rather than admission, was the more important predictor, a proposal 
corroborated by a prospective cohort study [285]  which showed that individuals with 
hypercapnia at admission and discharge (‘irreversible hypercapnia’) had significantly 
higher 5-year mortality rates than those in whom hypercapnia resolved during their 
hospital stay. These findings support the recommendation by the British Thoracic 
Society that all patients with AECOPD complicated by respiratory failure should have 
ABG recorded before hospital discharge.[286]   
2.2.4.3.3 ACIDAEMIA 
Acidaemia usually implies a severe acute exacerbation of COPD. In AECOPD requiring 
hospitalisation, the severity of acidaemia predicts both in-hospital and 30-day 
mortality.[158, 254, 274, 287] Whilst it has not been shown to predict long-term 
mortality,[247, 264] the range of pH values in the relevant studies was narrow, which 
may have influenced results: one study involved patients with severe acidaemia (mean 
pH 7.24) requiring NIV,[264] while the other included few acidaemic patients (mean pH 
7.41).[247] 
2.2.4.4 BIOCHEMICAL & HAEMATOLOGICAL ANALYSIS  
In patients with severe AECOPD requiring treatment on ICU, low serum albumin 
identifies a group of individuals at increased risk of death in-hospital,[140, 158, 248] 
however in general patients with AECOPD, hypoalbuminaemia predicts mortality post-
discharge not in-hospital.[102, 247] In all patients hospitalised with AECOPD, renal 
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dysfunction,[158, 161, 288] and hyperglycaemia [138, 281] independently predict in-
hospital mortality. There is conflicting data surrounding the relationship between the 
presence of anaemia and the risk of death. Studies including individuals with 
pneumonia and AECOPD have shown an independent association between anaemia 
and mortality, both in-hospital [150] and following discharge.[250, 269] Other 
research, which excluded individuals with evidence of pneumonia, showed that the 
presence of anaemia does not predict death after admission for AECOPD.[248, 259, 
288] Anaemia may therefore act as a marker of severe pneumonia, in individuals with 
COPD, rather than severe AECOPD. Holland et al [289] showed, in a small retrospective 
study, that patients with eosinopenia on admission were at an increased risk of death 
compared to those with normal eosinophil counts, but important confounders were 
not included in their analysis and the findings have not yet been reproduced. 
Table 2.7 summarises the data regarding the association between biochemical and 
haematological indices and mortality following admission for AECOPD. 
 
 Table 2.7     Relationship between biochemical and haematological indices and mortality (Italics indicate - significance persists on multivariate 
analysis) 
Study Design & patient groupa Outcomesb 
Mortality 
rate 
Biochemical index associated 
with mortality 
Haematological index associated 
with mortality 
Baker [281] Retrospective. n=348 IHM 18% Hyperglycaemia  
Chakrabati 
[138] 
Prospective. AECOPD requiring NIV. n=88 Failure of NIV 17% Hyperglycaemia  
Wildman [158] 
Retrospective. ICU admissions with 
AECOPD or asthma. n=8527 
IHM 
35% in-
hospital 
Low sodium, high urea, high 
creatinine, hypoalbuminaemia 
WBC <4x10
9
, WBC >20x10
9
 
Holland [289] Retrospective. n=65 IHM 7.6%  Eosinopenia 
Ai-Ping [248] 
Retrospective. AECOPD requiring ICU. n=57 IHM 
24% in-
hospital 
Hypoalbuminaemia  
Ucgun [150] Prospective. AECOPD requiring ICU. n=151 IHM 33.1% 
Hypoalbuminaemia, elevated CRP, 
high creatinine 
Anaemia 
Baillard [290] Prospective. AECOPD requiring ICU. n=71 IHM 25% Elevated troponin  
Molinos [161] 
Prospective. Admissions with AECOPD and 
pneumonia. n=244 
IHM 9% Elevated creatinine  
Mohan [288] Prospective. n=151 IHM 25% 
High urea, creatinine. 
Hypoalbuminaemia, low sodium 
 
Rammaert 
[291] 
Prospective. AECOPD requiring IPPV. 
n=116 
Intensive care 
mortality 
25% Low HCO3
-
, elevated PCT Elevated WBC 
Chang [279] Prospective. n=250 
30-day 
mortality 
8.5% Elevated BNP, elevated troponin  
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 Study Design & patient groupa Outcomesb 
Mortality 
rate 
Biochemical index associated 
with mortality 
Haematological index associated 
with mortality 
Connors [102] 
Prospective. Admissions with severe 
AECOPD. n=1016 
180-day 
mortality 
33% 180-day Hypoalbuminaemia  
Ranieri [250] 
Prospective. Elderly admissions with 
AECOPD. n=244 
6-month 
mortality 
20% 6-month High cholesterol Anaemia 
Gunen [247] Prospective. n=205 
Long-term 
mortality 
33% 1-year Hypoalbuminaemia  
Brekke [269] 
Retrospective. n=897 
Long-term 
mortality 
24% 1-year Elevated troponin Anaemia 
a
 Study involves unselected patients hospitalised with AECOPD unless otherwise stated; 
b
 IHM – in-hospital mortality; WBC – white blood cell count; BNP – N-terminal pro-brain 
natriuretic peptide 
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2.2.4.5 MICROBIOLOGICAL ANALYSIS 
An infective agent was implicated in 78% of admissions to hospital with a severe 
AECOPD in one study.[133] However, in clinical practice, many patients suffer 
exacerbations where no pathogen can be identified. Mohan et al [288] and 
Bustamente-Fermosel [135] conclude that if a pathogenic organism is identified, there 
is an increased risk of in-hospital mortality. In a prospective cohort of patients 
requiring treatment with NIV, airway colonisation with gram-negative bacilli was 
associated with increased in-hospital mortality,[292] perhaps reflecting more severe 
disease and the development of secondary bronchiectasis. This is consistent with data 
from patients with stable disease where the isolation of non-usual pathogens 
(including gram-negative bacilli) was independently associated with long-term 
mortality.[232] 
2.2.4.6 CARDIAC INVESTIGATIONS 
In individuals with COPD, cardiovascular disease more frequently causes death than 
COPD itself.[55] The presence of atrial fibrillation or ventricular arrhythmias on the 
admission ECG was shown by Fuso et al [243] to be predictive of in-hospital death. 
Raurich et al [271] suggested that ECG evidence of cor pulmonale was associated with 
in-hospital death in patients with AECOPD undergoing mechanical ventilation. A 
prospective cohort study of 263 patients surviving AECOPD to discharge showed that 
individuals with ≥1 signs of cor pulmonale on ECG at discharge had an increased risk of 
long-term mortality.[293] It was also demonstrated that electrocardiographic evidence 
of right ventricular hypertrophy and right atrial overload, were independently 
predictive of long-term mortality. 
Impairment of left ventricular function (ejection fraction < 45% on transthoracic 
echocardiography) is also predictive of higher mortality following AECOPD.[135] 
Acute exacerbations result in significant physiological disturbance and place a 
significant burden on, what may be an already impaired, heart. Troponins are released 
by injured myocardial cells and act as a biomarker of myocardial damage. In patients 
admitted with AECOPD requiring admission to ICU, elevated troponin I was a strong 
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independent predictor of in-hospital death.[290] It is unclear whether it is the severity 
of the exacerbation, and resultant hypoxia and hypotension, which results in 
myocardial damage and increases mortality, or whether elevated troponin identifies a 
high risk subgroup of patients with co-existent cardiac disease and hence increased 
mortality. This study did not record any markers of acute heart failure and therefore 
the presence of coexistent cardiac disease may explain the elevated troponin and the 
increased mortality rates identified. Three further studies have shown that elevated 
troponin on admission predicts long-term mortality following discharge,[252, 269, 294] 
although two of these studies [269, 294] retrospectively studied patients hospitalised 
with AECOPD in whom a troponin was measured. Therefore, the unavoidable selection 
bias in these analyses means the findings need to be interpreted with caution and 
require additional prospective research.  
2.2.4.7 RADIOLOGICAL INVESTIGATIONS  
In individuals admitted to hospital with pneumonia, the presence of COPD has been 
found to be associated with increased in-hospital mortality,[161, 295, 296] and in 
AECOPD the presence of pneumonia is often seen to be a marker of a severe 
exacerbation. However, the relationship between pneumonia and mortality in patients 
with AECOPD has been infrequently studied. This is in part because the presence of 
radiographic consolidation on admission often precludes entry in studies of AECOPD. 
Two previous studies [135, 141] which have included unselected patients with 
AECOPD, including those with pneumonic exacerbations, have shown an association 
between pneumonia and mortality, but no independent relationship. A large 
retrospective study in patients with AECOPD showed that a diagnostic code of 
‘pneumonia-influenza’ was independently associated with an increased risk of death in 
hospital.[297] However, the diagnosis of COPD and the meaning of the diagnosis 
‘pneumonia-influenza’ are uncertain and therefore the true relationship between 
pneumonia and mortality in AECOPD remains unestablished. A single prospective study 
showed radiographic evidence of coexistent left ventricular failure to be independently 
predictive of long-term mortality.[252] 
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2.2.5 DEVELOPMENTS DURING HOSPITAL ADMISSION 
Several authors have shown that the development of acute non-respiratory medical 
complications during the hospital stay is associated with increased in-hospital and 
post-discharge mortality. This has been discussed in section 2.2.2.7. 
Antonelli-Incalzi [244] showed that a longer hospital stay (highest quartile versus 
lowest quartile) independently predicted long term mortality following discharge. The 
location of care has also been found to be a predictor of in-hospital and 30-day 
mortality in a large retrospective study.[240] In the latter study, admission to wards 
other than respiratory or ICU (for example, general medicine, elderly care and surgical 
wards) occurred in 85% of cases and was associated with an increased risk of in-
hospital mortality independent of confounders. This is relevant to current UK practice 
where only 30% of patients are admitted under the care of a respiratory or ICU 
physician.[12]  
2.2.6 PREDICTING MORTALITY IN AECOPD TREATED WITH ASSISTED 
VENTILATION 
In the discussion above, indices which predict outcome in AECOPD requiring 
ventilatory assistance have not been separated from those which predict outcome in 
patients with AECOPD without respiratory failure. This is because AECOPD requiring 
NIV is now commonly managed on general respiratory or medical wards and should be 
viewed as a severe variant of AECOPD but not as a different entity. Also, in a patient 
hospitalised with AECOPD, all of the indices discussed above are potentially relevant. 
However, once a patient has developed acidaemic respiratory failure requiring 
ventilatory assistance, it is important to consider specific prognostic variables for this 
patient group.   
Although some agreement between prognostic studies in exacerbations requiring 
assisted ventilation is found, there have been few robust prognostic markers 
identified. This reflects differences in participants’ disease severity, and in the study 
outcomes used. Furthermore, typically a composite outcome of either need for 
invasive ventilation or death is used and given that there are frequently a small 
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number of deaths, the prognostic factors probably predict the need for invasive 
ventilation rather than mortality.  
In general, factors that identify the degree of physiological derangement during the 
acute exacerbation predict higher in-hospital mortality following NIV. For example, 
higher APACHE II scores,[139, 144] lower conscious level [139, 150] and worse 
respiratory acidosis [282, 284] are all independently associated with increased 
mortality. Furthermore, complications during the hospital stay [147, 298] and 
comorbidity [142, 150] were also predictive of in-hospital mortality. 
Interestingly, Levy et al [276] identified higher admission PaCO2 as protective against 
mortality and Anton et al [283] report that patients with lower FEV1 had better 
outcomes following NIV than those with higher values. These two findings are at odds 
with other studies and also suggest that those with more severe underlying disease 
have better outcomes. However, it is difficult to apply the findings by Levy to 
individuals with AECOPD given that only 30% of the study population were receiving 
NIV for AECOPD. This surprising result of Anton et al may be because, in their study, 
patients with less severe COPD (i.e. a higher FEV1) being treated on intensive care may 
have been experiencing a more severe acute illness and hence at a higher risk of 
treatment failure (i.e. patients with higher FEV1 and milder exacerbations have been 
selected out because they did not require intensive care), whereas patients with lower 
FEV1 may be pushed in to respiratory failure, and therefore require intensive care, by a 
relatively less severe acute illness and therefore be at a lower risk of death. 
Few studies have examined predictors of long-term mortality in patients requiring 
assisted ventilation however they suggest that medical complications,[147, 298] severe 
stable-state dyspnoea,[264] older age,[266] and frequent prior health resource use 
[264, 266] are all predictive of mortality following discharge.  
Table 2.8 summarises the key findings of the research investigating predictors of 
mortality in patients requiring NIV for AECOPD. 
 
 Table 2.8     Predictors of mortality following treatment of AECOPD with assisted ventilation (Italics indicate - Significance persists on multivariate 
analysis) 
Study Designa Outcomeb Mortality rate Factors associated with worse outcome 
Confalonieri [139] Prospective cohort. n=1,033 IHM or need for IPPV 13.7% IHM 
Older age, high APACHE II, high PaCO2, high RR. Low GCS, low pH, low 
PaO2/FiO2 
Scarpazza 
[299] 
Prospective cohort. AECOPD with 
ARF and DNACPR order. n=62 
IHM 12.9% IHM Older age, high APACHE II, low GCS, pH (after 1 hour) 
Plant [284] RCT. n=236 IHM or need for IPPV 10% IHM Low pH, high PaCO2, reduced PaO2 
Levy [276] 
Prospective. Patients requiring 
NIV with DNACPR order. n=114† 
IHM 57% IHM Weak cough, low PaCO2 
Schettino [277] Prospective. Patients requiring 
NIV with DNACPR order. n=137† 
IHM 64.9% IHM High SAPS, high WBC, high HR. Low GCS, low haematocrit, low albumin 
Ai Ping [248] 
Retrospective. AECOPD requiring 
ICU. n=57 
IHM 24% IHM 
Older age, previous IPPV, low albumin, high APACHE II, low FEV1, cardiac 
comorbidity 
Baillard [290] 
Prospective. AECOPD requiring 
ICU. n=71 
IHM 25% IHM Elevated troponin, high SAPS, low GCS 
Rammaert [291] 
Prospective. AECOPD requiring 
IPPV. n=116 
Intensive care 
mortality 
25% High SAPS, MODS, low HCO3
-
, elevated PCT, elevated WBC 
Ambrosini [282] Retrospective. n=59† IHM or need for IPPV 8.5% IHM 
Reduced weight, impaired neurological status, high APACHE II, poor 
compliance with NIV, low pH 
Anton [283] Prospective. n=44† IHM or need for IPPV 20% IHM Impaired consciousness, high FEV1 
Soo Hoo [171] Prospective. n=14 NIV failure or IHM Not specified Edentulous, radiological consolidation, poor compliance with therapy 
Putinati [144] Retrospective. n=75 IHM or need for IPPV 11.8% IHM Low weight, high APACHE II, low albumin, low pH, high PaCO2 
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Ucgun [150] 
Prospective. AECOPD requiring 
ICU with ARF. n=151 
IHM 33% IHM 
Comorbidity, hypotension, cardiac arrhythmia, low GCS, high APACHE II, 
low haemoglobin, elevated creatinine, high CRP, low pH, low HCO3
-
, 
complication of ventilation, pneumonia, low PaCO2 
Mohan [142] 
Prospective. AECOPD requiring 
ICU. n=116 
IHM 16.7% IHM Comorbidity, tachycardia, hypoalbuminaemia, acidaemia, pneumonia 
Carratu [274] Prospective. n=122  Failure of NIV or IHM 12% Medical complication, pneumonia, CKD 
Chakrabati [138] Prospective. n=88 Failure of NIV or IHM 17% Age, high blood glucose, tachypnoea, high APACHE II score, low pH 
Jeffrey [287] 
Prospective. AECOPD with ARF. 
n=139 
IHM 12% Low pH, high urea, low blood pressure 
Roberts [146] Retrospective. n=1077 IHM 25% Increased time from admission to need for NIV, tachypnoea, Low HCO3
-
 
Liu [259] 
Retrospective. AECOPD requiring 
IPPV. n=138 
IHM 39.9% Comorbidity, high APACHE II score, low pH, sepsis, MODS 
Scala [147] Prospective. n=159 
Failure of NIV or IHM 
and 6-month mortality 
16% IHM. 35.3% 
6-month 
Presence of acute comorbidity* , low FEV1, non-cardiovascular 
comorbidity,‡ inability to perform ADL‡ 
Fernandez [298] 
Retrospective. ICU admissions 
requiring NIV. n=233† 
IHM and 6-month 
mortality 
33% IHM DNACPR order, Acute renal failure, need for vasoactive drugs 
Seneff [258] 
Retrospective. AECOPD requiring 
ICU. n = 362 
IHM and 6-month 
mortality 
23.8% IHM 
Increased age, length of hospital stay (prior to ICU admission), abnormal 
non-respiratory physiology, abnormal respiratory physiology. 
Raurich [271] 
Retrospective. AECOPD requiring 
ICU. n=101 
IHM and 2-yr mortality 25.7% IHM Older age, cor pulmonale, cardiac arrhythmia, MODS 
Chu [264] Prospective. n=110 
Mortality after 
discharge 
49% 1-year MRCD 4-5, LTOT, low BMI, high prior health resource use 
6
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Echave-Sustaeta 
[266] 
Prospective. n=120 Long-term mortality 52.7% 19-month 
Prolonged length of stay, older age, low pH, high PaCO2, low FEV1, high 
prior health resource use, domiciliary NIV 
Wildman [246] 
Prospective. AECOPD or asthma 
treated on ICU. n=832 
180-day mortality 37.9% 
Older age, Male sex, length of hospital stay, reduced functional status, 
low mid arm muscle circumference, AF, GCS 
a
 Study involves unselected patients hospitalised with AECOPD requiring NIV unless otherwise stated; 
b
 IHM – in-hospital mortality; *acute comorbidity – e.g. shock, acute renal 
impairment, anaemia, hyponatraemia. †includes patients with and without AECOPD; ‡ only predictive of 6-month mortality 
SAPS – simplified acute physiology score; RR – respiratory rate; GCS – Glasgow coma score; DNACPR – do not attempt cardiopulmonary resuscitation; WBC – white blood cell 
count; LTOT – long term oxygen therapy; BMI – body mass index; ADL – activities of daily living; ARF – acidaemic respiratory failure; IPPV – invasive ventilation; MODS – multiorgan 
dysfunction syndrome; PCT – procalcitonin; NIV – non invasive ventilation; AF – atrial fibrillation 
6
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2.2.7 CLINICAL PREDICTION TOOLS 
In stable disease, clinical prediction tools, such as the BODE index (Table 2.2), have 
been shown to be valuable prognostic tools that help guide management, but their 
application to the population hospitalised with AECOPD is uncertain. Some 
investigators have attempted to develop clinical prediction instruments in AECOPD but 
most of the tools have not been validated outside the derivation cohort. Furthermore, 
many studies have investigated a highly selected group of patients (for example, 
patients requiring intensive care), and therefore their conclusions may not be relevant 
to practitioners working outside this environment. The relevant findings of this 
research are described below and summarised in Table 2.9. 
Wildman et al developed two prognostic instruments to aid prediction of in-hospital 
[158] and six-month mortality [246] from two large cohorts of patients with acute 
exacerbations of COPD or asthma admitted to an ICU. The COPD and Asthma 
Physiology Score (CAPS) was developed for the prediction of in-hospital mortality and 
uses the following physiological indices: heart rate; mean arterial pressure; pH; 
sodium; urea; creatinine; albumin; WBC. Each variable is assigned a score resulting in a 
total score out of 100. Higher scores are associated with worse in-hospital mortality. 
The discriminating ability of CAPS (area under receiver operator characteristic curve 
(AUROC) = 0.72), with regard to in-hospital mortality, exceeded that of APACHE II 
(AUROC = 0.66). However, the retrospective methodology resulted in significant 
missing data with results for urea and albumin being absent for 14-32%. The authors 
assumed that missing values were within the normal range and therefore the final 
model may overestimate, or underestimate, the risk of mortality. The prognostic tool 
aimed at predicting six-month mortality included the following variables: CAPS; male 
sex; functional limitation; presence of atrial fibrillation; days spent in hospital; age; mid 
arm circumference; and GCS. The final model performed well (AUROC = 0.76) and both 
of the above tools showed good discrimination in their derivation cohorts and both 
underwent internal validation. However, their utility in a population of patients 
hospitalised with AECOPD not requiring intensive care is uncertain. 
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Roche et al [156] aimed to develop a clinical prediction tool in individuals presenting to 
the Emergency Department with AECOPD. The instrument that they developed was 
based upon: patient age; the number of ‘clinical signs of severity’ (defined by authors); 
and the level of dyspnoea. This model demonstrated good discrimination for mortality 
in both the derivation (AUROC = 0.79), and validation cohorts (AUROC = 0.83). The 
investigators were however hampered by slow recruitment which may have led to 
recruitment bias and the subjective nature of their pre-defined ‘clinical signs of 
severity’ means that application of such an instrument will vary from institution to 
institution, and from doctor to doctor. 
Tabak et al [155] retrospectively identified almost 90,000 admissions with AECOPD 
from 191 hospitals and developed the BAP-65 (Blood urea nitrogen >25 mg/dL (≡ 
serum urea > 8.9 mmol/L), Altered mental status, Pulse rate >109/min, Age >65 years). 
On external validation in a second large retrospective cohort [300] this tool was found 
to be a good discriminator for in-hospital mortality (AUROC = 0.77). However, the 
accuracy of the diagnosis of AECOPD in this study is uncertain: patients were identified 
using admission coding data which is known to prone to error;[301] and no smoking 
history or spirometric confirmation of airflow obstruction was obtained from patients. 
Furthermore, the population studied were considerably less unwell than the 
population of patients hospitalised in the UK, according to the National COPD Audit: 
2.1% of patients received ventilatory assistance compared to 12% in the UK National 
Audit.[12]  
Ruiz-Gonzalez et al [221] investigated variables associated with a composite outcome 
of: mortality (in-hospital or 15 days following discharge); need for ICU care; or 
development of acute cardiac failure. The instrument has not been validated and the 
small number of deaths recorded (21) suggest that it is probably a stronger predictor 
of the other outcomes than of mortality. 
The CURB-65 tool is a well validated, simple to use, instrument that accurately predicts 
morbidity and mortality in individuals presenting to hospital with community acquired 
pneumonia (section 1.2.4).[160] Chang and colleagues,[163] suggest that this 
instrument may be of prognostic value in AECOPD without complicating pneumonia. 
They showed that CURB-65 was independently predictive of 30-day mortality after 
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adjusting for other common prognostic indices, and that CURB-65 had good 
discrimination for 30-day mortality (AUROC = 0.73). External validation of these results 
is needed prior to their introduction to clinical practice. 
Mohan et al [288] attempted to predict in-hospital mortality in a population of 
unselected admissions with AECOPD. In this prospective study, a simple instrument 
based upon serum creatinine and sodium levels on admission was produced. This 
equation produced showed good discriminating properties with AUROC = 0.73. 
However, no validation cohort was included and therefore it is unclear whether this 
prognostic tool is applicable outside of this study population. 
Connors [102] analysed 1016 patients admitted with AECOPD and paCO2 > 6.65 kPa. A 
formula aimed at predicting six-month mortality following discharge was developed. It 
was based upon: APACHE II score; age; paO2 / FiO2; BMI; albumin; cor pulmonale; and 
comorbidity. The model demonstrated fair discrimination in the subsequent validation 
by the same authors (AUROC = 0.731) but there has been no external validation. 
A small study [263] describing a prognostic tool aimed at predicting three-year 
mortality based on BMI and MRCD (Table 1.1) showed promise in its derivation cohort, 
but has not been externally validated. 
A prediction score based on the following five variables: chronic renal failure; ECG 
evidence of RVH; FEV1 < 590ml; ECG signs of IHD; and age was found to be predictive 
of five-year mortality following discharge for AECOPD (sensitivity 63%, specificity 
77%).[244] This instrument has not been validated. 
Anton and colleagues [283] attempted to develop a prediction equation to help predict 
failure of treatment in individuals requiring NIV. An equation based upon: change in pa-
CO2 on NIV; initial pH; baseline FEV1; and initial paCO2 was shown to have an optimal 
sensitivity of 0.97 and a specificity of 0.9. However, there were only a small number of 
individuals in both the derivation cohort (n = 44) and the validation cohort (n = 15) and 
therefore this predictive tool should be used with caution. Confalonieri et al [139] 
developed a clinical prediction tool to help risk stratify patients with AECOPD requiring 
NIV. 1,033 individuals were prospectively identified and, on multivariate analysis, pH, 
respiratory rate, APACHE II score, and GCS were all significantly associated with 
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treatment failure and death and were therefore included in the prediction tool. The 
prognostic model had a high discriminative capability (AUROC = 0.88) and encouraging 
results from an external validation (AUROC = 0.83), but it is important to note that the 
outcome for both of the above studies was ‘failure of NIV’ and therefore it is not 
possible to use these tools to solely predict mortality in AECOPD.  
 
 Table 2.9     Summary of the clinical prediction tools developed for predicting mortality following hospitalisation for AECOPD 
Study Design‡ Outcome Variables included in model Discrimination Validated? 
Wildman [158] Retrospective. ICU admissions. IHM 
Heart rate, blood pressure, pH, sodium, urea, 
creatinine, albumin, WBC 
AUROC = 0.718 
Yes. Internal 
validation 
Tabak [155] Retrospective IHM 
blood urea concentration, altered mental status, pulse 
rate >109/min, age >65 years 
AUROC = 0.72 
Yes. External 
validation 
Roche [156] 
Prospective ED attendances 
with AECOPD 
IHM Age, clinical signs of severity, dyspnoea grade AUROC = 0.79 
Yes. Internal 
validation 
Mohan [288] Prospective. IHM Serum creatinine, serum sodium AUROC = 0.73 No 
Wildman [246] 
Prospective. AECOPD or asthma 
treated on ITU or HDU 
Six-month 
mortality 
CAPS, age, male sex, mid arm circumference, functional 
impairment, atrial fibrillation, length of stay, GCS 
AUROC = 0.75 
Yes. Internal 
validation 
Connors [102] Prospective admissions with 
severe AECOPD 
Six-month 
mortality 
APACHE III, age, PaO2/FiO2, BMI, level of disability*, 
albumin, CHF, cor pulmonale, comorbidity 
AUROC = 0.731 
Yes. Internal 
validation 
Tsimogianni[263] Prospective. 3-yr mortality BMI, MRC Dyspnoea score AUROC = 0.83 No 
Antonelli-Incalzi 
[244] 
Prospective discharges following 
AECOPD 
Five-yr 
mortality 
Age, ECG evidence of RVH, ECG evidence of IHD, 
chronic renal failure, FEV1 
Sensitivity 63%, 
specificity 77%
†
 
No 
Ruiz-Gonzalez [221] Prospective. 
Mortality or 
need for ICU 
Confusion, CRP ≥ 50mg/L, ≥ 2 comorbidities, current 
smoking status 
AUROC = 0.80 No 
Anton [283] 
Prospective. AECOPD requiring 
NIV 
Failure of NIV 
Change in PaCO2 on NIV, initial pH, baseline FEV1, and 
initial PaCO2 
Sensitivity 0.97, 
specificity 0.9
† 
Yes. Internal 
validation 
Confalonieri [139] 
Prospective. AECOPD requiring 
NIV 
Failure of NIV pH, respiratory rate, APACHE II score, GCS AUROC = 0.88 
Yes. External 
validation 
* assessed by Katz ADL score; ‡ unselected admissions with AECOPD unless otherwise stated; † for optimum cut-off 
IHM – in-hospital mortality; CAPS – COPD and asthma physiology score; ADL – activities of daily living; BMI – body mass index; WBC – white blood cell count; CHF – congestive 
heart failure; IHD – ischaemic heart disease; RVH – right ventricular hypertrophy; GCS – Glasgow Coma Score 
7
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2.2.8 SUMMARY OF PROGNOSTICATION FOLLOWING HOSPITALISATION FOR 
AECOPD 
A vast array of prognostic indices associated with mortality following admission for 
AECOPD has been identified. However, some indices appear to be of value in 
predicting both in-hospital and post-discharge mortality: older age; previous 
admissions for AECOPD; and comorbidity (although acute comorbidity appears to 
predict in-hospital mortality, whereas the overall comorbidity burden appears to be a 
stronger predictor of mortality following discharge). 
Clinical practice is often influenced by the assumption that patients with more severe 
underlying disease are likely to have worse in-hospital outcomes. For example, 
decisions regarding appropriateness of invasive ventilation are often made on the 
basis of the severity of COPD. In general, the results from the studies discussed above 
support this approach. Although some well-established markers of disease severity 
such as low FEV1 or hypercapnia have not routinely been found to predict in-hospital 
mortality, their discriminative value may be limited by the narrow range seen in the 
hospitalised population, most of whom have severe COPD. However, other variables 
reflecting severe underlying disease (i.e. the number of prior hospitalisations for 
AECOPD; the severity of dyspnoea; and low BMI) do have an important influence on in-
hospital mortality, confirming the hypothesis that patients with more severe 
underlying disease are more likely to die in hospital. 
Although in-hospital mortality is related to the severity of underlying disease, the main 
influence on in-hospital mortality appears to be the severity of the acute illness. 
Markers of acute physiological impairment, especially non-respiratory variables, acute 
non-respiratory comorbidity or organ dysfunction, and the presence of acidaemia are 
all strong independent predictors of in-hospital mortality.  
If patients survive to discharge, the severity of the acute illness has less impact on 
subsequent mortality with the severity of the underlying disease (low FEV1, severe 
dyspnoea, low BMI etc) becoming the more important factor. Functional disability and 
impairment of quality of life also independently predict long-term mortality. 
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Despite some agreement regarding prognostic indices, it has not been possible to 
combine the identifiable prognostic indices in to a clinical prediction tool that is both 
applicable outside of the study population and easy to use, and as a result, clinicians 
remain unable to risk-stratify patients according to their risk of death.  
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CHAPTER 3 PREDICTING HOSPITAL READMISSION FOLLOWING ADMISSION 
FOR ACUTE EXACERBATIONS OF COPD 
Readmission following discharge from hospital for AECOPD is common and has been 
reported to occur in 34% of patients within three months,[254] and in up to 87% of 
patients within 1 year.[14, 15, 302, 303]  
Several authors have investigated the risk of hospitalisation in stable COPD,[25, 57, 
115, 199, 304] but few have studied variables associated with a high rate of 
readmission following hospitalisation for AECOPD. Clearly this is of importance to 
clinicians managing AECOPD in hospital and the available data are reviewed below. 
Table 3.1, Table 3.2 and Table 3.3 provide a summary of the important research in this 
area.  
3.1 SOCIODEMOGRAPHIC FACTORS 
Sociodemographic variables independently predictive of hospital readmission in 
patients admitted to hospital with AECOPD include: older age,[14, 305, 306] male 
sex,[14, 307] admission from a nursing home,[308] and being unmarried or 
widowed.[309] Cao et al [307] suggested that it is not age that independently predicts 
readmission, but prolonged disease duration (>5 years). 
3.2 PREVIOUS ADMISSIONS AND SEVERITY OF UNDERLYING DISEASE 
Consensus exists regarding the predictive value of some indices. The number of 
previous admissions (typically within the previous 12 months), for both respiratory and 
non-respiratory illnesses, has been repeatedly shown to independently predict 
readmission.[14, 254, 264, 303, 308, 310] The severity of underlying disease, measured 
by FEV1,[306, 307, 311] or by the presence of cor pulmonale,[312] has also been 
shown to be independently predictive of readmission. Hypercapnia, another marker of 
the severity of underlying disease, was suggested by Almagro [310] to be 
independently predictive of readmissions, although Groenewegen [15] and Costello 
[285] could not identify an association. However, there was an important difference in 
the severity of hypercapnia between Almagro’s study (mean PaCO2 ≈ 5.8kPa) and 
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Groenewegen’s and Costello’s (mean PaCO2 = 6.74kPa and 6.79kPa respectively). The 
discriminative effects of hypercapnia in predicting readmission may therefore have 
been lost in these two negative studies because they involved a group of individuals 
who were, on average, already hypercapnic. It is not possible, therefore, to dismiss 
hypercapnia as not being predictive of readmission. The association between 
dyspnoea severity and readmission has been infrequently studied and no authors have 
identified an independent relationship, although five studies have shown a univariate 
association with readmission.[264, 307, 310, 313, 314] 
3.3 HEALTH RELATED QUALITY OF LIFE, PSYCHOLOGICAL WELLBEING AND 
FUNCTIONAL IMPAIRMENT 
Prospective cohort studies have identified that individuals with low health status 
(measured by SGRQ) are at significantly increased risk of readmission during the 
following year compared to patients with better quality of life. Stehr et al [315] 
showed that patients who had recently been bereaved were more likely to be 
rehospitalised. Osman [316] prospectively followed up 266 individuals discharged 
following AECOPD for 12 months. SGRQ was recorded for each individual during 
admission. No significant difference was found in the total SGRQ score in survivors and 
non-survivors but all components of the SGRQ (symptoms, activity and impacts) were 
independently associated with readmission within 12 months (high scores on SGRQ 
increased risk of readmission). Gudmundsson [305] undertook a similar prospective 
cohort study and identified the SGRQ activity and symptom subscores as being 
significantly associated with readmission within 1 year. It was also shown that in 
individuals with low health status, the presence of anxiety (Hospital Anxiety and 
Depression Scale (HADS) anxiety > 8) identified a subgroup with significantly increased 
rates of readmission. Depression, although frequently prevalent in individuals 
discharged from hospital following AECOPD, has not been shown to independently 
predict readmission [157, 309] even in those with underlying poor health status as 
measured by SGRQ.[305] This contrasts with data investigating mortality where 
depression has been shown to predict death. It has been hypothesised that a 
depressed individual’s hopelessness and lack of motivation to change their 
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circumstances result in not seeking medical attention when unwell, thus reducing the 
readmission rates but increasing the risk of mortality following discharge.[262] 
Functional impairment, as measured by an inability to manage ADLs or self care 
without assistance, has been shown to independently predict readmission.[254, 264, 
308] 
3.4 COMORBIDITY 
Although a relationship between comorbidity and hospital readmission exists, it differs 
from that seen when mortality is the outcome of interest.  
Coexistent asthma or cardiac comorbidities, including pulmonary hypertension, are 
independently predictive of readmission [14, 302] whereas, diabetes is apparently 
protective.[14] These findings contrast with those on mortality where the coexistence 
of diabetes is associated with a higher mortality [33] and asthma is protective.[14] 
Perhaps the extensive community support available for patients with diabetes ensures 
that episodes of AECOPD are recognised and treated promptly, with hospital admission 
thereby averted. Most studies have found no relationship between the comorbidity 
burden, measured using CCI (Table 17.1), and readmission,[15, 310] although a single 
study did identify a independent relationship.[306] However, alternative measures of 
the burden of comorbid conditions (the total number of comorbidities, and alternative 
comorbidity scoring tool, the Chronic Disease Score)[317] are stronger predictors of 
readmission.[309, 318] Possibly, the prognostic influence of individual comorbidities 
included in the CCI conflicts, in a similar way that asthma and diabetes conflict, and 
this may explain why the CCI does not appear to have a strong relationship with 
readmission.  
3.5 OTHER ASSOCIATIONS WITH HOSPITAL READMISSION 
BMI is a strong independent predictor of mortality in both stable COPD and AECOPD, 
but low BMI is not independently predictive of hospital readmission.[15, 34, 264, 303, 
307, 310, 312, 319] High respiratory muscle load (measured by the Pressure Time 
Index) at discharge independently predicts readmission,[312] and low fat free mass 
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and muscle mass are associated with rehospitalisation within 3 months, but not 
independent of other variables.[34]  
At discharge, patients prescribed high dose inhaled corticosteroids;[308] oral 
theophylline;[185] and maintenance oral corticosteroids [15, 185, 303] are at an 
increased risk of hospital readmission, independent of other variables. LTOT 
independently predicts hospital readmission,[312, 320] and home nebulised 
bronchodilators [254, 305] and inhaled anticholinergics [303] have been shown to be 
associated with readmission, although the relationship is not independent of other 
variables and other studies have not confirmed these findings.[185, 305]  
3.6 CLINICAL PREDICTION TOOLS FOR HOSPITAL READMISSION 
Although risk factors for hospital readmission in patients admitted with AECOPD have 
been identified, no clinical prediction tools have been developed. This is in contrast to 
the population of hospitalised adult general medical patients where many attempts at 
developing clinical prediction tools for readmission have been made. In the hospitals 
where this study was conducted, two readmission prediction tools were commonly 
used to assist decisions regarding resource allocation: the LACE [321] and PARR [322] 
predictive tools. The LACE (Length of stay, emergent Admission, Comorbidity, visits to 
the Emergency department within the previous six months) tool was developed in 
Canada on a large, prospectively recruited cohort (n = 4812) of patients surviving a 
hospital admission. The tool is simple to use and underwent external validation 
although it was shown to only have moderate discrimination for 30-day readmission or 
death (AUROC = 0.684). The PARR (the Patients At Risk for Rehospitalisation) tool was 
developed in the United Kingdom on a retrospective sample of 24,276 patients 
discharged following hospitalisation due to a chronic medical condition (including 
COPD). The discrimination of this tool for 12-month readmission was moderate 
(AUROC = 0.685) and its clinical utility is limited by the complex risk calculation 
required and its reliance on data not routinely available during hospital admission.  
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3.7 SUMMARY OF THE LITERATURE PREDICTING READMISSIONS 
A summary of the literature that identifies predictors of readmission is detailed in 
Table 3.1 to Table 3.3. In all tables, emphasis with italics indicates that the variable was 
a significant predictor of readmission on multivariate analysis. 
 
 Table 3.1     Factors associated with hospital readmission – Sociodemographic details, health related quality of life and functional status  
Study Designa 
Readmission 
rate 
Sociodemographic factors 
Quality of life & psychological 
wellbeing 
Functional status 
McGhan [14] Retrospective. n=51,353 25% 1-year Increasing age, male sex   
Lusuardi [306] Prospective. n=931 17.7% 6-month Increased age   
Cao [307] Retrospective. n=186 67% 1-year 
Male sex, prolonged disease 
duration 
  
Groenewegen [15] Prospective. n=171 55% 1-year Younger age   
Wong [309] Retrospective. n=109 Not specified Unmarried   
Lau [308] Retrospective. n=551 59% 1-year NH residency  Dependence in self care 
Gudmundsson [305] Prospective. n=416 61% 1-year Increasing age High SGRQº, high anxiety levels^  
Vega Reyes [320] Prospective. n=93 40% 1-year  High SGRQº (activity component)  
Osman [316] Prospective. n=266 41% 1-year  High SGRQº (all components)  
Almagro [310] Prospective. n=129 58% 1-year  High SGRQº (all components)  
Stehr [315] Retrospective. n=33 Not specified  Recent bereavement  
Roberts [254] Retrospective. n=1,221 34% 3-month   Dependence in self care 
Chu [264] 
Prospective. AECOPD 
requiring NIV 
80% 1-year   
Reduced functional 
status* 
Garcia-Aymerich [303] Prospective. n=340 63% 1-year  Low QoL Low physical activity 
Italics indicate that variables is an independent predictor of readmission on multivariate analysis; 
a
 Study involves unselected patients with AECOPD surviving to discharge unless 
otherwise stated; * low Katz ADL score; ^ significant only in individuals with low health status (SGRQ>60); º High SGRQ = low health status; QoL – quality of life; NH – nursing 
home; SGRQ – St. George’s Respiratory Questionnaire 
8
1 
8
1 
 Table 3.2     Factors associated with hospital readmission - clinical history, hospital admission, and investigations  
Study Designa Readmission rate Clinical history Investigations 
McGhan [14] Retrospective. n=51,353 25% 1-year Previous hospitalisations  
Chu [264] Prospective. AECOPD requiring NIV. n=110 80% 1-year Previous hospitalisations  
Lusuardi [306] Prospective. n=931 17.7% 6-month  Low FEV1 
Bartolomeo [323] Retrospective. n=123,162 34% 1-year Discharge from ICU, admission with ARF  
Pouw [324] Retrospective. n=28 Unspecified Weight loss during initial admission  
Murata [325] Retrospective. n=213 Unspecified Previous hospitalisations Low FEV1, high FEV1/FVC 
Almagro [310] Prospective. n=129 58% 1-year Previous hospitalisations, severity of dyspnoea Hypercapnia 
Lau [308] Retrospective. n=551 59% 1-year Previous hospitalisations, hospital stay >5 days Rt heart strain†; high HCO3
-
 
Roberts [254] Retrospective. n=1,221 34% 3-month Previous hospitalisations Low FEV1 
Garcia-Aymerich [326] Case-control. n=172 Unspecified ≥3 hospitalisations in previous year Low FEV1 
Cao Retrospective. n=186 67% 1-year  Low FEV1 
Garcia-Aymerich [303] Prospective. n=340 63% 1-year ≥3 hospitalisations in previous year Low FEV1, Low PaO2 
Gudmundsson [305] Prospective. n=416 61% 1-year Hospital stay >5 days, current smoking Low FEV1, low FVC 
Tsoumakidou [311] Prospective. n=67 Not specified  COPD severity * 
Wong [309] Retrospective. n=109 Not specified  COPD severity*, high WCC 
Bhatt [327] Retrospective. n=100 87% 1-year  Hypomagnesaemia 
Echave-Sustaeta [266] Prospective. AECOPD requiring NIV. n=120 66% 1-year High hospital length of stay Low FEV1, high PaCO2 
Italics indicate that variables is an independent predictor of readmission on multivariate analysis;
 a
 Study involves unselected patients with AECOPD surviving to discharge unless 
otherwise stated; *when measured using GOLD or ERS criteria; † assessed by ECG; ARF – acidaemic respiratory failure; HCO3
-
 - bicarbonate; ICU – intensive care unit; WCC – white 
blood cell count 
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 Table 3.3     Factors associated with hospital readmission – comorbidity and medication  
Study Designa Readmission rate Comorbidities Medications 
McGhan [14] Retrospective. n=51,353 25% 1-year 
Asthma, pulmonary hypertension. 
(Diabetes, hypertension protective) 
 
Lusuardi [306] Prospective. n=931 17.7% 6-month CCI  
Groenewegen [15] Prospective. n=171 55% 1-year  Maintenance corticosteroids 
Roberts [254] Retrospective. n=1,221 34% 3-month  High total number of medications, home nebuliser 
Sin [185] Retrospective. n=22,640 25% 1-year  
Oral theophyllines, maintenance corticosteroids 
(ICS protective) 
Almagro [310] Prospective. n=129 58% 1-year Cor pulmonale  
Gonzalez [312] Prospective. n=112 32.1% 1-year Cor pulmonale LTOT 
Vega Reyes [320] Prospective. n=93 40% 1-year  LTOT 
Wong [309] Retrospective. n=109 Not specified 
Total number of comorbidities, 
coronary artery disease, LVF 
LTOT 
Lau [308] Retrospective. n=551 59% 1-year  High dose ICS 
Gudmundsson [305] Prospective. n=416 61% 1-year  
LTOT, home nebuliser, theophylline. (Inhaled 
anticholinergics protective) 
Garcia-Aymerich [326] 
Prospective, case-control. 
n=172 
n/a  LTOT underprescription 
Garcia-Aymerich [303] Prospective. n=340 63% 1-year  Inhaled anticholinergics 
Italics indicate that variables is an independent predictor of readmission on multivariate analysis;
 a
 Study involves unselected patients with AECOPD surviving to discharge unless 
otherwise stated; ICS – inhaled corticosteroids; LTOT – long term oxygen therapy; LVF – left ventricular failure / dysfunction; CCI – Charlson comorbidity index 
8
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3.8 PREDICTING OUTCOMES IN AECOPD - SUMMARY 
Summarising the research discussed above is difficult because of varied methodologies 
and populations studied. There does however appear to be an overlap between 
certain predictors of mortality and readmission as well as some key differences. The 
severity of physiological derangement is an important predictor of in-hospital and 
post-discharge mortality but has less influence on readmission rates. Similarly, along 
with other comorbidities discussed above, the link between coexistent cardiovascular 
disease and death does not appear to be as strong when predicting readmission. 
Anxiety, measured by the HADS, is a stronger predictor of readmission than mortality 
whereas depression, measured using the same scale, predicts mortality but not 
readmission. Nutritional depletion is an independent predictor of mortality in stable 
and acute COPD. However, many authors have been unable to identify an association 
with readmission, although many of these studies involved a population with relatively 
well preserved BMI (mean BMI >24 in all studies).  
It is important, therefore, to consider the outcomes of readmission and mortality 
separately. The strength of the relationships between relevant variables and outcome 
in patients hospitalised with AECOPD is summarised in Table 3.4. Only articles showing 
an independent association with outcome have been included and the following 
criteria have been used to grade the strength of the association: strong evidence – at 
least 3 studies showing independent relationship; moderate evidence – 2 studies 
showing independent relationship; weak evidence – 1 study showing independent 
relationship. 
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Table 3.4     Relationships between different variables and outcomes following 
hospitalisation for AECOPD 
 In-hospital mortality Post-discharge 
mortality† 
Hospital 
readmission 
Strong evidence 
(listed in order of 
weight of supporting 
evidence) 
Older age 
Elevated acute physiology 
scores 
Impaired consciousness 
Cardiac comorbidity 
Poor nutritional status‡ 
Prior hospitalisations 
Tachypnoea / respiratory 
distress 
Hypotension 
Acute comorbidity 
Acidaemia 
Hypoxaemiaⁿ 
Renal impairment 
Hypoalbuminaemia 
Positive sputum 
microbiology 
Cardiac comorbidity 
Functional limitation 
Poor nutritional status‡ 
Low FEV1 
Older age 
Prior hospitalisations 
Cor pulmonale
Ω
 
Stable-state dyspnoea 
Diabetes 
Acute comorbidity 
Poor quality of life 
 Depression 
Maintenance steroids 
Hypercapnia 
Elevated troponin 
Underlying malignancy 
Prior hospitalisations 
Older age 
Low FEV1 
Functional limitation 
Poor quality of life 
Maintenance 
steroids 
Comorbidity burden
d
 
Moderate evidence 
Hypercapnia 
Hyponatraemia 
Comorbidity burden 
Male sex 
Low FEV1
b
 or low PEFR 
Tachycardia 
Hyperglycaemia 
Stable-state dyspnoea 
Hypoalbuminaemia 
Male sex 
Anaemia 
 
Cor pulmonale
Ω
 
LTOT 
Male sex 
 
Weak evidence 
Higher monthly income 
Current smoking 
LTOT 
Functional limitation 
Institutional care 
High BNP / troponin / PCT 
Abnormal WBC 
AECOPD severity^ 
Cerebrovascular disease 
Chronic liver disease 
Underlying malignancy 
Maintenance steroids 
Coexistent pneumonia 
Low serum bicarbonate 
Anaemia 
Cor pulmonale 
Weak cough 
Disease duration 
Current smoking 
> 60 cigarette pack years 
Hypoxaemiaⁿ 
Unmarried 
Comorbidity burden 
Thromboembolic disease 
Chronic renal 
impairment 
Impaired consciousness 
Unintentional weight 
loss 
Tachycardia 
Length of hospital stay 
 
 
Long duration of 
COPD 
Unmarried / 
widowed  
Institutional care 
Hypercapnia 
Anxiety 
Asthma 
Oral theophylline 
High dose ICS 
Inhaled 
anticholinergics 
Respiratory muscle 
overload
c
 
Cardiac comorbidity 
 
86 
 In-hospital mortality Post-discharge 
mortality† 
Hospital 
readmission 
Inappropriate location of 
care
b
 
†
 Excluding studies investigating mortality within 30 days of discharge; ‡ low BMI or low % of ideal body 
weight; ⁿ hypoxaemia on ABG, low alveolar-arterial gradient, or low PaO2 / FiO2 ratio; ^ according to 
Anthonisen Criteria; 
Ω
clinical diagnosis of cor pulmonale, pulmonary hypertension on echocardiogram, 
or presence of bilateral pedal oedema; 
b
 admitted to any ward except respiratory or intensive care; 
c
 
measured non-invasively using pressure-time index; 
d
 high total number of comorbidities, high chronic 
disease score, or CCI >1.[318] 
AECOPD – acute exacerbation of COPD; LTOT – long-term oxygen therapy; PEFR – peak expiratory flow 
rate; CCI – Charlson comorbidity index; FEV1 – forced expiratory volume in 1 second; ICS – inhaled 
corticosteroids; WBC – white blood cell count; BNP - N-terminal pro-brain natriuretic peptide; PCT - 
procalcitonin 
Potential prognostic variables (apart from the presence of chronic comorbid conditions 
and older age which have been shown to predict all three outcomes) can be broadly 
classified in to the following categories: markers of the severity of acute illness (e.g. 
acidaemia, hypoxaemia, acute comorbidity); markers of underlying disease severity 
(e.g. low FEV1, previous hospitalisation, cor pulmonale); and poor health status (e.g. 
low quality of life, impaired functional status). Their relative impacts on the outcomes 
discussed here (in-hospital mortality, post discharge mortality and hospital 
readmission) vary, as depicted schematically in Figure 3.1. 
Figure 3.1     Schematic representation of relative impact of 3 main groups of variables 
on different outcomes 
 In-hospital death Mortality after 
discharge 
Hospital 
readmission 
Markers of acute 
illness severity 
   
Markers of underlying 
disease severity 
   
Impaired health  
status 
   
Despite considerable research on patients hospitalised with AECOPD, we are still 
unable accurately to predict the important clinical outcomes in an individual patient. 
No single predictor variables have been shown to robustly predict outcome and 
prognostic models that have shown promise in their derivation cohort have frequently 
not been validated.  
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Hospitalisation for AECOPD becomes more frequent with advancing disease and places 
an enormous burden upon the patients and the healthcare system. Large prospective 
studies to develop tools which accurately predict readmission and mortality (both in-
hospital and following discharge) would help to inform clinical decisions, such as the 
appropriate escalation of care and optimum utilisation of resources for safely 
facilitating early discharge and reducing readmissions, as well as better identifying 
patients with unmet palliative care needs. This would help to direct healthcare 
resources to those most likely to benefit and to reduce the significant burden of 
morbidity in this disease.  
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CHAPTER 4  ASSESSING HEALTH AND QUALITY OF LIFE 
4.1 DEFINITIONS 
The wellbeing of an individual or individuals health status was traditionally defined 
biologically by survival rates and the absence of disease, but as healthcare quality and 
provision have improved, our expectations have risen and our view of health status is 
now best explained by a biopsychosocial model, incorporating the concepts of 
physical, mental, social and spiritual well-being in to the traditional biological 
viewpoint.  
Reflecting the above changes, health status is currently defined by the WHO as “the 
state of health of a person or population assessed with reference to morbidity, 
impairments, anthropological measurements, mortality, and indicators of functional 
status and quality of life”.[328] Quality of life is a broad multidimensional concept 
including evaluations of both positive and negative aspects of life,[329] whereas 
health-related quality of life (HRQoL) encompasses the aspects of quality of life that 
affect both physical and mental health. The definitions of health status, QoL and 
HRQoL vary in the literature resulting in terminological confusion. From this point 
forward I will use the term quality of life (QoL) when discussing health and quality of 
life assessment, although I accept that the instruments I refer to are limited and do not 
measure the full breadth of this concept. 
It has been demonstrated that outcome measures traditionally used in COPD studies, 
such rate of FEV1 decline, are only weakly correlated with an individual’s symptoms, 
vitality, functional capabilities and feelings of personal well-being (i.e. their quality of 
life).[186, 330, 331] This has led to the development of a number of instruments aimed 
at assessing and estimating the impact disease has on an individual’s QoL. The 
instruments can be divided into generic tools – to be used in a wide variety of 
conditions, and specific tools – designed for use in a specific condition and to assess 
the disease-specific impact on QoL. In addition, aspects of health status not assessed 
by generic or disease specific instruments, such as psychological wellbeing and 
functional status, can be reliably and accurately assessed using specific questionnaires.  
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4.2 GENERIC QOL INSTRUMENTS 
Compared to disease-specific questionnaires, generic QoL instruments are broader in 
scope and allow comparisons to be made across different patient populations. 
However, they often include questions that are irrelevant to a particular condition and 
they are therefore limited in their ability to detect small changes in quality of life.  
Examples of generic QoL instruments include the 36-item Short Form Health Survey 
(SF-36), the Sickness Impact Profile (SIP) and the Nottingham Health Profile (NHP). 
Generic instruments can also be used to screen for the presence of anxiety and 
depression, or to assess the degree of functional impairment that an individual 
experiences. 
The SIP has been validated in COPD,[332] but its use is limited by its lack of 
discrimination in mild COPD and the time taken to administer. The SF-36 is quick and 
simple to administer and has been shown to predict hospitalisation in COPD,[333] but 
it has been found to be less responsive than disease specific questionnaires (section 
4.3).[334] The NHP has also been shown to be reliable and responsive in COPD [333] 
although the minimally important clinical difference (MCID) is unknown and therefore 
its ability to detect clinically important changes in QoL is limited. Therefore, generic 
QoL instruments were not used in our study. 
4.3 SPECIFIC QOL INSTRUMENTS 
Disease-specific instruments attempt to define the effects of one condition on QoL. 
Although developed for use in a single condition, some of the instruments have been 
used in other related conditions thus extending their usage. Examples used in COPD 
include: the chronic respiratory disease questionnaire (CRQ); the St. George’s 
Respiratory Questionnaire (SGRQ); the Breathing Problems Questionnaire (BPQ); and 
the Seattle Obstructive Lung Disease Questionnaire (SOLDQ). Disease specific 
questionnaires (CRQ and SGRQ) have been found to be substantially more responsive 
than generic measurements at assessing response to treatments in individuals with 
COPD.[334] 
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4.3.1 THE CHRONIC RESPIRATORY DISEASE QUESTIONNAIRE (CRQ)  
The CRQ is a measure of QoL in patients with chronic airflow limitation.  It was 
originally designed for use in patients with chronic airflow limitation of any cause and 
has been shown to be responsive, reliable and valid; changes in the CRQ correlate with 
changes in individuals lung function, exercise capacity and their physician’s overall 
assessment of the individual’s condition.[335] It has also been used to obtain 
responsive measures of acute changes in quality of life during AECOPD.[336] 
The questionnaire contains 20 questions addressing four domains – dyspnoea, fatigue, 
emotional function and mastery. The questions regarding fatigue, emotional function 
and mastery are standardised requiring the patient to indicate the most appropriate 
answer on a seven point scale. The dyspnoea domain is personalised where the 
individual chooses five activities that make them breathless and then rates how 
breathless performing those activities has made them over the preceding two weeks. 
The CRQ is therefore able to assess the limitation that COPD has on patient-specific 
activities. This, however, makes it difficult to compare the dyspnoea domain results 
between individuals, and the scale is more useful for comparing results for the same 
individual. Lower scores in each domain reflect more severe impairment and the MCID 
for the CRQ has been accepted to be 0.5 in any one domain.[337] 
The original questionnaire was designed to be interviewer-administered and was 
recommended to take approximately 25 minutes. Williams et al [338] developed a self-
reported version of the CRQ and found it to be a reproducible and reliable 
measurement of health status in patients with COPD. 
The CRQ has been found to be more sensitive to change than generic health status 
measurements [339, 340] and the BPQ.[341] On direct comparison in individuals with 
COPD, the CRQ has been shown to have similar reliability, responsiveness and validity 
to the SGRQ.[342] 
4.3.2 THE ST. GEORGE’S RESPIRATORY QUESTIONNAIRE (SGRQ) 
The SGRQ is a 50 item questionnaire which has been validated in both COPD and 
asthma.[343] It consists of three subscales: symptoms (eight questions), activity (16 
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questions) and impacts (26 questions). Responses are weighted and results are 
calculated by dividing the summed weights by the maximal possible weight and 
expressing the results as a percentage. The weights were originally derived from 
individuals with asthma but have been validated in patients with COPD.[333] The 
responses are aggregated into a total score and sub-domains for symptoms, activity 
and impacts. For each domain (symptoms, activity, impacts and total), scores range 
from 0 (no impairment) to 100 (maximum impairment or death).  
The questionnaire has been demonstrated to be responsive, reliable and valid in 
individuals with both stable COPD and AECOPD.[332, 343, 344] Results from the SGRQ 
correlate with frequency of respiratory symptoms, exercise performance, 
breathlessness, mood state and annual frequency of exacerbations.[345] The 
questionnaire has been shown to outperform generic instruments at detecting 
impairments in QoL [346] and is effective at assessing the response to a variety of 
therapies.[333] 
The SGRQ takes 15-20 minutes to complete and can be self-administered by patients 
without difficulty.[347] The MCID is 4 points [344] and Ferrer et al [348] established 
population normal values for the SGRQ so that individual results can be interpreted in 
context. 
Due to the weight of literature supporting their use, and their advantage over both 
generic and other disease-specific QoL instruments, the SGRQ and CRQ were chosen 
for use in our study. 
4.4 ASSESSMENT OF FUNCTIONAL STATUS 
‘Functional status’ refers to the limitation that health problems place on an individual’s 
ability to perform their usual behaviours and activities [349] and is an important part 
of an individual’s assessment of health. Functional status usually worsens (i.e. 
limitation increases) as the severity of COPD increases. The term ‘activities of daily 
living’ (ADL) is defined as the basic physical, psychological, social or spiritual needs that 
fulfil usual roles and maintain health and well-being and is used in the assessment of 
functional status.[350] Activities of daily living can either be classed as basic (i.e. 
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concerned with primary biological functions – bathing, eating, toileting etc) or 
instrumental (i.e. enable individuals to live independently within a community – 
housework, shopping, managing money etc). Assessment of instrumental ADL is of 
more value in patients with chronic diseases living in the community. Instrumental 
ADLs require high energy exposure and therefore, compared to basic ADLs, are more 
likely to be restricted early on in the disease process, therefore providing a more 
sensitive assessment of functional status than basic ADL.[349] 
The Nottingham Extended Activities of Daily Living (NEADL) scale [351] is a self-
administered questionnaire assessing the impact of disease on functional status. It is 
divided into four categories (mobility – 6 activities, kitchen – 5 activities, domestic – 4 
activities and leisure – 6 activities). The respondent is asked to score for each activity 
whether they: 0 - are unable to perform the activity; 1 - require help to perform the 
activity; 2 - perform it independently but with difficulty; or 3 - perform it 
independently with ease. Although originally designed as a 22-item questionnaire, one 
of the items has been dropped due to poor test-retest reliability.[351] 
Originally a total score out of 21 was obtained by rating the individual as either 
dependent (score = 0) or independent (score = 1) for each activity. Higher scores 
reflect greater independence. The MCID between measurements is two points [352]. 
This method of applying the NEADL has been shown to be reliable and effective in 
assessing functional status in patients with COPD.[351, 353, 354] Alternatively, 
obtaining a total score out of 63 (MCID to detect clinically relevant change = 5)[355] 
has also been studied in COPD [356] and we choose to use this methodology because it 
may be more sensitive to small changes in functional status. The NEADL has also been 
shown to be a better discriminator of respiratory disability in elderly subjects than an 
alternative common measure of functional status (the Barthel Index).[353] 
In addition to the NEADL, a simple yet useful measure of functional status is 
performance status (Table 4.1). This five-point scale was initially used in the oncology 
field but the National UK COPD audits [12, 254] have demonstrated its utility in 
predicting mortality in AECOPD following discharge. Subsequently, this tool has also 
been shown to be associated with in-hospital mortality in AECOPD.[260] 
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Table 4.1     Performance status [12] 
Description Performance status 
Normal activity 0 
Strenuous activity limited 1 
Limited activity but able to self care 2 
Limited self care 3 
Bed or chair bound, no self care 4 
 
4.5 ASSESSMENT OF PSYCHOLOGICAL WELLBEING 
There is a high prevalence of psychiatric morbidity in non-psychiatric medical clinics 
and depression is common in COPD. Zigmund et al [357] developed the Hospital 
Anxiety and Depression Scale (HADS) to help clinicians screen patients for anxiety and 
depression. HADS is simple to administer and has been shown to be acceptable by the 
population for which it was designed.[358] It has been shown to be a reliable, valid and 
responsive instrument to assess the symptoms of mood disorders [358] and has 
previously been used effectively in assessing the prevalence and impact of mood 
disorders in individuals with COPD.[359] The instrument has two subscales – anxiety 
and depression, and the total value for each subscale is 21. A score less than 8 is 
regarded as normal, a score of 11 or greater indicates the probable presence of anxiety 
or depression, and score between 8 and 10 is suggestive of the presence of a mood 
disorder. Using a cut-off of 8 as diagnostic, HADS has been shown to have a sensitivity 
of 80% and a specificity of 90% in a population of depressed patients.[262] The MCID 
of the HADS in anxiety or depression is 1.5.[360] 
4.6 PREDICTORS OF QUALITY OF LIFE RECOVERY FOLLOWING AECOPD 
In stable COPD, it has been shown that quality of life decline is associated with: both 
single and frequent episodes of AECOPD;[112, 127, 361] hospitalisation for 
AECOPD;[111]; lower FEV1;[60, 111] lower levels of physical activity;[362] male 
sex;[363] lower body weight;[363] more severe stable-state dyspnoea;[363, 364] 
frequent respiratory symptoms;[363] and greater comorbidity.[111]  
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Few studies have investigated indices associated with recovery (or decline) in quality of 
life following AECOPD. Tsai et al [365] showed in 330 patients attending the ED with 
AECOPD that, compared to patients whose quality of life fully recovered within two 
weeks, patients whose quality of life had not fully recovered: had a greater smoking 
burden; were less likely to have coexistent asthma; were more likely to have 
experienced AECOPD in the previous year; were more likely to be prescribed oxygen at 
home; were more likely to have coronary artery disease or congestive cardiac failure; 
and had higher oxygen saturations at the time of their ED attendance. However, the 
only factor found to independently predict quality of life recovery was a history of 
frequent (≥ 2) AECOPD.  
Following hospitalisation for AECOPD, Wang et al [313] showed that low FEV1 was 
associated with, and high levels of stable-state dyspnoea were independently 
predictive of, a subsequent decline in quality of life. These findings have not been 
confirmed by other authors and the only other study which attempted to identify 
predictors of quality of life decline following hospitalisation failed to identify any 
factors independently associated with outcome.[366] 
Therefore, although an assessment of the likelihood of subsequent recovery of an 
individual’s quality of life is important and recommended in many treatment decisions 
in AECOPD requiring hospitalisation,[174] there is little evidence of useful prognostic 
indices, aside from exacerbation frequency, to assist the treating clinician. 
Furthermore, all of the above studies used quality of life decline (or recovery) as the 
outcome variable. This is likely to have identified patients whose QoL declined from a 
well preserved baseline level rather than patients whose QoL deteriorated from an 
initially low level. However, the most clinically relevant group to identify is those who 
had an initially poor QoL which subsequently deteriorated because these patients may 
benefit from closer observation and more supportive care, or from early discussion of 
palliative care options. Different measures of subsequent QoL decline / recovery used 
in this study are outlined in section 12.4.1 and our definition of poor QoL following 
hospital discharge is described in section 13.6.1.  
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AIMS AND METHODS 
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CHAPTER 5 RESEARCH AIMS 
Two distinct populations were studied and therefore the methods and results are 
included, for each population, under the relevant part (Part 1 - Predicting outcome 
following hospitalisation for AECOPD; and Part 2 - Longitudinal assessment of quality 
of life and health resource following hospitalisation for AECOPD). The following aims 
refer distinctly to either Part 1 (Aims 1a to g) or Part 2 (Aims 2a and 2b). 
5.1 COEXISTENT PNEUMONIA IN AECOPD 
Aim 1a: to compare the characteristics and outcomes of patients with and without 
coexistent pneumonia 
Frequently, studies of AECOPD have excluded patients with pneumonia and therefore 
the impact of pneumonia in AECOPD remains uncertain. We wished to describe the 
characteristics of patients with pAECOPD and compare this to their non-pneumonic 
counterparts. We also wished to assess the impact of pneumonia on mortality and 
readmission in AECOPD and the prognostic strength of CURB-65 (Table 1.6) in both 
pAECOPD and npAECOPD. 
5.2 EVALUATION OF THE EXTENDED MRC DYSPNOEA SCALE AND 
MALNUTRITION UNIVERSAL SCREENING TOOL 
Aim 1b: evaluation of the extended MRC Dyspnoea Scale with specific reference to 
correlation with survival, quality of life, readmission rates length of stay and frequency 
of hospital readmission. 
Aim 1c: evaluation of Malnutrition Universal Screening Tool with specific reference to 
correlation with survival, quality of life, readmission rates length of stay and frequency 
of hospital readmission. 
The severity of dyspnoea during a stable state, measured by the traditional MRCD 
scale (Table 1.1) is a strong predictor of mortality in AECOPD. A previous study in our 
hospital [367] has suggested that subdividing individuals with traditional MRCD 5 in to 
two levels, depending on their ability to independently perform washing or dressing, 
more accurately predicted the risk of hospital admission following discharge than the 
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traditional scale. This novel modification of the MRCD is termed the Extended MRCD 
(eMRCD) and is detailed in Table 5.1: 
Table 5.1     The Extended MRC Dyspnoea scale 
Grade Degree of breathlessness related to exercise 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying or walking up a slight hill 
3 
Walks slower than contemporaries on level ground because of breathlessness, or has to 
stop for breath when walking at own pace 
4 Stops for breath when walking about 100m or after a few minutes on level ground 
5a Too breathless to leave the house unaided but independent in washing and / or dressing 
5b Too breathless to leave the house unaided and requires assistance in washing and dressing 
The relationship between the extended MRCD scale (Table 5.1) and mortality has not 
previously been investigated, and the suggestion that eMRCD may be a better 
discriminator for hospital readmission [367] requires further investigation. We 
therefore wished to clarify the association between MRCD and outcome in AECOPD, 
and investigate whether eMRCD is a stronger predictor of mortality and readmission 
than MRCD. 
Poor nutritional status is an important prognostic index in AECOPD (section 2.2.4.1), 
but malnutrition can be measured in a variety of ways and no single, easy to measure 
index has been found to accurately predict both short and long-term mortality, and 
readmission. The Malnutrition Universal Screening Tool (MUST) has been shown to be 
a useful prognostic tool in elderly acute general medical admissions [39, 41] but its 
utility in patients with AECOPD has not been investigated. 
We therefore wished: to report the estimated risk of malnutrition in our population 
according to MUST; and to assess the prognostic strength of MUST compared to BMI 
and weight loss in AECOPD. 
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Table 5.2     The 'Malnutrition Universal Screening Tool' ('MUST') 
Nutritional measurement Score 
Body mass index (BMI), 
>20 
18.5-20 
<18.5 
 
0 
1 
2 
Unplanned weight loss in past 6 months, 
<5% 
5-10% 
>10% 
 
0 
1 
2 
If patient acutely ill and there has been, or is likely to 
be, little nutritional intake for >5 days 
2 
Total MUST score 
Low risk of malnutrition 
Moderate risk of malnutrition 
High risk of malnutrition 
/6 
0 
1 
≥ 2 
MUST is reproduced here with the kind permission of BAPEN (British Association for Parenteral and 
Enteral Nutrition).[368] 
 
5.3 PREDICTING OUTCOME FOLLOWING HOSPITALISATION FOR 
AECOPD 
Aim 1d:  identify independent predictors of in-hospital mortality following 
hospitalisation for AECOPD and develop a clinical prediction tool to accurately predict 
the risk of in-hospital mortality. 
Aim 1e:  identify independent predictors of in-hospital mortality in patients receiving 
assisted ventilation following hospitalisation for AECOPD.  
 Aim 1f:  identify independent predictors of twelve-month mortality following 
hospitalisation for AECOPD. 
Aim 1g: identify independent predictors of early and frequent readmission, and develop 
a clinical prediction tool, in patients surviving to discharge following hospitalisation 
with AECOPD. 
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Chapter 2 and Chapter 3 detail the current difficulties that clinicians face when 
attempting to predict outcome in AECOPD. Therefore, we aimed to identify, in a broad 
population of patients with AECOPD, independent predictors of mortality and 
readmission. Furthermore, we aimed to develop clinical prediction tools to assist 
clinicians in the prediction of in-hospital mortality and early readmission following 
discharge in a population hospitalised for AECOPD.  
The planned prediction tools should be easily memorised and simple to use, and would 
therefore contain a limited number of variables, with predictor variables consisting of, 
ideally, two or three categories. The prediction tools would be internally validated 
during this study, but external validation would require subsequent studies. 
Predicting short and long-term survival has been more extensively researched in 
patients with acidaemic respiratory failure requiring assisted ventilation than in 
general patients with AECOPD (Table 2.8) yet many of these studies have only been 
performed in the intensive care setting or have strict entry criteria. We aimed to 
identify independent predictors of short-term survival in this population. Comparisons 
with previously published data would be problematic and were therefore not 
undertaken. In most previous research, prognostic data (particularly APACHE and 
CAPS) were collected at the time of clinical deterioration, for example at the time of 
admission to ICU or commencement of ventilation. In the present study, most 
physiological data in patients requiring ventilation were collected at admission to 
hospital. Therefore, comparing our predictive model with the performance of APACHE 
and CAPS in our study is flawed because APACHE and CAPS were designed to be 
calculated at the time of clinical decline. 
5.4 LONGITUDINAL ASSESSMENT OF QUALITY OF LIFE AND HEALTH 
RESOURCE USE 
Aim 2a: Assess quality of life and subsequent health resource use among survivors of 
AECOPD. 
The time course of recovery of symptoms and quality of life following hospitalisation 
for AECOPD has been infrequently studied. We wished to document health resource 
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use and the recovery, or decline, of quality of life and survival in a population of 
patients discharged from hospital following AECOPD, and in a subgroup of patients 
who received assisted ventilation during their hospital stay. We aimed to compare the 
baseline characteristics and subsequent quality of life following discharge of patients 
who received assisted ventilation with those who did not. 
A central aim of this part of the study was to identify predictors to assist clinical 
decisions regarding escalation of care or timing of discussion of end-of-life care. We 
therefore aimed to identify patients at risk of death or at risk of survival with poor QoL 
following discharge. Consequently, we wished to characterise the population who 
experienced poor quality of life following discharge, and then identify independent 
predictors of poor quality of life or death. 
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CHAPTER 6 PATIENTS AND METHODS 
6.1 ETHICAL APPROVAL 
Ethical approval was sought and granted from NHS County Durham and Tees Valley 
Research Ethics Committee 2. 
6.2 PARTICIPANT RECRUITMENT 
All patients admitted to either North Tyneside General Hospital (NTGH) or Wansbeck 
General Hospital (WGH) (Northumbria Health NHS Foundation Trust) with a diagnosis 
of an acute exacerbation of COPD were eligible for inclusion in to the study. Participant 
recruitment began on 19th December 2008 and ended on 30th June 2010. Participants 
were identified through a variety of methods. In our trust, the Respiratory Specialist 
Nurses (RSpN) are informed of all patients admitted with an exacerbation of COPD. As 
well as obtaining participant details from the RSpN, close contact was maintained with 
the Medical Admissions Units, the Respiratory wards and the ICU in order to maximise 
patient recruitment and to include a comprehensive range of severity of AECOPD. 
Once participant details were obtained, the case notes were reviewed either whilst 
they were an in-patient, or post-discharge in a minority of cases. A small number of 
patients either rapidly died or were discharged from hospital prior to identification by 
the research team. In order to optimise participant recruitment (and minimise 
potential bias) hospital discharge records were screened and any not already included 
in the study were identified. The case notes were then reviewed individually and if 
eligible, the individual was recruited in to the study. 
6.3 INSTITUTION BACKGROUND 
Northumbria Health NHS Foundation Trust is situated in the North East of England and 
is geographically one of the largest NHS trusts in the UK, providing healthcare to over 
half a million people. The two main hospitals are: North Tyneside General Hospital, 
which has 534 in-patient beds and admits over 28,000 non-elective cases per year; and 
Wansbeck General Hospital, which has 396 in-patient beds and admits over 29,000 
non-elective cases per year. NTGH is located in an urban area, 8 miles from Newcastle 
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City Centre, with an estimated COPD prevalence higher than the UK national 
average.[3] WGH is situated in Ashington, which is surrounded by a largely rural 
community and services a vast catchment area ranging from Tyneside to the Scottish 
Borders, and from North East coast to as far west as Haltwhistle. Wansbeck General 
Hospital is serviced by a number of smaller rural cottage hospitals where patients can 
be cared for, closer to their home, once their acute illness has recovered. The North 
East of England has the largest proportion of most deprived areas in the UK [369] and, 
in some areas of North Tyneside and Northumberland, measures of health deprivation 
and disability are amongst the highest in the country.[370] 
6.4 INCLUSION CRITERIA 
Inclusion criteria were: admission from the primary place of residence; age greater 
than 35 years; current or former smoker with a smoking history of greater than 10 
cigarette-pack years; a clinician’s diagnosis of COPD, supported by spirometry; and an 
acute exacerbation of COPD. COPD was defined as the presence of compatible 
symptoms coupled with airflow obstruction on spirometric measurement (FEV1 / FVC < 
70%). An acute exacerbation of COPD was defined as “an acute worsening of the 
patient’s condition from the stable-state, which is sustained and warrants the patient 
to seek additional treatment”.[105] Both infective and non-infective exacerbations 
were included and radiographic consolidation did not preclude inclusion in the study. 
The participants’ first admission to hospital during the period of the study was termed 
their index admission and data regarding readmissions and mortality was obtained 
from this point onwards. A participant could not be enrolled in the study more than 
once. 
6.5 EXCLUSION CRITERIA 
Patients were excluded if: they did not meet any of the above inclusion criteria; they 
had a life-threatening active malignancy (estimated survival < 1 year) or other serious 
life-threatening co-morbidity (i.e. If it was believed that the patient was unlikely to 
survive their admission because of an alternative diagnosis); or if they were in receipt 
of domiciliary ventilatory support prior to admission. Individuals were not included if it 
was felt by the treating clinician, or confirmed through subsequent investigations, that 
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the primary reason for admission was: pulmonary thromboembolic disease; 
pneumothorax; asthma; pulmonary fibrosis; bronchiectasis; cardiac failure; or pleural 
effusion.     
6.6 DATA COLLECTED 
In order to ensure that our prediction tool would be of clinical relevance we 
concentrated on data that were readily available to the admitting clinical team or to 
the RSpN who review patients on admission. 
6.6.1 PRE-ADMISSION STATUS 
Data were collected on: sociodemographic characteristics; residence prior to 
admission; need for social support (paid carers) prior to hospitalisation; smoking status 
(current smoker, former smoker – defined as self-reported abstinence of tobacco 
smoking for at least 3 months); smoking load (recorded as cigarette pack years (cpy): 
20 cigarettes per day for 1 year = 1 cpy); self-reported annual frequency of 
exacerbations of COPD (“How many times have you received antibiotics or steroids for 
treatment of a chest infection in the past 12 months?”); the number of admissions 
(both respiratory and non-respiratory) in the preceding 12 months; independence in 
performing activities of daily living (washing, dressing, feeding, cooking, cleaning); 
number of previous exacerbations requiring NIV or invasive ventilation (including 
dates); previous participation in pulmonary rehabilitation course (including dates); 
details of the participants’ maintenance therapies; their ‘exercise tolerance’ (defined 
as the estimated distance they can walk in metres unaided on the flat before having to 
stop for a rest); whether the participant can leave the house unaided; and their degree 
of breathlessness measured by both the MRCD (Table 1.1) and eMRCD (Table 5.1) 
scales. The patient was asked to estimate the amount of unintentional weight loss 
experienced in the three months prior to admission. If the patient was unable to report 
this, and weight measurements at the appropriate time points were available, it was 
calculated. 
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6.6.2 PREVIOUS SPIROMETRY AND SEVERITY OF COPD 
Details of participants’ most recent documented spirometric measurement were 
recorded. In participants presenting for the first time with suspected COPD, or those 
with no previous documented spirometry, spirometry was either performed at the 
time of hospital discharge or after six weeks post discharge in order to identify the 
presence or absence of airflow obstruction (FEV1 / FVC < 0.70). Although spirometry 
performed at any time was used to satisfy inclusion criteria, only spirometry 
performed within two years of admission was used in data analysis.  
6.6.3 COMORBIDITIES 
Case notes were reviewed in order to obtain a detailed list of the participants’ co-
morbidities. Co-morbidities were deemed to be present if: they were mentioned in the 
admission clerking document, a hospital clinic letter or a primary care referral letter; or 
if an investigation demonstrated the condition to be present.  Specifically, cor 
pulmonale was present if: 1) pedal oedema was present in the absence of an 
alternative cause; or 2) estimated pulmonary artery systolic pressure (PASP) > 
30mmHg on transthoracic echocardiography.[371] Bronchiectasis required the 
presence of the typical symptoms of chronic cough and sputum production coupled 
with characteristic abnormalities on thoracic imaging. Left ventricular dysfunction was 
recorded if transthoracic echocardiography demonstrated left ventricular ejection 
fraction (LVEF) < 45%. Participants were listed as having depression if it was either 
included as an admission or discharge diagnosis in the hospital records, or if the 
participant was in the receipt of medication for treatment of depression. Abnormal 
bone densitometry results were required for the diagnosis of osteoporosis to be 
recorded. Charlson Comorbidity Index (Table 17.1) was calculated retrospectively. 
6.6.4 ADMISSION DATA 
A number of physiological indices obtained on arrival in hospital were recorded (pulse 
rate, blood pressure, respiratory rate, temperature, GCS and arterial oxygen saturation 
on stated level of inspired oxygen). Height and weight measurements, either from 
admission or from a recent clinic attendance (≤ 3 months, only if no recent weight loss 
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reported by patient), were used to calculate the body mass index (BMI – weight 
(kg)/height (m)2), and combined with information regarding recent weight loss, the 
MUST score (Table 5.2) was obtained.  
Furthermore, the following were recorded at hospital admission: self-reported 
expectoration of purulent sputum; the presence of pedal oedema; the presence of an 
acute confusional state; bedside assessment of cough effectiveness (‘effective cough’ - 
able to generate a forceful cough or if they were able to expectorate sputum; ‘partially 
effective cough’ - able to cough but could not generate sufficient force to mobilise 
secretions and fully expectorate sputum; ‘ineffective cough’ - unable to generate any 
significant force to their cough.) The participants’ resuscitation status was recorded in 
one of the following three categories: for invasive ventilation if clinically indicated; for 
non-invasive ventilation if clinically indicated; for cardiopulmonary resuscitation if 
clinically indicated.   
6.6.5 INVESTIGATIONS 
The results from a number of investigations performed on admission were recorded, 
or calculated:  
Table 6.1     Investigations performed on admission 
 Investigation 
Blood biochemistry 
Sodium, Potassium, Urea, Creatinine, Glucose and C-Reactive 
Protein concentration 
Blood haematology 
Haemoglobin, Total White Cell Count, Neutrophil count 
Haematocrit, Eosinophil count 
Arterial blood gas (ABG) analysis FiO2, pH, H
+
 concentration, paCO2, paO2, actual HCO3
-
, Base excess 
Chest X-ray Presence or absence of radiographic consolidation 
6.6.6 ACIDAEMIC EXACERBATIONS 
All arterial blood gas results recorded during the participants’ admission were 
scrutinised. The exacerbation was termed ‘acidaemic’ if at any point during admission 
the participant developed acidaemic respiratory failure (ARF) (pH < 7.35 and pCO2 > 
6kPa).  In all acidaemic exacerbations, the arterial blood gas results that first 
demonstrated the presence of ARF were documented and the following were 
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recorded: the time between admission and recognition of acidaemia; whether the 
patient went on to receive assisted ventilation (NIV or IPPV); whether the patient 
improved on medical therapy and did not need ventilatory support; or whether there 
was a clinical decision not to institute ventilatory support. For participants who 
received assisted ventilation, the results of blood gas analysis and the participants’ 
respiratory rate were recorded at 1-2 hours and 4-6 hours after the initiation of 
therapy. The total length of time ventilated was documented as well as the outcome.  
6.6.7 DISCHARGE 
At discharge, spirometry, if performed, was logged. Maintenance therapies were 
documented. The discharge destination was recorded and it was noted if the patient 
was being discharged with more social care than they were in receipt of on admission. 
Length of stay (days) was calculated based upon the time spent in the acute hospital 
(i.e. time spent in cottage hospitals following discharge was not included). 
6.6.8 OUTCOME DATA 
12 months after enrolment in the study, details of participants’ mortality were 
collected from the Public Health Mortality File. Date of death, place of death (home, 
hospice or hospital) and cause of death was documented.  
Hospital records were reviewed for details of hospital readmissions. The total number 
of hospital readmissions within 12 months of enrolment and the time to first 
readmission were noted. For this study, the readmission outcomes of interest were 
chosen to be: hospital readmission or death without readmission within 90 days of 
discharge (known as readmission or death from this point forward); and frequent (2 or 
more hospital admissions during the 12 months following discharge) readmission. 
We selected the dependent variables for our subsequent analyses based upon what 
we believed to be the most clinically pertinent outcomes: in-hospital mortality; 12-
month mortality; 90-day readmission or death; and frequent readmission. 
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6.7 STATISTICAL METHODS - GENERAL 
Data were quantitative in nature and analysed using both SPSS-15 for Windows (IBM, 
NY, USA) and SigmaPlot-11 (Systat Software, CA, USA). Exact p values were used where 
appropriate, a two-sided p value < 0.05 was taken as statistically significant and 95% 
confidence intervals (CI) were reported for areas under the receiver operator 
characteristic curve (AUROC) and odds ratios (OR). 
6.7.1 MISSING DATA 
Great care was taken during data collection to minimise missing data. However, 
complete data capture was not possible and the amount of missing data for each 
variable is shown in Table 17.2. Variables not listed had complete (100%) data capture. 
When considering missing data, it is important to decide whether the data was missing 
completely at random (MCAR), missing at random (MAR) or missing not at random 
(MNAR). Using the example of recording BMI on admission to hospital, Table 6.2 
explains these terms:  
Table 6.2     Missing data nomenclature 
Reason for missing 
data 
Definition [372] Explanation 
Missing completely at 
random (MCAR) 
No systematic differences between the 
missing and observed values. 
The measurement scales were 
broken and therefore BMI not 
recorded. 
Missing at random (MAR) 
Systematic difference between missing 
and observed values. Reason for 
‘missingness’ is due to other independent 
variables and does not relate to missing 
data itself. 
Missing BMI lower than 
observed BMI because older 
patients more likely to be 
bed-bound and therefore less 
likely to have BMI measured. 
Missing not at random 
(MNAR) 
Systematic difference between missing 
and observed values. Reason for 
‘missingness’ is related to outcome. 
BMI missing because patient 
died before measurement 
could be made 
Potential bias can be introduced when dealing with missing data that is not MCAR 
however such biases can be overcome by using data imputation methods (such as 
Expectation-Maximisation (EM) analysis, section 6.7.1.1) which allows individuals with 
109 
incomplete data to be included.[373] Alternate options for dealing with missing 
variables, such as simple exclusion of missing values (using pairwise or listwise 
deletion) or mean imputation, introduce bias.[373] In a clinical observational study, it 
is unlikely that missing data will be MCAR, and it is not possible to distinguish between 
MAR and MNAR using the observed data. If data is MAR then data imputation 
methods, such as EM analysis, can be used. In our population, MAR was the most likely 
explanation for ‘missingness’ in the majority of cases and it has been recommended 
that, in “most realistic scenarios”, even if data is not MAR, “departures from MAR are 
not large enough to invalidate MAR-based analysis.”[373] Therefore, imputation using 
the EM algorithm was performed. 
6.7.1.1 EXPECTATION-MAXIMISATION (EM) ALGORITHM 
Traditional methods of data imputation include mean imputation (e.g. replacing 
missing BMI data with the mean BMI of the population) or regression substitution (e.g. 
predicting missing BMI data using other variables), however both of these methods 
result in a diminished standard error that may introduce bias.[373]  
The EM algorithm is a process whereby missing data can be estimated and a smaller 
reduction in standard error results,[374] and can be used if data is MAR.[374, 375] The 
EM algorithm consists of a two-step iterative process where firstly (E step), missing 
variables are replaced by the predicted scores from a series of regression equations 
(where the remaining observed variables are used to estimate the regression 
coefficients). In the second M step, the complete dataset (including estimated data) is 
used to recalculate the regression coefficients. The regression coefficients are then 
used to recalculate the missing variables at the next E step, and the process begins 
again. The algorithm repeatedly cycles through these steps until the difference 
between estimations falls below a pre-specified criterion.[374] 
For all missing variables in our study, EM imputation was performed and results are 
shown in Table 17.3. For continuous variables, the imputed data value replaced the 
missing value, and for categorical variables, the imputed data value was rounded to fit 
with possible values of the categorical variable, as recommended by Schafer.[376]  
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All subsequent univariate analyses were performed using both the complete and 
original (with missing data excluded pairwise) data set and the results for original, 
incomplete variables (Table 17.4 and Table 17.5) are unchanged from the complete 
dataset. 
6.7.2 ASSESSMENT OF NORMALITY 
Assessment of normality was performed for all continuous variables by visual 
inspection of the histogram (Appendix B), as well as analysing the mean, median, 
interquartile range, standard deviation, kurtosis and skewness. Specific statistical tests 
for normality (for example, the Kolmogrov-Smirnov test) can be used to check the 
assumption of normally distributed (parametric) data, however, a limitation of these 
tests is that the larger the sample size, the more likely it is to get significant results 
even with only very slight deviations from normality.[377] Therefore, in our large 
sample, the main method to assess normality was visual inspection of the histogram. 
Parametric tests were performed on variables assumed to come from a normal 
distribution and non-parametric tests were used on non-normally distributed 
variables. 
6.7.3 POPULATION DESCRIPTION 
Descriptive statistics were used to characterise the patient sample, using proportions 
for categorical variables, means with standard deviations (SD) for parametric variables, 
or medians with inter-quartile ranges (IQR) for non-parametric variables. 
6.7.4 UNIVARIATE COMPARISONS 
2-test was used to compare categorical variables, Student’s T-test to compare 
parametric data, and Mann-Whitney U to compare non-parametric variables. To 
examine for trends between multiple groups, ANOVA was used for parametric data 
and Kruskal-Wallis was used for non-parametric variables. Bonferroni’s correction was 
applied to Student’s T test or Mann-Whitney U respectively, to identify between group 
differences.[377] 
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6.8 STATISTICAL METHODS – PART 1 
In addition to the statistical analyses described in section 6.7, variables associated 
with, and independently predictive of, outcome were identified. Logistic regression 
analysis was used to identify predictors of outcome (in-hospital mortality, 12-month 
mortality, 90-day readmission, and frequent readmission). 
For the prediction of mortality, all patients included in the study were analysed, 
whereas, for the prediction of readmission, only the patients who survived the index 
admission were analysed. 
6.8.1 VARIABLE SELECTION FOR REGRESSION ANALYSES 
Univariate associations with outcome were assessed using Student’s t-test, Mann-
Whitney U test, and 2-test (for parametric, non-parametric, and categorical variables 
respectively). Variables with an association with outcome at the significance level of < 
0.10 were carried forward to multivariate testing. Categorical variables with a 
markedly asymmetric split (< 10% of the population in one category) were excluded 
from multivariate testing. An assessment of face validity was also performed for all 
candidate prognostic indices. For example, if there was no biological plausible 
explanation for the relationship between the candidate variable and outcome, or if the 
direction of the relationship between the variable and outcome was in contrast to 
previous research and clinical reasoning, then the variable was excluded.[378] 
Multicollinearity exists when two or more predictor variables are moderately or highly 
correlated. Multicollinearity, to some extent, is inevitable in observational studies but, 
if harmful, can lead to an unstable final regression model which generalises poorly 
outside the study population or can result in nonsensical results.[379] However, it is 
not possible to completely remove collinearity between predictor variables but 
‘harmful’ collinearity can be identified using the following criteria: 
1) Strong significant pairwise correlation between continuous variables 
(collinearity suggested if correlation coefficient > 0.70)[379]; or  
2) High variance inflation factors (VIF): collinearity suggested if largest VIF > 3 or if 
mean VIF > 1.5.[377, 379]; or 
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3) Variables which share high (> 0.50) variance proportions for a corresponding 
low eigenvalue and condition index (i.e. condition index > 30);[377, 379] or 
4) Two variables which measure very similar concepts. 
If high levels of collinearity were detected, and conceptually, it was clear that the 
variables are measuring similar factors, one of the variables was excluded from the 
analysis.[379] For the purposes of this study, the variable with either the weakest 
statistical or conceptual association with outcome on univariate analysis was excluded.  
The univariate relationships between maintenance medications and outcome were 
assessed however, with two exceptions, they were not included in multivariate 
analyses. Only medications which had set eligibility criteria or which might be related 
to underlying COPD disease severity (for example, LTOT or home nebuliser therapy) 
were included in multivariate testing. All other maintenance medications are likely to 
either be collinear with each other or with the participant’s comorbidities. 
Furthermore, significant associations between medications and outcome are likely to 
be biased by ‘confounding by indication’.[380] 
Therefore, all eligible variables showing an association with outcome (p < 0.10) on 
univariate testing that did not show evidence of collinearity were included in the 
logistic regression analysis. 
6.8.2 LOGISTIC REGRESSION ANALYSIS 
Backward stepwise multivariable logistic regression analysis, including all variables 
selected using methods described in section 6.8.1, was performed separately for all of 
the above outcomes (dependent variables). At each step of the regression model, the 
likelihood ratio statistic was used to remove the variables with the weakest association 
with outcome (p > 0.05). Odds ratios were reported with 95% confidence intervals. 
For multivariate models with variables in their original form (i.e. with variables on a 
continuous scale where appropriate), the odds of developing the relevant outcome 
were calculated using the equation below and are shown underneath the table 
summarising each regression model: 
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Where β0 is the Y intercept of the regression model and βn is the regression coefficient 
of the corresponding variable Xn. Based upon this, the predicted probability of 
outcome can be calculated and used for the assessment of model accuracy (section 
6.8.2.2): 
                                              
6.8.2.1 CHECKING MODEL FIT AND ASSUMPTIONS 
In order to assess whether the model was an accurate representation of the observed 
data, outliers were identified by screening studentised residuals. If more than 5% of 
cases are outliers (studentised residual > ±1.96) this implies an unacceptable level of 
error within the model.[377] To further investigate potential statistical outliers, Cook’s 
distance (values greater than 1 suggest that the individual case may be distorting the 
regression model); and leverage values (scores 3 times greater than the expected 
mean leverage indicate cases that might be substantially influencing the model) were 
reported.[377] The expected mean leverage for the population can be calculated 
(expected mean leverage = k+1 / 920, where k = number of variables in the final 
regression model) and compared to the observed mean leverage. Outliers (residual > ± 
1.96) which substantially influenced the model (Cook’s distance > 1 or leverage > 
3(k+1) / 920) were reported and investigated to identify reasons for their distance 
from, and influence on, the regression model.[377] 
6.8.2.2 ASSESSING MODEL ACCURACY 
The accuracy of a prognostic model (i.e. the degree to which predictions match 
outcomes) consists of two components: calibration and discrimination. Calibration 
refers to whether predicted probabilities agree with observed probabilities, and 
discrimination refers to the ability to distinguish between patients with different 
outcomes.[381] Although perfect discrimination and calibration are ideal, the relative 
importance of each varies with the intended application: good calibration would be 
important when trying to counsel patients regarding individual risk, whereas 
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discrimination is more important when trying to stratify patients according to severity 
of disease.[382] Fundamentally, if a model has poor discrimination then no 
adjustments can be made to improve the model, but if poor calibration is present, 
certain adjustments can be made without requiring more data.[381] 
Calibration can be assessed using the Hosmer-Lemeshow goodness-of-fit test (HLGFT) 
which forms subgroups of patients and compares the observed proportion of 
outcomes with the predicted probabilities.[383] The statistic has a 2 distribution and a 
non-significant result (p > 0.05) implies that calibration is satisfactory. However, this 
statistic has limited power to detect poor calibration [384] and therefore, calibration 
can be further assessed by plotting the observed proportion of outcome against the 
predicted probability of outcome, for deciles of risk. Well-calibrated models having a 
line of best fit gradient of 1, while models providing over-optimistic predictions will 
have a gradient of less than 1.[382, 385] The distance from individual coordinates to 
the line of best fit provides information about whether the model is well calibrated 
across all deciles of risk. 
Discrimination refers to the ability to distinguish high-risk patients from low-risk 
patients and is commonly quantified by a measure of concordance, the c-statistic. In 
logistic regression, with a binary dependent variable, the c-statistic is identical to the 
AUROC. 
6.8.2.2.1 RECEIVER OPERATOR CHARACTERISTIC (ROC) CURVES 
For a single binary predictor (or diagnostic test), a simple 2 x 2 contingency table can 
be used to assess how well the predictor (or diagnostic test) predicts outcome (or 
disease) (Table 6.3). The sensitivity (the proportion of true positive results) and 
specificity (the proportion of true negative results) can be calculated and it is 
preferable to have high values for both sensitivity and specificity. 
  
115 
Table 6.3     Calculating sensitivity and specificity 
 
Outcome 
positive 
Outcome 
negative 
Predictor 
positive 
 
TP 
A 
 
FP 
B 
Predictor 
negative 
C 
FN 
D 
TN 
 
TP – true positive; FP – false positive; FN – False negative; TN - true negative 
The receiver operator characteristic (ROC) curve consists of a graphical plot of 
sensitivity against 1-specificity for different discrete cut off points for a diagnostic test 
or prognostic index. The AUROC summarises the discriminative ability of the test or 
predictor across a full range of cut offs. AUROC can take on any value between 0 and 1, 
with 1 being a perfect predictor of outcome, and 0.5 indicating that the test performs 
no better than pure chance. As a rule of thumb, it has been estimated that a diagnostic 
test with AUROC > 0.9 has high accuracy, while 0.7 to 0.9 indicates moderate accuracy 
and 0.5 to 0.7 low accuracy.[386] It is important to note, however, that the AUROC for 
prognostic models is usually lower than for diagnostic tests and ‘good prognostic tools’ 
typically have an AUROC between 0.75 and 0.85.[383, 387] Statistical comparisons of 
AUROC of different models (applied to the same population – paired comparison) can 
be made using the method of DeLong et al.[388] 
ROC curves were drawn, and AUROC and differences between AUROC were calculated, 
using SigmaPlot-11.  
6.8.2.3 ASSESSING MODEL VALIDITY 
Compared to performance in another dataset, prognostic models will have better 
performance on the dataset from which they were derived.[389] The ‘gold-standard’ 
method to assess generalisability is to perform external validation where the model fit 
CA
A
FNTP
TP



 ySens i tivi t
 
DB
D
FPTN
TN
ySpecificit




 
 
116 
and its predictive ability are reassessed on a similar population which differs from the 
derivation cohort in both time and geography.[390] However, although necessary prior 
to implementation in clinical practice, external validation requires a further study at a 
different time in a different population, to the original dataset, and is therefore time-
consuming and expensive. In the absence of external validation, internal validation is 
often used to give further confidence to the prognostic model prior to future external 
validation. 
The pseudo-R2 (i.e. Nagelkerke’s R2) value provides an estimation of the amount of 
variance in the outcome variable that is explained by the model, and can be used to 
estimate model performance, with higher values implying better generalisability. An 
alternative option is to split the cohort so that a proportion of patients are used to 
derive the prognostic tool and a second distinct proportion used to validate it (split-
sample validation). However, this: does not replace the need for external validation; 
limits the power of the derivation cohort therefore weakening the developed 
prognostic tool; and requires a very large sample size to provide a reliable 
approximation to external validation.[389] A method which can be used to assess 
internal validation which uses the entire study population to both derive and internally 
validate the prognostic tool is bootstrapping. 
Bootstrapping is a well known method to assess variability in test statistics and, in a 
predictive logistic regression model, is recommended as a better method to assess 
internal validity than split-sample validation.[389] The bootstrap is a resampling 
procedure where a dataset is randomly sampled with replacement (i.e. when an item 
is sampled it is immediately replaced) multiple times.[391] From the resampled 
dataset, conclusions can be drawn regarding the internal consistency of the data and 
tests of model performance (e.g. AUROC) can be bootstrapped to check internal 
validity. To assess internal validity of the prognostic models developed here, bootstrap 
estimates (using 10,000 bootstrap samples) of the AUROC were performed and 
reported with 95% confidence intervals.  
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6.8.3 DEVELOPING A PREDICTIVE TOOL 
6.8.3.1 TOOL OUTLINE 
We wished to develop a prognostic tool that would both accurately predict outcome 
and be simple to remember and to use in clinical practice. Therefore, the predictive 
instrument would ideally contain a limited number of variables and the predictor 
variables should be categorical, with only 2 or 3 categories. Therefore, prior to 
selecting variables for our predictive tool, all continuous variables were dichotomised 
or categorised. Categorical variables with a markedly asymmetric split (< 10% of the 
population in one category) were excluded from further analyses. 
6.8.3.2 SELECTING APPROPRIATE CUT OFFS 
Visual inspection of the ROC curve can be used to identify which cut off value 
optimises both sensitivity and specificity. The coordinate of the ROC curve which lies 
closest to either the upper left-hand corner of the graph (y = 1, x = 0) when predicting 
mortality, or closest to the bottom right-hand corner (y = 0, x = 1) when predicting 
survival, corresponds to the ‘best’ cut off value (Figure 6.1).  
Figure 6.1     Using ROC curve to select most appropriate cut offs for variables that are 
independently predictive of outcome 
 
A single cut off point may not always be obvious from ROC curve analysis (Figure 6.1) 
and therefore, in such situations we used further methods to confirm appropriate cut-
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offs. We therefore used the following hierarchy of decisions to assign categories to 
continuous variables: 1. ROC curve analysis; 2. Results from previous relevant research; 
3. A clinically appropriate cut off; 4. Using a median split.  
6.8.3.3 IDENTIFYING PREDICTOR VARIABLES AND ASSIGNING WEIGHTS 
All variables associated with outcome on univariate analysis were, following 
categorisation, entered into a backward stepwise logistic regression analysis, as 
outlined in sections 6.8.2 and 6.8.2.1. The β coefficient was then used to select 
variables with the strongest association with outcome to be retained in the predictive 
tool. For pragmatic reasons, between 5 and 7 predictive indices were included in the 
clinical prediction tool. The β coefficient was also used to assign relative weights to the 
predictor variables so that particularly strong predictors scored more highly than less 
strong predictors.[392] 
6.8.3.4 ASSESSING PREDICTIVE TOOL PERFORMANCE 
Discrimination of the predictive tool for in-hospital mortality was assessed via AUROC. 
Comparison between AUROC of the predictive tool and other prognostic scores (i.e. 
APACHE, CAPS and CURB-65 prognostic scores) was made using the method described 
by Delong.[388] Internal validation of the predictive tool was performed by 
bootstrapping the AUROC and obtaining 95% confidence intervals. Calibration of the 
tool was assessed by comparing the predicted probability of outcome (according to the 
regression model including all uncategorised variables, described in section 6.8.2.2) 
against the observed probability of outcome, for each grade of the predictive tool. 
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PART 1: PREDICTING OUTCOME 
FOLLOWING HOSPITALISATION FOR 
AECOPD 
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CHAPTER 7  DATA SCREENING AND POPULATION DESCRIPTION 
7.1 MISSING VALUES AND DATA IMPUTATION 
Data on 920 patients were collected. Prior to further analysis, pH was converted to 
hydrogen ion concentration ([H+] = 10-pH) and results converted back to pH where 
appropriate to assist interpretation. Details of missing data for the remaining 920 
patients were collected and the characteristics of patients with missing data values are 
shown in Table 17.2. Variables with < 1% missing values (respiratory rate, temperature, 
sodium, haemoglobin, white cell count, haematocrit, urea, creatinine, CRP, and 
eosinophil count) are not shown. Most variables had few (< 10%) missing values 
although serum glucose, the number of exacerbations in the previous year, and 
spirometry within 2 years of admission had frequent missing values (> 10%). There 
were no differences between patients with and without serum glucose values, 
although patients with missing spirometry and exacerbation frequency data were: 
older; had a higher comorbidity burden; were more likely to be male (for exacerbation 
frequency only); experienced more severe stable-state dyspnoea; and had a lower 
BMI. 
Data for missing values were imputed using EM algorithm (section 6.7.1.1), the results 
of which are shown in Appendix C (Table 17.3). Comparisons between the imputed and 
original dataset for variables with < 1% missing values were virtually identical, with no 
significant differences, and are therefore not shown. Mean, standard deviation and 
standard error are shown for all variables (including non-parametric data) in order to 
assist more detailed comparison between the original and imputed dataset. 
All subsequent analyses are reported using the complete dataset. All univariate 
analyses were repeated using the original dataset and there are no significant 
differences in results between the two datasets (Appendix D, Table 17.4 and Table 
17.5).  
The distribution of individual variables was assessed as detailed in section 6.7.2. 
Histograms, descriptive statistics, and the assessment of distribution (parametric or 
non-parametric) are shown in section Appendix B. 
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7.2 POPULATION DESCRIPTION 
7.2.1 SUMMARY OF STUDY POPULATION 
Summary characteristics of the 920 patients recruited are listed in Table 7.1. Mean 
patient age was 73.1 and most: had a significant smoking history; were markedly 
limited by dyspnoea during their stable state; and reported frequent episodes of 
AECOPD in the year preceding admission. Most also had severe airflow obstruction, 
multiple medical comorbidities, and although mean BMI was within the normal range, 
16.7% were underweight (BMI < 18.5 kgm-2).  
Table 7.1     Population summary 
Variable Value* 
Sociodemographic details, 
Admission hospital (NTGH), % 
Age (years) 
Female, % 
Smoking load (CPY), median (IQR) 
Institutional care, % 
 
54.9 
73.1 (10.0) 
53.9 
45 (32 to 60) 
6.5 
Markers of disease severity, 
Number of hospital admissions in previous year, median (IQR) 
Number of AECOPD in previous year, median (IQR) 
FEV1 % predicted 
MRCD, median (IQR) 
 
0 (0 to 1) 
3 (1 to 4) 
43.6 (17.2) 
4 (4 to 5) 
Comorbidity & nutritional status, 
CCI, median (IQR) 
BMI, kgm
-2
 
 
2 (1 to 3) 
24.6 (6.3) 
* values quoted are mean (SD) unless otherwise stated; CPY – cigarette pack years; CCI - Charlson 
comorbidity index 
A more detailed description of the population follows in Chapter 9. 
7.2.2 COMPARISON BETWEEN HOSPITAL SITES 
There was no difference in sociodemographic details, between patients admitted to 
each of the two institutions involved in this study. There were also similar average 
values for: markers of health resource use in the previous year; severity of stable-state 
dyspnoea; comorbidity burden; and nutritional status. There was however, a clinically 
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small but statistically significant difference in FEV1 % predicted, with lower mean 
values in the WGH cohort (Table 7.2). 
Table 7.2     Comparison of population description between institutions 
Variable NTGH* (n=505) WGH* (n=415) 
Sociodemographic details, 
Age (years) 
Female, % 
Smoking load (CPY), median (IQR) 
Institutional care prior to admission, % 
 
73.1 (10.4) 
54.5 
45 (32 to 60) 
6.5 
 
73.1 (9.7) 
53.3 
45 (32 to 60) 
6.5 
Markers of disease severity, 
Number of hospital admissions in previous year, median (IQR) 
Number of AECOPD in previous year, median (IQR) 
FEV1 % predicted 
MRCD, median (IQR) 
 
0 (0 to 1) 
3 (1 to 4) 
44.8 (16.7)† 
4 (3 to 5) 
 
0 (0 to 1) 
3 (2 to 4) 
42.1 (17.6)† 
4 (4 to 5) 
Comorbidity & nutritional status, 
CCI, median (IQR) 
BMI, kgm
-2
 
 
2 (1 to 3) 
24.4 (6.2) 
 
2 (1 to 3) 
24.7 (6.4) 
* values quoted are mean (SD) unless otherwise stated; † significant difference between NTGH and 
WGH, p=0.016; CPY – cigarette pack years; CCI – Charlson comorbidity index 
7.2.3 MORTALITY FOLLOWING HOSPITALISATION FOR AECOPD 
96 (10.4%) died during the index admission and 115 (12.5%) died within 30 days of 
admission. The mortality rates from admission were: 19.0% at 90 days; 23.5% at 180 
days; and 31.6% at 1 year (Figure 7.1). For those who died within 12 months of 
admission, median time to mortality following admission was 50 (IQR 13 to 184) days. 
In-hospital mortality was similar at both institutions (10.3% at NTGH, 10.6% WGH, p = 
0.88), and there was no significant difference between institutions in 12-month 
survival following admission (Log-rank p = 0.41). 
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Figure 7.1     Proportion of patients surviving following hospitalisation for AECOPD, 
stratified according to site of hospital admission 
 
Most of the 291 deaths (78.4%) during the follow-up period were due to respiratory 
causes although the relative proportion of deaths due to non-respiratory causes 
increased as the time to death increased (Table 7.3). 
Table 7.3     Cause of death stratified according to time from admission to death 
 Respiratory cause, 
n (%) 
Cardiovascular cause, 
n (%) 
Other cause, 
n (%) 
In-hospital mortality 86 (89.6) 3 (3.1) 7 (7.3) 
30-day mortality 100 (87) 9 (7.8) 6 (5.2) 
12-month mortality 227 (78.3) 29 (10) 35 (12.0) 
7.2.4 READMISSION 
Of the 824 patients surviving the index admission, the proportions of patients who 
were readmitted, or who died without being readmitted, to hospital were: 21.0% 
within 28 days of discharge; 37.3% within 90 days; 51.8% within 180 days; and 66.3% 
within 1 year (Figure 7.2). Median admission-free survival time was 168 (IQR 136 to 
200) days. There was no significant difference in readmission rates between 
institutions (Log rank p = 0.14). There was no difference in the 90-day readmission rate 
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(not including deaths without readmission) in this study compared to the UK National 
COPD Audit (33.4% v. 33% respectively).[12] 
The median annual number of readmissions following hospital discharge was 1 (IQR 0 
to 2, range 0 to 15) and 287 (34.7%) patients experienced frequent (≥ 2) readmissions 
during the year following discharge. There was no difference between the number of 
patients experiencing frequent readmissions between institution (p = 0.64). 
Figure 7.2     Survival curve for readmission following discharge, stratified according to 
admission hospital site 
 
For all patients surviving to discharge, whether they were readmitted or not, the 
median total length of stay during the follow-up period was 2 (IQR 0 to 14, range 0 to 
228) days, and, of those patients who experienced at least 1 readmission (n = 546), 
medial total length of stay was 9 (IQR 2 to 23) days. 
7.2.5 DEVELOPMENTS DURING ADMISSION 
7.2.5.1 ASSISTED VENTILATION  
At the time of, or shortly after, hospital admission, 18.8% (173) of patients had 
acidaemic respiratory failure (pH < 7.35 and paCO2 > 6kPa) and were therefore 
potential candidates for assisted ventilation. Of these, 33 (19.1%) improved with 
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medical therapy and did not require assisted ventilation and in 10 (5.8%) assisted 
ventilation was deemed not clinically appropriate. Therefore, 130 (75.1%) patients 
were ventilated (127 treated with NIV and 3 intubated and ventilated) shortly after 
admission to hospital.  
A further 84 (9.1%) patients developed acidaemic respiratory failure during their 
hospital stay and of these: 11 (13.1%) improved with medical therapy; 4 (4.8%) were 
deemed not suitable for assisted ventilation; and 69 (82.1%) were ventilated (68 
treated with NIV, 1 intubated and ventilated) (Appendix F, Figure 17.1). 
7.2.5.2 SPECIALIST CARE, LENGTH OF STAY AND DISCHARGE LOCATION 
Overall, 67.4% of patients were under the care of a respiratory consultant during at 
least part of their hospital stay. Significantly more patients at the larger institute in our 
study (NTGH) were cared for by a respiratory consultant for some period of their 
hospital stay (72.1% at NTGH v. 61.7% at WGH, p = 0.0009).  
Median length of stay was 6 (IQR 8 days) and there was no significant difference in 
length of stay between NTGH and WGH (median (IQR) 6 (8) v. 6 (7) respectively, p = 
0.0600). The apparent trend to a shorter length of stay at WGH is likely to be due to 
different geographical locations and catchment areas. In comparison to NTGH, WGH is 
located in a rural setting with a number of satellite, rural cottage hospitals available to 
facilitate early discharge of patients to a location close to their home, particularly in 
patients thought likely to require institutional care in the medium to long-term. The 
discharge destinations of patients surviving the index admission highlight the larger 
proportion of patients discharged from WGH to a community or rehabilitation hospital 
(Table 7.4): 
Table 7.4     Discharge destination and admission institution 
Discharge destination NTGH, n (%) WGH, n (%) 
Home 376 (83.0) 316 (85.2) 
Sheltered accommodation 37 (8.2) 10 (2.7) 
Residential care 12 (2.6) 6 (1.6) 
Nursing home 18 (4) 2 (0.5) 
Community / rehabilitation hospital 10 (2.2) 37 (10) 
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CHAPTER 8  CONSOLIDATION, DYSPNOEA AND NUTRITION 
8.1 COEXISTENT CONSOLIDATION AND THE EXTENDED MRC DYSPNOEA 
SCORE 
Aim 1a: to compare the characteristics and outcomes of patients with and without 
coexistent pneumonia 
Aim 1b: evaluation of the extended MRC Dyspnoea Scale with specific reference to 
correlation with survival, readmission rates length of stay and frequency of hospital 
readmission. 
8.1.1 COEXISTENT PNEUMONIA IN AECOPD 
299 (32.5%) patients had evidence of consolidation on the admission chest radiograph 
(pAECOPD). Compared to npAECOPD, patients with coexistent consolidation were: 
older; had more severe lung function impairment; and had a greater comorbidity 
burden (Table 8.1). Furthermore, pAECOPD was also associated with more markers of 
exacerbation severity: more frequent acute confusion; lower blood pressure; lower 
serum albumin; higher paCO2; higher urea; and higher neutrophil count. pAECOPD was 
associated with increased risks of adverse outcome: need for ventilation; length of 
hospital stay; and in-hospital mortality, although there was no difference in 28-day 
readmission rates amongst survivors of the initial admission (Table 8.1). 
Table 8.1     Characteristics of pneumonic and non-pneumonic exacerbations 
Variable pAECOPD*,  
n = 299 
npAECOPD*,  
n = 621 
p 
value 
Sociodemographic details, 
Age (years) 75.8 (9.1) 71.7 (10.2) <0.0001 
Female, % 49.5 56.0 0.0665 
Smoking load (CPY), median (IQR) 43 (30 to 60) 45 (32 to 60) 0.42 
Institutional care, % 9.4 5.2 0.0217 
Markers of disease severity, 
Number of hospital admissions in previous 
year, median (IQR) 
1 (0 to 1) 0 (0 to 1) 0.18 
Number of AECOPD in previous year, median 
(IQR) 
3 (1 to 4) 3 (1 to 4) 0.87 
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Variable pAECOPD*,  
n = 299 
npAECOPD*,  
n = 621 
p 
value 
FEV1 % predicted 45.4 (16.6) 42.7 (17.4) 0.0261 
MRCD, median (IQR) 4 (4 to 5) 4 (3 to 5) 0.0520 
Housebound, % 38.8 32.2 0.0540 
Comorbidity & nutritional status, 
CCI, median (IQR) 2 (1 to 3) ‡ 2 (1 to 3) ‡ 0.0150 
BMI, kgm
-2
 24.4 (6.0) 24.7 (6.4) 0.52 
Severity of acute exacerbation, 
Purulent sputum, % 56.2 47.8 0.0201 
Acute confusion, % 18.4 9.8 0.0004 
Pedal oedema, % 29.8 24.6 0.11 
Heart rate, min
-1
 103.9 (22.3) 102.1 (20.0) 0.23 
Respiratory rate, min
-1
 26.2 (6.9) 25.9 (6.0) 0.44 
Diastolic blood pressure, mmHg 72.2 (17.9) 78.1 (16.2) <0.0001 
Albumin, g/L 36.2 (4.8) 39.4 (4.4) <0.0001 
pH (median, IQR) 7.42 (7.35 to 7.46) 7.41 (7.36 to 7.45) 0.64 
paCO2, kPa (median, IQR) 5.6 (4.7 to 7.3) 6.0 (5.1 to 7.5) 0.0190 
Urea, mmol/L (median, IQR) 7.9 (5.7 to 11.2) 6.0 (4.4 to 8.4) <0.0001 
Glucose, mmol/L
 
(median, IQR) 7.1 (6.0 to 8.2) 6.8 (6.0 to 8.0) 0.18 
Neutrophil count, x10
9
/L (median, IQR) 11.7 (8.3 to 15.5) 8.3 (6.2 to 11.7) <0.0001 
Developments during hospital admission, 
Assisted ventilation, % 27.1 19.0 0.0062 
Length of stay, days (median, IQR) 7 (4 to 13) 6 (3 to 10) <0.0001 
In-hospital mortality, % 20.1 5.8 <0.0001 
28-day readmission, %† 20.1 21.4 0.68 
* values quoted are mean (SD) unless otherwise stated; † in patients surviving to discharge, n=824; ‡ 
pAECOPD greater than npAECOPD; CPY – cigarette pack years; CCI – Charlson comorbidity index (Table 
17.1) 
8.1.2 THE EXTENDED MRC DYSPNOEA SCALE 
The distribution of patients within each dyspnoea grade and the frequency of 
outcomes for the total population and the pAECOPD and npAECOPD subgroups are 
shown in Table 8.2 and Table 8.3. Pre-admission, during a period of clinical stability, 
315 (34.2%) patients were too breathless to leave the house (MRCD 5). Of these, 173 
(54.9%) were independent in washing and / or dressing (eMRCD 5a) and 142 (45.1%) 
were dependent in washing and dressing (eMRCD 5b) (Table 5.1).  
Of the 96 patients who died in hospital, 30 were eMRCD 5a (17.3% mortality) and 47 
eMRCD 5b (33.1% mortality) (p = 0.0015). The higher in-hospital mortality rate in 
eMRCD 5b is not explainable by clinicians limiting the level of care or introducing early 
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palliative care in this group: of the 51 patients with eMRCD 5b who met the criteria for 
assisted ventilation, 44 received it. In both the pAECOPD and npAECOPD subgroups, 
patients with eMRCD 5b had a higher in-hospital mortality rate than 5a (p = 0.0533 and 
p = 0.0846 respectively) (Table 8.2). For the total population, eMRCD 5b had a 
significantly higher 30-day (p = 0.0313) and 12-month (p = 0.0002) mortality rate.  
The 28-day readmission or death rate was significantly higher for eMRCD 5b than 
eMRCD 5a in the case of npAECOPD (p = 0.0017). It was absolutely, but non-
significantly, higher in the total population (p = 0.0858). In pAECOPD, the rate was non-
significantly lower with eMRCD 5b than 5a (p=0.21); this is likely to be due to a survivor 
effect given the high in-hospital mortality in the former group. The 90-day readmission 
or death rate for both the total population and the subgroup without coexistent 
consolidation was higher with eMRCD 5b than 5a (p = 0.0008 and p = 0.0003 
respectively). In pAECOPD, the 90-day readmission or death rate increased as 
dyspnoea severity increased, although there was no difference between 5b and 5a (p = 
0.81). There was a significant difference in the number of patients who experienced 
frequent readmission across both the traditional and extended MRCD scales (p = 
0.0002 for MRCD and p = 0.0005 for eMRCD), although there was no significant 
difference between 5b and 5a. 
 
 Table 8.2     Relation of dyspnoea grade and presence or absence of consolidation to mortality 
Dyspnoea grade n In-hospital mortality, n (%) 30-day mortality, %* 12-month mortality, %* 
Total npAECOPD pAECOPD Total Total 
1 6 0 0 0 0 0 
2 46 0 0 0 0 2 (4.3) 
3 171 4 (2.3) 2 (1.6) 2 (4.4) 5 (2.9) 19 (11.1) 
4 382 15 (3.9) 1 (0.4) 14 (11.8) 23 (6.0) 82 (21.5) 
5 315 77 (24.4) 33 (16.6) 44 (37.9) 87 (27.6) 188 (59.7) 
5a 173 30 (17.3)† 15 (12.4) 15 (28.8) 39 (22.5)‡ 87 (50.3)† 
5b 142 47 (33.1)† 18 (23.1) 29 (45.3) 48 (33.8)‡ 101 (71.1)† 
* from time of hospital admission; † significant difference between 5a and 5b, p<0.01; ‡ significant difference between 5b and 5a, p<0.05 
Table 8.3     Relation of dyspnoea grade and presence or absence of consolidation to readmission 
Dyspnoea grade n 28-day readmission or death, %* 90-day readmission or death, %* Frequent readmission, % 
Total npAECOPD pAECOPD Total npAECOPD pAECOPD Total 
1 6 0 0 0 1 (16.7) 1 (20.0) 0 1 (16.7) 
2 46 3 (6.5) 3 (10.7) 0 5 (10.9) 5 (17.9) 0 11 (23.9) 
3 167 21 (12.6) 15 (12.1) 6 (14.0) 34 (20.4) 28 (22.6) 6 (14.0) 35 (21.0) 
4 367 75 (20.4) 55 (21.0) 20 (19.0) 129 (35.1) 91 (34.7) 38 (36.2) 145 (39.5) 
5 238 74 (31.1) 52 (31.3) 22 (30.6) 138 (58.0) 90 (54.2) 48 (66.7) 94 (39.5) 
5a 143 38 (26.6) 24 (22.6)† 14 (37.8) 70 (49.0)† 46 (43.4)† 24 (64.9) 55 (38.5) 
5b 95 36 (37.9) 28 (46.7)† 8 (22.9) 68 (71.6)† 44 (73.3)† 24 (68.6) 39 (41.1) 
* Of those surviving to discharge (n=824), the number of patients readmitted or who died without being readmitted, within the stated time period; † significant difference 
between 5a and 5b, p<0.005 
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8.1.3 PNEUMONIA, DYSPNOEA AND CURB-65 
Of the 299 patients with pAECOPD, median CURB-65 score was 2 (IQR 1 to 3) and 109 
(36.5%) had CURB-65 scores of 3 to 5 and therefore a high risk of mortality (Table 8.4). 
Mortality rates for each CURB-65 score were higher in pAECOPD than npAECOPD. For 
comparison, the expected mortality in community acquired pneumonia is shown in the 
last column. 
Table 8.4     Distribution of patients, and rates of mortality, according to CURB-65 score 
CURB-65 
Score 
Total population npAECOPD pAECOPD 
n (%) 
Mortality, 
% 
n 
Mortality, 
% 
n 
Mortality, 
% 
Expected mortality 
in CAP, %* 
0  135 (14.7) 4.4 115 2.6 20 15 0.6 
1 278 (30.2) 4.0 208 1.9 70 10.0 3.0 
2 295 (32.1) 9.5 195 6.2 100 16.0 6.1 
3 169 (18.4) 20.1 87 16.1 82 24.4 16.1 
4 36 (3.9) 36.1 15 20 21 47.6 36.9 
5 7 (0.8) 57.1 1 n/a 6 66.7 43 
*for community acquired pneumonia (from Aujesky et al)[393] 
The discriminatory ability, of MRCD, eMRCD and CURB-65 to predict in-hospital 
mortality were assessed and compared using AUROC (Table 8.5). In the population as a 
whole, eMRCD had significantly better discrimination for mortality than either MRCD 
(p = 0.0012) or CURB-65 (p = 0.0193), and in npAECOPD there was a non-significant 
trend to better discrimination for eMRCD compared to both CURB-65 (p = 0.0528) and 
MRCD (p = 0.0571). In pAECOPD, eMRCD performed significantly better than CURB-65 
(p = 0.0168), and there were also non-significant trends favouring both eMRCD over 
MRCD (p = 0.0714) and MRCD over CURB-65 (p = 0.0630). The discriminative strength 
of eMRCD for in-hospital mortality is shown in Figure 8.1. 
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Table 8.5     Area under ROC curve for prediction of in-hospital mortality 
 MRCD eMRCD CURB-65 
Total 0.769 (0.73 to 0.81) 0.794 (0.75 to 0.84)†‡ 0.717 (0.66 to 0.77) 
npAECOPD 0.809 (0.75 to 0.87) 0.833 (0.77 to 0.90) 0.719 (0.63 to 0.81) 
pAECOPD 0.740 (0.68 to 0.80) 0.759 (0.70 to 0.82)‡ 0.661 (0.58 to 0.74) 
† significant difference compared to MRCD, p<0.01; ‡ significant difference compared to CURB-65, 
p<0.05 
Figure 8.1     The discrimination of eMRCD for in-hospital mortality for the total 
population, non-pneumonic and pneumonic exacerbations of COPD  
 
Compared to the discrimination of mortality, among the total population of patients 
surviving to discharge, eMRCD was a less strong predictor of single and frequent 
readmission: AUROC28-day = 0.631, 0.588 to 0.675; AUROC90-day = 0.683, 0.648 to 0.718; 
AUROCfrequent = 0.576, 0.539 to 0.614 (Figure 8.2). 
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Figure 8.2     The discrimination of eMRCD for readmission for the total population  
 
8.2 NUTRITIONAL STATUS, MORTALITY AND READMISSION 
Aim 1c: evaluation of the Malnutrition Universal Screening Tool with specific reference 
to correlation with survival, readmission rates length of stay and frequency of hospital 
readmission. 
Mean BMI (SD) within our population was 24.6 (6.3) kgm-2: 16.3% were underweight (< 
18.5 kgm-2); 18.3% were obese (≥ 30 kgm-2) and 2.2% were morbidly obese (≥ 40 kgm-
2). 226 (24.6%) reported at least 5% of unintentional weight loss in the previous six 
months, and 341 (37.1%) were at least at a moderate risk of malnutrition (MUST ≥ 1). 
The distribution of nutritional parameters within our population is shown in Figure 8.3.  
 
134 
Figure 8.3     Distribution of nutritional parameters within the population 
 
Low BMI (< 18.5 kgm-2) was associated with the highest risk of in-hospital mortality 
compared to other BMI categories. Our data showed evidence of the ‘obesity paradox’ 
(lower mortality risk in overweight individuals with COPD, section 1.1.3.1.2) with the 
lowest mortality rate in obese patients (30 – 39.99 kgm-2). There was a non-linear 
relationship between BMI and both in-hospital and 12-month mortality (Figure 8.4): 
the risk of death increased in the morbidly obese (≥ 40 kgm-2). More self-reported 
weight loss and a high risk of malnutrition were both strongly associated with in-
hospital and 12-month mortality.  
Hospital readmission was strongly and linearly associated with unintentional weight 
loss and malnutrition risk, whereas there was a U-shaped relationship with BMI (Figure 
8.4). In agreement with the data on mortality, the highest rates of readmission were in 
the underweight and morbidly obese individuals. No relationship was found between 
nutritional status and frequent readmissions, perhaps due to the association between 
nutritional parameters and mortality. 
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Table 8.6     Distribution of nutritional measurements within our population and their 
association with in-hospital mortality and readmission following discharge 
Nutritional 
parameter 
n* In-hospital 
mortality, % 
12-month 
mortality, % 
n† 90-day 
readmission, 
%† 
Frequent 
readmission, %‡ 
BMI, kgm
-2
 
< 18.5 
18.5 - 24.99 
25 – 29.99 
30 – 39.99 
≥ 40 
 
154 
354 
244 
148 
20 
 
18.8 
10.7 
8.2 
4.7 
10.0 
p
 =
 0
.0
0
1
2
 
 
53.2 
35.0 
23.8 
19.6 
35.0 
p
 <
 0
.0
0
0
1
 
 
125 
316 
224 
141 
18 
 
50.4 
34.2 
34.8 
34.8 
50.0 
p
 =
 0
.0
1
3
 
 
36.0 
34.5 
37.9 
28.4 
38.9 
p
 =
 0
.4
4
 
Weight loss, 
< 5% 
5 - 10% 
> 10% 
 
694 
130 
96 
 
7.9 
18.5 
17.7 
p
 =
 0
.0
0
0
1
 
 
26.5 
43.8 
61.5 
p
 <
 0
.0
0
0
1
 
 
639 
106 
79 
 
33.3 
47.2 
55.7 
p
 =
 0
.0
0
0
1
 
 
33.6 
36.8 
40.5 
p
 =
 0
.4
3
 
MUST, 
0 
1 
≥ 2 
 
579 
117 
224 
 
6.9 
12 
18.8 
p
 <
 0
.0
0
0
1
 
 
23.1 
35.9 
55.4 
p
 <
 0
.0
0
0
1
 
 
539 
103 
182 
 
32.8 
35.9 
51.1 
p
 =
 0
.0
0
0
1
 
 
34.3 
32.0 
37.4 
p
 =
 0
.6
3
 
 * at admission to hospital, n=920; † of patients surviving to discharge, n=824, and including patients 
who died without being readmitted; ‡ ≥ 2 hospital readmissions within 12 months of discharge 
To further investigate the increase in risk of mortality and readmission at very high 
BMI values, a plot of in-hospital and 12-month mortality rates, and 90-day readmission 
rates, against BMI (split into categories with n > 20) is shown in Figure 8.4. This 
suggests that BMI has a non-linear relationship with 12-month mortality and 90-day 
readmission or death. It is difficult to comment on the shape of the in-hospital 
mortality line because of the small number of deaths in patients with a very high BMI 
(2 deaths in BMI ≥ 40 kgm-2). 
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Figure 8.4     Graph showing risk of mortality and readmission according to BMI 
 
In our population, underweight patients were older and had greater impairment of 
lung function compared to obese and morbidly obese individuals (Table 8.7). Therefore 
the relationship between low BMI and outcome may be explained by the effects of age 
and lung function. However, when comparing morbidly obese patients to obese 
patients, there was no difference in age or the severity of underlying disease to explain 
the higher 12-month mortality and 90-day readmission in morbidly obese individuals 
(Table 8.7). This suggests that the effect of very high BMI on outcome is mediated 
through other mechanisms: increased prevalence of cardiovascular comorbidity and 
diabetes; or limitation in respiratory function due to the restrictive effects of central 
adiposity.  
Table 8.7     Age and FEV1 stratified by BMI 
 BMI (kgm-2) 
Variable < 18.5 
18.5 to 
24.99 
25 to 
29.99 
30 to 39.99 ≥ 40 
Age, years (mean, SD) 75.1 (9.9) 73.5 (10.3) 73.2 (9.7) 70.6 (9.5)*† 
66.1 
(8.9)*†‡ 
FEV1 % predicted (mean, 
SD) 
38.9 
(16.5) 
42.1 (17.3) 44.8 (17.1)* 
49.3 
(16.0)*† 
47.7 (15.8) 
* significant difference compared to BMI <18.5; † significant difference compared to BMI 18.5 to 24.99; 
‡ significant difference compared to BMI 25 to 29.99. 
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CHAPTER 9  PREDICTING MORTALITY IN PATIENTS HOSPITALISED WITH 
AECOPD 
9.1 PREDICTING IN-HOSPITAL MORTALITY 
Aim 1d:  identify independent predictors of in-hospital mortality following 
hospitalisation for AECOPD and develop a clinical prediction tool to accurately predict 
the risk of in-hospital mortality. 
9.1.1 UNIVARIATE ASSOCIATIONS WITH IN-HOSPITAL MORTALITY 
9.1.1.1 SOCIODEMOGRAPHIC DETAILS 
There was no association between in-hospital mortality and patient sex, admission 
institution and overall smoking load. However, older age, residence in institutional 
care prior to admission, abstinence from cigarette smoking, and need for assistance 
with activities of daily living were all associated with in-hospital mortality (Table 9.1).  
Table 9.1     Sociodemographic details and their relationship with in-hospital mortality 
Variable Total 
population, 
n=920 
Survived to 
discharge, 
n=824 
Died in 
hospital, 
n=96 
p 
value 
Age 73.1 (10.0) 72.3 (10.0) 79.2 (8.0) <0.0001 
Female, % 53.9 54.2 51.0 0.59 
Admission hospital (NTGH), % 54.9 55 54.2 0.91 
Institutional care, % 6.5 5.2 17.7 <0.0001 
Social care prior to admission, % 22.9 20.1 46.9 <0.0001 
Current smoker, % 44.3 45.9 31.3 0.0069 
Smoking load (CPY), median 
(IQR) 
45 (32 to 60) 45 (32 to 60) 42.5 (30 to 60) 0.69 
NTGH – North Tyneside General Hospital; CPY – cigarette pack years 
9.1.1.1.1 SMOKING STATUS 
The direction of the relationship between smoking status and mortality is at first sight 
surprising, with ex-smokers at increased risk of in-hospital mortality. This is in contrast 
to previous research and clinical reasoning. It was acknowledged that smoking status 
was inconsistently reported by patients, and was biased by both a survivor effect 
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(ongoing smokers at increased risk of premature death prior to potential entry in to 
study) and by confounding effects of age and COPD severity (i.e. older patients and 
those with severe disease are more likely to have been successfully treated with 
smoking cessation therapies). Comparing current smokers with ex-smokers confirmed 
this hypothesis: ex-smokers were older (mean (SD) age = 76 (9.2) v. 69 (9.9) years, p < 
0.0001), had worse lung function (mean (SD) FEV1 = 0.93 (0.45) L v. 1.01 (0.42) L, p = 
0.0057), had a greater comorbidity burden (median (IQR) CCI = 2 (2) v. 2 (2), p = 
0.0024), and were more breathless during stable state (median (IQR) eMRCD = 4 (1) v. 
4 (2), p < 0.0001). The association with mortality is in spite of current smoking status 
being associated with more markers of severe AECOPD compared to ex-smokers: 
median (IQR) pH = 7.39 (0.10) in current smokers v. 7.40 (0.09) in ex-smokers, p=0.007; 
and median (IQR) paO2 = 8.3 (3.4) v. 8.8 (3.2), p = 0.030. Therefore, the relationship 
between smoking status and mortality is likely to be a surrogate for other prognostic 
variables and, due also to concerns over the validity of the information, current 
smoking status was removed from further analyses. 
9.1.1.2 HEALTH RESOURCE USE AND DISEASE SEVERITY 
Many patients had been hospitalised during the year prior to admission: 37.8% had 
experienced at least 1 respiratory admission (range 0 to 12), and 48.2% had 
experienced at least 1 admission for any cause (range 0 to 14). Most patients included 
in the study had experienced frequent episodes of AECOPD during the previous year 
(median AECOPD = 3, range 0 to 18). 
Patients who died in-hospital had: lower FEV1, FEV1 % predicted and FVC values; higher 
scores on the traditional and extended MRCD scales (higher score indicated more 
severe dyspnoea); and lower exercise tolerance. There was a trend to increased 
mortality in patients who had experienced more frequent hospitalisation (for any 
cause) in the year preceding admission (Table 9.2). 
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Table 9.2     Prior health resource use, markers of disease severity and in-hospital 
mortality 
Variable Total 
population, 
n=920 
Survived to 
discharge, 
n=824 
Died in 
hospital, 
n=96 
p 
value 
Health resource use, 
Number of respiratory admissions in 
previous year, median (IQR) 
0 (0 to 1) 0 (0 to 1) 0 (0 to 1) 0.58 
Total number of admissions in 
previous year, median (IQR) 
0 (0 to 1) 0 (0 to 1) 1 (0 to 2) 0.0946 
Number of AECOPD in previous year, 
median (IQR) 
3 (1 to 4) 3 (1 to 4) 3 (2 to 4) 0.57 
Previous assisted ventilation, % 11.7 11.3 15.6 0.23 
Previous pulmonary rehabilitation, % 9.5 9.8 6.3 0.28 
Spirometry, 
FEV1 (litres) 0.97 (0.4) 0.99 (0.4) 0.83 (0.3) <0.0001 
FEV1 % predicted 43.6 (17.2) 44.0 (17.4) 39.9 (14.2) 0.0099 
FVC (litres) 2.15 (0.8) 2.18 (0.8) 1.86 (0.6) <0.0001 
FEV1 / FVC, median (IQR) 
0.45 (0.37 to 
0.53) 
0.45 (0.37 to 0.53) 
0.44 (0.39 to 
0.53) 
0.91 
Exercise capacity and disease complications, 
MRCD, median (IQR) 4 (4 to 5) 4 (3 to 5) 5 (5 to 5) <0.0001 
eMRCD, median (IQR) 4 (4 to 5a) 4 (3 to 5a) 5a (5a to 5b) <0.0001 
Exercise tolerance (metres), median 
(IQR) 
25 (10 to 80) 30 (15 to 100) 10 (5 to 20) <0.0001 
Cor pulmonale, % 10.0 9.8 11.5 0.72 
9.1.1.3 COMORBIDITY 
Comorbidity, particularly cardiovascular comorbidity, was common in our population. 
For example, hypertension was present in approximately 40% of patients, and 
ischaemic heart disease in just under 30%.  Significant associations with mortality were 
found with atrial fibrillation, cerebrovascular disease, chronic kidney disease, chronic 
cognitive impairment and the overall comorbidity burden (CCI, Table 17.1). There was 
a trend to an increased risk of mortality in patients with coexistent pulmonary fibrosis 
and valvular heart disease, although both of these conditions were rare in our cohort 
(prevalence of 1.7% and 3.3% respectively) (Table 9.3).  
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The low prevalence rate of certain comorbid conditions in our population is surprising. 
For example, obstructive sleep apnoea (OSA) is estimated to have a population 
prevalence of approximately 10% [394] but was only recorded in 1.6% of our 
population: this may be explained by the difficulties in diagnosing OSA in patients with 
coexistent COPD.[394] 
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Table 9.3     Comorbidity and in-hospital mortality 
Variable Total 
population, 
n=920 
Survived to 
discharge, 
n=824 
Died in 
hospital, 
n=96 
p value 
Respiratory, 
Bronchiectasis, % 6 5.6 9.4 0.17 
Asthma, % 4.9 5.1 3.1 0.47 
Pulmonary fibrosis, % 1.7 1.5 4.2 0.0759 
Obstructive sleep apnoea, % 1.6 1.6 2.1 1.0 
Cardiovascular, 
Hypertension, % 39.6 39.2 42.7 0.51 
Cerebrovascular disease, % 14 12.6 26 0.0007 
Ischaemic heart disease, % 29.3 29.5 28.1 0.81 
Atrial fibrillation, % 12.5 10.9 26 <0.0001 
LV dysfunction, % 7.3 7.4 6.3 0.84 
Thromboembolic disease, % 3.8 3.9 3.1 0.79 
Valvular heart disease, % 3.3 2.9 6.3 0.12 
Peripheral vascular disease, % 7.9 7.8 9.4 0.69 
General, 
Diabetes mellitus, % 14.8 14.7 15.6 0.88 
Osteoporosis, % 12.6 12.0 17.7 0.14 
Rheumatoid arthritis, % 4.0 4.0 4.2 1.0 
Cognitive impairment, % 5.4 4.6 12.5 0.0035 
Chronic kidney disease, % 6.7 5.7 15.6 0.0010 
Anxiety / depression, % 24.2 24.8 19.8 0.32 
Chronic liver disease, % 0.7 0.6 1.0 1.0 
Peptic ulcer disease, % 6.5 6.3 8.3 0.51 
Past history of cancer, % 7.7 7.4 10.4 0.31 
History of active cancer, % 3.8 3.8 4.2 0.78 
Comorbidity burden, 
Charlson Comorbidity Index, 
median (IQR) 
2 (1 to 3) 2 (1 to 3) 2 (1 to 3) 0.0028 
9.1.1.4 PRESCRIBED MEDICATION ON ADMISSION 
Approximately 1 in 8 patients had severe resting hypoxaemia necessitating treatment 
with LTOT and 21% were in receipt of some form of home oxygen therapy. This reflects 
the severity of COPD within this population and is consistent with our data on 
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spirometry and stable-state dyspnoea (section 7.2). Most patients were being treated 
with both ICS and inhaled long-acting beta agonist, and the majority received these 
drugs via a combination inhaler. In keeping with national guidelines, most patients 
were also prescribed an inhaled anticholinergic agent. In total, 9.1% of patients were 
receiving long-term treatment with oral corticosteroids (for any indication), and 
despite evidence of potential harm [15] 70% of these (59 patients) were receiving long-
term oral corticosteroids for the treatment of COPD.  
Individuals in receipt of either LTOT or any form of home oxygen therapy were at a 
significantly higher risk of in-hospital mortality compared to those not receiving 
oxygen. There were no other significant associations with death for any other 
medications (Table 9.4). 
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Table 9.4     Maintenance medications at admission and in-hospital mortality 
Variable Total 
population, 
n=920 
Survived to 
discharge, 
n=824 
Died in 
hospital, 
n=96 
p 
value 
Respiratory, 
LTOT, % 12.4 11.3 21.9 0.0042 
Ambulatory oxygen, % 3.4 3.4 3.1 1.0 
Short burst oxygen, % 7.8 7.6 9.4 0.69 
Home oxygen therapy,* % 21.1 19.8 32.3 0.0057 
Home nebuliser, % 16.6 16.6 16.7 1.0 
Inhaled corticosteroid (ICS), % 81.6 81.3 84.4 0.49 
ICS dose (BDP equivalent), median 
(IQR) 
2000 (1000 to 
2000) 
2000 (1000 to 
2000) 
2000 (2000 
to 2000) 
0.69 
Inhaled long-acting beta agonist, % 77.7 77.5 79.2 0.80 
Combination inhaler, % 72.1 71.8 74 0.72 
Inhaled anticholinergic, % 70.8 70.3 75 0.35 
Long-term oral corticosteroid, % 9.1 8.7 12.5 0.26 
Carbocysteine, % 16.1 15.8 18.8 0.46 
Theophylline, % 8 7.9 9.4 0.69 
Cardiovascular, 
Statin, % 44.9 45.3 41.7 0.52 
Beta-blocker, % 10.8 10.8 10.4 1.0 
ACE inhibitor, % 24.2 24.4 22.9 0.80 
Angiotensin receptor blocker, % 5.7 5.6 6.3 0.81 
Diuretic, % 35.4 34.6 42.7 0.14 
Other, 
Benzodiazepine,† % 5.8 5.6 7.3 0.64 
Opiate,† % 0.9 0.8 1 1.0 
* either LTOT, ambulatory O2 or short burst O2; † prescribed for the symptomatic relief of dyspnoea / 
anxiety; ICS – inhaled corticosteroid; BDP – beclomethasone diproprionate; ACE – Angiotensin 
converting enzyme 
9.1.1.5 ADMISSION CLINICAL DATA 
Purulent sputum was reported to have been expectorated during the exacerbation by 
51.3% of patients, although a further 25.1% were recorded as having a non-effective 
cough which may have resulted in an inability to clear purulent secretions from the 
lungs. One in eight patients were acutely confused at hospital admission and most 
patients were tachycardic and tachypnoeic. Although most patients were 
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normotensive, 17.7% were hypotensive (systolic blood pressure (BP) < 90 mmHg or 
diastolic BP ≤ 60 mmHg) on admission. Almost a third of patients had evidence of 
coexistent radiographic consolidation at admission to hospital. 
Significant associations with mortality are shown in Table 9.5 and the strongest 
associations were with: cough effectiveness; acute confusion; high respiratory rate; 
low temperature; low BMI; weight loss; high MUST score; and radiographic 
consolidation. 
Table 9.5     Clinical information on admission and in-hospital mortality 
Variable Total 
population, 
n=920 
Survived to 
discharge, 
n=824 
Died in 
hospital, 
n=96 
p value 
History and examination findings, 
Purulent sputum, % 51.3 52.6 39.6 0.0202 
Ineffective cough, % 11.8 9.3 33.3 <0.0001 
Pedal oedema, % 27.7 26.9 34.5 0.16 
Acute confusion, % 12.6 10.0 35.4 <0.0001 
Heart rate (min
-1
) 102.7 (20.8) 102.7 (20.5) 102.7 (23.3) 0.98 
Initial non-invasive investigations, 
Systolic BP (mmHg) 139.3 (28.4) 139.7 (28.1) 135.4 (30.6) 0.16 
Diastolic BP (mmHg) 76.2 (17.0) 76.6 (16.7) 72.8 (19.1) 0.0384 
Respiratory rate (min
-1
) 26.0 (6.3) 25.8 (6.1) 27.8 (7.6) 0.0038 
Temperature (C), median (IQR) 36.9 (36.4 to 37.5) 36.9 (36.4 to 37.6) 
36.8 (36.2 to 
37.3) 
0.0914 
SpO2 (%), median (IQR) 92 (87 to 96) 92 (87 to 96) 92 (86 to 96) 0.99 
BMI (kgm
-2
) 24.6 (6.3) 24.8 (6.3) 22.5 (6.1) 0.0007 
Weight loss > 5%, % 24.6 22.5 42.7 <0.0001 
CXR consolidation, % 32.5 29.0 62.5 <0.0001 
BP – blood pressure 
9.1.1.6 BLOOD RESULTS ON ADMISSION 
Abnormal blood gas values were common: 18.3% were in type 1 respiratory failure 
(paO2 < 8kPa) at admission, and 20.3% were in type 2 respiratory failure (paO2 < 8kPa 
and paCO2 > 6kPa). 184 (20%) were acidaemic on hospital admission (pH < 7.35 or H
+ > 
45 nmol/L). Of these, 173 had a predominant respiratory acidaemia (pH <7.35 and 
paCO2 > 6kPa), and 11 had a metabolic acidaemia. 
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Individual associations with mortality are shown in Table 9.6: low pH (high H+); high 
paCO2; high potassium; high urea; low albumin; high CRP; low haemoglobin; high 
neutrophil count; and low eosinophil count were all strongly associated with mortality. 
Table 9.6     Blood results on admission and in-hospital mortality 
Variable Total population, 
n=920 
Survived to 
discharge, n=824 
Died in 
hospital, n=96 
p 
value 
Arterial blood gas values, 
H
+
 (nmol/L), median (IQR) 38.9 (35.5 to 43.7) 38.0 (7.2) 41.7 (16.8) 0.0008 
pH, median (IQR) 7.41 (7.36 to 7.45) 7.42 (7.37 to 7.45) 
7.38 (7.28 to 
7.45) 
0.0008 
paO2 (kPa), median (IQR) 8.7 (7.3 to 10.7) 8.7 (7.3 to 10.5) 8.4 (7.1 to 12.7) 0.82 
paCO2 (kPa), median (IQR) 5.9 (4.9 to 7.5) 5.8 (4.9 to 7.3) 6.4 (5.2 to 9.2 0.0044 
Bicarbonate (mmol/L) 29.1 (6.5) 29.0 (6.3) 30.0 (8.0) 0.22 
Acidaemic exacerbation, 
%‡ 
19.3 18.1 30.2 0.0062 
Biochemistry, 
Sodium (mmol/L) 136.3 (4.6) 136.3 (4.5) 136.7 (5.0) 0.39 
Potassium (mmol/L) 4.32 (0.6) 4.3 (0.5) 4.5 (0.7) 0.0016 
Urea (mmol/L), median 
(IQR) 
6.5 (4.7 to 9.3) 6.3 (4.6 to 8.8) 9.5 (6.0 to 14.2) <0.0001 
Creatinine (μmol/L), 
median (IQR) 
93 (77 to 114) 92 (77 to 112) 100 (75 to 148) 0.0428 
Albumin (g/L) 38.3 (5.1) 38.6 (4.9) 35.4 (5.3) <0.0001 
Glucose (mmol/L), median 
(IQR) 
6.9 (6.0 to 8.1) 6.9 (6.0 to 8.0) 7.4 (6.0 to 8.9) 0.0301 
CRP (mg/L), median (IQR) 42 (11 to 117) 36 (10 to 111) 89 (30 to 145) 0.0001 
Haematology, 
Hb (g/dL) 13.6 (1.9) 13.6 (1.9) 13.0 (2.2) 0.0043 
Haematocrit 0.411 (0.058) 0.412 (0.57) 0.399 (0.064) 0.0425 
White cell count (x10
9
/L), 
median (IQR) 
12.0 (9.1 to 15.5) 11.8 (9.1 to 15.3) 12.7 (9.5 to 17.1) 0.0682 
Neutrophil count (x10
9
/L), 
median (IQR) 
9.2 (6.9 to 12.8) 9.1 (6.8 to 12.6) 10.5 (7.7 to 15.2) 0.0081 
Eosinophil count (x10
9
/L), 
median (IQR) 
0.1 (0 to 0.2) 0.1 (0 to 0.2) 0 (0 to 0.1) <0.0001 
‡ pH < 7.35 (H
+
 >  45) and pCO2 > 6kPa 
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9.1.2 IDENTIFYING INDEPENDENT PREDICTORS OF MORTALITY 
All variables which were potentially prognostically significant had been identified by 
the univariate analysis and therefore, those associated with outcome at a p-value < 
0.10 were considered eligible for multivariate analysis. Categorical variables with a 
markedly asymmetric split (< 10% in one category) were excluded from further 
analysis. 
9.1.2.1 VARIABLE SELECTION 
To assess multicollinearity (section 6.8.1), variables with clear potential for collinearity 
were screened first and consequently: FEV1 % predicted was retained over FEV1 
(Pearson’s r = 0.74, p < 0.0001); eMRCD was retained over both MRCD (Spearman’s ρ = 
0.984, p < 0.0001) and exercise tolerance (ρ = -0.85, p < 0.0001); neutrophil count was 
retained over total WCC (ρ = 0.90, p < 0.0001); and haemoglobin was retained over 
haematocrit (r = 0.95, p < 0.0001). H+ and paCO2 were strongly correlated (r = 0.69, p < 
0.0001) and more detailed collinearity testing suggested they were collinear (VIF > 3 
for both variables): paCO2 was therefore excluded from further analysis. Zero-order 
correlations between the remaining potential continuous predictor variables are 
shown in Appendix E (Table 17.6). Due to the suggestion of a non-linear relationship 
between BMI and mortality (Table 8.6), BMI was entered as < 18.5 or ≥ 18.5 kgm-2. 
Repeating the collinearity diagnostics after obvious collinearity had been removed 
confirmed no significant multicollinearity between our potential independent 
variables: no absolute VIF > 3, mean VIF = 1.39, and no evidence of multicollinearity 
from analysis of eigenvalues, condition indices and variance proportions. 
9.1.2.2 MULTIVARIABLE REGRESSION MODELLING 
A prognostic model was developed using the following variables: age; number of 
admissions in the previous year; FEV1 % predicted; FVC; eMRCD; diastolic blood 
pressure; respiratory rate; temperature; body mass index; H+; paO2; potassium; urea; 
creatinine; albumin; glucose; CRP; haemoglobin; neutrophil count; eosinophil count; 
social care prior to admission; cerebrovascular disease; atrial fibrillation; LTOT; acute 
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confusion; ineffective cough; purulent sputum production; CXR consolidation; and 
recent weight loss greater than 5%. 
Backward stepwise logistic regression analysis identified the following variables as 
independent predictors of in-hospital mortality (Table 9.7) 
Table 9.7     Independent predictors of in-hospital mortality – Model 1 
Variable B S.E. OR (95% CI) p value 
eMRCD 0.89 0.14 2.43 (1.83 – 3.22) <0.0001 
CXR consolidation 1.16 0.28 3.18 (1.86 – 5.47) <0.0001 
Eosinophil count, x10
9
/L
 
-4.89 1.41 0.0075 (0.0005 – 0.12) 0.0005 
Temperature, C -0.51 0.15 0.60 (0.45 – 0.80) 0.0006 
Atrial fibrillation 1.01 0.33 2.74 (1.43 – 5.28) 0.0025 
Ineffective cough 0.97 0.33 2.64 (1.39 – 5.01) 0.0031 
Age, years 0.036 0.016 1.04 (1.00 – 1.07) 0.0256 
Cerebrovascular disease 0.68 0.33 1.98 (1.05 – 3.75) 0.0353 
Albumin, g/L -0.055 0.028 0.95 (0.90 – 1.00) 0.0485 
H
+
, nmol/L 0.021 0.01 1.02 (1.00 – 1.04) 0.0492 
Glucose, mmol/L 0.074 0.038 1.08 (1.00 – 1.16) 0.0513 
Intercept 9.725 5.656   
S.E. – standard error; OR – odds ratio; CI – confidence interval 
Odds of in-hospital death = e^ - [9.725 + (0.89 × eMRCD) - (0.51 × temperature) + (0.021 × Hydrogen 
ions) + (0.036 × age) - (4.89 × eosinophil count) + (0.68 if cerebrovascular disease) + (1.01 if Atrial 
Fibrillation) + (1.16 if CXR consolidation) + (0.97 if cough ineffective) + (0.074 × glucose) - (0.055 × 
albumin)] 
The regression model explained 43% of the variance in outcome (Nagelkerke’s R2 = 
0.428) and the HLGFT suggested that the model is well calibrated and a good fit of the 
data (p = 0.379). 
28 (3.0%) cases were identified as statistical outliers (studentised residuals > ±1.96) 
and the mean leverage value of the population = 0.0130 (expected mean leverage = 
(11+1)/920 = 0.0130). Of those cases with a residual > ±1.96, none had a Cook’s 
distance > 1 and although one case was identified as having a significant influence on 
the regression analysis (leverage > 0.0391), this individual died suddenly and 
unpredictably from a stroke (i.e. the cause of death was not directly related to the 
cause of admission). This case was not excluded from the analysis because its distance 
from the regression model was both explainable and reflected ‘real-life’ clinical 
practice. 
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Based on the regression analysis, observed probabilities were plotted against 
predicted probabilities for patients grouped according to deciles of risk (Figure 9.1). 
The slope of this calibration plot was 1.04 (perfect calibration = 1.0) and all data points 
are closely clustered around the line of best fit, suggesting that calibration is good 
across all deciles of risk. Furthermore, discrimination of the regression model was 
excellent: AUROC = 0.896 (0.868 to 0.925) (Figure 9.2). 
Figure 9.1     Calibration plot of predicted versus observed probability for in-hospital 
mortality 
 
Figure 9.2     ROC curve showing discrimination of regression model for in-hospital 
mortality 
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9.1.3 DEVELOPING A CLINICAL PREDICTION TOOL 
All continuous variables associated with mortality on univariate analysis (section 9.1.1) 
were categorised according to methods described in section 6.8.3.2. Categorical 
variables were entered in to a backward stepwise logistic regression model to identify 
the strongest independent predictors of mortality. Categorical variables with < 10% of 
the population in one category were excluded from subsequent analyses. Variables 
which showed evidence of collinearity (section 9.1.2.1) were also excluded. There was 
no evidence of multicollinearity between the remaining categorical variables: mean VIF 
= 1.24, no absolute VIF > 1.52, and no evidence of multicollinearity on analysing 
eigenvalues, condition indices or variance proportions. 
Therefore, the following dichotomous variables were entered in to a backward 
stepwise logistic regression analysis:  
Table 9.8     Categorical variables entered in to multivariate regression analysis 
Variable Categories 
 0† 1 2 
Age (years) < 80 ≥ 80  
Total number of admissions in the previous year < 3 ≥ 3  
Social care prior to admission No Yes  
eMRCD 1 to 4 5a 5b 
FEV1 (% predicted) < 50 ≥ 50  
FVC (L) < 2 ≥ 2  
Diastolic blood pressure (mmHg)* < 60 ≥ 60  
Respiratory rate (min
-1
)* < 30 ≥ 30  
Temperature (°C)* < 37 ≥ 37  
BMI (kgm
-2
) ≥ 18.5 < 18.5  
Recent weight loss (%) < 5 ≥ 5  
pH* ≥ 7.3 < 7.3  
Potassium (mmol/L)* < 5 ≥ 5  
Urea (mmol/L)* < 7 ≥ 7  
Creatinine (μmol/L)* < 120 ≥ 120  
Albumin (g/L)* ≥ 36 < 36  
Glucose (mmol/L)* < 8 ≥ 8  
Haemoglobin (g/dL)* ≥ 12 < 12  
Neutrophil count (x10
9
/L)* < 9 ≥ 9  
Eosinophil count (x10
9
/L)* ≥ 0.05 < 0.05  
CRP (mg/L)* < 50 ≥ 50  
LTOT No Yes  
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Variable Categories 
 0† 1 2 
Atrial fibrillation (AF) No Yes  
Cerebrovascular disease No Yes  
Acute confusion* No Yes  
Ineffective cough* No Yes  
Radiographic consolidation* No Yes  
† reference category for regression analysis; * at the time of hospital admission 
The regression model (Table 9.9) accounted for 42% of the variance in the outcome 
variable (Nagelkerke’s R2 = 0.423) and was a good fit of our data (HLGFT, p = 0.385). No 
regression assumptions were violated by our model and none of the small number of 
statistical outliers (2.8% of cases) significantly influenced the regression model 
(acceptable leverage values and Cook’s distance <1). 
Table 9.9      Independent categorical predictors of in-hospital mortality – Model 2 
Variable B Odds Ratio (95% CI) Significance 
eMRCD 1 – 4 
eMRCD 5a 
eMRCD 5b 
 
1.63 
1.99 
1 
5.11 (2.62 – 9.97) 
7.30 (3.77 – 14.2) 
 
<0.0001 
<0.0001 
Consolidation 1.06 2.88 (1.69 – 4.90) <0.0001 
Eosinophil count < 0.05 x10
9
/L 1.02 2.76 (1.58 – 4.83) 0.0001 
pH < 7.3 0.99 2.68 (1.41 – 5.09) 0.0026 
AF 0.98 2.66 (1.39 – 5.09) 0.0032 
Ineffective cough 0.94 2.57 (1.37 – 4.84) 0.0033 
Albumin < 36 g/L 0.84 2.32 (1.36 – 3.96) 0.0020 
Cerebrovascular disease 0.70 2.02 (1.18 – 3.42) 0.0369 
Age > 80 0.70 2.01 (1.18 – 3.42) 0.0106 
BMI < 18.5kgm
-2
 0.60 1.83 (1.00 – 3.33) 0.0486 
Intercept -4.30   
For pragmatic reasons, the strongest five variables were chosen to comprise our 
prognostic tool (eMRCD, eosinophils, consolidation, AF and pH) and relative weights 
were assigned according to the regression coefficient (B). Table 9.10 shows how to 
calculate the resulting DECAF (Dyspnoea, Eosinopenia, Consolidation, Acidaemia, atrial 
Fibrillation) score: 
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Table 9.10     The DECAF Score 
Variable Score 
Dyspnoea: 
eMRCD 5a 
eMRCD 5b 
 
1 
2 
Eosinopenia (< 0.05 x10
9
/L) 1 
Consolidation 1 
Acidaemia (pH < 7.3) 1 
atrial Fibrillation 1 
Maximum DECAF score /6 
9.1.3.1 ASSESSING PREDICTIVE TOOL ACCURACY 
To ensure that the methodology for developing the DECAF tool had not significantly 
weakened its performance, when compared to the regression model described in 
section 9.1.2.2 (termed ‘Model 1’), the calibration between DECAF and Model 1 was 
assessed by plotting the predicted probability of mortality (according to Model 1) and 
the observed probability of death, for each DECAF grade (Figure 9.3). The observed 
proportion of patients dying for each DECAF grade can be seen to be well calibrated 
with the predicted probability according to Model 1. It can also be seen that as DECAF 
grade increases, both the observed and predicted probabilities of dying increase. 
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Figure 9.3     Observed and predicted probabilities of death stratified by DECAF score 
 
Performance of the tool for discrimination of in-hospital mortality was assessed using 
ROC curve analysis. The AUROC for the DECAF score was 0.858 (95% CI 0.822 – 0.895). 
Internal validation was performed and the mean (95% CI) AUROC of 10,000 
bootstrapped samples was 0.858 (0.819 – 0.894). Comparing the discrimination of 
DECAF and Model 1 identified a small but significant difference (p < 0.0001) in 
discrimination for in-hospital mortality (AUROCmodel 1 = 0.896, 0.867 to 0.925, and 
AUROCDECAF = 0.858, 0.822 to 0.895). 
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Figure 9.4     ROC curves showing discrimination of model 1 and DECAF score 
 
In-hospital mortality rates, and sensitivity and specificity, for the DECAF score are 
shown in Table 9.11: 
Table 9.11     DECAF score and in-hospital mortality 
DECAF Score n In-hospital mortality, % Sensitivity* Specificity* 
0 201 0.5 1 0 
1 291 2.1 0.99 0.24 
2 226 8.4 0.93 0.59 
3 125 24 0.73 0.84 
4 57 45.6 0.42 0.96 
5 20 70 0.15 0.99 
6 0 n/a n/a n/a 
* Positive test result = score ≥ corresponding DECAF score 
In our cohort, the DECAF score performed significantly better for the prediction of in-
hospital mortality than: the Acute Physiology and Chronic Health Evaluation (APACHE) 
II prognostic index [395] (AUROC = 0.73, DECAF v. APACHE II p <0.0001); the COPD and 
Asthma Physiology Score (CAPS) [158] (AUROC = 0.71, p <0.0001); and the BAP-65 
score [155] (AUROC = 0.68, p<0.0001)  which have all been proposed as useful 
predictive instruments in AECOPD (Figure 9.5).[139, 158, 300]  
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In patients with AECOPD, DECAF was a significantly stronger predictor of in-hospital 
mortality than CURB-65 for both patients with (AUROC = 0.77 v. 0.66, p = 0.003, n = 
299) (Figure 9.6, panel A) and without (AUROC = 0.87 v. 0.72, p = 0.002, n = 621) 
(Figure 9.6, panel B) coexistent consolidation. Although derived for in-hospital 
mortality, the utility of the DECAF score to predict 30-day mortality was also assessed. 
The AUROC of DECAF for the prediction of 30-day mortality was 0.82 (0.78 to 0.86) 
and, in the subgroup with coexistent consolidation, it was a stronger predictor than 
CURB-65 (AUROC = 0.75 v. 0.64, p=0.0026). 
Figure 9.5     ROC curve showing discrimination of DECAF score for in-hospital mortality 
in the total population, n = 920 
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Figure 9.6     ROC curve showing discrimination of DECAF score and CURB-65 for in-
hospital mortality for patients with (n=299, panel A) and without (n=621, panel B) 
complicating pneumonia 
 
9.2 PREDICTING LONG-TERM MORTALITY 
Aim 1f:  identify independent predictors of twelve-month mortality following 
hospitalisation for AECOPD.  
9.2.1 UNIVARIATE ASSOCIATIONS WITH 12-MONTH MORTALITY 
Similarly to in-hospital mortality (section 9.1.1), older age, institutional care and an 
inability to live at home independently were all associated with 12-month mortality. 
Males had a higher risk of death, although this was not statistically significant (Table 
9.12).  
Table 9.12     The relationship between sociodemographic details and 12-month 
mortality 
Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 
12-months, 
n=291 
p 
value 
Age 73.1 (10.0) 70.9 (9.8) 77.8 (8.7) <0.0001 
Female, % 53.9 56 49.5 0.0754 
Admission hospital (NTGH), % 54.9 55.6 53.3 0.52 
Institutional care, % 6.5 3.0 14.1 <0.0001 
Social care prior to admission, % 22.9 14.5 41.2 <0.0001 
Smoking load (cpy), median 
(IQR) 
45 (32 to 60) 45 (32 to 60) 45 (30 to 60) 0.63 
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Individuals with more severe underlying disease were at an increased risk of 12-month 
mortality: more frequent hospitalisation (for any cause), a previous episode of AECOPD 
treated with assisted ventilation, greater lung function (FEV1 and FVC) impairment, 
worse stable-state breathlessness and exercise capacity, and presence of cor 
pulmonale were all associated with an increased risk of death (Table 9.13). 
Table 9.13     Prior health resource use and markers of disease severity, and the 
association with 12-month mortality 
Variable Total 
population, 
n=920 
Survived 12-
months, 
n=621 
Died within 12-
months, n=291 
p 
value 
Health resource use, 
Number of respiratory 
admissions in previous year, 
median (IQR) 
0 (0 to 1) 0 (0 to 1) 0 (0 to 1) 0.26 
Number of non-respiratory 
admissions in the previous year, 
median (IQR) 
0 (0 to 0) 0 (0 to 0) 0 (0 to 1) <0.0001 
Total number of admissions in 
previous year, median (IQR) 
0 (0 to 1) 0 (0 to 1) 1 (0 to 2) 0.0016 
Number of AECOPD in previous 
year, median (IQR) 
3 (1 to 4) 3 (1 to 4) 3 (2 to 4) 0.46 
Previous assisted ventilation, % 11.7 9.9 15.8 0.0061 
Previous pulmonary 
rehabilitation, % 
9.5 9.5 9.3 0.90 
Spirometry, 
FEV1 (litres) 0.97 (0.44) 1.02 (0.44) 0.86 (0.41) <0.0001 
FEV1 % predicted 43.6 (17.2) 45.2 (17.6) 40.0 (15.5) <0.0001 
FVC (litres) 2.15 (0.78) 2.25 (0.79) 1.93 (0.72) <0.0001 
FEV1 / FVC, median (IQR) 
0.45 (0.37 to 
0.53) 
0.45 (0.37 to 
0.53) 
0.44 (0.38 to 
0.52) 
0.54 
Exercise capacity and disease complications, 
MRCD, median (IQR) 4 (4 to 5) 4 (3 to 4) 5 (4 to 5) <0.0001 
eMRCD, median (IQR) 4 (4 to 5a) 4 (3 to 4) 5a (4 to 5b) <0.0001 
Exercise tolerance (metres), 
median (IQR) 
25 (10 to 80) 50 (20 to 150) 15 (10 to 30) <0.0001 
Housebound, % 34.3 20.3 64.6 <0.0001 
Cor pulmonale, % 10.0 7.8 14.8 0.0010 
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No respiratory comorbidities were associated with higher 12-month mortality although 
coexistent asthma was protective. Several cardiovascular (cerebrovascular disease, 
atrial fibrillation, left ventricular (LV) dysfunction and valvular heart disease) and 
general (chronic cognitive impairment, chronic kidney disease, and a history of 
malignancy) comorbidities were associated with long-term mortality. The contrast 
between the prognostic importance of respiratory and non-respiratory comorbidities is 
consistent with the data on prior health resource use (Table 9.13) which showed that a 
marker of non-respiratory comorbidity (i.e. hospital admission due to non-respiratory 
cause) was associated with mortality, whereas an admission for a respiratory cause 
(which reflects respiratory comorbidity) was not. 
Table 9.14     Comorbidity and long-term mortality 
Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 12-
months, n=291 
p 
value 
Respiratory, 
Bronchiectasis, % 6 5.6 6.9 0.46 
Asthma, % 4.9 5.9 2.7 0.0476 
Pulmonary fibrosis, % 1.7 1.3 2.7 0.17 
Obstructive sleep apnoea, % 1.6 1.4 2.1 0.58 
Cardiovascular, 
Hypertension, % 39.6 39.4 39.9 0.94 
Cerebrovascular disease, % 14 11.8 18.9 0.0056 
Ischaemic heart disease, % 29.3 28.1 32.0 0.24 
Atrial fibrillation, % 12.5 9.9 18.2 0.0006 
LV dysfunction, % 7.3 5.6 11.0 0.0041 
Thromboembolic disease, % 3.8 3.7 4.1 0.71 
Valvular heart disease, % 3.3 2.5 4.8 0.0758 
Peripheral vascular disease, 
% 
7.9 7.0 10.0 0.15 
General, 
Diabetes mellitus, % 14.8 14.9 14.4 0.92 
Osteoporosis, % 12.6 11.6 14.8 0.20 
Rheumatoid arthritis, % 4.0 3.5 5.2 0.28 
Cognitive impairment, % 5.4 2.4 12.0 <0.0001 
Chronic kidney disease, % 6.7 4.3 12.0 <0.0001 
Anxiety/depression, % 24.2 23.5 25.8 0.46 
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Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 12-
months, n=291 
p 
value 
Chronic liver disease, % 0.7 0.6 0.7 1 
Peptic ulcer disease, % 6.5 5.6 8.6 0.0867 
Past history of cancer, % 7.7 6.8 9.6 0.15 
History of active cancer, % 3.8 2.5 6.5 0.0050 
Comorbidity burden, 
Charlson Comorbidity Index, 
median (IQR) 
2 (1 to 3) 2 (1 to 2) 2 (1 to 3) <0.0001 
Maintenance home oxygen therapy, long-term oral corticosteroid therapy, and diuretic 
therapy were associated with 12-month mortality (Table 9.15). Our finding that 
maintenance systemic corticosteroids are associated with an increased risk of death is 
in agreement with previous studies (section 2.2.2.6) but may be confounded by 
underlying disease severity. Previous studies have shown statin [245] and beta-blocker 
[114] therapy to be protective against mortality, but in the present study, no 
relationships with mortality were identified. 
Table 9.15     Medications on admission to hospital and long-term mortality 
Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 12-
months, n=291 
p 
value 
Respiratory, 
LTOT, % 12.4 8.6 20.6 <0.0001 
Ambulatory oxygen, % 3.4 2.4 5.5 0.0186 
Short burst oxygen, % 7.8 7.3 8.9 0.43 
Home oxygen therapy,* % 21.1 16.5 30.9 <0.0001 
Home nebuliser, % 16.6 15.6 18.9 0.22 
Inhaled corticosteroid (ICS), % 81.6 81.6 81.8 1 
ICS dose (BDP equivalent), 
median (IQR) 
2000 (1000 to 
2000) 
2000 (1000 to 
2000) 
2000 (1000 to 
2000) 
0.92 
Inhaled long-acting beta 
agonist, % 
77.7 78.2 76.6 0.61 
Inhaled anticholinergic, % 70.8 69.8 72.9 0.35 
Long-term oral corticosteroid, % 9.1 7.8 12.0 0.0483 
Carbocysteine, % 16.1 15.9 16.5 0.85 
Theophylline, % 8 7.9 8.2 0.90 
Cardiovascular, 
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Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 12-
months, n=291 
p 
value 
Statin, % 44.9 44.5 45.7 0.78 
Beta-blocker, % 10.8 10.3 11.7 0.57 
ACE inhibitor, % 24.2 25.1 22.3 0.41 
Angiotensin receptor blocker, % 5.7 5.7 5.5 1 
Diuretic, % 35.4 32.9 40.9 0.0215 
Other, 
Benzodiazepine,† % 5.8 5.1 7.2 0.22 
Opiate,† % 0.9 0.8 1.0 0.71 
* either LTOT, ambulatory O2 or short burst O2; † prescribed for the symptomatic relief of dyspnoea / 
anxiety; ICS – inhaled corticosteroid; BDP – beclomethasone diproprionate; ACE – Angiotensin 
converting enzyme 
Similarly to in-hospital mortality (Table 9.5), patients were at an increased risk of death 
if: they were confused; or had an ineffective cough; or did not expectorate purulent 
sputum. Furthermore, similar markers of acute physiological derangement 
(hypotension, tachypnoea etc) and nutritional depletion were associated with in-
hospital and 12-month mortality. It is of interest that diastolic hypotension (< 
60mmHg) was associated with both in-hospital and 12-month mortality whereas 
systolic hypotension (< 90mmHg) was only associated with 12-month mortality, 
suggesting that diastolic hypotension is the more useful prognostic marker. Low 
oxygen saturation had no discriminative value for in-hospital mortality but was 
significantly associated with long-term mortality (Table 9.16). 
Table 9.16     Findings at admission and long-term mortality 
Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 
12-months, 
n=291 
p value 
History and examination findings, 
Purulent sputum, % 51.3 54.6 44.0 0.0033 
Ineffective cough, % 11.8 8.1 19.9 <0.0001 
Pedal oedema, % 26.3 24.6 29.9 0.11 
Acute confusion, % 12.6 7.8 23.0 <0.0001 
Heart rate (min
-1
) 102.7 (20.8) 103.1 (20.6) 101.7 (21.1) 0.34 
Initial non-invasive investigations, 
Systolic BP (mmHg) 139.3 (28.4) 140.9 (28.0) 135.8 (29.0) 0.0122 
Diastolic BP (mmHg) 76.2 (17.0) 77.2 (16.7) 74.1 (17.5) 0.0094 
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Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 
12-months, 
n=291 
p value 
Respiratory rate (min
-1
) 26.0 (6.3) 25.5 (5.98) 27.1 (6.87) 0.0002 
Temperature (C), median (IQR) 36.9 (36.4 to 37.5) 
36.9 (36.4 to 
37.6) 
36.8 (36.3 to 
37.3) 
0.0048 
SpO2 (%), median (IQR) 92 (87 to 96) 90.8 (7.41) 89.6 (8.43) 0.0533 
BMI (kgm
-2
) 24.6 (6.3) 25.4 (6.16) 22.7 (6.23) <0.0001 
Weight loss >5%, % 24.6 17.6 39.5 <0.0001 
MUST score, median (IQR) 0 (0 to 1) 0 (0 to 1) 1 (0 to 2) <0.0001 
CXR consolidation, % 32.5 27.2 44.0 <0.0001 
BP – blood pressure 
Individuals with severe exacerbations (low pH, high paCO2) were at a greater risk of 
long-term mortality. Consistent with the data on renal comorbidity (Table 9.14), 
patients with evidence of higher serum creatinine were also at a higher risk of death. 
Eosinopenia, which was shown to be a strong independent predictor of in-hospital 
mortality (section 9.1.2), did not discriminate for mortality 12-months following 
admission. 
Table 9.17     Laboratory investigations at admission and 12-month mortality 
Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 
12-months, 
n=291 
p value 
Arterial blood gas values, 
H
+
 (nmol/L), median (IQR) 38.9 (35.5 to 43.7) 
38.0 (34.7 to 
42.7) 
39.8 (35.5 to 
45.7) 
<0.0001 
pH, median (IQR) 7.41 (7.36 to 7.45) 
7.42 (7.37 to 
7.46) 
7.40 (7.34 to 
7.45) 
<0.0001 
paO2 (kPa), median (IQR) 8.7 (7.3 to 10.7) 8.7 (7.3 to 10.4) 8.5 (7.1 to 11.4) 0.81 
paCO2 (kPa), median (IQR) 5.90 (4.9 to 7.5) 5.70 (4.9 to 7.1) 6.19 (5.1 to 8.4) 0.0002 
Bicarbonate (mmol/L) 29.1 (6.5) 28.8 (6.06) 29.7 (7.38) 0.0514 
Acidaemic exacerbation, %‡ 19.5 16.9 25.1 0.0041 
Biochemistry, 
Sodium (mmol/L) 136.3 (4.6) 136.2 (4.41) 136.6 (4.95) 0.29 
Potassium (mmol/L) 4.32 (0.56) 4.26 (0.52) 4.44 (0.61) <0.0001 
Urea (mmol/L), median (IQR) 6.50 (4.7 to 9.3) 6.0 (4.4 to 8.2) 
8.10 (5.7 to 
11.9) 
<0.0001 
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Variable Total 
population, 
n=920 
Survived 12-
months, n=621 
Died within 
12-months, 
n=291 
p value 
Creatinine (μmol/L), median 
(IQR) 
93.0 (77 to 114) 91.0 (77 to 110) 98.0 (75 to 139) 0.0039 
Albumin (g/L) 38.4 (4.79) 39.3 (4.46) 36.4 (4.86) <0.0001 
Glucose (mmol/L), median (IQR) 6.90 (6.0 to 8.1) 6.90 (6.1 to 8.0) 6.90 (5.8 to 8.2) 0.41 
CRP (mg/L), median (IQR) 41.5 (11 to 117) 31 (9 to 108) 63 (19 to 132) 0.0001 
Haematology, 
Haemoglobin (g/dL) 13.6 (1.95) 13.8 (1.82) 13.1 (2.11) <0.0001 
Haematocrit 0.410 (0.058) 0.416 (0.054) 0.399 (0.064) 0.0002 
White cell count (x10
9
/L), 
median (IQR) 
11.9 (9.1 to 15.5) 
11.9 (9.1 to 
15.3) 
11.9 (9.4 to 
16.2) 
0.37 
Neutrophil count (x10
9
/L), 
median (IQR) 
9.2 (6.9 to 12.8) 9.0 (6.8 to 12.6) 9.5 (7.1 to 13.0) 0.13 
Eosinophil count (x10
9
/L), 
median (IQR) 
0.1 (0 to 0.2) 0.1 (0 to 0.2) 0 (0 to 0.1) 0.32 
9.2.2 INDEPENDENT PREDICTORS OF 12-MONTH MORTALITY 
All variables associated with 12-month mortality (p < 0.10) were selected as potential 
covariates for logistic regression analysis (categorical variables with < 10% of the 
population in one category excluded). No additional variables, which on clinical 
grounds were thought to be prognostically important, were identified by the above 
univariate analysis. Prior to multivariate analysis, all candidate variables were screened 
for multicollinearity (section 6.8.1): FEV1 % predicted was therefore retained over FEV1 
(Pearson’s r = 0.770); haemoglobin was retained over haematocrit (r = 0.95, p 
<0.0001); diastolic BP was included instead of systolic BP (r = 0.636 and eigenvalues 
suggest collinearity); eMRCD was retained over exercise tolerance (ρ =-0.845); CRP was 
retained over temperature at admission (ρ = 0.238 and eigenvalues suggest 
collinearity); and hydrogen ion concentration was retained over paCO2 (Spearman’s-ρ = 
-0.616 and eigenvalues suggest collinearity). Furthermore, cough effectiveness was 
included instead of purulent sputum at admission, and BMI was included as a 
dichotomous variable (BMI < 18.5 kgm-2) due to its non-linear relationship with 12-
month mortality (Table 8.6). Following exclusion of these variables, there were no 
strong zero order correlations between potential predictors (Appendix E, Table 17.6), 
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but more detailed collinearity testing suggested that there might be persistent 
collinearity between predictor variables (mean VIF = 1.53, no absolute VIF >3). 
However, no specific interaction between variables could be identified through further 
collinearity screening, and no variables could be excluded because collinearity was 
suspected on clinical grounds. Furthermore, given the suggestion of only minor 
collinearity (mean VIF ≈ 1.50) no further variables were excluded. 
Table 9.18 details the independent predictors of 12-month mortality following 
hospitalisation for AECOPD (termed ‘Model 3’). Further tests of model performance 
showed that: 2.7% of cases were statistical outliers (no outliers were significantly 
influential on the model i.e. acceptable Cook’s distances and leverage values); model 
calibration was satisfactory (HLGFT, p = 0.559, and a calibration plot shows the model 
to be well calibrated across all deciles of risk (Figure 9.7)). Model 3 accounted for 
42.5% of the variance in 12-month mortality (Nagelkerke’s R2 = 0.425). 
Figure 9.7     Calibration plot of predicted against observed probability of 12-month 
mortality for Model 3 
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Table 9.18     Independent predictors of 12-month mortality – Model 3 
Variable B S.E. OR (95% CI) p value 
eMRCD 0.71 0.10 2.04 (1.68 to 2.48) <0.0001 
Age (years) 0.05 0.01 1.05 (1.03 to 1.07) <0.0001 
Albumin, g/L -0.07 0.02 0.930 (0.891 to 0.970) 0.0007 
Urea, mmol/L 0.06 0.02 1.06 (1.02 to 1.10) 0.0038 
Unexplained weight loss > 5% 0.57 0.20 1.77 (1.19 to 2.64) 0.0047 
CXR consolidation 0.55 0.20 1.73 (1.18 to 2.54) 0.0053 
BMI < 18.5 kgm
-2
 0.62 0.23 1.86 (1.19 to 2.92) 0.0064 
Ineffective cough 0.63 0.27 1.88 (1.11 to 3.18) 0.0187 
FEV1 (% predicted) -0.01 0.01 0.987 (0.975 to 0.998) 0.0239 
LTOT 0.56 0.25 1.74 (1.06 to 2.86) 0.0283 
Male sex 0.35 0.18 1.42 (0.997 to 2.02) 0.0522 
CRP -0.001 0.00 0.998 (0.996 to 1.00) 0.0624 
Respiratory rate 0.03 0.01 1.03 (0.998 to 1.05) 0.0642 
Intercept -5.88 1.34   
Odds of 12-month mortality = e ^ - [-5.88 + (0.71 x eMRCD) + (0.05 x age) - (0.07 x albumin) + (0.06 x 
urea) + (0.57 if unexplained weight loss >5%) + (0.55 if CXR consolidation) + (0.62 if BMI < 18.5kgm
-2
) + 
(0.63 if ineffective cough) – (0.01 x FEV1 % predicted) + (0.56 if LTOT) + (0.35 if male) – (0.001 x CRP) + 
(0.03 x respiratory rate)] 
Model 3 showed good discrimination for 12-month mortality: AUROC = 0.850 (95% CI 
0.824 to 0.877) (Figure 9.8) and the result was internally valid (bootstrapped AUROC = 
0.849, 95% CI 0.823 to 0.876). The DECAF score was a good predictor of 12-month 
mortality (AUROC = 0.730, 95% CI 0.695 to 0.765), but was weaker (p < 0.0001) than 
both Model 3 and the eMRCD scale (AUROC = 0.766, p = 0.0170) (Figure 9.8).  
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Figure 9.8     ROC curve showing discrimination of Model 3 and the DECAF score for 12-
month mortality 
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CHAPTER 10  PREDICTING READMISSION IN PATIENTS SURVIVING TO 
DISCHARGE FOLLOWING HOSPITALISATION WITH AECOPD 
Aim 1g: identify independent predictors of early and frequent readmission, and develop 
a clinical prediction tool, in patients surviving to discharge following hospitalisation 
with AECOPD. 
10.1 UNIVARIATE ASSOCIATIONS WITH READMISSION OR DEATH 
The association between indices and (a) 90-day readmission or death and (b) frequent 
(≥ 2 within 12 months of discharge) readmission are shown in Table 10.1 to Table 10.6. 
Older age, male sex and an inability to manage independently at home were all 
associated (p < 0.10) with an increased risk of 90-day readmission or death. A greater 
smoking burden was significantly associated with increased risk of frequent 
readmissions (Table 10.1). 
Table 10.1    Sociodemographic details and their association with readmission following 
discharge 
Variable 
Total 
population, 
n=824 
90-day readmission or 
death 
Frequent readmission 
No, n=517 Yes, n=307 No, n=537 Yes, n=287 
Age (years) 72.3 (10.0) 71.1 (9.7)‡ 74.5 (10.2)‡ 72.3 (10.3) 72.5 (9.5) 
Female, % 54.2 56.5
∆
 50.5
∆
 55.5 51.9 
Institutional care, % 5.2 3.3† 8.5† 5.0 5.6 
Social care prior to 
admission, % 
20.1 13.3‡ 31.6‡ 18.4
∆
 23.3
∆
 
Smoking load (cpy), 
median (IQR) 
45 (32 to 60) 45 (32 to 60) 48 (32 to 60) 
42 (30 to 
58)† 
50 (35 to 
62)† 
Values shown are mean (SD) unless stated otherwise. Significant differences between presence and 
absence of stated outcome: *p<0.05; †p<0.01; ‡p<0.001; 
∆ 
p<0.10; cpy – cigarette pack years 
Individuals who experienced frequent episodes of health resource use (hospital 
admissions or episodes of AECOPD in the preceding year, or previous AECOPD 
requiring treatment with NIV), or had more severe underlying disease (lower FEV1 % 
predicted, worse stable-state dyspnoea, or cor pulmonale), were at a higher risk of 
both single and frequent readmission following discharge (Table 10.2).  
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Table 10.2     Prior health resource use, markers of disease severity and their 
association with readmission 
Variable 
Total 
population, 
n=824 
90-day readmission or 
death 
Frequent readmission 
No, n=517 Yes, n=307 No, n=537 Yes, n=287 
Health resource use, 
Number of respiratory 
admissions in previous year, 
median (IQR) 
0 (0 to 1) 0 (0 to 1)‡ 0 (0 to 1)‡ 0 (0 to 1)‡ 1 (0 to 2)‡ 
Total number of admissions 
in previous year, median 
(IQR) 
0 (0 to 1) 0 (0 to 1)‡ 1 (0 to 2)‡ 0 (0 to 1)‡ 1 (0 to 2)‡ 
Number of AECOPD in 
previous year, median (IQR) 
3 (1 to 4) 2 (1 to 4)‡ 3 (2 to 5)‡ 2 (1 to 4)‡ 3 (2 to 5)‡ 
Previous NIV, % 10.4 8.7* 13.4* 7.4‡ 16.0‡ 
Previous pulmonary 
rehabilitation, % 
9.8 9.7 10.1 8.8 11.8 
Spirometry, 
FEV1 (litres) 0.99 (0.4) 1.02 (0.4)† 0.93 (0.4)† 1.01 (0.5)* 0.94 (0.4)* 
FEV1 % predicted 44.0 (17.4) 45.5 (17.6)† 41.5 (16.8)† 
45.4 
(17.5)† 
41.4 
(17.1)† 
FVC (litres) 2.18 (0.8) 2.25 (0.8)† 2.07 (0.8)† 2.21 (0.8) 2.13 (0.8) 
Exercise capacity and disease complications, 
MRCD, median (IQR) 4 (3 to 5) 4 (3 to 4)‡ 4 (4 to 5)‡ 4 (3 to 5)‡ 4 (4 to 5)‡ 
eMRCD, median (IQR) 4 (3 to 5a) 4 (3 to 4)‡ 4 (4 to 5a)‡ 4 (3 to 5a)‡ 
4 (4 to 
5a)‡ 
Exercise tolerance (metres), 
median (IQR) 
30 (15 to 
100) 
50 (20 to 
180)‡ 
20 (10 to 
50)‡ 
40 (15 to 
150)‡ 
20 (10 to 
60)‡ 
Housebound, % 29.0 19.5‡ 45.0‡ 27.0
∆
 32.8
∆
 
Cor pulmonale, % 9.8 6.8‡ 15.0‡ 9.1 11.1 
Values shown are mean (SD) unless stated otherwise. NIV – non-invasive ventilation. Significant 
differences between presence and absence of stated outcome: *p<0.05; †p<0.01; ‡p<0.001; 
∆
p<0.1 
Histories of anxiety or depression, or cerebrovascular disease, were associated with an 
increased rate of both measures of readmission. Coexistent ischaemic heart disease 
was associated with a significantly higher rate of frequent readmission although was 
non-significantly associated with a lower rate of 90-day readmission. This discrepancy 
is difficult to explain and the latter non-significant association (p = 0.07) may not be a 
true finding. Furthermore, a history of obstructive sleep apnoea, chronic kidney 
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disease, and the presence of an active malignancy were all associated with 90-day 
readmission. However, these findings should be interpreted with caution given the 
small number of patients with these three diagnoses in our cohort. Lastly, the overall 
comorbidity burden (CCI) was strongly associated with both outcomes (Table 10.3). 
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Table 10.3     Comorbidity and its association with readmission 
Variable 
Total population, 
n=824 
90-day readmission 
or death 
Frequent 
readmission 
No, n=517 Yes, n=307 
No, 
n=537 
Yes, 
n=287 
Respiratory, 
Bronchiectasis, % 5.6 6.2 4.6 5.0 6.6 
Asthma, % 5.1 5.4 4.6 5.2 4.9 
Pulmonary fibrosis, % 1.5 1.4 1.6 1.1 2.1 
Obstructive sleep apnoea, % 1.6 0.8* 2.9* 1.1 2.4 
Cardiovascular, 
Hypertension, % 39.2 38.9 39.7 41.3
∆
 35.2
∆
 
Cerebrovascular disease, % 12.6 10.3† 16.6† 9.9† 17.8† 
Ischaemic heart disease, % 29.5 37.3
∆
 33.2
∆
 27.2* 33.8* 
Atrial fibrillation, % 10.9 8.9* 14.3* 10.8 11.1 
LV dysfunction, % 7.4 5.2† 11.1† 7.4 7.3 
Valvular heart disease, % 2.9 2.3 3.9 2.6 3.5 
Peripheral vascular disease, % 7.8 6.8 9.4 8.2 7.0 
General, 
Diabetes mellitus, % 14.7 14.9 14.3 14.0 16.0 
Osteoporosis, % 12 12.0 12.1 11.4 13.2 
Rheumatoid arthritis, % 4.0 3.9 4.2 3.9 4.2 
Thromboembolic disease, % 3.9 3.3 4.9 3.9 3.8 
Cognitive impairment, % 4.6 3.1† 7.2† 4.3 5.2 
Chronic kidney disease, % 5.7 4.3* 8.1* 5.4 6.3 
Anxiety/depression, % 24.8 22.2* 29.0* 21.6† 30.7† 
Chronic liver disease, % 0.6 0.4 1.0 0.6 0.7 
Peptic ulcer disease, % 6.3 5.6 7.5 6.3 6.3 
Past history of cancer, % 7.4 6.2 9.4 8.0 6.3 
History of active cancer, % 3.8 2.5* 5.9* 3.5 4.2 
Composite score, 
Charlson Comorbidity Index, 
median (IQR) 
2 (1 to 3) 2 (1 to 2)‡ 2 (1 to 3)‡ 
2 (1 to 
3)* 
2 (1 to 
3)* 
Significant differences between presence and absence of stated outcome: *p<0.05; †p<0.01; ‡p<0.001; 
∆
p<0.1 
In agreement with the results reported in Table 10.2, individuals with more severe 
disease, who required treatment with home oxygen therapy (LTOT or short burst 
oxygen), were at an increased risk of readmission (Table 10.4). Patients in receipt of 
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nebulised bronchodilators or carbocysteine were also more likely to be readmitted, 
however the clinical significance of these relationships are uncertain because 
commonly, nebulised bronchodilators and maintenance carbocysteine are provided to 
those patients most at risk of admission and exacerbation. Long-term oral 
corticosteroids were associated with an increased risk of both 90-day and frequent 
readmission, and patients receiving a higher dose of inhaled corticosteroid also had 
more frequent readmission. In addition, patients who experienced frequent 
readmissions were more likely to be prescribed long-acting beta-agonists and inhaled 
anticholinergic agents. 
Table 10.4     Maintenance medications at hospital discharge and their association with 
readmission 
Variable 
Total 
population, 
n=824 
90-day readmission or 
death 
Frequent readmission 
No, n=517 
Yes, 
n=307 
No, n=537 Yes, n=287 
Respiratory, 
LTOT, % 13.3 10.8† 17.6† 11.5* 16.7* 
Ambulatory oxygen, % 3.8 3.3 4.6 3.5 4.2 
Short burst oxygen, % 8.9 7.5
∆
 11.1
∆
 6.7† 12.9† 
Home oxygen therapy
ϕ
, % 22.9 19.3‡ 29.0‡ 19.2‡ 30.0‡ 
Home nebuliser, % 16.6 13.0‡ 22.8‡ 13.2‡ 23.0‡ 
Inhaled corticosteroid (ICS), % 88.3 87.6 89.6 87.2 90.6 
ICS dose (BDP equivalent), 
median (IQR) 
2000 (1000 
to 2000) 
2000 (1000 
to 2000) 
2000 
(1000 to 
2000) 
2000 (1000 
to 2000)* 
2000 
(2000 to 
2000)* 
Inhaled long-acting beta agonist, 
% 
86.5 85.9 87.6 84.5* 90.2* 
Combination inhaler, % 83.1 82.2 84.7 80.6† 87.8† 
Inhaled anticholinergic, % 80.6 82.2 77.9 78.6* 84.3* 
Long-term oral corticosteroid, % 8.0 6.8
∆
 10.1
∆
 6.3* 11.1* 
Carbocysteine, % 19.4 18.4 21.2 14.9‡ 27.9‡ 
Theophylline, % 7.4 7.2 7.8 7.6 7.0 
Cardiovascular, 
Statin, % 44.4 42.7 47.2 43.4 46.3 
Beta-blocker, % 11.0 10.1 12.7 10.6 11.8 
ACE inhibitor, % 22.9 21.9 24.8 21.8 25.1 
170 
Variable 
Total 
population, 
n=824 
90-day readmission or 
death 
Frequent readmission 
No, n=517 
Yes, 
n=307 
No, n=537 Yes, n=287 
Angiotensin receptor blocker, % 5.2 5.2 5.2 5.0 5.6 
Diuretic, % 34.7 30.0‡ 42.7‡ 26.8 30.3 
Other, 
Benzodiazepine,ⁱ % 6.4 5.6 7.8 5.4
∆
 8.4
∆
 
Opiate,ⁱ % 0.7 0.2
∆
 1.6
∆
 0.7 0.7 
Significant differences between presence and absence of stated outcome: *p<0.05; †p<0.01; ‡p<0.001; 
∆
p<0.1; ⁱ prescribed for the symptomatic relief of dyspnoea / anxiety; 
ϕ
 either LTOT, ambulatory O2 or 
short burst O2; ICS – inhaled corticosteroid; BDP – beclomethasone diproprionate; ACE – Angiotensin 
converting enzyme 
 
Few clinical or laboratory measurements available at admission or during the hospital 
stay were shown to predict readmission following discharge. Of interest, we found no 
relationship between low BMI and readmission rates although high self-reported 
weight loss and malnutrition risk (MUST score) were strongly associated with 
readmission or death within 90 days of discharge. We found no relationship between 
high paCO2 and outcome and the only laboratory measurement significantly associated 
with both single and frequent readmissions was a high eosinophil count. Low albumin 
was strongly associated with 90-day readmission or death whereas, conversely, higher 
albumin scores were associated with frequent readmission (Table 10.5). This is 
because of the strong relationship between lower albumin values and mortality, i.e. 
patients with lower albumin scores have a shorter survival time and are therefore less 
likely to be frequently readmitted to hospital. 
Table 10.5     Clinical and laboratory findings at admission and their association with 
readmission 
Variable 
Total 
population, 
n=824 
90-day readmission or 
death 
Frequent readmission 
No, n=517 Yes, n=307 No, n=537 Yes, n=287 
History and examination findings, 
Purulent sputum, % 52.6 52.3 53.0 51.7 54.3 
Ineffective cough, % 9.3 7.5* 12.4* 9.1 9.8 
Pedal oedema, % 26.9 23.2† 33.2† 25.1 30.3 
Acute confusion, % 10.0 7.7† 13.7† 10.1 9.8 
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Variable 
Total 
population, 
n=824 
90-day readmission or 
death 
Frequent readmission 
No, n=517 Yes, n=307 No, n=537 Yes, n=287 
Initial non-invasive investigations, 
Heart rate (min
-1
) 102.7 (20.5) 102.9 (19.8) 102.4 (21.6) 102.3 (20.5) 103.4 (20.5) 
Systolic BP (mmHg) 139.7 (28.1) 140.6 (27.9) 138.2 (28.4) 138.9 (28.7) 141.3 (26.9) 
Diastolic BP (mmHg) 76.6 (16.7) 77.3 (16.5) 75.4 (17.0) 76.2 (16.8) 77.3 (16.5) 
Respiratory rate (min
-1
) 25.8 (6.1) 25.8 (6.0) 25.7 (6.3) 25.8 (5.9) 25.8 (8.5) 
Temperature (C), 
median (IQR) 
36.9 (36.4 to 
37.6) 
36.9 (36.4 to 
37.6) 
36.9 (36.4 to 
37.5) 
36.9 (36.4 
to 37.6) 
36.8 (36.4 
to 37.4) 
SpO2 (%), median (IQR) 
92.0 (87.3 to 
96.0) 
92.0 (88.0 to 
96.0) 
92.0 (87.0 to 
96.0) 
92.0 (88.0 
to 96.0) 
93.0 (87.0 
to 98.0) 
BMI (kgm
-2
) 24.8 (6.3) 25.1 (6.0) 24.4 (6.7) 24.9 (6.3) 24.7 (6.4) 
Weight loss >5%, % 22.5 17.6‡ 30.6‡ 21.2 24.7 
MUST score, median 
(IQR) 
0 (0 to 1) 0 (0 to 1)‡ 0 (0 to 2)‡ 0 (0 to 1) 0 (0 to 1) 
CXR consolidation, % 29 28.4 30.0 31.1
∆
 25.1
∆
 
Arterial blood gas values, 
H
+
 (nmol/L), median 
(IQR) 
38.0 (35.5 to 
42.7) 
38.0 (35.5 to 
42.7) 
38.9 (35.5 to 
43.7) 
38.0 (34.7 
to 42.7) 
38.9 (35.5 
to 42.7) 
pH, median (IQR) 
7.42 (7.37 to 
7.45) 
7.42 (7.37 to 
7.45) 
7.41 (7.36 to 
7.45) 
7.42 (7.37 
to 7.46) 
7.41 (7.37 
to 7.45) 
paO2 (kPa), median (IQR) 
8.7 (7.3 to 
10.5) 
8.7 (7.3 to 
10.5) 
8.7 (7.2 to 10.7) 
8.7 (7.3 to 
10.5) 
8.7 (7.3 to 
10.7) 
paCO2 (kPa), median 
(IQR) 
5.8 (4.9 to 7.3) 
5.7 (4.9 to 
7.2) 
6.0 (4.9 to 7.6) 
5.7 (4.8 to 
7.2) 
5.9 (4.9 to 
7.5) 
Bicarbonate (mmol/L) 27.7 (5.2) 27.6 (5.0) 27.9 (5.5) 27.6 (5.1) 28.0 (5.3) 
Acidaemic exacerbation, 
%‡ 
23.7 23.2 24.4 23.6 23.7 
Biochemistry, 
Sodium (mmol/L) 136.3 (4.5) 136.1 (4.5)
∆
 136.6 (4.6)
∆
 136.2 (4.5) 136.4 (4.6) 
Potassium (mmol/L) 4.3 (0.5) 4.3 (0.5) 4.3 (0.5) 4.3 (0.5) 4.3 (0.5) 
Urea (mmol/L), median 
(IQR) 
6.3 (4.6 to 8.8) 
6.0 (4.4 to 
8.5)* 
6.7 (4.9 to 9.3)* 
6.4 (4.7 to 
9.1) 
6.2 (4.5 to 
8.2) 
Creatinine (μmol/L), 
median (IQR) 
92 (77 to 112) 
93 (77 to 
112) 
91 (76 to 112) 
92 (77 to 
115) 
92 (77 to 
109) 
Albumin (g/L) 38.7 (4.6) 39.2 (4.6)‡ 38.0 (4.6)‡ 38.4 (4.8)* 39.2 (4.1)* 
Glucose (mmol/L), 
median (IQR) 
6.9 (6.0 to 8.0) 
7.0 (6.1 to 
8.0)
∆
 
6.7 (5.8 to 8.0)
∆
 
6.9 (6.0 to 
8.0) 
6.8 (6.0 to 
7.8) 
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Variable 
Total 
population, 
n=824 
90-day readmission or 
death 
Frequent readmission 
No, n=517 Yes, n=307 No, n=537 Yes, n=287 
CRP (mg/L), median 
(IQR) 
36 (10 to 111) 34 (9 to 116) 39 (11 to 104) 
42 (10 to 
118)
∆
 
27 (9 to 
91)
∆
 
Haematology, 
Hb (g/dL) 13.6 (1.9) 13.8 (1.8)† 13.4 (2.1)† 13.7 (1.9) 13.6 (1.8) 
Haematocrit 0.43 (0.06) 0.42 (0.05)* 0.40 (0.06)* 0.41 (0.06) 0.41 (0.06) 
White cell count 
(x10
9
/L), median (IQR) 
11.8 (9.1 to 
15.3) 
11.8 (9.1 to 
15.1) 
12 (9.1 to 16.1) 
12.0 (9.1 to 
15.5) 
11.6 (9.1 to 
15.2) 
Neutrophil count 
(x10
9
/L), median (IQR) 
9.1 (6.8 to 
12.6) 
9.1 (6.8 to 
12.6) 
9.1 (6.8 to 12.8) 
9.2 (6.9 to 
12.7) 
8.8 (6.5 to 
12.4) 
Eosinophil count 
(x10
9
/L), median (IQR) 
0.1 (0 to 0.2) 
0.1 (0 to 
0.1)* 
0.1 (0 to 0.2)* 0 (0 to 0.1)† 
0.1 (0 to 
0.2)† 
Values shown are mean (SD) unless stated otherwise. Significant differences between presence and 
absence of stated outcome: *p<0.05; †p<0.01; ‡p<0.001; 
∆
p<0.1; BP – blood pressure 
Length of the index hospital stay was positively correlated with risk of 90-day 
readmission or death, and patients who required increased social care immediately 
following hospital discharge had a higher risk of readmission or death compared to 
those who did not require increased care. There was no relationship between need for 
assisted ventilation during the index admission and subsequent readmission risk (Table 
10.6). 
Table 10.6     Developments during hospital admission and their association with 
readmission 
Variable 
Total 
population, 
n=824 
90-day readmission or 
death 
Frequent 
readmission 
No, n=517 Yes, n=307 
No, 
n=537 
Yes, 
n=287 
Received assisted ventilation, % 18.2 17.2 19.9 17.1 20.2 
Length of stay (days), median 
(IQR) 
6 (4 to 11) 6 (3 to 10)‡ 8 (4 to 12)‡ 
6 (4 to 
11) 
7 (3 to 
11) 
Increased care package at 
discharge, % 
11.3 9.5* 14.3* 12.3 9.4 
Specialist respiratory care, % 68.2 68.5 67.8 68.0 68.6 
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10.2 INDEPENDENT PREDICTORS OF 90-DAY READMISSION OR DEATH 
After screening for collinearity (section 6.8.1): FEV1 % predicted was retained over FEV1 
(Pearson’s r = 0.748); albumin was retained over both haemoglobin and haematocrit (r 
= 0.377 and 0.313 respectively, and eigenvalues suggest collinearity); the total number 
of admissions in the previous year was retained over the number of respiratory 
admissions (Spearman’s-ρ = 0.852); and eMRCD was retained over exercise tolerance 
(ρ = -0.845) and MRCD (ρ = 0.990). Zero-order correlations between the remaining 
potential continuous prognostic variables are shown in Appendix E (Table 17.8). Pedal 
oedema at admission and a past history of cor pulmonale were thought likely to be 
collinear and they were therefore combined into a single variable: cor pulmonale or 
pedal oedema at admission. Individual comorbidities were entered instead of the CCI 
and the level of dependency prior to admission was assessed by the need for social 
care rather than residence in institutional care. Following exclusion of these variables, 
there was no significant collinearity between potential independent predictors (mean 
VIF = 1.36; highest individual VIF = 2.59). 
The remaining variables underwent backward stepwise logistic regression analysis 
which identified the following independent predictors of outcome (Table 10.7): 
Table 10.7     Independent predictors of 90-day readmission or death – ‘Model 4’ 
Variable B S.E. OR (95% CI) p value 
eMRCD 0.53 0.09 1.69 (1.42 to 2.02) <0.0001 
Number of hospitalisations in the previous year 0.28 0.06 1.32 (1.18 to 1.48) <0.0001 
Recent unexplained weight loss >  5% 0.51 0.19 1.66 (1.15 to 2.40) 0.0067 
Cor pulmonale or pedal oedema 0.44 0.17 1.56 (1.11 to 2.18) 0.0097 
Social care prior to admission 0.48 0.21 1.62 (1.07 to 2.44) 0.0213 
Serum glucose -0.07 0.03 0.933 (0.873 to 0.997) 0.0402 
Male sex 0.31 0.16 1.36 (0.988 to 1.87) 0.0595 
Atrial fibrillation 0.42 0.25 1.52 (0.934 to 2.48) 0.0916 
Intercept -3.04 0.45   
S.E. – standard error; OR – odds ratio; CI – confidence interval 
Odds of readmission or death = e ^ - [-3.04 + (0.53 x eMRCD) + (0.28 x number of hospitalisations in the 
previous year) + (0.51 if recent unexplained weight loss >5%) + (0.44 if cor pulmonale or pedal oedema) + 
(0.48 if social care prior to admission) - (0.07 x serum glucose) + (0.31 if male sex) + (0.42 if atrial 
fibrillation)] 
 
174 
Severe stable-state dyspnoea; recent unexplained weight loss; and frequent hospital 
admissions in the preceding year were all strong independent predictors of 90-day 
outcome. Our results suggest that a high glucose on admission is weakly protective 
against poor outcome in those surviving to discharge. This is, perhaps, at odds with 
clinical reasoning as well as our results (Table 9.6) and previous research on in-hospital 
mortality (section 2.2.4.4). Although McGhan et al [14] showed a comorbid history of 
diabetes was protective against readmission, which is in keeping with the association 
we have shown between glucose and readmission, the lack of association between 
diabetes and readmission in our study suggests that this is not a true result and may 
not generalise beyond the study population. 
 The regression model was estimated to predict 23.3% of the variance of the 
dependent variable (Nagelkerke’s R2 = 0.233) and was a satisfactory fit of the overall 
dataset (HLGFT, p = 0.72). Plotting the observed probability of readmission against 
predicted probability, per decile of risk, confirms a well calibrated model, with data 
points closely aligned to the line of best fit (Figure 10.1). 11 cases were statistical 
outliers although none of these cases significantly influenced the regression model 
(satisfactory leverage values and Cook’s distances). The regression model has good 
discrimination for 90-day readmission or death: AUROC = 0.752, 95% CI 0.718 to 0.785, 
and bootstrap estimation of the AUROC confirmed that our results were internally 
consistent (AUROC = 0.751, 95% CI 0.717 to 0.783). 
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Figure 10.1     Calibration plot for regression model of 90-day readmission 
 
Figure 10.2     Discrimination of Model 4 (Table 10.7) for the prediction of 90-day 
readmission 
 
10.2.1 DEVELOPING A CLINICAL PREDICTION TOOL FOR 90-DAY 
READMISSION 
Using the same methods described in section 6.8.3.2, variables associated with 90-day 
readmission or death were categorised (Table 10.8) and independent categorical 
predictors of 90-day readmission were identified using backwards stepwise logistic 
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regression analysis (Table 10.9). Due to concerns over validity and generalisability, 
serum glucose was excluded from the analysis.  
Table 10.8     Categorical variables entered in to logistic regression analysis 
Variable Categories 
 0† 1 2 3 
Age, years < 75 ≥ 75   
Number of hospitalisations in the previous year < 2 ≥ 2   
Number of episodes of AECOPD in the previous year < 3 ≥ 3   
FEV1 % predicted ≥ 30 < 30   
FVC, litres ≥ 1.9 < 1.9   
eMRCD 1 to 3 4 5a 5b 
Serum sodium, mmol/L* ≥ 135 < 135   
Eosinophil count, x10
9
/L* < 0.05 ≥ 0.05   
Urea, mmol/L* < 6.5 ≥ 6.5   
Albumin, g/L* ≥ 38 < 38   
Length of hospital stay, days < 7 ≥ 7   
Acute confusion* No Yes   
Recent unexplained weight loss < 5% ≥ 5%   
Sex Female Male   
Social care prior to admission No Yes   
Stroke disease No Yes   
Ischaemic heart disease No Yes   
Atrial fibrillation No Yes   
Cor pulmonale or pedal oedema No Yes   
Anxiety or depression No  Yes   
LTOT No Yes   
Home nebuliser No Yes   
Previous AECOPD requiring NIV No Yes   
† reference category for regression analysis; * at the time of hospital admission 
The regression model (Table 10.9) explained 22.9% of the variance in the outcome 
variable (Nagelkerke’s R2 = 0.229) and was a good fit of the overall dataset (HLGFT, p = 
0.31). There were few (1.2%) statistical outliers, and no outliers had a significant 
influence on the regression model (all leverage values < 0.036 and Cook’s distances < 
1). 
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Table 10.9     Independent categorical predictors of 90-day readmission or death 
Variable B S.E. OR (95% CI) p value 
eMRCD 
1 to 3 
4 
5a 
5b 
 
 
0.62 
0.94 
1.72 
 
 
0.22 
0.26 
0.32 
 
1 
1.86 (1.22 to 2.84) 
2.56 (1.53 to 4.28) 
5.58 (2.98 to 10.4) 
 
 
0.0038 
0.0003 
<0.0001 
≥ 2 hospitalisations in previous 12 months  1.02 0.19 2.76 (1.92 to 3.99) <0.0001 
Recent unexplained weight loss > 5% 0.57 0.19 1.76 (1.22 to 2.55) 0.0025 
Social care prior to admission 0.47 0.21 1.59 (1.05 to 2.41) 0.0270 
Cor pulmonale or pedal oedema 0.43 0.17 1.54 (1.10 to 2.16) 0.0121 
Urea ≥ 6.5 mmol/L 0.32 0.16 1.38 (1.00 to 1.90) 0.0469 
Eosinophil count ≥ 0.05x10
9
/L* 0.31 0.16 1.36 (0.993 to 1.87) 0.0555 
Intercept -1.32 0.20   
S.E. – standard error; OR – odds ratio; CI – confidence interval. *at hospital admission 
Based on the above findings, scores were assigned to all categorical independent 
predictors that remained significant in the final model, and the CRUSHED (Cor 
pulmonale (or pedal oedema); Recent unexplained weight loss; elevated Urea; Social 
care; previous Hospitalisations; extended Dyspnoea score) predictive tool was 
developed (Table 10.10). 
Table 10.10     The CRUSHED prognostic score 
Variable Score 
Cor pulmonale or pedal oedema 1 
Recent unexplained weight loss > 5% 1 
Urea ≥ 6.5 mmol/L 1 
Social care prior to admission 1 
≥ 2 hospitalisations in previous 12 months 2 
extended MRC Dyspnoea score 
1 to 3 
4 
5a 
5b 
 
0 
1 
2 
3 
Maximum CRUSHED score 9 
The distribution of patients across the CRUSHED score, and the associated readmission 
rate, sensitivity and specificity are shown in Table 10.11. The discrimination of 
CRUSHED score was good for 90-day readmission or death (AUROC = 0.735, 95% CI 
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0.701 to 0.770), and moderate for 28-day readmission or death (AUROC = 0.691, 95% 
CI 0.647 to 0.734) (Figure 10.3). Internal validation confirmed the performance of the 
tool to be good for 90-day readmission (bootstrapped AUROC = 0.735, 95% CI 0.700 to 
0.769). 
Table 10.11     The CRUSHED score and 90-day readmission or death 
CRUSHED Score n 90-day readmission, n (%) Sensitivity* Specificity* 
0 69 11.6 1 0 
1 175 16.0 0.97 0.10 
2 173 30.1 0.88 0.34 
3 127 40.9 0.71 0.56 
4 118 48.3 0.58 0.72 
5 81 56.8 0.36 0.85 
6 44 70.5 0.19 0.93 
7 24 91.7 0.11 0.97 
8 10 80.0 0.05 0.99 
9 3 100 0.012 1 
* Positive test result = score ≥ corresponding CRUSHED score 
Figure 10.3     ROC curve showing discrimination of CRUSHED score for 90-day and 28-
day readmission or death 
 
179 
There was no significant difference in discrimination between Model 4 and the 
CRUSHED score (p = 0.059). The calibration between the CRUSHED score and the 
predicted probabilities according to Model 4 (Table 10.7) is shown in Figure 10.4. This 
shows a stepwise increase in the predicted probability of readmission for each 
CRUSHED grade, and the CRUSHED score is well calibrated to Regression Model 4 
across most risk categories (CRUSHED grade 0 to 6). There is suboptimal calibration for 
patients at a very high risk of outcome (CRUSHED grades 7, 8, 9) where the observed 
proportion of outcome lies outside the predicted probability however, this may be due 
to the small numbers of patients within these grades. 
Figure 10.4     Calibration between the observed probability according to CRUSHED 
score and the predicted probability of readmission according to Model 4 
 
Model 4 
180 
10.3 INDEPENDENT PREDICTORS OF FREQUENT READMISSION 
Variables which were not collinear, but were associated with frequent readmission (p < 
0.10) on univariate analysis were entered in to backward stepwise logistic regression 
analysis (Table 10.12).  
Table 10.12     Independent predictors of frequent hospital readmission (‘Model 5’) 
Variable B S.E. OR (95% CI) p value 
Total number of hospitalisations in previous 
year 
0.42 0.06 1.52 (1.35 to 1.71) <0.0001 
Previous NIV for AECOPD 0.72 0.24 2.06 (1.28 to 3.32) 0.0030 
Serum albumin, g/L 0.04 0.02 1.05 (1.01 to 1.08) 0.0107 
Cerebrovascular disease 0.60 0.23 1.82 (1.15 to 2.86) 0.0101 
Hypertension -0.35 0.16 0.708 (0.513 to 0.977) 0.0355 
Intercept -2.80 0.69   
S.E. – standard error; OR – odds ratio; CI – confidence interval 
Nagelkerke’s R2 for the regression model was 0.153 and the model was a satisfactory 
fit of the data (HLGFT, p = 0.271). Only 4 cases were statistical outliers and none had a 
significant influence on the regression model. Plotting predicted against observed 
probabilities of frequent readmission (Figure 10.5) shows that the regression model 
has good calibration overall although it slightly overestimates the risk of frequent 
readmission (line of best fit gradient = 0.846). The discrimination of Model 5 for 
frequent readmission was satisfactory (AUROC = 0.701, 0.662 to 0.739) and was 
internally valid (bootstrapped AUROC = 0.700, 0.661 to 0.738) (Figure 10.6). 
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Figure 10.5     Calibration plot for Model 5 for the prediction of frequent readmission 
 
Figure 10.6     Discrimination of Model 5 for frequent readmission following hospital 
discharge 
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CHAPTER 11  PREDICTING IN-HOSPITAL MORTALITY IN PATIENTS RECEIVING 
ASSISTED VENTILATION 
Aim 1e:  identify independent predictors of in-hospital mortality in patients receiving 
assisted ventilation following hospitalisation for AECOPD.  
199 (21.6%) patients required assisted ventilation during their hospital stay due to 
development of ARF; commenced at the time of admission in 130. Compared to the 
remainder of the population (n = 721), patients treated with assisted ventilation: were 
more likely to be female; had more severe lung function impairment; had more severe 
stable-state dyspnoea; had less comorbidity; and had markers suggesting they were 
experiencing a more severe acute exacerbation (more frequent coexistent 
consolidation and acute confusion) (Table 11.1). Patients receiving assisted ventilation 
were more likely to die in hospital (24.6% v. 6.5%, p < 0.0001) and had a longer median 
length of stay (10 v. 6 days, p < 0.0001). There were no differences between the two 
groups in rates of readmission or death following discharge. 
Table 11.1     Characteristics of patients receiving assisted ventilation, and comparisons 
with patients not ventilated 
Variable 
Patients receiving assisted 
ventilation, n=199 
Patients not receiving 
assisted ventilation, n=721 
Sociodemographic details, 
Admission hospital (NTGH), % 54.3 55.1 
Age (years) 73.6 (9.8) 72.9 (10.1) 
Female, % 61.3† 51.9† 
Smoking load (cigarette pack years), 
median (IQR) 
46 (35 to 60) 45 (31 to 60) 
Institutional care, % 6.5 6.5 
Markers of disease severity, 
Number of hospital admissions in 
previous year, median (IQR) 
0 (0 to 1) 0 (0 to 1) 
Number of AECOPD in previous 
year, median (IQR) 
3 (1 to 4) 3 (1 to 4) 
FEV1 % predicted 38.1 (16.1)† 45.1 (17.1)† 
MRCD, median (IQR) 4 (4 to 5)† 4 (3 to 5)† 
Cor pulmonale, % 18.1† 7.8† 
LTOT, % 23.1† 9.4† 
Comorbidity & nutritional status, 
CCI, median (IQR) 2 (1 to 3)† 2 (1 to 3)†* 
BMI, kgm
-2
 25.1 (7.0) 24.4 (6.1) 
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Variable 
Patients receiving assisted 
ventilation, n=199 
Patients not receiving 
assisted ventilation, n=721 
Admission information and hospital outcomes, 
Coexistent consolidation, % 40.7† 30.2† 
Acute confusion, % 26.6† 8.7† 
In-hospital mortality, % 24.6† 6.5† 
30-day mortality, % 26.6† 8.6† 
Length of stay (days), median (IQR) 10 (6 to 16)† 6 (3 to 10)† 
Readmission or death‡ 
28-day 
90-day 
 
22.0 
40.7 
 
20.8 
36.5 
† significant difference between patients receiving and not receiving assisted ventilation; * CCI 
significantly higher in patients not receiving assisted ventilation; ‡ in patients surviving to discharge; CCI 
– Charlson comorbidity index  
To assist comparisons with the published randomised controlled trials in the use of NIV 
in patients hospitalised with NIV,[170, 396] which included patients with mild to 
moderate acidaemia (7.25 ≤ pH < 7.35) and reported an in-hospital mortality rate of 
~10%, Table 11.2 shows the mortality rates in patients receiving ventilation in this 
study, stratified according to the severity of acidaemia. 
Table 11.2     In-hospital mortality rates in ventilated patients, stratified according to 
severity of acidaemia 
pH Acidaemic at hospital admission, n = 130 Acidaemic at any time, n = 199 
n In-hospital mortality, n (%) n In-hospital mortality, n (%) 
< 7.25 54 11 (20.4) 80 27 (33.8) 
7.25 to 7.35 76 9 (11.8) 119 22 (18.5) 
11.1.1 UNIVARIATE ASSOCIATIONS WITH IN-HOSPITAL MORTALITY IN 
PATIENTS RECEIVING ASSISTED VENTILATION 
As with the total population (section 9.1.1), patients who died in hospital after being 
treated with assisted ventilation were older and less likely to be living independently 
(Table 11.3). Although associated with in-hospital death in the total population (Table 
9.2), spirometric measures of disease severity (FEV1 and FVC) had no relationship with 
mortality in patients ventilated (Table 11.4). It is worth noting, however, that patients 
receiving assisted ventilation had lower mean FEV1 values than those not ventilated 
and therefore the narrow range of FEV1 values in ventilated patients may have limited 
its discriminative strength. As with the total population of 920 patients studied, among 
the 199 who were treated with assisted ventilation, the severity of stable-state 
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dyspnoea (MRCD, eMRCD) and exercise capacity were strongly associated with in-
hospital mortality. 
There was a similar overall burden, and distribution, of comorbidity in the total 
population (n = 920) (Table 9.3) and the subgroup receiving assisted ventilation (Table 
11.5). Also, similarly to the total population, cerebrovascular disease, chronic kidney 
disease and the overall comorbidity burden (CCI) were associated with in-hospital 
death, but no respiratory comorbidities were associated with mortality. Osteoporosis 
was also associated with mortality in those ventilated and interestingly, coexistent 
anxiety or depression may have been protective against death (p = 0.0578). No pre-
admission maintenance medications were associated with in-hospital mortality (Table 
11.6), and in particular, patients in receipt of LTOT were not at a greater risk of death. 
It should, however, be noted that a larger proportion of patients treated with assisted 
ventilation were in receipt of LTOT compared to the total population (23.1% v. 12.4% 
respectively). 
Patients with an ineffective cough on admission, who received assisted ventilation 
during their hospital stay, had a higher mortality. Similarly to the total population, 
coexistent pneumonia and poor nutritional status (low BMI or recent weight loss) were 
associated with mortality (Table 11.7). Interestingly, low oxygen saturation appeared 
to be protective against mortality, however this is likely to be because the most unwell 
patients received high-flow oxygen treatment in the pre-hospital setting and therefore 
had higher oxygen saturations compared to less unwell patients who did not receive 
(high-flow) oxygen prior to admission. Furthermore, patients with well preserved 
oxygen saturation at admission to hospital are unlikely to have had ARF at admission, 
and therefore well preserved oxygen saturation at admission is likely to be associated 
with a longer time to recognition of ARF. 
Similar biochemical and haematological markers were associated with mortality in 
patients receiving assisted ventilation as in the total population (high urea, low 
albumin, high CRP, low haemoglobin, high neutrophil count and low eosinophil count), 
although in the former, creatinine, potassium and glucose were not associated with 
mortality (Table 11.8). 
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Table 11.3     Sociodemographic details of ventilated patients and in-hospital mortality 
Variable Population 
ventilated, 
n=199 
Survived 
admission, 
n=150 
Died in-
hospital, 
n=49 
p 
value* 
Age 73.6 (9.8) 71.8 (9.7) 79.2 (8.2) <0.0001 
Female, % 61.3 60.0 65.3 0.61 
Admission hospital (NTGH), % 54.3 52.7 59.2 0.51 
Institutional care, % 6.5 6.0 8.2 0.74 
Social care prior to admission, % 27.6 24.0 38.8 0.0647 
Smoking load (cpy), median (IQR) 46 (35 to 60) 53 (35 to 60) 40 (32.5 to 60) 0.24 
* comparison between patients surviving admission and those who died during admission in patients 
treated with assisted ventilation 
Table 11.4     Health resource use, disease severity and mortality in ventilated patients 
Variable Population 
ventilated, 
n=199 
Survived 
admission, 
n=150 
Died in-
hospital, 
n=49 
p 
value* 
Health resource use, 
Number of respiratory admissions in 
previous year, median (IQR) 
0 (0 to 1) 0 (0 to 1) 0 (0 to 1) 0.31 
Total number of admissions in previous 
year, median (IQR) 
0 (0 to 1) 0 (0 to 1) 1 (0 to 2) 0.22 
Number of AECOPD in previous year, 
median (IQR) 
3 (1 to 4) 3 (1 to 4) 3 (2 to 4) 0.81 
Previous NIV for AECOPD, % 26.1 28.7 18.4 0.19 
Previous pulmonary rehabilitation, % 9.5 10.0 8.2 1.0 
Spirometry, 
FEV1 (litres) 0.788 (0.36) 0.807 (0.38) 0.732 (0.28) 0.21 
FEV1 % predicted 38.1 (16.1) 37.9 (16.5) 38.7 (14.7) 0.75 
FVC (litres) 1.83 (0.70) 1.87 (0.72) 1.73 (0.62) 0.21 
FEV1 / FVC, median (IQR) 43 (36 to 50) 43 (35 to 50) 
43 (37.5 to 
51.5) 
0.78 
Exercise capacity and disease complications, 
MRCD, median (IQR) 4 (4 to 5) 4 (4 to 5) 5 (5 to 5) <0.0001 
eMRCD, median (IQR) 4 (4 to 5a) 4 (4 to 5a) 5a (5a to 5b) <0.0001 
Exercise tolerance (metres), median 
(IQR) 
20 (10 to 50) 20 (10 to 50) 10 (6 to 20) <0.0001 
Housebound, % 50.3 41.3 77.6 <0.0001 
Cor pulmonale, % 18.1 18.7 16.3 0.83 
* comparison between patients surviving admission and those who died during admission in patients 
treated with assisted ventilation 
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Table 11.5     Comorbidity and mortality in patients treated with assisted ventilation 
Variable Population 
ventilated, 
n=199 
Survived 
admission, 
n=150 
Died in-
hospital, 
n=49 
p value* 
Respiratory, 
Bronchiectasis, % 6.0 4.7 10.2 0.17 
Asthma, % 3.0 3.3 2.0 1.0 
Pulmonary fibrosis, % 1.5 0.7 4.1 0.15 
Obstructive sleep apnoea, % 2.0 1.3 4.1 0.25 
Cardiovascular, 
Hypertension, % 43.2 43.3 42.9 1 
Cerebrovascular disease, % 10.6 6.7 22.4 0.0053 
Ischaemic heart disease, % 23.1 22.0 26.5 0.56 
Atrial fibrillation, % 12.6 10.7 18.4 0.21 
LV dysfunction, % 7.0 6.0 10.2 0.34 
Thromboembolic disease, % 5.0 5.3 4.1 1.0 
Valvular heart disease, % 3.0 2.7 4.1 0.64 
Peripheral vascular disease, % 5.0 4.0 8.2 0.27 
General, 
Diabetes mellitus, % 17.6 19.3 12.2 0.29 
Osteoporosis, % 12.6 9.3 22.4 0.0242 
Rheumatoid arthritis, % 2.5 2.0 4.1 0.60 
Cognitive impairment, % 4.5 4.7 4.1 1.0 
Chronic kidney disease, % 7.0 4.0 16.3 0.0072 
Anxiety / depression, % 24.6 28.0 14.3 0.0578 
Chronic liver disease, % 1.0 1.3 0 1.0 
Peptic ulcer disease, % 5.0 4.7 6.1 0.71 
Past history of cancer, % 5.5 3.3 12.2 0.0281 
History of active cancer, % 2.5 2.0 4.1 0.60 
Comorbidity burden, 
Charlson Comorbidity Index, median 
(IQR) 
2 (1 to 3) 2 (1 to 2) 2 (1 to 3) 0.0132 
* comparison between patients surviving admission and those who died during admission in patients 
treated with assisted ventilation 
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Table 11.6     Medications at admission and mortality in ventilated patients 
Variable Population 
ventilated, 
n=199 
Survived 
admission, 
n=150 
Died in-
hospital, 
n=49 
p 
value* 
Respiratory, 
LTOT, % 23.1 21.3 28.6 0.33 
Ambulatory oxygen, % 4.5 4.7 4.1 1.0 
Short burst oxygen, % 13.1 13.3 12.2 1 
Home oxygen therapy,
ϕ
 % 37.2 35.3 42.9 0.40 
Home nebuliser, % 16.1 15.3 18.4 0.66 
Inhaled corticosteroid (ICS), % 77.9 77.3 79.6 0.84 
ICS dose (BDP equivalent), 
median (IQR) 
2000 (1000 to 
2000) 
2000 (1000 to 
2000) 
2000 (2000 to 
2000) 
0.38 
Inhaled long-acting beta agonist, 
% 
75.9 75.3 77.6 0.85 
Inhaled anticholinergic, % 68.8 66.0 77.6 0.16 
Long-term oral corticosteroid, % 8.0 7.3 10.2 0.55 
Carbocysteine, % 12.6 10.0 20.4 0.0797 
Theophylline, % 9.0 7.3 14.3 0.16 
Cardiovascular, 
Statin, % 42.7 43.3 40.8 0.87 
Beta-blocker, % 8.0 7.3 10.2 0.55 
ACE inhibitor, % 27.6 27.3 28.6 0.86 
Angiotensin receptor blocker, % 5.0 4.0 8.2 0.27 
Diuretic, % 43.2 42.0 46.9 0.62 
Other, 
Benzodiazepine,† % 8.0 9.3 4.1 0.37 
Opiate,† % 0.5 0 2.0 0.25 
* comparison between patients surviving admission and those who died during admission in patients 
treated with assisted ventilation; 
ϕ
 either LTOT, ambulatory O2 or short burst O2; ICS – inhaled 
corticosteroid; BDP – beclomethasone diproprionate; ACE – Angiotensin converting enzyme 
 
Table 11.7     Clinical findings at admission to hospital and mortality in patients treated 
with assisted ventilation 
Variable Population 
ventilated, 
n=199 
Survived 
admission, 
n=150 
Died in-
hospital, 
n=49 
p 
value* 
History and examination findings, 
Purulent sputum, % 48.2 48.6 46.7 0.87 
Ineffective cough, % 23.6 20.0 34.7 0.0515 
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Variable Population 
ventilated, 
n=199 
Survived 
admission, 
n=150 
Died in-
hospital, 
n=49 
p 
value* 
Pedal oedema, % 41.5 43.4 34.9 0.38 
Acute confusion, % 26.6 24.7 32.7 0.27 
Heart rate (min
-1
) 107.3 (20.6) 108.0 (20.7) 105.0 (20.2) 0.37 
Initial non-invasive investigations, 
Systolic BP (mmHg) 141.8 (27.6) 142.0 (26.9) 141.1 (30.0) 0.84 
Diastolic BP (mmHg) 77.6 (18.5) 78.3 (18.4) 75.4 (18.8) 0.34 
Respiratory rate (min
-1
) 27.1 (7.4) 26.9 (6.9) 27.9 (8.8) 0.43 
Temperature (C), median (IQR) 36.9 (0.91) 36.9 (0.89) 36.7 (0.95) 0.21 
SpO2 (%), median (IQR) 89 (80 to 96) 88 (79 to 96) 93 (85 to 96.5) 0.0228 
BMI (kgm
-2
) 25.1 (6.96) 25.7 (6.90) 23.3 (6.90) 0.0363 
Weight loss >5%, % 23.1 18.7 36.7 0.0117 
CXR consolidation, % 40.7 36.0 55.1 0.0200 
* comparison between patients surviving admission and those who died during admission in patients 
treated with assisted ventilation 
Table 11.8     Laboratory results at admission and in-hospital mortality in patients 
treated with assisted ventilation 
Variable Population 
ventilated, 
n=199 
Survived 
admission, 
n=150 
Died in-
hospital, n=49 
p 
value* 
Biochemistry, 
Sodium (mmol/L) 136.5 (5.11) 136.4 (5.34) 136.8 (4.37) 0.65 
Potassium (mmol/L) 4.60 (0.59) 4.59 (0.57) 4.65 (0.67) 0.57 
Urea (mmol/L), median (IQR) 7.1 (5.1 to 10.8) 6.8 (5.0 to 10.6) 8.8 (6.1 to 12.0) 0.0374 
Creatinine (μmol/L), median 
(IQR) 
92 (74 to 120) 93 (78 to 119) 90 (73 to 136) 0.83 
Albumin (g/L) 38.1 (5.07) 38.6 (4.96) 36.4 (5.09) 0.0085 
Glucose (mmol/L), median 
(IQR) 
7.5 (6.6 to 9.3) 7.5 (6.6 to 9.3) 7.6 (6.2 to 8.8) 0.71 
CRP (mg/L), median (IQR) 49 (14 to 112) 43 (11 to 98) 
77 (28.5 to 
130.5) 
0.0084 
Haematology, 
Hb (g/dL) 13.7 (2.17) 13.9 (2.16) 13.2 (2.15) 0.0337 
Haematocrit 0.425 (0.068) 0.431 (0.068) 0.406 (0.063) 0.0242 
White cell count (x10
9
/L), 
median (IQR) 
12.2 (9.5 to 15.2) 12.2 (9.1 to 15.0) 
12.6 (9.7 to 
18.2) 
0.26 
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Variable Population 
ventilated, 
n=199 
Survived 
admission, 
n=150 
Died in-
hospital, n=49 
p 
value* 
Neutrophil count (x10
9
/L), 
median (IQR) 
9.3 (7.0 to 12.8) 9.1 (6.8 to 12.5) 
10.6 (7.7 to 
16.9) 
0.0488 
Eosinophil count (x10
9
/L), 
median (IQR) 
0 (0 to 0.1) 0 (0 to 0.2) 0 (0 to 0.1) 0.0037 
* comparison between patients surviving admission and those who died during admission in patients 
treated with assisted ventilation 
Of the 199 patients who received assisted ventilation, 4 patients were immediately 
invasively ventilated and 195 were initially treated with NIV: of these, 4 patients 
progressed to invasive ventilation due to failure of NIV. At hospital admission, patients 
with a lower pH, and higher paCO2 appeared to, counterintuitively, be at a lower risk of 
mortality. However this is due to the strong effect that the time from admission to the 
development of ARF has on mortality. Therefore, the patients at the highest risk of 
death were those who had no evidence of respiratory failure (i.e. higher pH and lower 
paCO2) at admission, but then deteriorated and developed ARF later during their 
hospital stay. 
At the time of commencement of assisted ventilation, median (IQR) pH was 7.26 (7.19 
to 7.30) and most patients had severe hypercapnia (median (IQR) = 9.9 (8.4 to 11.7) 
kPa) (Table 11.9). Of the 186 patients who had ABG data recorded 1 to 2 hours after 
commencing assisted ventilation, 136 (73.1%) showed evidence of improvement 
(increase in pH), compared to ABG at ventilation commencement, and 50 (26.9%) had 
not improved. 4 to 6 hours after ventilation commencement, acidaemia had improved 
to some extent in 114 (76.5%) and worsened or not improved in 35 (23.5%). The 
relationships between subsequent ABG results and mortality are shown in Table 11.9. 
Table 11.9     Blood gas results during initiation of assisted ventilation and mortality 
Variable Population 
ventilated, 
n=199 
Survived 
admission, n=150 
Died in-
hospital, n=49 
p 
value* 
ABG results at hospital admission, n = 199 
Hydrogen ion concentration 
(nmol/L), median (IQR) 
51.3 (42.7 to 
58.9) 
51.3 (45.4 to 58.9) 
43.7 (36.3 to 
56.2) 
0.0039 
pH, median (IQR) 
7.29 (7.23 to 
7.37) 
7.29 (7.23 to 7.34) 
7.36 (7.25 to 
7.44) 
0.0039 
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Variable Population 
ventilated, 
n=199 
Survived 
admission, n=150 
Died in-
hospital, n=49 
p 
value* 
paCO2 (kPa), median (IQR) 
9.20 (7.20 to 
11.3) 
9.50 (7.58 to 11.5) 
7.60 (5.55 to 
10.1) 
0.0017 
paO2 (kPa), median (IQR) 
8.40 (6.80 to 
12.0) 
8.60 (6.70 to 12.4) 
7.90 (6.80 to 
11.0) 
0.39 
Bicarbonate (mmol/L) 33.6 (7.30) 34.1 (7.20) 31.9 (7.43) 0.0631 
Time from admission to first 
recognition of ARF (hours), 
median (IQR) 
1.51 (0.50 to 
14.8) 
1.24 (0.41 to 4.16) 
10.7 (1.32 to 
99.6) 
<0.0001 
ABG at commencement of assisted ventilation, n=199 
Hydrogen ion concentration 
(nmol/L), median (IQR) 
59.9 (50.1 to 
64.6) 
53.7 (49.8 to 62.0) 
58.9 (50.7 to 
72.4) 
0.0309 
pH, median (IQR) 
7.26 (7.19 to 
7.30) 
7.28 (7.21 to 7.30) 
7.23 (7.13 to 
7.31) 
0.0309 
paO2 (kPa), median (IQR) 8.1 (6.9 to 10.1) 8.1 (6.9 to 9.8) 7.7 (6.8 to 10.5) 0.30 
paCO2 (kPa), median (IQR) 9.9 (8.4 to 11.7) 10.0 (8.5 to 11.6) 10.1 (9.1 to 12.7) 0.75 
Bicarbonate (mmol/L) 33.2 (8.44) 34.3 (7.19) 30.8 (8.36) 0.0055 
RR, min
-1
 27.8 (8.12) 26.8 (8.13) 30.8 (7.36) 0.0022 
ABG 1-2 hours post ventilation commencement, n=186 
Hydrogen ion concentration 
(nmol/L), median (IQR) 
49.5 (44.7 to 
57.5) 
49.0 (44.7 to 56.2) 
51.3 (45.2 to 
59.6) 
0.17 
pH, median (IQR) 
7.31 (7.24 to 
7.35) 
7.31 (7.25 to 7.35) 
7.29 (7.22 to 
7.34) 
0.17 
pH improved, %
◘
 73.1 73.4 72.1 0.98 
paO2 (kPa), median (IQR) 8.7 (7.6 to 10.5) 8.7 (7.6 to 10.5) 8.9 (7.7 to 11.2) 0.63 
paCO2 (kPa), median (IQR) 9.0 (7.3 to 10.7) 9.2 (7.5 to 10.8) 8.4 (7.1 to 10.5) 0.38 
Bicarbonate (mmol/L) 32.9 (7.8) 33.8 (7.3) 30.1 (8.8) 0.0067 
RR, min
-1
 22.3 (7.3) 21.1 (6.4) 26.2 (9.0) 0.0018 
ABG 4-6 hours post ventilation commencement, n=149 
Hydrogen ion concentration 
(nmol/L), median (IQR) 
47.9 (41.7 to 
53.7) 
47.9 (41.7 to 53.7) 
51.3 (45.2 to 
59.6) 
0.0438 
pH, median (IQR) 
7.32 (7.27 to 
7.38) 
7.32 (7.27 to 7.38) 
7.29 (7.23 to 
7.35) 
0.0438 
pH improved, %† 76.5 75.9 78.8 0.50 
paO2 (kPa), median (IQR) 9.2 (8.1 to 10.6) 9.2 (8.0 to 10.5) 9.3 (7.9 to 10.7) 0.92 
paCO2 (kPa), median (IQR) 8.8 (7.2 to 10.4) 8.8 (7.2 to 10.4) 8.9 (7.4 to 10.2) 0.88 
Bicarbonate (mmol/L) 33.3 (7.4) 33.8 (7.6) 31.7 (6.5) 0.15 
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Variable Population 
ventilated, 
n=199 
Survived 
admission, n=150 
Died in-
hospital, n=49 
p 
value* 
RR, min
-1 
20.7 (6.1) 19.9 (5.2) 23.4 (8.1) 0.0288 
Progress of assisted ventilation, 
Invasively ventilated, %‡ 2.0 2.0 2.1 1.0 
Length of assisted ventilation 
(days), median (IQR) 
4 (1 to 5) 4 (2 to 6) 3 (1 to 6) 0.0023 
ARF – acidaemic respiratory failure; * comparison between patients surviving admission and those who 
died during admission in patients treated with assisted ventilation; † compared to pH at ventilation 
commencement; ‡ progressed to invasive ventilation following failure of NIV 
The time between admission and the first recognition of ARF was strongly positively 
correlated with in-hospital mortality (Table 11.9) and a detailed breakdown of time to 
respiratory acidosis and mortality in patients treated with assisted ventilation is shown 
in Figure 11.1. The risk of mortality increased significantly if acidaemia developed after 
4 hours, and further increased in patients developing acidaemia after 72 hours (65% in-
hospital mortality).  
Figure 11.1     Time between admission and treatment with assisted ventilation, and 
the respective in-hospital mortality 
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11.1.2 INDEPENDENT PREDICTORS OF MORTALITY IN PATIENTS RECEIVING 
ASSISTED VENTILATION 
Categorical variables with a markedly asymmetric split were excluded and all variables 
associated with in-hospital mortality (p < 0.10) were assessed for evidence of 
multicollinearity (section 6.8.1). Where appropriate, physiological measurements at 
the time of ventilation commencement were included instead of those recorded at the 
time of admission. Individual comorbidities were chosen over the CCI. Zero-order 
correlations between the remaining potential predictors are shown in Appendix E 
(Table 17.7). The remaining variables showed no evidence of significant collinearity 
(mean VIF = 1.37; maximum VIF = 1.79). 
The final regression model is shown in Table 11.10. The model was estimated to 
account for 55% of the variance in the dependent variable (Nagelkerke’s R2 = 0.55) and 
was a satisfactory fit of the dataset (HLGFT, p = 0.658; 7 (3.5%) statistical outliers; and 
acceptable leverage values and Cook’s distances).  
Table 11.10     Independent predictors of in-hospital mortality in patients treated with 
assisted ventilation – ‘Model 6’ 
Variable B S.E. OR (95% CI) p value 
eMRCD 0.87 0.26 2.38 (1.44 to 3.95) 0.0007 
Age (years) 0.09 0.03 1.09 (1.03 to 1.15) 0.0029 
HCO3
-
 concentration (mmol/L)* -0.09 0.03 0.912 (0.856 to 0.971) 0.0038 
Ineffective cough† 1.53 0.55 4.61 (1.57 to 13.5) 0.0055 
Time to recognition of ARF (hours) 0.01 0.00 1.01 (1.00 to 1.02) 0.0076 
Neutrophil count (x10
9
/L)† 0.11 0.04 1.12 (1.03 to 1.22) 0.0105 
Unintentional weight loss >5% 1.35 0.56 3.85 (1.29 to 11.5) 0.0156 
History of anxiety or depression -1.45 0.61 0.235 (0.071 to 0.774) 0.0173 
Cerebrovascular disease 1.54 0.67 4.68 (1.26 to 17.4) 0.0215 
Eosinophil count (x10
9
/L)† -5.63 2.86 0.004 (0.000 to 0.979) 0.0491 
Intercept -10.7 2.79   
* at the time of commencement of assisted ventilation; † at the time of hospital admission 
Odds of in-hospital mortality = e^ - [-10.7 + (0.87 x eMRCD) + (0.09 x age) – (0.09 x HCO3
-
 
concentration*) + (1.53 if ineffective cough†) + (0.01 x time to recognition of ARF) + (0.11 x neutrophil 
count) + (1.35 if unintentional weight loss >5%) – (1.45 if history of anxiety or depression) + (1.54 if 
cerebrovascular disease) - (5.63 x eosinophil count†)] 
Discrimination for in-hospital mortality for the model was excellent (AUROC = 0.913, 
0.869 to 0.956) (Figure 11.2) and internally valid (bootstrapped AUROC = 0.911, 0.863 
193 
to 0.950). A calibration plot of observed versus predicted probability of death, per 
decile of risk, showed the model to be well calibrated (gradient = 0.98) and the 
coordinates were clustered close to the line of best fit (Figure 11.3). 
Figure 11.2     ROC curve showing discrimination of Model 6  
 
Figure 11.3    Calibration of the regression Model 6 for patients receiving assisted 
ventilation 
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PART 2 - LONGITUDINAL ASSESSMENT 
OF QUALITY OF LIFE AND HEALTH 
RESOURCE USE FOLLOWING 
HOSPITALISATION FOR AECOPD 
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CHAPTER 12 PATIENTS AND METHODS 
12.1 PARTICIPANT RECRUITMENT 
Patients admitted to either NTGH or WGH between 19th December 2008 and 19th 
September 2010 with an acute exacerbation of COPD, who survive to discharge, were 
eligible for entry in to the study. We aimed to prospectively recruit 100 patients with 
an exacerbation of COPD who were treated with assisted ventilation and 100 patients 
with an exacerbation of COPD who did not receive ventilation and then perform 
regular follow up for 1 year post discharge. Participants were approached during their 
hospital stay and written consent was obtained. No randomisation of patients 
occurred. It was expected that individuals with AECOPD receiving ventilation would be 
admitted less frequently than those with AECOPD not receiving assisted ventilation. All 
patients hospitalised with AECOPD receiving assisted ventilation were approached for 
consent.  In order to avoid differential recruitment bias, the number of individuals 
hospitalised with AECOPD not receiving ventilation who were approached for consent 
was matched, over a two week period, to the number receiving ventilation.  
12.2 INCLUSION AND EXCLUSION CRITERIA 
In addition to the criteria used for Part 1 (“Predicting mortality and readmissions 
following hospital admission for AECOPD”) detailed in section 6.4 and 6.5, participants 
were excluded if they had significant cognitive or sensory impairment (resulting in 
their inability to provide informed consent or to complete the questionnaires 
independently). Participants could be enrolled in both Part 1 and Part 2, but no 
participant could be enrolled more than once. 
12.3 DATA COLLECTED 
All of the data listed above in the generic methods (section 6.6) were collected for the 
participants involved in this part of the study. Following informed written patient 
consent, assessments were made once clinical stability had been reached close to 
discharge, and then six weeks, three months, six months and twelve months post-
discharge. Post-discharge assessments were performed by me in the out-patient 
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department or, in a minority of cases, in the participants’ home. Data were collected 
through a combination of case note review and direct participant interview.  
At each assessment: the number of exacerbations experienced since the last 
assessment, and time elapsed (in days) since resolution (defined as the completion of 
acute antibiotic and steroid therapy) of the most recent exacerbation, were 
documented. The number of hospital admissions since the last assessment, the 
number of hospital readmissions requiring treatment with assisted ventilation, and the 
length of hospital stay for each admission, were recorded. Any significant medical 
developments since the last assessment were also documented. If a patient died: date 
of death; place of death; and cause of death were collected from the Public Health 
Mortality File. 
Transcutaneous arterial oxygen saturation (recorded with Nonin Onyx 9500: fingertip 
pulse oximeter), body mass index (weight (kg)/height (m2)), MRCD (Table 1.1) and 
eMRCD (Table 5.1), and spirometry (pre-bronchodilator FEV1 and FVC, using a 
MicroLab portable digital volume transducer spirometer) were recorded at each visit.  
12.3.1 HEALTH STATUS MEASURES 
The St. Georges’ Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease 
Questionnaire (CRQ), Nottingham Extended Activities of Daily Living Scale (NEADL) and 
Hospital Anxiety and Depression Scale (HADS) were self-administered by the 
participant. The questionnaires were randomly ordered and supervision was available 
if difficulties arose. In all of the graphical examples below, a higher score on the QoL 
measure (i.e. a higher score on the y-axis) represents a better QoL. It is important to 
note that, for the questionnaires used in this study, this is not always applicable. Table 
12.1 summarises the measurement of each of the QoL questionnaires used. 
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Table 12.1     Summary of the QoL questionnaires used 
Questionnaire 
Range of 
possible 
scores 
Score 
assigned to 
death 
Interpretation 
Minimally 
clinically 
important 
difference (MCID) 
St Georges’ Respiratory 
Questionnaire (SGRQ) 
0 – 100 100 
Higher scores 
indicate worse QoL 
+/- 4 
Chronic Respiratory 
Disease Questionnaire 
(CRQ) 
1 – 7 1 
Lower scores indicate 
worse QoL 
+/- 0.5 
Hospital Anxiety and 
Depression Scale 
(HADS) 
0 – 21 (for 
each 
domain) 
n/a 
Higher scores 
indicate worse 
anxiety or depression 
+/- 1.5 
Nottingham Extended 
Activity of Daily Living 
Score (NEADL) 
0 – 63 0 
Lower scores indicate 
lower levels of 
activity 
+/- 5 
 
12.4 STATISTICAL METHODS  
12.4.1 QUALITY OF LIFE MEASURES 
A simple method to analyse the longitudinal quality of life measures would be to 
consider each time point separately and compare QoL scores at each time point 
between ventilated and non-ventilated patients. However, this approach has major 
problems: the analysis ignores the longitudinal nature of the data; follow-up QoL 
assessment needs to be performed at fixed time points; and multiple analyses are 
performed which is more likely to lead to a type 1 statistical error.[397] We therefore 
chose to use summary measures to analyse longitudinal quality of life data. It is 
important that the choice of summary measures is clinically meaningful [397] and 
consequently, we choose to use the following summary QoL measures:  
1) QoL at baseline (time of hospital discharge); 
2) mean change in QoL during the follow-up period; 
3) time taken to achieve best QoL; and 
4) time spent with a QoL better than the baseline level. 
199 
Figure 12.1 shows a hypothetical patient’s quality of life during the year following 
discharge, as recorded in Part 2 of this study. In this example, a higher questionnaire 
score indicates a better QoL. The hashed line represents the quality of life recorded at 
discharge and the solid line indicates the individual’s quality of life measured, using 
questionnaires described in section 12.3.1, at the following times after hospital 
discharge: six weeks; three months; six months; and 12 months. The follow-up period 
ended when either: a patient completed the 12-month assessment; the patient died; 
or the patient withdrew their consent to participate. If an individual missed a follow-up 
assessment and did not attend any subsequent scheduled visits, it was assumed that 
this patient withdrew their consent at the time of the last attended follow-up 
appointment.  
Figure 12.1     Longitudinal change in quality of life following discharge – example 
patient 
 
1) Quality of life at baseline 
This represents the quality of life recorded at a time of clinical stability close to 
hospital discharge (represented by the circle, Figure 12.2). This enables the 
identification and stratification of patients who entered the study with either a very 
good, or very poor, quality of life. This is a clinically important measure because 
patients whose QoL is very well maintained at baseline are more likely to show a 
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good, simply because of the constraints of the QoL measurement scale. Therefore, any 
subsequent information regarding longitudinal change in QoL needs to be referenced 
against the individual’s baseline measurement.  
Figure 12.2     Graph to illustrate quality of life at baseline measure 
 
2) (Time-adjusted) mean change in quality of life 
This metric provides an overall assessment of whether an individual’s quality of life has 
improved or deteriorated during the period of follow-up. Its calculation, for an 
individual, is illustrated in Figure 12.3: mean change in quality of life = [area above the 
patient’s baseline value (dark grey shading)] – [area below the patient’s baseline value 
(light grey shading)] divided by the follow-up time to provide a time-adjusted value. 
This can be compared to the MCID for the questionnaire to estimate whether, on 
average, an individual’s QoL improved (or declined) by a pre-defined clinically 
significant amount during follow-up. 
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Figure 12.3     Graph illustrating calculation and clinical implication of mean change in 
quality of life during follow-up period 
 
3) Time taken to achieve best quality of life 
The time taken to achieve the best quality of life (grey arrow, Figure 12.4) was, for the 
purposes of this study, used as an indicator of the time taken for the patient’s quality 
of life to recover following discharge. This measure helps identify patients who have a 
prolonged recovery following hospital discharge. 
Figure 12.4     Graph illustrating the time taken to achieve best quality of life 
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4) Time spent with QoL better than baseline level 
For patients with a very poor quality of life at baseline, it is often a clinical concern that 
their quality of life will never significantly improve, and may even continue to 
deteriorate, and this assumption often influences clinical decisions. The length of time 
spent with a quality of life above the baseline level (grey arrows, Figure 12.5) provides 
a useful quantification of subsequent quality of life that can be easily explained and 
understood by patients and clinicians alike. Expressing the time spent above baseline 
quality of life as a percentage of the total follow-up time will also assist interpretation 
and explanation (for example, “following hospital discharge, patient X spent 75% of 
time with a quality of life better than their baseline level”). 
Figure 12.5     Graph illustrating time spent with QoL better than baseline 
 
12.4.2 POPULATION DESCRIPTION, MISSING DATA AND DATA ANALYSIS 
The population description, univariate analyses and multivariate analyses were 
performed using the methodologies outlined in section 6.7. Missing values for 
admission clinical data were imputed as described in sections 6.7.1 and 7.1. It was 
assumed that there was a linear change in QoL between assessments and therefore if a 
participant failed to attend a follow-up appointment but their quality of life was 
recorded at the next scheduled visit, a time-adjusted average was imputed for the 
missing value by assuming a linear change between the two data points either side of 
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the missing assessment (Figure 12.6). Furthermore, similar to previous longitudinal 
QoL studies,[398, 399] for each questionnaire (except HADS) the score representing 
the worst QoL was assigned to represent death and, if a patient died during follow up, 
a linear decrease in QoL was assumed from the value of the last assessment to the 
value at the time of patient death (Figure 12.7). 
Figure 12.6     Longitudinal quality of life measurement in a patient who failed to 
attend a follow-up appointment 
 
Figure 12.7     Longitudinal QoL measurement in a patient who died prior to completing 
12-months follow-up 
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CHAPTER 13  RESULTS 
13.1 MISSING DATA AND VARIABLE DISTRIBUTION 
The dataset was virtually complete and the small number of missing values (serum 
glucose (30 missing); serum albumin (13 missing); ABG results, respiratory rate, 
temperature, potassium concentration, venous bicarbonate concentration and 
neutrophil count (≤ 5 missing)) were imputed using the analysis described in sections 
6.7.1 and 7.1.  
The distributions of the quality of life metrics described in section 12.4.1 are shown in 
Appendix B.2. All variables were treated as non-parametric except for the mean 
change in all QoL indices. 
13.2 POPULATION DESCRIPTION 
183 patients consented to participate in the longitudinal assessment of quality of life 
and health resource use following their discharge from hospital: 82 had received 
assisted ventilation during their hospital stay and 101 had not. In the total population, 
most patients (58.5%) were female and the majority (61.7%) were recruited from 
NTGH. The characteristics of the total population, and of those who received, and did 
not receive, ventilatory assistance, are shown in Table 13.1. 
Both the ventilated and non-ventilated patients in Part 2 of the study were broadly 
similar to the larger population included in Part 1. However, compared to the 
equivalent Part 1 patients, Part 2 patients who did not receive assisted ventilation 
were: younger; more likely to have completed a course of pulmonary rehabilitation in 
the past; slightly less breathless during stable-state; had slightly higher BMI; and had a 
longer length of stay. The longer length of stay is probably, in part, due to the 
difficulties in consenting and performing the discharge assessments on patients with a 
very short hospital stay.  For patients receiving assisted ventilation, there were trends 
to Part 2 patients being slightly younger (p = 0.0616) and more likely to have been 
previously treated with NIV (p = 0.0581) (Table 13.1). Therefore, compared to all 
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patients hospitalised with AECOPD, patients who consented to participate in Part 2 
were younger and had slightly milder disease severity. 
As expected, however, there were more obvious differences between the two 
populations included in Part 2 of the study. Compared to patients who did not receive 
ventilation, those who received assisted ventilation: were more likely to be female; 
were more likely to have experienced a previous admission requiring NIV; had lower 
FEV1 % predicted; had worse stable-state dyspnoea; were more likely to have cor 
pulmonale; were more likely to be receiving LTOT; and (almost inevitably) had a higher 
PaCO2 and a lower pH the time of hospital admission and a longer length of stay. The 
absence of a similar difference in PaO2 values between the two populations is likely to 
be a result of more of the ventilated group being treated with oxygen (78% of 
ventilated patients had the ABG measured whilst receiving supplementary oxygen 
versus 51.5% of the non-ventilated group, p = 0.0008). In summary, ventilated patients 
had evidence of more severe underlying COPD and were experiencing a more severe 
exacerbation at the time of hospital admission. Subsequent comparisons of quality of 
life data between these two cohorts needs to be interpreted in the light of these 
differences. 
 
 Table 13.1     Characteristics of patients enrolled in Part 2, with comparison to Part 1 patients and between Part 2 patients 
 Patients not receiving assisted ventilation Patients receiving assisted ventilation  
Variable Part 1 population* 
(n=674) 
Part 2 population 
(n=101) 
p 
value 
Part 1 population* 
(n=150) 
Part 2 population 
(n=82) 
p 
value 
p 
value† 
Sociodemographic details & prior health resource use, 
Age, years 72.5 (10.1) 68.7 (8.8) <0.0001 71.8 (9.7) 69.3 (9.2) 0.0616 0.63 
Female, % 53.0 51.5 0.831 60 67.1 0.32 0.0360 
No of hospital admissions in previous 
year (median, IQR) 
0 (0 to 1) 0 (0 to 1) 0.963 0 (0 to 1) 0 (0 to 2) 0.15 0.52 
Previous episode of assisted ventilation 
for AECOPD, % 
6.4 9.9 0.203 28.7 41.5 0.0581 <0.0001 
Previous pulmonary rehabilitation, % 9.8 18.8 0.0102 10 14.6 0.39 0.55 
Severity of underlying disease & comorbidity, 
FEV1 % predicted 46.4 (18.1) 42.9 (16.1) 0.0666 38.1 (16.6) 36.8 (18.3) 0.60 0.0184 
eMRCD (median, IQR) 4 (3 to 5a) 4 (3 to 4) 0.0486 4 (4 to 5a) 4 (4 to 5a) 0.63 <0.0001 
Cor pulmonale, % 8.0 6.9 0.843 16.3 18.3 0.84 0.0227 
LTOT, % 9.1 5.9 0.348 21.3 30.5 0.15 <0.0001 
Charlson Comorbidity Index (median, 
IQR) 
2 (1 to 3) 2 (1 to 2) 0.120 1 (1 to 2) 1 (1 to 2) 0.42 0.14 
BMI, kgm
-2
  24.6 (6.2) 25.9 (6.8) 0.0479 25.8 (7.0) 26.4 (7.2) 0.48 0.62 
MUST score (median, IQR) 0 (0 to 1) 0 (0 to 1) 0.895 0 (0 to 1) 0 (0 to 1) 0.90 0.52 
Clinical information on admission to hospital, 
CXR consolidation, % 27.4 28.7 0.812 36.0 28.0 0.25 1 
pH (median, IQR) 7.43 (7.40 to 7.46) 7.43 (7.39 to 7.47) 0.544 7.29 (7.23 to 7.34) 7.29 (7.24 to 7.34) 0.92 <0.0001 
paO2, kPa (median, IQR) 8.4 (7.3 to 10.1) 8.3 (7.2 to 10.0) 0.459 8.5 (6.7 to 12.4) 8.4 (6.6 to 12.2) 0.76 0.98 
2
0
6 
  Patients not receiving assisted ventilation Patients receiving assisted ventilation  
Variable Part 1 population* 
(n=674) 
Part 2 population 
(n=101) 
p 
value 
Part 1 population* 
(n=150) 
Part 2 population 
(n=82) 
p 
value 
p 
value† 
paCO2, kPa (median, IQR) 5.5 (4.8 to 6.4) 5.3 (4.9 to 6.5) 0.967 9.5 (7.6 to 11.6) 9.3 (7.6 to 11.6) 0.93 <0.0001 
Developments during admission, 
Length of stay, days 6 (3 to 9) 7 (4 to 11) 0.0059 10 (7 to 16) 10 (7 to 15) 0.79 <0.0001 
Values quoted are mean (SD) unless otherwise stated; *of those patients surviving to discharge; †comparison between Part 2 patients treated with assisted ventilation (n=82) and 
those not treated with assisted ventilation (n=102) 
2
0
7
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At the time of hospital discharge, patients who had received assisted ventilation during 
their hospital stay reported that, prior to hospitalisation, they had less severe 
respiratory symptoms (lower SGRQ symptom domain, p=0.021), but their respiratory 
symptoms had a greater impact on their emotional function (lower CRQ emotional 
function domain, p=0.0612) and levels of activity (lower NEADL, p = 0.0008). There 
were, however, no other differences in quality of life (measured using either SGRQ or 
CRQ) or symptoms of anxiety or depression between the two patient groups. 
Table 13.2     Comparison of health related quality of life measures recorded at hospital 
discharge between patients treated with and not treated with assisted ventilation 
*Values shown are median (IQR); †Lower scores indicate better quality of life; ‡Higher scores indicate 
better quality of life; SGRQ – St George’s Respiratory Questionnaire; CRQ – Chronic Respiratory Disease 
Questionnaire; HADS – Hospital Anxiety and Depression Scale; NEADL – Nottingham Extended Activity of 
Daily Living Scale. 
13.3 HEALTH RESOURCE USE AND MORTALITY FOLLOWING HOSPITAL 
DISCHARGE 
Of the total population (n = 183), most patients (n = 130, 71%) were rehospitalised at 
least once during the 12-month follow up period and the median number of 
readmissions was 1 (IQR 0 to 3; range 0 to 15). 35 (19.1%) patients required assisted 
ventilation during a hospital admission for the treatment of ARF. The majority of 
patients (n = 157, 86%) reported that they had experienced at least one episode of 
AECOPD during the follow up period and the median number of AECOPD was 3 (IQR 1 
Variable Ventilated (n=82)* Not ventilated (n=101)* p value 
SGRQ†, 
Symptoms 65.2 (49.3 to 80.9) 71.5 (60.7 to 83.0) 0.0260 
Activity 82.9 (72.7 to 92.5) 85.8 (66.8 to 92.5) 0.969 
Impacts 50.3 (38.1 to 68.8) 51.1 (36.0 to 62.9) 0.643 
Total 62.5 (51.9 to 73.6) 63.1 (52.3 to 73.5) 0.943 
CRQ‡, 
Dyspnoea 2.8 (2.2 to 3.8) 2.8 (2 to 4) 0.571 
Emotional function 2 (1.3 to 3) 3.7 (2.7 to 4.8) 0.0612 
Fatigue 3.3 (2.1 to 4.9) 2.5 (1.8 to 3.2) 0.172 
Mastery 2.8 (2 to 4.1) 3.3 (2.3 to 4.5) 0.138 
HADS†, 
Anxiety 8.5 (4 to 14) 8 (4.5 to 12.5) 0.347 
Depression 6 (3 to 10) 6 (3 to 8) 0.500 
NEADL‡, 31 (19 to 41) 38 (32 to 47.5) 0.0006 
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to 6; range 0 to 15). Overall, 33 (18.0%) patients died during the 12-month follow-up 
period. Of these patients, 12 (6.6%) died with 3 months of discharge and 19 (10.4%) 
died within 6 months of discharge. 
There was no significant difference in the risk of all-cause rehospitalisation between 
the ventilated and non-ventilated groups (p = 0.14) although patients who were 
originally treated with assisted ventilation experienced more frequent respiratory 
readmissions (p = 0.0339) and spent a longer period in hospital (p = 0.0393) during the 
subsequent year than those who were not treated with ventilation. Furthermore, 
patients who received assisted ventilation during their index admission were 
significantly more likely to require assisted ventilation during a subsequent hospital 
admission. There were no significant differences in the number of episodes of AECOPD 
or in the total number of readmissions (i.e. both respiratory causes and non-
respiratory causes) (Table 13.3). 
Table 13.3     Health resource use and mortality during follow-up 
Outcome Assisted ventilation, 
n=82 
Not ventilated, 
n=101 
p value 
Health resource use following discharge, 
Readmitted within 12-months, % 76.8 66.3 0.14 
Episodes of AECOPD, median (IQR) 3 (1 to 6) 3 (1 to 6) 0.94 
Total no. of readmissions, median 
(IQR) 
2 (1 to 3) 1 (0 to 2) 0.0877 
No. of respiratory readmissions, 
median (IQR) 
1 (0 to 3) 1 (0 to 2) 0.0339 
Total length of hospital stay (days), 
median (IQR) 
11 (1 to 28) 4 (0 to 18) 0.0393 
Readmission requiring assisted 
ventilation for ARF, % 
29.3 10.9 0.0023 
Mortality following discharge, 
3-month, % 9.8 4.0 0.14 
6-month, % 13.4 7.9 0.24 
12-month, % 22.0 14.9 0.25 
Patients treated with assisted ventilation were at a non-significantly higher risk of 
mortality compared to patients not ventilated (Table 13.3). The Kaplan-Meier survival 
curve showing the cumulative survival, stratified according to whether the patient 
received assisted ventilation, is shown in Figure 13.1. Although the lines diverge and 
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more ventilated patients died, there is no significant difference in cumulative survival 
between the two groups (Log-rank p = 0.20). 
Figure 13.1     12-month survival of ventilated and non-ventilated patients 
 
Most patients died from a respiratory cause (81.8%) and cardiovascular disease was 
the second commonest cause of 12-month mortality (12.1%). There was no clear 
relationship between time to death and the cause of death (Table 13.4). Four patients 
died with, or from, an advanced cancer (three with lung cancer) and malignancy was 
not implicated in any patients who died within six months of discharge. 
Table 13.4     Cause of death during follow-up in Part 2 patients 
 Respiratory cause, 
n (%) 
Cardiovascular cause, 
n (%) 
Other cause, 
n (%) 
3-month mortality 10 (83.3) 0 2 (16.7) 
6-month mortality  15 (78.9) 2 (10.5) 2 (10.5) 
12-month mortality 27 (81.8) 4 (12.1) 2 (6.1) 
 
 Ventilated 
 Not ventilated 
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13.4 QUALITY OF LIFE AT DISCHARGE AND SUBSEQUENT OUTCOME 
Compared to survivors, patients who died during follow up (n = 33) were less active 
with higher baseline (discharge) SGRQ Activity and lower NEADL scores (Table 13.5). 
There was also a trend to higher 12-month mortality in patients: whose COPD had a 
greater impact on their day-to-day life (SGRQ Impacts, p = 0.0714); who reported more 
depressive symptoms (HADS Depression, p = 0.0825); and who had a worse overall 
QoL (SGRQ Total, p = 0.13). 
Table 13.5     QoL at discharge and mortality within 12 months 
Quality of life measurement Died, n =33 Survived, n = 150 p value* 
SGRQ Symptoms, mean (SD)† 
SGRQ Activity, mean (SD)† 
SGRQ Impacts, mean (SD)† 
SGRQ Total, mean (SD)† 
63.3 (20.8) 
85.0 (12.8) 
55.7 (19.1) 
65.6 (15.2) 
66.7 (19.7) 
77.9 (16.3) 
48.9 (19.8) 
60.7 (17.1) 
0.38 
0.0209 
0.0714 
0.13 
CRQ Dyspnoea, median (IQR)‡ 
CRQ Emotional, median (IQR)‡ 
CRQ Fatigue, median (IQR)‡ 
CRQ Mastery, median (IQR)‡ 
2.8 (1.7 to 4.1) 
2.3 (1.5 to 3) 
3.7 (2.65 to 4.4) 
3 (2.15 to 4.15) 
2.8 (2.15 to 3.8) 
2.4 (1.5 to 3.3) 
3.4 (2.38 to 4.9) 
3.3 (2.2 to 4.5) 
0.56 
0.83 
0.69 
0.60 
HADS anxiety, median (IQR)† 
HADS depression, median (IQR)† 
8 (5 to 12.5) 
8 (5 to 10.5) 
8 (4 to 14) 
6 (3 to 9) 
0.93 
0.0825 
NEADL, median (IQR)‡ 28 (14 to 37) 38 (28 to 45) <0.0001 
†Lower values indicate improved quality of life; ‡Higher values indicate improved quality of life. SGRQ – 
St George’s Respiratory Questionnaire; CRQ – Chronic Respiratory Disease Questionnaire; HADS – 
Hospital Anxiety and Depression Scale; NEADL – Nottingham Extended Activity of Daily Living Scale. 
Patients who were readmitted during the follow up period reported lower baseline 
levels of activity (i.e. higher SGRQ Activity score and lower NEADL score) than non-
readmitted patients, but there were no significant differences in any other QoL 
measure (Table 13.6). 
Table 13.6     QoL at discharge and readmission during follow-up 
Mean change in quality of life Readmitted, n =130 Not readmitted, n = 53 p value* 
SGRQ Symptoms, mean (SD)† 
SGRQ Activity, mean (SD)† 
SGRQ Impacts, mean (SD)† 
SGRQ Total, mean (SD)† 
66.3 (19.5) 
81.1 (14.8) 
51.4 (20.5) 
62.6 (17.6) 
65.6 (20.8) 
74.6 (17.8) 
47.1 (17.6) 
59.1 (14.9) 
0.85 
0.0119 
0.19 
0.21 
CRQ Dyspnoea, median (IQR)‡ 
CRQ Emotional, median (IQR)‡ 
CRQ Fatigue, median (IQR)‡ 
CRQ Mastery, median (IQR)‡ 
2.8 (2 to 4) 
3.4 (2.4 to 4.9) 
2.3 (1.5 to 3) 
3 (2.3 to 4.3) 
2.8 (2 to 3.6) 
3.6 (2.4 to 4.8) 
2 (1.3 to 3.2) 
3.3 (1.8 to 4.9) 
0.46 
0.90 
0.56 
0.92 
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Mean change in quality of life Readmitted, n =130 Not readmitted, n = 53 p value* 
HADS anxiety, median (IQR)† 
HADS depression, median (IQR)† 
8 (4 to 14) 
6 (3 to 10) 
9 (4.5 to 13) 
6 (3 to 8) 
0.83 
0.37 
NEADL, median (IQR)‡ 34 (24 to 42) 42 (33 to 51) 0.0001 
†Lower values indicate improved quality of life; ‡Higher values indicate improved quality of life. SGRQ – 
St George’s Respiratory Questionnaire; CRQ – Chronic Respiratory Disease Questionnaire; HADS – 
Hospital Anxiety and Depression Scale; NEADL – Nottingham Extended Activity of Daily Living Scale. 
 
13.5 QUALITY OF LIFE FOLLOWING HOSPITAL DISCHARGE 
13.5.1 TOTAL POPULATION, N = 183 
Overall, 781 assessments were performed on 183 patients. Seven patients did not 
attend any follow-up appointments following hospital discharge and were therefore 
not included in the analysis of longitudinal QoL data. Eight patients died prior to 
attending their first assessment following discharge. Full details of the attendance at 
each scheduled assessment are shown in Appendix G (Figure 17.2). 
In the total population, compared to their reported status at discharge, most patients 
experienced: improved respiratory symptoms during the year of follow up (mean 
change in SGRQ symptoms = -8.65 (MCID = ±4)) and improved mastery of their 
condition; (mean change in CRQ mastery = 0.77 (MCID = ±0.5)); and less anxiety (mean 
change in HADS anxiety = -1.52 (MCID = ±1.5)). Although, on average, patients activity 
levels worsened during the 12 month follow-up (mean change in SGRQ activity = 1.79 
and mean change in NEADL = -3.44) neither of these changes were greater than the 
MCID for each instrument. The overall quality of life measured using the SGRQ (SGRQ 
total), the levels of depressive symptoms and the patients’ ability to undertake 
activities of daily living were stable during the follow-up period (Table 13.7).  
Most QoL measures peaked at 3 months following discharge, with the exception of 
activity levels (measured using NEADL and SGRQ activity) which peaked after 6 weeks. 
For all measures of QoL except those measuring patient activity (SGRQ Activity and 
NEADL), a quarter of patients took six months or longer to fully recover (i.e. reach their 
peak QoL). For all QoL measures, except those assessing activity, patients experienced 
a QoL better than their baseline for more than 50% of the subsequent year of follow-
up. 
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13.5.2 COMPARISON OF VENTILATED AND NON-VENTILATED PATIENTS 
There was a significant difference (p = 0.0193) in the mean change in QoL, measured 
using SGRQ total, between ventilated and non-ventilated patients: ventilated patients’ 
QoL was stable during follow up (mean change = 0.05); whereas non-ventilated 
patients experienced a clinically important improvement in their QoL (mean change = -
4.55). Both ventilated and non-ventilated patients experienced a clinically important 
improvement in their respiratory symptoms (measured using SGRQ symptoms) 
although the improvement was greater in the non-ventilated patients (p = 0.0172). 
Furthermore, the impact of their respiratory disease on an individual’s QoL (SGRQ 
impacts) improved significantly more (p = 0.0239) in patients not ventilated compared 
to those who required assisted ventilation (Table 13.7). No other QoL measure except 
the SGRQ highlighted any difference in QoL during follow-up between the two patient 
groups although there was a trend towards worse respiratory symptoms, measured 
using the CRQ Dyspnoea, during the follow-up period (p = 0.11). 
Compared to ventilated patients, patients who did not receive assisted ventilation 
spent a greater proportion of the total follow-up time with a quality of life (measured 
using all domains  of the SGRQ) better than their baseline (discharge) level, although 
these results did not achieve statistical significance (0.05 < p ≤ 0.10 for all SGRQ 
domains). For all other measures of health status there were no differences in the 
length of time spent with a quality of life better than the baseline level between the 
two populations, and there were no differences in the time taken to achieve the best 
recorded QoL (for any QoL measure) between the populations (Table 13.7). 
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Table 13.7     Quality of life during the follow up period 
QoL measure Total population, 
n=176 
Ventilated, 
n = 80 
Not ventilated, 
n = 96 
p 
value* 
Mean change in QoL (mean (SD)), 
SGRQ Symptoms† 
SGRQ Activity† 
SGRQ Impacts† 
SGRQ Total† 
-8.65 (19.5) 
1.79 (12.0) 
-2.98 (15.4) 
-2.47 (13.0) 
-4.80 (19.4) 
3.22 (10.2) 
-0.09 (15.5) 
0.05 (12.5) 
-11.8 (19.2) 
0.60 (13.3) 
-5.36 (14.9) 
-4.55 (13.2) 
0.0172 
0.15 
0.0239 
0.0193 
CRQ Dyspnoea‡ 
CRQ Emotional‡ 
CRQ Fatigue‡ 
CRQ Mastery‡ 
0.34 (1.28) 
0.42 (1.13) 
0.38 (1.16) 
0.77 (1.33) 
0.17 (1.16) 
0.42 (1.10) 
0.40 (1.12) 
0.66 (1.41) 
0.48 (1.37) 
0.42 (1.16) 
0.36 (1.20) 
0.87 (1.27) 
0.11 
0.98 
0.82 
0.30 
HADS anxiety† 
HADS depression† 
-1.52 (3.34) 
-0.44 (2.95) 
-1.30 (2.73) 
-0.43 (2.65) 
-1.70 (3.76) 
-0.45 (3.18) 
0.45 
0.43 
NEADL‡ -3.44 (7.98) -4.35 (8.32) -2.69 (7.64) 0.17 
Time taken to achieve best QoL, days (median (IQR)), 
SGRQ Symptoms 
SGRQ Activity 
SGRQ Impacts 
SGRQ Total 
91 (44 to 185) 
48 (0 to 111) 
88 (40 to 188) 
92 (46 to 188) 
92 (43 to 180) 
46 (0 to 102) 
91 (9 to 189) 
91 (40 to 186) 
91 (45 to 189) 
49 (0 to 179) 
87 (42 to 188) 
96 (48 to 190) 
0.27 
0.23 
0.72 
0.40 
CRQ Dyspnoea 
CRQ Emotional 
CRQ Fatigue 
CRQ Mastery 
87 (42 to 183) 
93 (46 to 192) 
87 (43 to 180) 
94 (48 to 190) 
96 (46 to 186) 
98 (49 to 190) 
90 (46 to 123) 
98 (46 to 192) 
79 (41 to 181) 
88 (42 to 193) 
86 (40 to 184) 
92 (49 to 189) 
0.28 
0.19 
0.77 
0.84 
HADS anxiety 
HADS depression 
90 (43 to 190) 
83 (0 to 184) 
96 (49 to 190) 
92 (0 to 187) 
87 (37 to 191) 
64 (26 to 112) 
0.21 
0.59 
NEADL 46 (0 to 109) 44 (0 to 104) 46 (0 to 174) 0.82 
Time spent better than baseline QoL, % of total follow-up time (median (IQR)),  
SGRQ Symptoms 
SGRQ Activity 
SGRQ Impacts 
SGRQ Total 
79 (37 to 100) 
26 (0 to 84) 
67 (22 to 100) 
70 (27 to 100) 
67 (25 to 100) 
13 (0 to 70) 
59 (4 to 98) 
57 (6 to 100) 
83 (48 to 100) 
35 (0 to 84) 
71 (36 to 100) 
83 (36 to 100) 
0.0678 
0.10 
0.0615 
0.0543 
CRQ Dyspnoea 
CRQ Emotional 
CRQ Fatigue 
CRQ Mastery 
71 (20 to 100) 
83 (32 to 100) 
83 (25 to 100) 
88 (46 to 100) 
59 (14 to 100) 
84 (30 to 100) 
83 (35 to 100) 
86 (25 to 100) 
84 (27 to 100) 
83 (34 to 100) 
83 (20 to 100) 
98 (59 to 100) 
0.12 
0.78 
0.98 
0.18 
HADS anxiety 
HADS depression 
78 (31 to 100) 
59 (0 to 100) 
76 (32 to 100) 
53 (0 to 100) 
79 (29 to 100) 
71 (12 to 100) 
0.77 
0.44 
NEADL 31 (0 to 77) 16 (0 to 65) 36 (0 to 84) 0.14 
* comparison between ventilated and not ventilated groups; †Lower values indicate improved quality of 
life; ‡Higher values indicate improved quality of life. SGRQ – St George’s Respiratory Questionnaire; CRQ 
– Chronic Respiratory Disease Questionnaire; HADS – Hospital Anxiety and Depression Scale; NEADL – 
Nottingham Extended Activity of Daily Living Scale. 
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13.5.3 LONGITUDINAL CHANGE IN QOL AND HOSPITAL READMISSION 
Table 13.8 explores the relationship between hospital readmission and subsequent 
QoL. This analysis shows that, compared to patients who were not readmitted during 
follow-up, readmitted patients had significantly less improvement in QoL for all 
measures except those assessing depressive symptoms (mean change in HADS 
depression, p = 0.50).  
Table 13.8     Mean change in QoL and hospital readmission 
Mean change in quality of life Readmitted, n =126 Not readmitted, n = 50 p value* 
SGRQ Symptoms† 
SGRQ Activity† 
SGRQ Impacts† 
SGRQ Total† 
-4.95 (17.6) 
3.06 (8.70) 
0.75 (13.8) 
0.46 (11.4) 
-17.9 (21.2) 
-1.42 (17.6) 
-12.2 (15.3) 
-9.79 (14.1) 
<0.0001 
0.0907 
<0.0001 
<0.0001 
CRQ Dyspnoea‡ 
CRQ Emotional‡ 
CRQ Fatigue‡ 
CRQ Mastery‡ 
-0.16 (1.20) 
0.25 (1.05) 
0.20 (1.06) 
0.48 (1.19) 
0.80 (1.37) 
0.86 (1.22) 
0.84 (1.28) 
1.53 (1.38) 
0.0028 
0.0010 
0.0008 
<0.0001 
HADS anxiety† 
HADS depression† 
-1.16 (3.31) 
-0.34 (2.94) 
-2.39 (3.28) 
-0.68 (2.99) 
0.0287 
0.50 
NEADL‡ -4.39 (7.73) -1.05 (8.17) 0.0119 
†Lower values indicate improved quality of life; ‡Higher values indicate improved quality of life. SGRQ – 
St George’s Respiratory Questionnaire; CRQ – Chronic Respiratory Disease Questionnaire; HADS – 
Hospital Anxiety and Depression Scale; NEADL – Nottingham Extended Activity of Daily Living Scale. 
 
13.6 IDENTIFYING INDIVIDUALS WITH POOR QUALITY OF LIFE FOLLOWING 
HOSPITAL DISCHARGE 
13.6.1 DEFINING “POOR QUALITY OF LIFE”  
The SGRQ was the most responsive measure for identifying change in quality of life in 
our population (Table 13.7). We therefore chose this instrument to help define “poor 
quality of life” and we combined the two populations described above (treated with 
assisted ventilation and not treated with assisted ventilation). An individual was said to 
have experienced a poor quality of life following hospital discharge if either:  
1) Their quality of life (SGRQ total) at discharge was within the worst (i.e. highest) 
50% of scores and their average quality of life over the follow up period 
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declined by a value greater than the MCID (i.e. mean change in quality of life <-
4); or  
2) They died within six months of hospital discharge. 
The remaining patients were regarded as having an acceptable QoL. Using these 
criteria, 29 patients experienced a poor quality of life (15 of whom required assisted 
ventilation) and their characteristics, and comparisons with patients with acceptable 
QoL, are shown in Table 13.9 to Table 13.11. Markedly asymmetric categorical 
variables (< 5% of the population in one category) are not shown. 
Compared to those with an acceptable QoL, patients who experienced a poor QoL: 
were more likely to be housebound; were more likely to be receiving social care 
support; had worse lung function; were more breathless during their stable-state; 
were more likely to have recently lost weight; and had a higher risk of malnutrition. 
Furthermore, those with a poor QoL: had a greater comorbidity burden and, 
specifically, were more likely to suffer from vascular disease (Table 13.9). At their index 
admission, patients who experienced a poor quality of life following discharge had: 
lower blood pressure; lower serum sodium, potassium and albumin concentrations; 
and lower blood haemoglobin concentrations (Table 13.10). There was no difference in 
subsequent QoL between patients who received assisted ventilation and those not 
ventilated. At the time of hospital discharge, only the SGRQ (which is used in the 
definition of poor QoL) and the reported activity levels (measured using the NEADL) 
differed between those who subsequently experienced a poor QoL and those who did 
not (Table 13.11). 
Table 13.9     Univariate associations between features prior to index admission and 
subsequent poor quality of life  
Variable* Acceptable QoL,  
n = 147  
Poor QoL,  
n = 29 
p value 
Sociodemographic details & prior health resource use, 
Age, years 68.8 (9.2) 71.0 (8.3) 0.24 
Female, % 59.9 62.1 1 
Cigarette pack years (median, IQR) 49 (36 to 64) 48 (38 to 62) 0.86 
Housebound, % 19.0 44.8 0.0067 
Social care prior to admission, % 12.9 31.0 0.0241 
No. of hospital admissions in previous year 
(median, IQR) 
0 (0 to 1) 1 (0 to 2) 0.0817 
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Variable* Acceptable QoL,  
n = 147  
Poor QoL,  
n = 29 
p value 
No. of AECOPD in previous year (median, IQR) 3 (1 to 5) 3 (1 to 5) 0.41 
Previous episode of NIV for AECOPD, % 23.8 24.1 1 
Previous pulmonary rehabilitation, % 17.0 17.2 1 
Severity of underlying disease, 
Home nebuliser, % 17.0 27.6 0.20 
LTOT, % 17.0 24.1 0.43 
Long-term prednisolone 9.5 17.2 0.32 
FEV1 % predicted 41.8 (17.8) 32.0 (13.0) 0.0052 
FVC, litres 2.12 (0.75) 1.74 (0.73) 0.0146 
eMRCD (median, IQR) 4 (3 to 4) 4 (4 to 5a) 0.0004 
Cor pulmonale, % 12.2 10.3 1 
BMI, kgm
-2
 26.5 (6.7) 24.3 (8.2) 0.13 
Recent weight loss >5%, % 22.4 44.8 0.0194 
MUST score 0 (0 to 1) 1 (0 to 2) 0.0010 
Comorbidity, 
Charlson comorbidity index (median, IQR) 1 (1 to 2) 2 (1 to 3) 0.0379 
Bronchiectasis, % 6.1 0 0.36 
Diabetes, % 16.3 10.3 0.58 
Hypertension, % 40.8 44.8 0.69 
Stroke disease, % 9.5 6.9 1 
IHD, % 23.1 41.4 0.0621 
AF, % 10.2 6.9 0.74 
Anxiety / depression, % 29.3 20.7 0.50 
History of cancer, % 8.8 10.3 0.73 
Osteoporosis, % 12.2 17.2 0.55 
Peripheral vascular disease, % 4.8 20.7 0.0090 
Rheumatoid arthritis, % 4.8 6.9 0.64 
Peptic ulcer disease, % 5.4 6.9 0.67 
* values shown are mean (SD) unless otherwise stated 
Table 13.10     Univariate associations between clinical information at the time of index 
hospital admission and subsequent poor quality of life 
Variable* Acceptable QoL,  
n = 147  
Poor QoL,  
n = 29 
p value 
Clinical information on admission to hospital, 
Pedal oedema, % 32.7 27.6 0.67 
Purulent sputum, % 53.1 44.8 0.43 
Acute confusion, % 10.9 6.9 0.74 
CXR consolidation, % 29.3 31.0 0.83 
Ineffective cough, % 10.2 13.8 0.52 
Pulse rate 109.3 (20.1) 110.4 (21.9) 0.79 
Diastolic blood pressure, mmHg 80.9 (19.0) 74.2 (15.8) 0.0793 
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Variable* Acceptable QoL,  
n = 147  
Poor QoL,  
n = 29 
p value 
Respiratory rate 26.2 (6.1) 26.5 (6.5) 0.81 
DECAF Score 1 (0 to 2) 2 (1 to 2) 0.14 
Laboratory investigations on admission to hospital, 
H
+
 concentration, nmol/L (median, IQR) 39.7 (35.3 to 47.5) 41.7 (36.9 to 52.3) 0.26 
paO2, kPa (median, IQR) 8.4 (7.1 to 11.3) 7.7 (6.7 to 9.2) 0.20 
paCO2, kPa (median, IQR) 6.7 (5.2 to 9.2) 7.7 (5.6 to 9.4) 0.35 
Arterial bicarbonate, mmol/L 30.6 (7.0) 31.0 (6.7) 0.78 
Sodium, mmol/L 136.4 (4.7) 134.4 (4.6) 0.0372 
Potassium, mmol/L 4.35 (0.56) 4.61 (0.49) 0.0228 
Chloride 97.8 (6.2) 96.5 (6.2) 0.30 
Urea, mmol/L (median, IQR) 6.0 (4.4 to 8.1) 6.4 (4.3 to 11.1) 0.26 
Creatinine, μmol/L (median, IQR) 87.0 (74.0 to 111.5) 92.5 (71.5 to 119.3) 0.77 
Albumin, g/L
 
39.6 (4.4) 37.3 (4.8) 0.0144 
Glucose, mmol/L (median, IQR) 7.1 (6.3 to 9.0) 7.1 (6.0 to 7.8) 0.67 
CRP, mg/L (median, IQR) 46.5 (11.3 to 109.0) 51.0 (12.0 to 115.0 0.76 
Hb, g/dL 14.1 (1.8) 13.4 (2.3) 0.0899 
Neutrophil count, x10
9
/L (median, IQR) 8.65 (6.48 to 12.1) 10.1 (6.20 to 11.8) 0.56 
Eosinophil count, x10
9
/L (median, IQR) 0.10 (0 to 0.20) 0.10 (0 to 0.20) 0.88 
* values shown are mean (SD) unless otherwise stated; H
+
 - hydrogen 
Table 13.11     Univariate associations between developments during the index 
admission, discharge quality of life and subsequent poor quality of life 
Variable* Acceptable QoL,  
n = 147  
Poor QoL,  
n = 29 
p value 
Developments during the index hospital admission, 
Treated with assisted ventilation, % 44.2 51.7 0.54 
Increased care package at discharge, % 8.2 10.3 0.72 
Specialist care, % 92.9 92.0 1 
Length of stay, days 8 (5 to 13) 10 (6 to 14) 0.28 
QoL recorded at discharge, 
SGRQ Symptoms, median (IQR)‡ 68.3 (52.0 to 81.7) 71.6 (55.2 to 82.4) 0.67 
SGRQ Activity, median (IQR)‡ 79.7 (66.6 to 92.5) 92.5 (79.4 to 92.5) 0.0165 
SGRQ Impacts, median (IQR)‡ 47.5 (34.1 to 63.0) 58.4 (46.3 to 64.5) 0.0603 
SGRQ Total, median (IQR)‡ 61.1 (48.7 to 72.4) 68.5 (63.0 to 73.7) 0.0339 
CRQ Dyspnoea, median (IQR)† 2.9 (2.2 to 3.8) 2.8 (1.7 to 4.2) 0.60 
CRQ Emotional, median (IQR)† 3.6 (2.4 to 5.0) 3.8 (2.6 to 4.4) 0.94 
CRQ Fatigue, median (IQR)† 2.3 (1.5 to 3.3) 2.3 (1.6 to 3.0) 0.96 
CRQ Mastery, median (IQR)† 3.3 (2.3 to 4.5) 2.7 (2.1 to 4.2) 0.32 
HADS anxiety, median (IQR)‡ 8 (4 to 14) 8 (6 to 11) 0.79 
HADS depression, median (IQR)‡ 6 (3 to 9) 6 (5 to 9) 0.24 
NEADL, median (IQR)† 38 (27 to 47) 30 (15 to 39) 0.0008 
* values shown are mean (SD) unless otherwise stated; †higher scores indicate better QoL; ‡lower 
scores indicate better QoL 
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During the period of follow-up, patients who experienced a poor QoL following 
discharge were significantly more likely to have: been readmitted to hospital (p = 
0.0034); experienced more frequent readmissions for respiratory causes (p = 0.0321); 
and spent longer in hospital (p = 0.0236) than patients with an acceptable QoL. There 
were no significant differences in either the number of AECOPD experienced, or the 
risk of rehospitalisation requiring assisted ventilation, between patients with a poor 
and acceptable QoL (Table 13.12). 
Table 13.12     Comparison of health resource use following discharge in patients with 
an acceptable and poor QoL 
Health resource use following discharge Acceptable QoL Poor QoL p value 
Total number of AECOPD, median (IQR) 3 (1 to 6) 2 (1 to 5) 0.18 
Hospital readmission, % 67.3 93.1 0.0034 
Total number of hospital readmissions, median (IQR) 1 (0 to 3) 2 (1 to 2) 0.39 
Number of respiratory readmissions, median (IQR) 1 (0 to 2) 2 (1 to 3) 0.0321 
Total length of stay during follow up (days), median (IQR) 4 (0 to 20) 15 (3 to 37) 0.0236 
Readmission requiring assisted ventilation, % 20.4 17.2 0.80 
 
13.7 INDEPENDENT PREDICTORS OF POOR QUALITY OF LIFE 
All variables associated with poor quality of life (p < 0.10) were entered in to a 
backward stepwise logistic regression analysis. In addition, important descriptive and 
prognostic variables (i.e. requirement for ventilation during index admission, sex, age, 
BMI, AF, coexistent radiographic consolidation, hydrogen ion concentration, PaCO2, 
and the length of stay of the index admission) were forced in to the regression 
analysis. Individual comorbidities were included instead of the CCI and IHD and 
peripheral vascular disease (PVD) were combined in to a single variable. BMI and 
recent weight loss were included instead of the MUST score. SGRQ scores at discharge 
were not entered because of their relationship with the dependent variable. There was 
evidence of some collinearity between the remaining potential predictor variables 
(mean VIF 1.75, largest absolute VIF = 3.69) although the correlation matrix of 
potential predictors did not identify any sources of collinearity (Table 17.9). Although it 
was likely that eMRCD and NEADL at discharge were collinear to some extent, the 
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statistical measures of collinearity did not suggest that either variable should be 
excluded from the analyses. 
Therefore, the following variables were entered in to the multivariate analysis: age; 
male sex; social care input prior to index admission; total number of hospital 
admissions in the preceding year; FEV1 % predicted; FVC; eMRCD; BMI; recent 
unexplained weight loss; AF; IHD or PVD; pH and paCO2 at admission; serum sodium, 
potassium and albumin at admission; haemoglobin concentration at admission; 
coexistent radiographic consolidation at admission to hospital; diastolic blood pressure 
at admission; length of hospital stay; NEADL score at hospital discharge; requirement 
for assisted ventilation during the index admission. 
Independent predictors of poor quality of life are shown in Table 13.13. The regression 
model (‘Model 7’) was estimated to predict 31% of the variance in the dependent 
variable (Nagelkerke’s R2 = 0.313) and was a satisfactory fit of the data (HLGFT, p = 
0.757). 
Table 13.13     Independent predictors of poor quality of life during follow-up – ‘Model 
7’, (n = 176) 
Variable B S.E. OR (95% CI) p value 
IHD or PVD 1.30 0.51 3.67 (1.34 to 10.0) 0.0112 
Serum sodium (mmol/L)* -0.11 0.05 0.893 (0.814 to 0.978) 0.0151 
NEADL† -0.05 0.02 0.954 (0.919 to 0.992) 0.0167 
Serum potassium (mmol/L)* 0.99 0.45 2.69 (1.11 to 6.49) 0.0278 
Serum albumin (g/L)* -0.11 0.05 0.898 (0.809 to 0.997) 0.0434 
FEV1 % predicted -0.03 0.02 0.968 (0.938 to 1.00) 0.0523 
Intercept 15.6 7.0   
* measured at admission to hospital; † measured at hospital discharge; IHD – ischaemic heart disease; 
PVD – peripheral vascular disease 
6 (3.4%) cases were statistical outliers from the regression model although none had a 
significant impact on the regression model (acceptable leverage values and Cook’s 
distances). Further assessment confirmed that across deciles of risk, the model was 
well calibrated (gradient = 0.92) (Figure 13.2), and the discrimination was excellent 
(AUROC = 0.829, 0.756 to 0.902) (Figure 13.3) and internally valid (bootstrapped 
AUROC = 0.828, 0.750 to 0.895). 
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Figure 13.2     Calibration plot for Model 7 against the observed probability of poor 
quality of life 
 
Figure 13.3     ROC curve showing the discrimination of Model 7 for poor quality of life 
 
The severity of stable-state dyspnoea (eMRCD) is strongly associated with poor QoL 
but is not retained in the final multivariate analysis. This is likely to be due to the 
inclusion of the NEADL which measures, in detail, patients self-reported activity levels 
encompassing much of the information included in the eMRCD. Although no tests of 
collinearity between NEADL and eMRCD were met, leaving NEADL out of the analysis 
resulted in eMRCD being retained (OR 1.85, 1.05 to 3.28, p = 0.0336) without any 
change in the remaining predictor variables (Table 13.14). The discrimination of this 
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model was good (AUROC = 0.836, 0.759 to 0.913) and was not significantly different 
from Model 7 (p = 0.73). Therefore, for ease of clinical application, eMRCD could be 
used instead of the more cumbersome NEADL.  
Table 13.14     Independent predictors of poor QoL using easy to measure indices 
Variable B S.E. OR (95% CI) p value 
IHD or PVD 1.32 0.51 3.73 (1.39 to 10.0) 0.0092 
Serum potassium (mmol/L)* 1.00 0.44 2.71 (1.14 to 6.41) 0.0235 
eMRCD 0.62 0.29 1.85 (1.05 to 3.28) 0.0336 
Serum sodium (mmol/L)* -0.10 0.05 0.905 (0.824 to 0.996) 0.0401 
Serum albumin (g/L)* -0.10 0.05 0.903 (0.817 to 0.998) 0.0449 
FEV1 % predicted -0.03 0.02 0.971 (0.939 to 1.00) 0.0809 
Intercept 9.27 7.2   
Nagelkerke’s R
2
 = 0.302; HLGFT = 0.391 
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CHAPTER 14 DISCUSSION – PART 1 
14.1 SUMMARY OF MAIN FINDINGS 
We have shown that, in patients hospitalised with acute exacerbations of COPD, 
important patient outcomes can be predicted accurately using clinical indices routinely 
available at the time of, or during, hospital admission. We have also described the 
extended MRC Dyspnoea Score which identifies a particular subgroup of patients (i.e. 
those with the most disabling stable-state dyspnoea) who are at an extremely high risk 
of in-hospital mortality. Furthermore, the eMRCD was found to be a strong 
discriminator for 12-month mortality. 
Table 14.1 summarises the key independent prognostic variables (i.e. p < 0.05 on 
multivariate analysis), in descending order of prognostic strength, for our three main 
measures of patient outcome. For all three outcomes, the severity of stable-state 
dyspnoea is the strongest predictor of outcome. eMRCD aside, similar to our summary 
of previous prognostic research (Figure 3.1), the risk of in-hospital mortality is mostly 
explained by markers indicating a severe acute illness (for example, coexistent 
consolidation, ineffective cough, worse acidaemia etc), whereas long-term mortality is 
associated with a combination of underlying markers of disease severity (for example, 
low BMI, low FEV1 % predicted, need for LTOT etc) and markers of a severe acute 
illness. Our study shows an overlap in predictors of in-hospital and 12-month mortality 
which is typically not present in previous research. However, we predicted 12-month 
mortality from the time of hospital admission (i.e. including in-hospital deaths) 
whereas most previous studies predicted long-term mortality from the time of hospital 
discharge (i.e. excluding in-hospital deaths). For the prediction of hospital readmission, 
prior health resource use and a broad assessment of functional impairment (need for 
formal social care prior to admission) are strong predictors and although we did not 
record individual QoL in this part of the study, these findings are consistent with 
previous research (Figure 3.1). 
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Table 14.1     Summary of the key independent prognostic indices (including 
continuous variables where applicable) for our three main outcomes 
In-hospital mortality 12-month mortality 90-day readmission or death 
eMRCD eMRCD eMRCD 
Coexistent consolidation Older age 
Greater total number of 
admissions in the previous year 
Lower eosinophil count
 
Lower serum albumin Recent unexplained weight loss 
Lower temperature Higher urea Cor pulmonale or pedal oedema 
Atrial fibrillation Unexplained weight loss Social care prior to admission 
Ineffective cough Coexistent consolidation Lower serum glucose 
Older age Lower BMI  
Cerebrovascular disease Ineffective cough  
Lower serum albumin Lower FEV1 (% predicted)  
Worse acidaemia LTOT  
The DECAF score accurately stratifies patients hospitalised with AECOPD according to 
their risk of in-hospital mortality and is a stronger discriminator of mortality than other 
well-established prognostic scores. Over 50% of our patients had a low risk DECAF 
score (DECAF 0 to 1) and a corresponding in-hospital mortality rate of 1.4%, and 
almost a quarter had a high risk DECAF score (DECAF 3 to 6) and a 34.6% risk of in-
hospital mortality. This information can be used at the time of hospital admission to 
help inform clinical decision making. 
We have identified robust independent predictors of both in-hospital mortality in 
patients requiring treatment with assisted ventilation and 12-month mortality in all 
hospitalised patients, and, in particular, have shown the time between admission and 
the development of acidaemic respiratory failure is a strong independent predictor of 
mortality in ventilated patients. 
In patients surviving to discharge, the CRUSHED score is a good discriminator of 90-day 
readmission or death and we report strong independent predictors of frequent 
readmission that could be used to assist in the early identification of patients at risk of 
poor outcome. 
14.2 STRENGTHS AND WEAKNESSES 
Our study conclusions are strengthened by the recruitment of a large number of 
sequential patients. Furthermore, although external validation is necessary, our 
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findings support the generalisability of the conclusions, in particular: the two 
institutions reflect different catchment areas (urban and rural) with different 
structures of care and a wide range of socio-economic status represented; our 
inclusion criteria ensured that a broad spectrum of patients with AECOPD were 
recruited; mortality (allowing for the difference in proportions with consolidation) and 
readmission rates were in line with UK national audit data; and performance of the 
prognostic tools on internal validation were strong. 
We are aware that comparisons between other prognostic tools and tools derived in 
this study (for example, the DECAF) will introduce bias in favour of our tools: 
prognostic performance is invariably stronger in derivation cohorts rather than in an 
external population. However, the large number of patients included, the 
generalisability of our methodology, and the size of the differences in prognostic 
performance, suggest that the stronger performance our tools (particularly the DECAF 
tool) compared to the other tools assessed is likely to be valid. 
In patients not acidaemic at admission but who deteriorated and required ventilatory 
assistance during the hospital stay (n = 68), only certain physiological measurements 
(arterial blood gas data and respiratory rate) were collected at the time of 
deterioration. Therefore, the analysis to identify predictors of in-hospital mortality in 
all (n = 199) ventilated patients (section 11.1.2) could potentially be improved by 
including a more detailed assessment of other important physiological variables at the 
time of deterioration in the 68 patients. However, a clinician faced with an acutely 
unwell patient who has developed acute respiratory failure is unlikely to be able to 
wait for collection and analysis of biochemical and haematological parameters. 
Furthermore, the regression model had a good R2 (0.584) suggesting that it explains a 
large proportion of the likely variance in the outcome variable (i.e. mortality). 
Therefore, not including variables at the time of clinical deterioration does not, in my 
opinion, weaken the clinical or statistical strength of this model. 
We acknowledge certain limitations in the way the data were obtained, but the study 
was designed to reflect the “real life” clinical situation. Thus, clinical information was 
gathered by medical, nursing and research staff using standard protocols, and the 
presence or absence of consolidation was recorded by the admitting medical team. 
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Although missing data were relatively few, data had to be imputed for a small number 
of variables. To ensure that imputation using EM analysis did not bias our results, 
univariate analyses were repeated using the original dataset and the conclusions were 
unchanged. 
14.3 STUDY FINDINGS AND COMPARISON TO PREVIOUS RESEARCH 
14.3.1 STUDY POPULATION 
Our study population is comparable to that reported in the UK National COPD 
Audit,[12] with similar: mean age; sex split; and admission clinical information (Table 
14.2). However, it is noteworthy that our study had: more current smokers; greater 
levels of dependency prior to hospitalisation (higher proportion of patients living in 
institutions or requiring paid social care); a higher proportion of patients in whom 
cardiopulmonary resuscitation was not deemed to be an appropriate treatment option 
if required; higher median blood creatinine concentrations; more frequent coexistent 
consolidation; and more frequent treatment with assisted ventilation. Therefore, there 
is evidence that our population are more dependent and more unwell than the 2008 
National Audit and both this observation and the higher proportion of patients with 
coexistent radiographic consolidation are likely to explain the differences in observed 
in-hospital mortality (10.4% in our study v. 7.7% in the National Audit). It is also 
important to note that the National Audit contained a large amount of missing data 
with over 50% missing values for some variables and this may further explain some of 
the differences. 
The higher rate of coexistent consolidation in our study is likely to be due to a number 
of factors. Firstly, there is varying practice regarding whether patients with coexistent 
consolidation should be included in the diagnosis of AECOPD (Section 1.2.4) and 
although consolidation was not an exclusion criterion for the National Audit, we 
believe that the stated rate of consolidation (16%) underestimates the true prevalence 
due to varying reporting among participating hospitals. Furthermore, the National 
Audit reported that a further 20% of radiographs had an abnormality not thought to be 
due to pneumonia, cancer or COPD. Due to the diagnostic confusion surrounding 
coexistent consolidation in AECOPD, a number of patients with consolidation may have 
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been included in this category. Lastly, 10% of radiographs in the National Audit were 
either not commented on, or of poor quality.  
The higher rates of assisted ventilation in our study may also partly explain the higher 
mortality. This reflects upon a more unwell population of patients in our study 
compared to the National Audit. In addition to the differences in disease and 
exacerbation severity highlighted in Table 14.2, more patients in the National Audit 
appeared to have ARF which was reversible with medical therapy and did not require 
NIV: despite similar rates of ARF (27.9% of our patients developed ARF at any time 
during their hospital stay compared to 26% in the National Audit) a greater proportion 
of our patients with ARF received ventilatory assistance (77.4% in our study compared 
v. 54.5% in the National Audit). A small proportion of this gap is due to differences in 
service provision: 3% of patients who required ventilation in the National Audit did not 
receive it because appropriate facilities were not available. However, it is likely that 
much of the difference is due to more patients in the National Audit having ARF 
reversible with medical therapy (and hence a milder exacerbation) with a consequent 
lower mortality rate.  
Therefore, although minor differences exist, our study population is comparable to 
that reported in the UK National COPD Audit and where differences exist, they are 
likely to be explained by a combination of: a more unwell population in our study; 
differences in the provision of care (particularly assisted ventilation) between the 
hospitals involved in our study and those participating in the National Audit; and a high 
rate of missing data in the National Audit. 
Table 14.2     Comparisons between our study and the UK National COPD Audit [12] 
Variable* Our study UK National COPD Audit  
Study population, n 920 9716 
Sociodemographic details, 
Age, mean (SD) 73.1 (10.0) 73 (10) 
Female, % 53.9 49.5 
Institutional care, % 6.5 5 
Social care prior to admission, % 22.9 17 
Current smoker, % 44.3 33 
Smoking load (cpy), median (IQR) 45 (32 to 60) 40 (30 to 60) 
Disease severity & comorbidity, 
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FEV1 % predicted, median (IQR) 41 (31.7 to 54) 38 (28 to 52) 
Respiratory rate (min
-1
), median (IQR) 25 (22 to 29) 24 (20 to 28) 
BMI (kgm
-2
), median (IQR) 24 (19.9 to 28.5) 24 (20 to 29) 
MRCD Grade 5, % 34.2 31 
1 or more significant medical comorbidities, % 80.5 77 
Admission clinical information, 
Purulent sputum, % 51.3 61 
Pedal oedema, % 27.7 32 
Coexistent pneumonia on admission CXR, % 32.5 16 
Serum albumin (g/L), median (IQR) 39 (36 to 42) 39 (35 to 42) 
Blood urea (mmol/L), median (IQR) 6.5 (4.7 to 9.3) 6.2 (4.6 to 8.7) 
Blood creatinine (μmol/L), median (IQR) 93 (77 to 114) 83 (68 to 105) 
pH, median (IQR) 7.41 (7.36 to 7.45) 7.41 (7.36 to 7.45) 
pH < 7.35, % 20.5 20 
DNACPR decision at admission, % 25.8 11 
Outcomes, 
Treated with assisted ventilation,† % 21.6 12 
In-hospital mortality, % 10.4 7.7 
Length of stay (days), median (IQR) 6 (3 to 11) 5 (3 to 10) 
Readmitted within 90-days,‡ % 33.4 33 
DNACPR – do not attempt cardiopulmonary resuscitation; * values are quoted according to their 
distribution in the National Audit to assist comparisons; † at any time during the hospital admission; ‡ 
excluding deaths without readmission 
14.3.2 CONSOLIDATION, DYSPNOEA AND MALNUTRITION 
In our study, compared to patients with npAECOPD, patients with pAECOPD were: 
older, more likely to be female; and had slightly better preserved spirometry (Table 
8.1). This is in contrast to the study by Lieberman et al [141] where no significant 
differences were found between npAECOPD and pAECOPD in these parameters. The 
difference in reported spirometry values is small and may be because our population 
were notably older (mean age 73.1 v. ~67 years) and the Lieberman study had less 
power: pAECOPD had better preserved spirometry than npAECOPD (FEV1 % predicted 
= 41.6 v. 40.7 respectively) but small numbers (n = 23 with pAECOPD) may explain a 
non-significant result. Lieberman et al [141] found no differences in the prevalence of 
diabetes and cardiovascular comorbidity between pAECOPD and npAECOPD and 
although our study showed that patients with pAECOPD had a greater total 
comorbidity burden (measured by CCI) than npAECOPD (Table 8.1), there were no 
significant differences in the prevalence of diabetes or cardiovascular comorbidities 
(results not shown). Therefore, although our population was older than that reported 
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by Lieberman et al, the level of comorbidities and the severity of underlying COPD in 
patients with pAECOPD is comparable between the two studies. The generalisability of 
our results is further supported by comparable findings in the two studies of a longer 
length of hospital stay and higher rates of in-hospital mortality in pAECOPD. 
We have shown that patients with coexistent consolidation have significantly higher 
rates of in-hospital mortality compared to those with simple exacerbations. The 
relationship between coexistent consolidation and outcome in patients hospitalised 
with AECOPD has been infrequently studied and although it is has been established 
that coexistent COPD is a predictor of poor outcome in patients with community 
acquired pneumonia,[161, 295, 296] only two studies [135, 141] have shown, in an 
unselected population of patients hospitalised with AECOPD, that coexistent 
consolidation is associated with increased mortality, and neither study adjusted for the 
effect of confounders. We have confirmed that, after adjusting for the effects of 
important confounders, coexistent consolidation independently predicts mortality. 
We have also shown that a routinely used clinical prediction tool in patients with 
pneumonia, the CURB-65 score, has suboptimal performance in patients hospitalised 
with pAECOPD (AUROC = 0.661). It has recently been suggested that the CURB-65 may 
be a useful clinical prediction tool in npAECOPD [163] and although our study confirms 
a similar predictive strength (AUROC for in-hospital mortality = 0.719) to a recent 
publication by Chang et al [163] (AUROC for 30-day mortality = 0.733), both the 
eMRCD and DECAF score outperformed CURB-65 for the prediction of in-hospital 
mortality in npAECOPD (Table 8.5). 
The severity of stable-state dyspnoea in patients hospitalised with AECOPD has rarely 
been reported. Similarly to our finding, the 2008 UK National COPD Audit [12] 
suggested that  approximately 30% of admitted patients were too breathless to leave 
the house (MRCD 5), but the conclusion was limited by missing data in more than half 
of the subjects audited. Other studies [58, 263, 264] have recorded dyspnoea severity 
only in patients surviving to discharge which underestimates its importance due to its 
strong association with mortality. Higher MRCD scores have previously been shown to 
be associated with greater in-hospital mortality in patients attending the emergency 
department with AECOPD,[156] an association we have confirmed for all patients 
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hospitalised with AECOPD. A recent study [314] showed an association between the 
traditional MRCD score and hospital readmission in patients enrolled in an early 
supported discharge scheme, but to our knowledge a similar association between 
MRCD and hospital readmission in all patients hospitalised with AECOPD has not been 
reported. 
Greater functional dependence has been shown to independently predict hospital 
readmission,[264, 308] and performance status, which includes an assessment of an 
individual’s ability to self care, has been shown to be predictive of 3-month mortality 
following admission.[254] Also, in patients surviving to discharge, a high level of 
functional dependence is associated with long-term mortality.[58, 102, 249] Most of 
the in-hospital deaths (80%) in our study occurred in patients with severe stable-state 
dyspnoea (MRCD 5). We have shown that combining a measure of functional 
dependence with the assessment of dyspnoea severity (eMRCD) improves the 
predictive ability of the traditional MRCD scale, with a significantly higher risk of 
mortality in patients housebound and dependent in washing and dressing (eMRCD 5b) 
than in those housebound but independent in washing and / or dressing (eMRCD 5a).  
Clinical decisions were in the hands of the admitting medical teams and uninfluenced 
by our study; however, we recognise that severe disability is likely to have been an 
important consideration in determining the management of individual patients. 
However, our finding does not appear to be explained by early introduction of 
palliative care, or limiting the level of care, in this population because, even among 
patients with the most severe limitation (eMRCD 5b), most of those potentially eligible 
for assisted ventilation received it, and there was no difference in this regard between 
eMRCD 5a and 5b. 
Using the extended scale, each increase in dyspnoea severity was accompanied by a 
significantly higher mortality, and the prediction of in-hospital mortality was 
significantly better using eMRCD than MRCD (AUROC = 0.794 v. 0.769; p=0.0012). 
Furthermore, eMRCD outperformed CURB-65 for the prediction of in-hospital 
mortality in both pAECOPD and npAECOPD (Table 8.5) and, in the total population, was 
a stronger predictor of 12-month mortality than the DECAF score (Figure 9.8). 
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In our study population, average BMI (mean BMI = 24.6 kgm-2) was similar to that 
reported in the National UK COPD Audit (median BMI = 24 kgm-2) [12] and many 
patients (16.3%) were underweight (BMI < 18.5 kgm-2). In agreement with previous 
research, low BMI was predictive of in-hospital [157, 247, 279] and long-term [33, 102, 
250, 263] mortality, and although associated with hospital readmission in our 
population, similarly to previous studies [15, 264, 307, 310] it was not independently 
predictive. Our results also suggest that BMI has a non-linear relationship with 
mortality (Figure 8.4), with the lowest rate of death in overweight patients (BMI 25 to 
29.99 kgm-2), which is consistent with data from both AECOPD [33] and stable disease 
[35]. Our suggestion that BMI has a non-linear relationship with readmission has not 
previously been reported. 
In single studies, recent unexplained weight loss has been shown to be predictive of 
long-term mortality [14] and early readmission [324] following hospitalization for 
AECOPD, as well as long-term mortality in stable disease [219]. Although Giron et al 
[34] failed to identify an association between weight loss and readmission, it is 
important to note that the generalisability of their results is uncertain due to the 
exhaustive patient selection undertaken. We have therefore confirmed the association 
between weight loss, mortality and readmission, and have also shown that recent 
unexplained weight loss is a strong independent predictor of both 12-month mortality 
and 90-day readmission or death. 
Lastly, our study is the first to show the MUST score to be a useful clinical and 
prognostic measure in patients hospitalised with AECOPD. The prevalence of high 
malnutrition risk (MUST ≥ 2) reported in our population (24.3%) is similar to a general 
population of elderly hospitalised patients (28.6%) [41] although lower than a 
hospitalised population of elderly care-home residents (41.3%).[39] In AECOPD, a high 
MUST score is associated with an increased risk of in-hospital death in agreement with 
the study of elderly hospitalised, general medical patients by Stratton et al,[39] 
however our study identified an association with hospital readmission which had not 
been shown by Stratton et al. The higher in-hospital mortality rate (20.7%) in the study 
of elderly patients, and the lower readmission rate (26.0%) compared to our study may 
explain differing relationships between MUST and readmission. 
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14.3.3 PREDICTING MORTALITY IN PATIENTS HOSPITALISED WITH AECOPD 
Our results show that in-hospital and 12-month mortality can be accurately predicted 
in AECOPD using indices routinely available at the time of hospital admission. 
Reasons for the slight discrepancy in the in-hospital mortality rate between our 
population and the UK National COPD Audit have been discussed (section 14.3.1) but it 
is important to note the similarities between our long-term mortality rates and those 
reported in other studies. In our population, 31.6% of all patients (n = 920) died within 
12 months of admission and 23.7% of patients who survived the index admission (n = 
824) died within 1 year. These figures are comparable to studies investigating similar 
unselected populations in similar health care settings where the quoted 1-year 
mortality rates from the time of hospital admission range from 23% to 33%,[15, 242, 
247] and 1-year mortality rates for patients surviving the index admission range from 
16% to 36%.[14, 58, 249, 251, 269] This further emphasises the generalisability of our 
study population. 
14.3.3.1 IN-HOSPITAL MORTALITY 
Many of the independent prognostic indices for in-hospital mortality (Table 9.7) are 
consistent with previously published research in AECOPD: increasing age;[156, 239] 
dyspnoea severity;[156] low BMI;[157] low pH;[135, 157] low serum albumin;[158, 
248, 288] cough effectiveness;[276] and coexistent consolidation.[141] Both 
cardiovascular and non-cardiovascular chronic comorbidity have been found to be 
associated with in-hospital mortality,[147] but, to our knowledge this is the first study 
to report, in an unselected population of AECOPD requiring hospitalisation, that both 
atrial fibrillation and cerebrovascular disease are independently predictive of in-
hospital mortality.  
Holland et al [289] previously reported that eosinopenia (< 0.04x109/L)  was associated 
with higher in-hospital mortality in AECOPD, but the study population was small (n = 
65) and the role of confounders was not evaluated. Our results show that eosinopenia 
is a strong independent predictor of in-hospital mortality. Of note, this finding is not 
due to better prognosis among patients with eosinophilia, as patients with confirmed 
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or suspected asthma were excluded, and only a small proportion had an eosinophil 
count above the usually quoted normal range (> 0.4x109/L, n = 55) at admission; if the 
latter are excluded from analysis, our conclusions remain unchanged (results not 
shown). It is noteworthy that Holland et al [289] excluded individuals who had recently 
received oral corticosteroids, and in our study, there was no significant difference in 
eosinophil count between patients receiving either long-term inhaled (p = 0.38) or oral 
(p = 0.51) corticosteroids and those not in receipt of these therapies. In murine 
models, eosinopenia has been shown to be induced by infection [400] and 
inflammation.[401] This response was independent of endogenous corticosteroids and 
persisted for longer than the neutrophilic response to the same stimuli.   Furthermore, 
eosinopenia has been shown to be a useful marker of sepsis in patients who are 
receiving intensive care.[402, 403] Therefore, although infrequently reported and 
recognised, previous research supports our finding that eosinopenia is of prognostic 
importance. 
The DECAF score shows promise for the risk stratification of patients hospitalised with 
AECOPD. ROC analysis suggests that it has excellent performance and is a stronger 
prognostic score than the CURB-65, APACHE or CAPS predictive tools. Roche et al [156] 
derived a predictive tool from 794 patients attending an emergency department with 
AECOPD. Their prognostic score showed good discrimination for in-hospital mortality 
(AUROC = 0.79) but may be less generalisable as it included subjectively assessed signs 
of clinical severity. The DECAF Score performed more strongly in our population than 
the tool described by Roche et al, and furthermore, the prognostic indices included in 
the DECAF score are objective with little potential for varying interpretation.  
The mortality rates for each grade of the DECAF score (Table 9.11) suggest the 
following risk categories: DECAF 0-1 (‘low risk’; in-hospital mortality = 1.4%); DECAF 2 
(‘moderate risk’; mortality = 8.4%); and DECAF 3-6 (‘high risk’; mortality = 34.6%). 
Consequently, more than half of patients hospitalised with AECOPD can be classified as 
‘low-risk’ for both in-hospital and 30-day mortality and might therefore potentially be 
suitable for early supported discharge schemes. In addition, the DECAF score identifies 
a group of patients at a particularly high risk of mortality (DECAF ≥ 3 = 34.6% in-
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hospital mortality) in whom early escalation of care, or early discussion of end-of-life 
care may be appropriate.  
In its derivation cohort, for the prediction of in-hospital mortality, DECAF outperforms 
the CURB-65, CAPS and APACHE prognostic scores and is also a good predictor of 12-
month mortality (AUROC = 0.730). The DECAF score is well calibrated to a dummy 
prognostic model including all independent predictors in their original form, ‘model 1’ 
(Figure 9.3). Although ‘model 1’ had a small but statistically significant improvement in 
discrimination compared to DECAF (Figure 9.4), this is outweighed by the ease with 
which DECAF can be clinically applied.  
14.3.3.2 LONG-TERM MORTALITY 
We have identified strong, easily measured predictors of long-term mortality in 
patients hospitalised with AECOPD. Of these, severe stable-state dyspnoea,[58, 263, 
264] older age,[15, 255] lower serum albumin,[102, 247] low BMI,[102, 247, 250] 
lower FEV1,[31, 242, 244, 270] unplanned weight loss [14] and LTOT prescription [58] 
have all been previously shown to be independently predictive of mortality following 
hospital discharge. Coexistent radiographic consolidation, although a recognised 
marker for in-hospital mortality in AECOPD (section 14.3.2), has not previously been 
shown to independently predict long-term mortality.  
Previous studies have shown that tachypnoea is independently predictive of the in-
hospital mortality of patients receiving assisted ventilation,[138, 139] and although 
Seneff et al [258] showed that more abnormal respiratory physiology (abnormal 
respiratory rate, PaCO2, pH or A-a gradient) was predictive of 180-day mortality in 
patients surviving intensive care admission, our results are the first to suggest that a 
high respiratory rate may be of long-term prognostic importance in unselected 
patients with AECOPD. However, the non-significant p value for this result on 
multivariate analysis (p = 0.0642) may suggest that this association is not generalisable 
outside of this study population. Furthermore, our results suggest that a low CRP is 
predictive of long-term mortality. This is contrary both to clinical reasoning and to the 
univariate association we found with in-hospital mortality (Table 9.6) (i.e. higher CRP 
associated with greater mortality) and is therefore difficult to explain. However, its 
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borderline significance on multivariate analysis (p = 0.0624) indicates that this is not a 
strong independent predictor and this unexpected result may also be limited to our 
dataset and not generalisable to clinical practice. 
It is noteworthy that no measure of comorbidity was independently predictive of 1-
year mortality despite strong univariate relationships between specific comorbidities 
and mortality following discharge (Table 9.14). This is likely to be, in part, due to the 
variable selection techniques employed in our analyses. We choose to exclude the 
Charlson comorbidity index and categorical variables where any category included < 
10% of the population. This was done to optimise the clinical utility and generalisability 
of our results by avoiding including measures that were both cumbersome and difficult 
to measure (i.e. the Charlson index), or that were prognostically useful only in a small 
proportion of the population. For this reason, both chronic kidney disease and LV 
dysfunction were excluded from the multivariate analysis despite strong univariate 
associations with outcome. 
14.3.3.3 PREDICTING IN-HOSPITAL MORTALITY IN PATIENTS RECEIVING 
ASSISTED VENTILATION 
In agreement with Roberts et al,[146] we have confirmed that, compared to patients 
not receiving assisted ventilation, ventilated patients had more severe underlying 
COPD. We have also shown that they have more markers to suggest a severe 
exacerbation than patients not receiving ventilation. The in-hospital mortality rate in 
our study (24.6%) is higher than the rates reported in the trials on which the use of NIV 
in AECOPD is based (typically ~10%),[170, 396] but comparable with both the 2008 
National COPD Audit (25%) and a ‘real-life’ perspective on ward-based treatment with 
NIV (32.9%).[176] The lower mortality rates in the large NIV trials are likely to be due 
to different selection methods: for example, the YONIV study [170] only recruited 
patients with mild to moderate acidaemia (7.25 ≤ pH < 7.35) and reported a median pH 
of 7.32, compared to 7.26 in our study. The subgroup of ventilated patients in our 
study most closely matched to the YONIV cohort (respiratory acidaemia at admission, 
with 7.25 ≤ pH < 7.35; Table 11.2) showed a similar mortality (11.8%) to the YONIV 
study (10.2%) emphasising that it is patient selection and not differences in the 
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provision or standard of care which explains the mortality difference.  We did not 
identify any association between requirement for assisted ventilation and readmission 
following discharge (Table 11.1). 
Roberts et al [146], reporting the findings of the 2008 UK National COPD Audit, showed 
that patients who were initially non-acidaemic on admission but later developed ARF 
during their hospital stay were at a high risk of mortality. Our more detailed 
investigation of the relationship between the time to recognition of ARF and mortality 
has confirmed that patients with ‘late-acidaemia’ (i.e. not acidaemic on admission but 
developing acidaemia during the hospital stay) have a particularly high mortality risk, 
independent of confounders: in-hospital mortality = 14.5% if ARF develops within 4 
hours of admission, but 65% if ARF develops more than 72 hours after admission 
(Figure 11.1). This has not been previously reported in the AECOPD literature but 
patients who initially improve on NIV and then deteriorate after 48 hours of admission 
have a particularly high in-hospital mortality rate.[172, 274] Based on these studies, it 
is suggested that patients who deteriorate in spite of NIV therapy should be 
considered for invasive ventilation; our study, in agreement with other studies of NIV 
use in the UK,[146, 176] shows that despite this evidence and the recommendation in 
the National UK NIV Guideline that IPPV should be considered in patients with very 
severe ARF (pH < 7.26) or in those who deteriorate after 48 hours on NIV,[174] very 
few (4/195, 2.1%) received invasive ventilation after initial treatment with NIV.  
We have shown that, in this population, a low eosinophil count is independently 
predictive of mortality which has not been investigated or reported previously. 
Furthermore, although several authors have shown that a high comorbidity burden 
[150, 259] or chronic non-respiratory comorbidity [147] are associated on univariate 
analysis with in-hospital mortality in patients requiring ventilation, to our knowledge, 
this is the first study to report that a past history of cerebrovascular disease is 
independently predictive of death. In addition, many authors have shown that low 
body weight or low BMI are associated with in-hospital mortality,[144, 282] but this is 
the first study to report that recent unexplained weight loss is independently 
predictive of death. 
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Other independent predictors of mortality in our population treated with assisted 
ventilation (Table 11.10) are consistent with previous research: time between 
admission and the development of ARF;[146] cough effectiveness;[276] and low 
arterial bicarbonate concentration.[146, 150] We identified older age as an 
independent predictor of mortality and, although many other studies [138, 139, 299] 
have shown a strong univariate relationship between age and mortality, none have 
shown this to be independent of confounders. This discrepancy may be because many 
of the studies of NIV in AECOPD have been undertaken in ICU and are likely to include 
a younger population than our study, and furthermore, much of the data collected in 
these studies is taken from the time of admission to ICU (i.e. the time of clinical 
deterioration). It may be that physiological measures at the time of clinical 
deterioration (which we did not collect in detail in this study) are stronger predictors of 
outcome than age and therefore, in these studies, age is not an independent 
prognostic marker. 
Only a single study has investigated the relationship between stable-state dyspnoea 
and mortality: Chu et al [264] showed that high MRCD scores were independently 
predictive of long-term mortality following treatment with NIV, and we have 
confirmed that this relationship exists for in-hospital mortality. Our finding that a high 
neutrophil count predicts mortality is consistent with previous research which has 
shown that a high total WBC [277, 291] and a high CRP [150] are associated with 
mortality.  
Our finding that a history of anxiety or depression is protective against in-hospital 
mortality has not been reported previously. On the contrary, in all patients 
hospitalised with AECOPD, depression (measured using the HADS) is associated with 
increased long-term mortality.[359] The relationship between a history of anxiety or 
depression and short-term mortality has not previously been reported in AECOPD and 
our finding is difficult to explain and consequently requires external validation before 
application to clinical practice.  
A low pH has frequently been found to independently predict mortality in patients 
requiring assisted ventilation,[259, 282, 284] but was not independently predictive of 
mortality in our study. However, in the three studies referenced above, arterial 
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bicarbonate was not included as a covariate in the multivariate analysis. In the only 
study of patients requiring ventilation to include both pH and arterial bicarbonate 
concentration in the multivariate analysis,[150] low bicarbonate was a strong 
independent predictor of death whereas low pH was only associated on univariate 
analysis. This is consistent with our results and it is likely that, in our study, arterial 
bicarbonate is included in the regression model ahead of pH because it relates to other 
important prognostic factors, such as the duration of respiratory failure (i.e. a normal 
bicarbonate concentration in the setting of ARF is likely to indicate a rapid clinical 
deterioration whereas an elevated bicarbonate level indicates underlying chronic 
respiratory failure), or the presence of a mixed respiratory and metabolic acidosis, a 
known adverse prognostic marker.[146] 
The model including all of the independent predictors (Table 11.10) was an excellent 
discriminator for in-hospital mortality (AUROC = 0.913) and the results are likely to be 
generalisable beyond the study population (excellent performance on bootstrapping 
and relatively high R2 value). 
14.3.4 PREDICTING READMISSION IN PATIENTS SURVIVING TO DISCHARGE 
FOLLOWING HOSPITALISATION FOR AECOPD 
In our population, 60.3% of patients surviving to discharge were readmitted within 12 
months, and 66.3% were readmitted, or died without being readmitted, within 12 
months. The reported annual readmission rates after AECOPD vary greatly from 25% to 
87% although most of these studies do not include death without readmission in their 
outcome definition. The 90-day readmission rate in our study (33.4% for readmission 
only; 37.3% for readmission or death without readmission) is very similar to the figure 
of 33% reported in the 2008 National UK COPD Audit,[12] suggesting that our results 
are representative of the UK as a whole. During the year following discharge, 34.8% of 
our cohort experienced frequent (≥ 2) readmissions. The definition of ‘frequent 
readmissions’ varies and has rarely been studied although: Bhatt et al [327] reported 
that 23% of patients surviving hospitalisation for AECOPD experienced ≥ 3 
readmissions in the subsequent 12 months; Garcia-Aymerich et al [303] reported that, 
during a median follow up period of 410 days, 40% of patients experienced ≥ 2 
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hospitalisations; and in a retrospective study, Cao et al [307] suggested that almost 
half (45.7%) of patients had ≥ 2 hospitalisations in the year prior to admission. 
We identified a number of simple to measure strong independent predictors of 90-day 
readmission or death (Table 10.7). Of these, severe stable-state dyspnoea,[264, 308] 
previous hospitalisations,[14, 264, 325] unexplained weight loss,[324] lower ability to 
self-care,[264, 308], cor pulmonale,[312] and male sex [14] have all been shown to be 
predictive of hospital readmission in previous research. As discussed above (section 
11.1.1) the finding that high glucose is protective against readmission is difficult to 
explain and requires further investigation.  
The clinical prediction tool for 90-day readmission, the CRUSHED score, is simple to 
measure and shows good discrimination for the prediction of readmission (AUROC = 
0.735). Furthermore, CRUSHED also shows moderate discrimination (AUROC = 0.691) 
for the identification of patients at risk of 28-day readmission or death. There was no 
significant difference between the CRUSHED score and Model 4 suggesting that 
CRUSHED is a good approximation of our most robust prediction tool for 90-day 
readmission. The CRUSHED tool was not directly compared with other readmission 
predictive tools however, when comparing performance in each tool’s derivation 
cohort, CRUSHED performed favourably compared to the LACE (AUROC for 30-day 
readmission or death = 0.684) and PARR (AUROC for 12-month readmission = 0.685) 
predictive tools.  
Therefore, the CRUSHED score provides a potential framework to risk-stratify patients 
hospitalised with AECOPD and consequently direct resources to patients most at risk of 
poor outcome. 
Bhatt et al [327] suggested that: a preserved FEV1; previous pneumococcal and 
influenza vaccination; a low BNP value; and low serum magnesium were associated 
with frequent (≥ 3 per annum) readmissions and the only independent predictor was 
low magnesium. However, many important well-known predictors of readmission 
were not evaluated in this study: dyspnoea severity; dependency in self-care; prior 
health resource use; and other blood tests apart from BNP and magnesium. Therefore 
it is uncertain whether the relationship between low magnesium and frequent 
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readmission would persist after inclusion of these potentially important confounders. 
A retrospective, but more extensive examination of potential predictors of 
readmission, [307] showed that: FEV1 < 50% predicted; a long duration of COPD; and 
consumption of psychotropic drugs (e.g. antidepressants, tranquilizers etc) were 
independently predictive of frequent readmission. However, it is uncertain whether 
these findings are comparable to our study because the outcome was readmission 
frequency during the year prior to admission and not readmission frequency following 
hospital discharge.  
We identified many variables strongly associated with frequent readmission on 
univariate analysis (Table 10.1 to Table 10.6) and the independent predictors of 
frequent readmission were: prior health resource use (assessed by either the 
frequency of hospitalisation in the past year or a previous hospital admission requiring 
NIV); high serum albumin at admission; a history of cerebrovascular disease; and no 
coexistent hypertension (Table 10.12). It is likely that the relationship between a 
preserved serum albumin concentration at admission and an increase risk of frequent 
readmission is likely to be partly explained by the strong relationship between low 
albumin and mortality following discharge (Table 9.18). Therefore patients with a 
higher albumin concentration were more likely to survive and therefore at a relatively 
higher risk of frequent readmission. Our finding that the strongest predictor of 
frequent readmission is prior health resource use is consistent with the data in stable 
disease investigating predictors of frequent exacerbations.[123]  
The regression model including all of the independent predictors showed satisfactory 
discrimination (AUROC = 0.701) and although bootstrapped internal validation implies 
that our results are likely to be generalisable, the relatively low Nagelkerke’s R2 value 
(R2 = 0.153) suggests that there are likely to be other important predictors of frequent 
readmission (for example, quality of life measures) which, if included, might produce a 
better predictive model. Although some of the individual prognostic indices identified 
in Model 5 may be of clinical utility to assist the identification of patients at risk of poor 
outcome, as a whole it lacks both prognostic strength and generalisability and hence 
further predictive tools for frequent readmission should be sought. 
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14.4 CLINICAL APPLICATION 
In 2010, the National UK COPD Guideline [44] identified the following research 
question as a high priority in COPD: “Could a simple multidimensional assessment be 
used to give a better indication of COPD outcomes than either FEV1 or other 
components measured alone in a wide range of COPD patients…?” The extensive 
review of the literature (Chapter 2 to Chapter 3) recognises that this question has been 
addressed in stable disease (Table 2.9), but there has been little research in patients 
hospitalised with AECOPD. Within the published literature, there is some agreement 
regarding important predictors of mortality and readmission (Table 3.4 and Figure 3.1) 
but robust, simple to use clinical prediction tools have not previously been developed. 
This study describes the DECAF tool which is simple to measure at the time of hospital 
admission and accurately stratifies patients according to their risk of in-hospital 
mortality. Therefore, at the time of hospital admission, patients at the highest risk of 
mortality can either be: managed in the most appropriate clinical setting (i.e. critical 
care or high dependency unit); monitored closely to ensure prompt action if evidence 
of clinical deterioration develops; and / or engaged in an early and well-informed 
discussion of prognosis and end-of-life care. It is perhaps the latter point which may 
have greatest clinical impact: an ability to provide accurate and informed prognostic 
information to patients, relatives and carers. In addition, application of the knowledge 
of the strong independent predictors of mortality in patients receiving assisted 
ventilation for ARF may help improve further the access to timely end-of-life care and 
improve communication with patients and relatives at this critical stage of a patient’s 
illness. 
Furthermore, although currently there are no firm recommendations regarding 
suitability criteria for entry in to Early Supported Discharge Schemes (ESD) following 
hospitalisation for AECOPD, it is advised that patient selection should depend on an 
assessment of prognosis.[44] Therefore, the DECAF score may provide a framework for 
selection for ESD and may increase the proportion of patients accepted on to such 
schemes. For example, if a low-risk DECAF score (DECAF = 0 – 1) were used to indicate 
suitability for ESD, approximately 50% of admitted patients might be considered, 
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compared to enrolment rates of approximately 25% of patients in most of the studies 
investigating ESD in AECOPD.[404] 
Hospital readmission places a large financial burden upon the health service, is 
associated with a decline in QoL [405] and an increased risk of mortality,[242] and is 
the outcome most feared by patients with COPD.[406] Clinical application of the 
CRUSHED score would enable the early identification of patients most at risk of 
readmission and actions  could be taken to try and help reduce the risk of readmission 
(for example, early clinical review post-discharge, better integration between primary 
and secondary care, respiratory specialist nurse involvement, or early referral for 
pulmonary rehabilitation). 
14.5 FURTHER RESEARCH QUESTIONS 
The development of clinical prediction models in clinical practice has four stages: 
development; validation; impact analysis; and implementation.[407] All prognostic 
models or clinical prediction tools that we have developed were internally validated 
and we believe that the results are generalisable to all patients hospitalised with 
AECOPD in the UK. However, formal external validation is optimal prior to clinical 
application. In addition to further validation work, it needs to be shown that utilising 
the tool in clinical practice can improve important clinical outcomes.  
Options for further research include: 
 Can risk stratification of patients hospitalised with AECOPD, in terms of their 
DECAF score, be used to help guide in-hospital management and improve 
patient outcomes? In particular, do patients at a suspected high risk of death 
benefit from earlier and more intensive medical management?  
 Can a low DECAF score allow patients at a low-risk of in-hospital mortality be 
enrolled on to Early Supported Discharge Schemes and safely managed in the 
community? 
 Is it possible to reduce the risk of malnutrition, according to MUST, and 
consequent risk of mortality and readmission in patients hospitalised with 
AECOPD at a high malnutrition risk? 
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 Does eosinopenia independently predict mortality in conditions similar to 
AECOPD, for example: community acquired pneumonia; or exacerbations of 
bronchiectasis? 
 Given the pressure on pulmonary rehabilitation services, does the CRUSHED 
score provide a feasible mechanism to select the patients at risk of early 
hospital readmission following discharge who may benefit most from early 
rehabilitation following discharge? 
244 
CHAPTER 15 DISCUSSION – PART 2 
15.1 SUMMARY OF MAIN FINDINGS 
Our results detail the longitudinal changes in QoL experienced by a large cohort of 
patients surviving hospitalisation for AECOPD. We have shown that, for the majority of 
patients, QoL takes approximately three months to recover following discharge 
although measures of patient activity peaked after six weeks of follow-up. In stable 
COPD, individuals who are hospitalised experience a greater decline in longitudinal 
QoL compared to stable patients who do not require hospitalisation.[111] In the 
present study of longitudinal QoL changes following hospitalisation for AECOPD, most 
patients did not experience an overall decline in QoL during follow-up and, for certain 
QoL domains (disease-specific symptoms, mastery of their condition and anxiety 
levels), it improved by a clinically important amount. For patients who were 
readmitted within 12 months of discharge, QoL was significantly lower than patients 
who were not readmitted, however, even for readmitted patients, QoL did not decline 
on average. 
We have also shown that the QoL of patients treated with assisted ventilation was 
stable during follow-up although, when measured using the SGRQ, there was a 
significantly larger improvement in non-ventilated patients. Therefore, in spite of 
frequent poor outcomes (mortality and readmission) in patients discharged following 
hospitalisation for AECOPD, especially those who require assisted ventilation, the 
majority of patients did not experience a declining QoL and hence our results suggest 
that treatment decisions cannot be influenced by an assumption that following 
discharge, an inevitable decline in QoL will ensue.  
Patients with advanced COPD report the most important element of end-of-life care to 
be “not to be kept alive on life support when there is little hope of meaningful 
recovery”.[89] We therefore attempted to identify individuals who experienced a poor 
QoL (section 13.6.1) following discharge in order to assist decisions surrounding level 
of care and end-of-life care. In our study, 29 patients experienced a poor QoL following 
discharge and, compared to those with an acceptable QoL, patients with a poor 
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subsequent QoL: were less active; had greater lung function impairment; had been 
more breathless during the stable-state prior to admission; were more likely to have 
lost weight and were at a higher malnutrition risk; had greater comorbidity; and at 
admission to hospital had lower serum sodium, potassium and albumin 
concentrations. Of these, a history of vascular disease, lower serum sodium, lower 
activity levels, higher serum potassium, and lower serum albumin on admission 
independently predicted poor QoL. Clinical application of these prognostic indices may 
improve discussions around end-of-life care and address the unmet palliative care 
needs of patients with severe COPD. 
15.2 STRENGTHS AND WEAKNESSES 
This is the largest study to date investigating QoL following hospital admission for 
AECOPD and is the only study to measure the longitudinal change in QoL over the year 
following discharge. As a consequence, one of its main strengths is that it addresses an 
important clinical question never previously answered: “how does individuals’ quality 
of life vary after discharge following hospitalisation for AECOPD?” Similar to the points 
outlined in the Part 1 discussion (section 14.2), we believe that because of the size of 
this study and broad recruitment methodology, our results are generalisable beyond 
the study population. 
Although a chronic condition with a typically progressive course, COPD can be 
associated with frequent exacerbation and short-term fluctuations in an individual’s 
symptoms and QoL. Therefore, studies investigating QoL change between only two 
time points, or intervals widely spaced in time, will not reflect the short-term variation 
which individual patients experience. Our study, due to multiple longitudinal QoL 
measurements, will better take account of this subtle variation.  
When considering longitudinal changes in QoL we opted to take account of patient 
death in a similar way to that used in the measurement of preference-based QoL (i.e. 
utility), whereby the lowest possible score on the measurement scale is assigned to 
indicate patient death.[408] Of the few longitudinal QoL studies in patients surviving 
hospitalisation for AECOPD, none included death as an important component of an 
individual’s QoL. In similar fashion, death is not included in studies of QoL change in 
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stable COPD although in the non-COPD literature, some authors have used similar 
methodology to ours.[397, 399] We chose to include death in the assessment because 
of its clear clinical relevance when considering long-term change in QoL. In any 
population of patients similar to ours (i.e. severe underlying COPD surviving 
hospitalisation for AECOPD) it is likely that most deaths following discharge will be the 
result of either progressive organ (i.e. respiratory or cardiac) failure, malignancy, or an 
acute exacerbation of COPD: all of which are likely to be associated with a declining 
QoL leading up to the point of death. It is much less likely that the cause of death will 
be a sudden cardiac event with no preceding decline in QoL. This assumption is 
supported by a longitudinal QoL study in individuals with severe COPD which showed 
that, in the patients who died during follow up, QoL (measured using the SGRQ) 
deteriorated linearly prior to death.[409] Therefore, ignoring death will not accurately 
represent the QoL experienced by the patient. The time-course of QoL decline prior to 
death is uncertain and, whilst we are aware that assuming a linear decline prior to 
death will not reflect the short-term variation in QoL that an individual is likely to 
experience, this is a well-established method of analysing sequential QoL data [60, 
119, 409] and is consistent with the findings of the longitudinal QoL study in severe 
COPD described above.[409] Furthermore, if the trajectory of QoL change is non-linear, 
area under the curve (AUC) is a better approximation of true QoL change than direct 
comparisons at each time point,[119] and therefore our use of AUC further improves 
the accuracy of our assessment. 
We have attempted to define quantitatively whether an individual experienced a poor 
QoL following discharge from hospital. National guidelines recommend that, in 
patients hospitalised with AECOPD, clinical decision making should be influenced by an 
assessment of the “potential for recovery to a quality of life acceptable to the 
patient”.[174] Our study is the first to identify prognostic markers which could help 
clinicians more accurately predict the likelihood of QoL recovery or decline in an 
individual patient. We are aware that all QoL measurement scales are limited by floor 
and ceiling effects: individuals with well preserved baseline QoL (i.e. at the top of the 
measurement scale) are more likely to report a decline in QoL during follow-up than 
patients with a very low baseline score (i.e. at the bottom of the measurement scale) 
whose QoL cannot worsen due to the confines of the measurement scale. In our 
247 
definition of poor QoL (section 13.6.1), we therefore included only patients who had 
an initially poorer than average baseline QoL and who also experienced a clinically 
important decline during follow-up. This definition may result in some patients who, 
despite a well preserved baseline value, experienced very poor QoL following 
discharge not being included. However, our definition will identify patients who have 
the greatest clinical need for either increased medical and supportive care, and / or for 
early discussion of end-of-life care.  Furthermore, we chose death within six months of 
discharge in our definition of poor QoL. Although some individuals may have been 
defined as having a poor QoL solely because they died within six months of discharge, 
rather than because of a clinically important measured decline in QoL, we chose this 
methodology because: firstly, in this population, the likely decline in QoL prior to death 
is important and not ignorable; and secondly, we believe that when trying to identify 
patients with “little hope of meaningful recovery”,[89] death is an important outcome. 
15.3 STUDY FINDINGS AND COMPARISON WITH PREVIOUS RESEARCH 
15.3.1 STUDY POPULATION AND BASELINE QOL 
In our subgroup of patients surviving hospitalisation for AECOPD undergoing 
longitudinal follow-up, we found the expected differences between patients who 
received assisted ventilation and those who did not: greater lung function impairment; 
a higher proportion receiving LTOT; worse stable-state dyspnoea; lower pH and higher 
paCO2 at admission; and longer length of stay (Table 13.1). This is similar to the findings 
of Roberts et al [146] who showed that, despite frequent missing data, compared to 
patients without ARF, those with respiratory acidaemia had: greater functional 
dependency; worse stable-state dyspnoea; and worse lung function impairment.  
Despite these important differences between our ventilated and non-ventilated 
patients, those who were ventilated reported better COPD symptoms at baseline (i.e. 
time of hospital discharge) compared to those not ventilated (Table 13.2). This finding 
is, at first, difficult to explain but ventilated patients may report less symptoms 
because they are less active (significant difference in NEADL scores and eMRCD). Also, 
ventilated patients had a longer hospital stay than non-ventilated patients and their 
QoL may have recovered in-hospital to a higher level than that of non-ventilated 
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patients. Furthermore, the effect of a recent life-threatening illness on individuals’ self-
reported quality of life is uncertain. Therefore, although the SGRQ asks patients about 
their symptoms during the preceding four weeks, the recent survival after a life-
threatening illness and the possibility of a greater in-hospital recovery in QoL may have 
skewed the ventilated patients’ towards reporting less COPD-related symptoms. It is 
important to note that apart from the SGRQ Symptoms domain there were no other 
significant differences in QoL according to the SGRQ, the CRQ, or the HADS. 
Our patients required frequent health resource use during the follow-up period (Table 
13.3). Most patients (71.0%) were readmitted within 12 months of discharge and those 
treated with assisted ventilation during their index admission were more likely to be 
readmitted for both a respiratory cause (p = 0.0339) and an episode of AECOPD 
requiring assisted ventilation (p = 0.0023) than those not initially ventilated. The 
overall 12-month mortality rate for patients recruited to Part 2 of the study was 
slightly lower than comparable Part 1 patients (i.e. those who survived their index 
admission): 18.0% versus 23.7% respectively. The entry criteria for Part 2 will have 
excluded some patients at a high risk of post-discharge mortality (for example, chronic 
confusional states or significant comorbidity causing the patient to be unable to 
complete the longitudinal assessments, such as a severe stroke) and Table 13.1 
highlights that patients enrolled in Part 2 were slightly younger than Part 1 patients 
which may further have influenced the mortality rate.  In this subgroup of 183 
patients, there was a non-significantly higher mortality rate in ventilated patients 
compared to non-ventilated patients although, given the relatively large absolute 
differences in mortality (22.0% v. 14.9% 12-month mortality), this may represent a true 
finding with a lack of statistical power explaining the non-significant result. 
15.3.2 ASSOCIATIONS BETWEEN BASELINE QOL AND SUBSEQUENT OUTCOME 
In this study, the baseline QoL measures associated with subsequent readmission and 
mortality were those assessing patients’ activity levels (SGRQ Activity and NEADL). This 
agrees with the findings of Almagro et al [58] who showed the SGRQ Activity subscale 
to be independently predictive of long-term mortality. Gudmundsson et al [255] 
showed all SGRQ domains to be associated with long-term mortality, a finding that we 
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have not replicated. There were, however, clinically important QoL differences in our 
study between patients who died and survived in terms of the SGRQ Impacts and Total 
subscores, and therefore a lack of statistical power (33 deaths in our study compared 
to 122 deaths in the study by Gudmundsson et al) may explain the non-significant 
results. In a second manuscript reporting on the same population, Gudmundsson et al 
[305] showed higher scores for all SGRQ domains except Symptoms to be significantly 
associated with rehospitalisation following discharge, and Osman et al [316] showed 
significant univariate associations between higher scores on all SGRQ domains and 
readmission. However, in both these populations, average QoL was better (i.e. lower 
SGRQ scores) than in the population reported here, which may further explain the lack 
of an association between SGRQ Symptoms and Impacts with outcome in the present 
study. Additionally, our results suggest patients with more depressive symptoms 
according to the HADS score were at higher risk of mortality (p = 0.0825): an 
association consistent with previous research.[58, 249, 262]  
15.3.3 LONGITUDINAL CHANGE IN QUALITY OF LIFE FOLLOWING HOSPITAL 
DISCHARGE 
 We have shown that for all patients (n = 183), overall quality of life, measured using 
either SGRQ or CRQ, did not decline during follow-up and, for specific QoL domains 
(SGRQ symptoms and CRQ mastery), it improved by a clinically important amount 
(Table 13.7). Activity levels, however, did decline during follow-up, although for all 
patients (n = 183), the average decline was less than the MCID. For those not treated 
with assisted ventilation, individuals’: symptoms, disease impact and total QoL 
(measured using the SGRQ); mastery of their condition (measured using the CRQ); and 
self-reported levels of anxiety (measured using the HADS) improved both more than 
the MCID and, for the SGRQ and CRQ indices, more than ventilated patients. Despite 
less improvement in QoL in ventilated patients compared to non-ventilated patients, it 
is noteworthy that for all QoL measures apart from SGRQ symptoms, ventilated 
patients’ QoL was maintained at their baseline level and, in contrast to the previously 
reported prognostic pessimism in AECOPD,[104] did not inexorably decline.  
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We are not aware of any publications comparing change in QoL between ventilated 
and non-ventilated patients and, in general, there is little published data on 
longitudinal change in QoL in patients surviving hospital admission for AECOPD. Most 
studies assessing change in QoL over time in AECOPD discharged from hospital are 
either: cross-sectional and aim to identify predictors of quality of life at a single time-
point; or measure QoL at only two time points and rely on patient recollection of their 
QoL during the intervening period.  
Both of the studies which recorded QoL at more than two time points only assessed 
short term changes and therefore do not compare directly with our results. O’Reilly et 
al [131] showed that patient-reported activity limitation and psychological symptoms 
improved during hospital admission, but deteriorated between hospital discharge and 
three months post discharge although the statistical significance of these results is not 
stated. Patients were also asked to provide a global valuation of their perception of 
their QoL. Comparing patient valuations at three months to discharge levels confirms 
that, in the O’Reilly study, patients’ perceived QoL exhibited a statistically significant 
decline. These results appear to conflict with the only other similar study [366] which 
showed that patients’ symptoms improved progressively from admission (day 0) to day 
40 (post-discharge). However, the latter study assessed symptoms whereas O’Reilly et 
al assessed activity limitation, and neither study interpreted the change in QoL in the 
context of an MCID for the instrument and therefore, although both studies show 
absolute changes in QoL, it is not known whether these changes are of clinical 
significance. Therefore, given the different time periods investigated, the different QoL 
components measured and the uncertainty over whether the changes identified were 
clinically important, it is uncertain how these results compare to our findings.  
Comparisons can be drawn between our results on the change in QoL in patients 
treated with assisted ventilation and two previous studies: Wildman et al [177] asked 
patients to compare their QoL at six months following intensive care for an 
exacerbation of COPD or asthma with their recall of QoL prior to hospital admission; 
and Connors et al [102] asked a cohort of patients hospitalised with severe AECOPD to 
provide a global assessment of their QoL at six months following discharge. Wildman 
et al showed that in patients surviving intensive care following an exacerbation of 
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COPD or asthma, 73% of patients reported that their QoL was better than or 
equivalent to before hospital admission; and Connors et al reported that 51% of 
patients hospitalised with a severe AECOPD claimed to have good, very good or 
excellent QoL six months after discharge. Although it is not possible to compare our 
findings quantitatively with those of Wildman and Connors, the suggestion that 
patients hospitalised with underlying severe COPD and a severe exacerbation do not 
inevitably experience a decline in QoL following discharge is consistent with our 
findings regarding the mean change in ventilated patients (Table 13.7). The only other 
study investigating longer term QoL change in patients surviving hospitalisation for 
AECOPD [410] reported that six years after hospitalisation for AECOPD requiring IPPV, 
the majority (72%) of living patients were self-sufficient and there were no significant 
differences in QoL scores measured at baseline and six years post discharge. However, 
only a small number of patients completed follow-up (16.2%) and therefore, it is 
uncertain how these findings apply to most of the patients hospitalised with AECOPD 
and whether they can help clinical decision making at the time of hospital admission. 
Andenæs et al [120] assessed QoL change (using the SGRQ) over a nine month period 
in patients hospitalised with AECOPD. It is not clear from the manuscript whether 
ventilated patients were included in the study, but given the low in-hospital mortality 
rate (3.9%) it is likely that most were not ventilated and therefore the results are 
comparable with the change in QoL in our patients not treated with assisted 
ventilation. Andenæs et al showed that, for all SGRQ components except the 
symptoms domain, QoL was significantly better (both statistically and clinically) at nine 
months following discharge than at admission. This differs only slightly from our 
findings (Table 13.7), where non-ventilated patients showed an overall improvement 
in all SGRQ domains except SGRQ activity. These minor discrepancies may be a result 
of two important differences: Andenæs et al only recorded QoL at two time-points 
and, compared to our methodology, this was less likely to reflect the typical fluctuation 
in individuals’ symptoms; also, they recorded baseline QoL soon after hospital 
admission rather than at hospital discharge which, given that O’Reilly et al [131] 
showed patient-reported activity limitation improved during hospital admission and 
not after discharge, is likely to explain our finding of a lack of improvement in SGRQ 
activity. 
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In the present study, for most measures of QoL, patients reported their best QoL at 
three months following discharge. The time course of recovery in QoL following 
hospitalisation for AECOPD has not been previously reported with previous studies 
only recording QoL at a single time point after hospital discharge. In AECOPD treated in 
the community there are varying reports of the length of time taken for QoL to 
recover: Seemungal et al [106] showed that the median time to recovery of specific 
symptoms (cough, dyspnoea and coryzal symptoms) was seven days; however, 
Spencer et al [119] showed that overall QoL (measured using SGRQ) continued to 
recover up to 26 weeks following presentation with AECOPD. Therefore, although no 
direct comparisons are available, our findings are consistent with those reported in 
patients treated with AECOPD in the community. 
In our study, the only measures of QoL which did not peak at the three month 
assessment were individuals’ activity levels (SGRQ Activity and NEADL) which appeared 
to recover more rapidly within six weeks of discharge. However, it is possible that 
activity levels never fully recovered and the apparent early recovery is because activity 
levels deteriorated after six weeks (perhaps due to hospital readmission or further 
AECOPD). This hypothesis is supported by the mean decline in activity levels and the 
short period of time spent with activity levels better than baseline (Table 13.7) as well 
as the findings of a study of patients treated for AECOPD in the community.[119] The 
latter study showed that, in patients who experienced a further exacerbation following 
the initial episode, all domains of the SGRQ improved during the first four weeks 
following treatment but after this, the SGRQ Activity domain began to decline.  
Longitudinal QoL, for almost all QoL measures, was significantly worse in patients who 
experienced an episode of rehospitalisation following discharge compared to those not 
readmitted. This agrees with the data from stable disease whereby patients who 
experienced a hospital readmission had worse QoL than those not hospitalised,[111] 
however the cause of this relationship is uncertain. 
15.3.4 PREDICTING SUBSEQUENT POOR QOL FOLLOWING DISCHARGE 
We identified 29 patients who, according to our definition outlined in section 13.6.1, 
had a poor QoL following discharge. These patients, compared to those with an 
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acceptable QoL, had more severe underlying COPD: higher levels of functional 
dependence; worse stable-state dyspnoea; greater lung function impairment; more 
frequent comorbid IHD (p = 0.0621) and peripheral vascular disease; a greater 
comorbidity burden; and worse baseline QoL. Most measures of acute physiological 
derangement and the proportion of patients treated with assisted ventilation were 
similar between the two groups suggesting that the severity of the index exacerbation 
was not associated with a subsequent poor QoL. There were significant differences in 
serum albumin concentration (lower albumin concentration in patients with a 
subsequent poor QoL), however given the lack of differences in other measures of 
acute illness, this difference may reflect poor nutritional status which was associated 
with subsequent poor QoL: patients experiencing a subsequent poor QoL had a non-
significantly lower BMI (p = 0.13) and a higher proportion of recent unexplained weight 
loss (p = 0.0194) (Table 13.9).  
We also found that lower serum sodium concentrations and higher serum potassium 
concentrations at admission to hospital were associated with post-discharge poor QoL. 
In Part 2 patients, higher potassium concentration was strongly positively correlated 
with hydrogen ion concentration at admission (Spearman’s ρ = 0.43, p < 0.0001) which 
was non-significantly associated with poor QoL (p = 0.26) and, in Part 1, strongly 
associated with long-term mortality (Table 9.17). Therefore, although the two 
variables were not collinear, the relationship between high potassium and poor QoL 
may be via its relationship with hydrogen ion concentration. The relationship between 
lower serum sodium and subsequent poor QoL has a number of possible explanations: 
low serum sodium may be a marker of the presence of, or treatment for, underlying 
comorbidities (for example, cardiac, liver or renal failure) or cor pulmonale, although it 
is important to note that in our study there were no direct relationships between 
either cor pulmonale or pedal oedema and poor QoL; low serum sodium is also an 
adverse prognostic marker in patients with AECOPD requiring ventilation [158, 288] 
and its association with poor QoL may be via its relationship with mortality. At the time 
of hospital discharge, the only QoL measure associated with poor QoL, except those 
used its definition, was activity levels measured using the NEADL.  
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No previous studies have attempted to define and predict poor QoL in patients with 
COPD. The most comparable studies are those identifying factors associated with a 
lack of QoL recovery although it is important to note that this methodology is often 
biased by a ‘floor effect’ which occurs with all QoL measurement scales (section 15.2). 
Furthermore, very few of these studies have investigated patients hospitalised with 
AECOPD and most investigate stable disease.  
QoL decline in stable COPD is associated with: lower activity levels,[362] more severe 
stable-state dyspnoea,[363, 364] greater comorbidity,[111, 361] and worse baseline 
QoL,[361] all of which are consistent with our results. In our study, lower FEV1 was 
retained in the final regression model (p = 0.0523) which is consistent with data in 
both stable disease and following hospitalisation with AECOPD, where lower FEV1 is an 
established predictor of QoL decline.[60, 111, 313, 364, 366] A single study in stable 
COPD [363] showed low BMI to be associated with QoL decline which is consistent 
with our strong association between recent weight loss and poor QoL.   
Tsai et al [365] investigated short term (two week) recovery in QoL following hospital 
discharge with AECOPD and reported that comorbid coronary artery disease and 
previous episodes of AECOPD were associated with QoL decline. Although no 
relationship between prior AECOPD and poor QoL was found in our study, we did show 
that prior hospitalisation was non-significantly associated (p = 0.0817) with poor QoL. 
The biochemical abnormalities we reveal as being associated and independently 
predictive of mortality have not been previously described. 
We identified six independent predictors of poor QoL (‘Model 7’): comorbid IHD or 
PVD; lower serum sodium concentration; higher activity levels (according to NEADL); 
higher serum potassium concentration; lower serum albumin concentration; and lower 
FEV1 % predicted (Table 13.13). Tests of model assumptions were satisfactory and the 
model showed good discrimination for poor QoL in its derivation cohort and on 
internal validation (bootstrapped AUROC = 0.828, 0.750 to 0.895). Although the NEADL 
was independently predictive of poor QoL, it is a cumbersome tool which may limit its 
use in clinical practice. If NEADL is omitted from multivariate analysis, eMRCD emerges 
as in independent predictor (OR 1.85, 1.05 to 3.28, p = 0.0336) and the other 
predictors remain in the model. The model including eMRCD was slightly less 
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generalisable (Nagelkerke’s R2 = 0.302), but remained a satisfactory fit of the overall 
dataset (HLGFT, p = 0.391) and had equivalent discrimination (AUROC = 0.836, 0.759 to 
0.913) to Model 7 (p = 0.73). Therefore, our results suggest that clinicians could use 
the more pragmatic eMRCD instead of the NEADL for the prediction of poor QoL 
following hospital discharge. 
15.4 CLINICAL APPLICATION 
In a large population of older patients with severe exacerbations of severe underlying 
COPD, overall QoL does not deteriorate significantly following discharge, and in those 
not requiring assisted ventilation, it improves by a clinically important amount. 
Therefore, patients, carers and clinicians may be reassured by the knowledge that, 
despite high rates of mortality and readmission following discharge, it is likely that an 
individual’s QoL will not deteriorate from the level experienced during the few weeks 
prior to hospital discharge. For clinicians, this may inform decision making with regards 
to escalation of care. For example, an inability to accurately prognosticate in AECOPD 
[411] has, consistent with national recommendations,[174] hitherto resulted in 
decisions regarding appropriate level of care being frequently made on the basis of 
clinicians’ perceptions of individuals’ QoL. It is our contention that many patients are 
denied potentially beneficial intensive care due to widespread beliefs that QoL 
inexorably declines following discharge. These results challenge this perception and 
may improve the access to intensive care for patients with AECOPD, which may result 
in improved clinical outcomes. 
The use of the predictive indices described in Table 13.13 and Table 13.14 could enable 
clinicians to identify patients at risk of poor QoL following hospitalisation for AECOPD. 
Early identification of those at risk may permit an open and informed discussion of 
future treatment options. For example, given that the majority of patients will be 
rehospitalised during the subsequent year, and almost a third of ventilated patients 
and over 10% of non-ventilated patients will experience a readmission requiring 
assisted ventilation, patients whose QoL is expected to be poor may choose alternative 
treatment options to further hospitalisation or ventilatory assistance if the situation 
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arises. Furthermore, clinicians would be able to discuss end-of-life treatment options 
and, if acceptable, improve access to end-of-life services for appropriate patients. 
15.5 FURTHER RESEARCH QUESTIONS 
We have attempted to define poor QoL in patients surviving hospitalisation for 
AECOPD, however, to validate our definition, comparison with patients’ illness 
perceptions would be both informative and interesting. Furthermore, a detailed 
qualitative exploration of the wishes and expectations of patients with, or at risk of, a 
poor QoL would help inform end-of-life decision making in COPD. It is also uncertain 
whether individuals’ views regarding treatment options and future care changes as 
QoL improves or deteriorates and understanding this relationship may help clinicians 
assess the impact of treatments and future events on patients’ wishes and 
expectations. Therefore, potential future research questions include: 
 For patients who are expected to experience a poor QoL following discharge, 
what are their preferences and expectations with regards to future care? 
 Is there a relationship between patient-reported QoL and patient preferences 
regarding treatment, future care and end-of-life care? 
The results reporting here may also have implications for future therapies. Treatments 
may be more clinically or cost-effective if directed at patients most at risk of poor 
outcome. Certain treatments may prevent QoL decline and others may be particularly 
effective at preventing or reversing the decline in QoL experienced by certain patients. 
Consequently, potential future research questions include: 
 Many patients, particularly ventilated patients, experience an early and 
significant decline in activity levels. Can pulmonary rehabilitation, commenced 
during the in-hospital stay, result in sustained improvements in QoL post 
discharge? 
 Given the effect of subsequent readmission on longitudinal QoL (Table 13.8), 
can therapies aimed at reducing readmission risk (i.e. treatments aimed at 
reducing AECOPD frequency) alter longitudinal QoL in patients surviving 
hospitalisation for AECOPD? 
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CHAPTER 16  FINAL CONCLUSIONS 
This detailed study of a large cohort of patients hospitalised with AECOPD has many 
important findings, some in agreement with the published literature and some not 
previously reported. The most important results are summarised below: 
 Prognostication in AECOPD requiring hospitalisation can be improved using 
routinely available clinical indices.  
 The extended MRC Dyspnoea Score is a particularly strong predictor of 
subsequent outcome (mortality, readmission and poor QoL) and should 
routinely be recorded in all patients hospitalised with an exacerbation.  
 We have shown the DECAF score to be an accurate clinical prediction tool 
whose appropriate utilisation could result in improved patient outcomes. 
 A longer time between admission and the development of acidaemic 
respiratory failure is a strong independent predictor of mortality in patients 
requiring treatment with assisted ventilation. 
 The CRUSHED predictive tool appears to be a stronger predictor of readmission 
than two other commonly used predictive tools (the LACE and PARR tools) 
developed to predict readmission in general hospitalised patients. 
 Following discharge, most patients’ QoL did not decline and for certain QoL 
domains, improved by a clinically important amount. 
 Clinical application of the clinical predictors of poor QoL may assist clinicians in 
the identification of, and reasoned discussion with, patients at greatest risk of 
poor recovery following discharge. This may improve clinical and patient 
decision making, and perhaps improve access to end-of-life services for those 
most in need. 
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APPENDIX A. CHARLSON COMORBIDITY INDEX (CCI) 
Table 17.1     Charlson comorbidity index 
Comorbidity Relative score 
Metastatic solid tumour 6 
AIDS 6 
Moderate-to-severe liver disease 3 
Hemiplegia 2 
Moderate-to-severe renal failure 2 
Diabetes with end organ damage 2 
Neoplasia 2 
Leukaemia/lymphoma 2 
Myocardial infarction 1 
Congestive heart failure 1 
Peripheral vascular disease 1 
Cerebrovascular disease 1 
Dementia 1 
Chronic pulmonary disease 1 
Connective tissue disease 1 
Peptic ulcer disease 1 
Mild liver disease 1 
Diabetes 1 
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APPENDIX B. VARIABLE DISTRIBUTION 
APPENDIX B.1. PART 1 
The distributions of all independent variables collected at the time of hospital 
admission are shown below. Assessment of normality was performed using the 
methods described in section 6.7.2. 
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Hydrogen ion concentration PaO2 (mmHg) PaCO2 (mmHg) 
Bicarbonate Base excess Sodium 
Potassium Urea Creatinine 
Chloride Albumin Serum bicarbonate 
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Serum glucose Haemoglobin 
White cell count Neutrophil count 
Haematocrit 
Eosinophil count 
C-reactive protein 
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 APPENDIX C. MISSING DATA AND DATA IMPUTATION 
Table 17.2     Characteristics of patients with missing data 
  
Age, years 
(mean) 
Female (%) FEV1 % predicted 
(mean) 
CCI 
(median) 
BMI (mean) MRCD 
(median) 
Length of stay, 
days (median) 
Death in-
hospital, % 
Variable 
% 
missing 
P M P M P M P M P M P M P M P M 
Glucose 19.3 73.3 72.2 52.8 58.4 44.4 43.1 2 2 24.8 23.8 4 4 6 7 10.6 9.6 
AECOPD in past year 15.2 72.3* 77.3* 55.9* 42.9* 43.7 47.2 2* 2* 24.8* 23.1* 4* 5* 6 6 6.9* 30* 
Spirometry
∆
 14.3 72.1* 78.6* 53.7 55.3 n/a n/a 2* 2* 24.9* 22.6* 4* 5* 6 7 7.2* 29.5* 
Albumin 7.3 73.1 72.0 54.0 52.2 44.1 44.9 2 2 24.6 24.2 4 4 6* 5* 11.1* 1.5* 
HCO3
-
, BE 6.8 73.0 74.3 54.7 42.9 43.9 47.4 2 2 24.6 24.2 4 4 6 5 10.7 6.3 
pH (H
+
), pO2, pCO2 6.3 73.0 74.7 54.6 43.1 43.8 49.1 2 2 24.6 24.0 4 4 6.5* 4* 10.7 6.9 
BMI 4.3 72.9* 76.2* 54.3 45 44.3 40.2 2* 1* n/a n/a 4* 5* 6 5.5 9.1* 40* 
K
+
 1.3 73.0 74.5 53.7 66.7 44.1 47.2 2 1.5 24.6 25.5 4 4 6 7.5 10.5 8.3 
P – Data present; M – data missing; AECOPD – acute exacerbations of COPD; HCO3- - bicarbonate; BE – base excess; BMI – body mass index; K+ - potassium; CCI – Charlson 
Comorbidity Index; MRCD – MRC Dyspnoea Scale; * significant difference between ‘present’ and ‘missing’, p<0.05; 
∆
including FEV1, FEV1 % predicted, FVC and FEV1/FVC 
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 Table 17.3     Details of missing data and results of EM imputation 
  Original dataset Complete dataset† 
Variable % missing mean SD SE mean mean SD SE mean 
Glucose 19.3 7.49 2.96 0.11 7.45 2.71 0.089 
Number of AECOPD in past year 15.2 3.02 2.64 0.095 3.02 2.47 0.082 
FEV1* 14.3 0.99 0.45 0.016 0.97 0.44 0.014 
FEV1 % predicted* 14.3 44.1 18.0 0.64 43.6 17.2 0.57 
FVC* 14.3 2.19 0.81 0.029 2.15 0.78 0.026 
Albumin 7.3 38.2 5.20 0.18 38.3 5.06 0.17 
H
+ 
6.3 41.4 10.8 0.369 41.2 10.6 0.348 
pCO2 6.3 6.62 2.60 0.088 6.56 2.55 0.084 
pO2 6.3 10.3 6.21 0.21 10.3 6.02 0.20 
HCO3
- 
6.8 29.2 6.47 0.22 29.1 6.52 0.21 
BE 6.8 3.47 5.23 0.18 3.42 5.27 0.17 
BMI 4.3 24.6 6.42 0.22 24.6 6.31 0.21 
K
+ 
1.3 4.32 0.56 0.019 4.32 0.56 0.018 
Only includes variables with >1% missing. Variables with less than 1% missing inc: RR, Temp, Na, Hb, WCC, Haematocrit, Urea, Creatinine, CRP, eosinophils. *within 2 years of 
admission; † includes original and imputed data 
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APPENDIX D.  UNIVARIATE ANALYSES USING ORIGINAL (I.E.  INCOMPLETE) 
VARIABLES 
Table 17.4     Univariate relationships between original, incomplete variables and 
mortality following hospital admission 
Variable n (% of 920) In-hospital 
mortality, p value 
12-month 
mortality, p value 
AECOPD in past year 780 (85) 0.85 0.52 
FEV1 788 (86) 0.0178 0.0001 
FEV1 % predicted 788 (86) 0.17 0.0009 
FVC 788 (86) 0.0075 <0.0001 
BMI 880 (96) 0.0011 <0.0001 
Hydrogen ion concentration 862 (94) 0.0024 <0.0001 
paO2 862 (94) 0.87 0.99 
paCO2 862 (94) 0.0128 0.0002 
HCO3
- 
857 (93) 0.44 0.0208 
Albumin 853 (93) <0.0001 <0.0001 
K
+
 908 (99) 0.0021 <0.0001 
Glucose 742 (81) 0.0313 0.28 
Table 17.5     Univariate relationships between original, incomplete variables and 
readmission following hospital discharge 
Variable n (% of 
824) 
90-day readmission or 
death, p value 
Frequent readmission,     
p value 
AECOPD in past year 726 (88) <0.0001 <0.0001 
FEV1 731 (89) 0.0171 0.0112 
FEV1 % predicted 731 (89) 0.0043 0.0006 
FVC 731 (89) 0.0116 0.0836 
BMI 800 (97) 0.13 0.56 
Hydrogen ion 
concentration 
770 (93) 0.47 0.23 
paO2 770 (93) 0.56 0.81 
paCO2 770 (93) 0.26 0.27 
HCO3
- 
765 (93) 0.40 0.50 
Albumin 758 (92) 0.0013 0.0159 
K
+
 813 (99) 0.26 0.62 
Glucose 663 (80) 0.0435 0.37 
 
 APPENDIX E. CORRELATION MATRICES FOR POTENTIAL PREDICTOR VARIABLES FOR REGRESSION ANALYSES 
APPENDIX E.1. CORRELATION MATRIX OF POTENTIAL CONTINUOUS PROGNOSTIC VARIABLES, FOR BOTH IN-HOSPITAL AND 12-
MONTH MORTALITY, IN ALL PATIENTS HOSPITALISED WITH AECOPD 
Table 17.6     Correlations between potential continuous prognostic variables in all patients hospitalised with AECOPD (n = 920) 
 Age 
Previous 
admissions 
FEV1 % 
pred 
FVC eMRCD dBP RR Temp SpO2 H
+ paO2 HCO3
- K+ Urea Creatinine Albumin Glucose Hb nØ eØ CRP 
Age 1 0.09† 0.14‡ -0.28‡ 0.33‡ -0.14‡ 0.13‡ -0.03 -0.06 -0.01 -0.02 -0.02 0.07* 0.33‡ 0.28‡ -0.27‡ 0.02 -0.33‡ 0.03 -0.07* 0.14‡ 
Previous 
admissions 
 1 -0.06 -0.03 0.23‡ 0.04 0.06 -0.03 0.01 -0.06* 0.02 -0.01 -0.03 -0.06 -0.06 -0.03 -0.03 -0.15‡ 0.00 0.16‡ -0.09† 
FEV1 % pred   1 0.43‡ -0.26‡ -0.08* -0.05 0.07* 0.04 -0.24‡ 0.01 -0.40‡ -0.15‡ 0.12‡ 0.23‡ -0.03 0.01 -0.12‡ -0.03 -0.02 0.01 
FVC    1 -0.39‡ 0.05 -0.09† -0.02 0.08* -0.25‡ 0.02 -0.39‡ -0.02 -0.02 0.19‡ 0.09† -0.09† 0.16‡ -0.05 0.02 -0.07* 
eMRCD     1 -0.10† 0.14‡ -0.05 -0.05 0.14‡ 0.05 0.19‡ 0.14‡ 0.17‡ 0.00 -0.25‡ 0.02 -0.18‡ 0.10† -0.03 0.08* 
dBP      1 0.13‡ -0.01 0.11† 0.09† 0.09† 0.03 0.02 -0.23‡ -0.17‡ 0.31‡ 0.01 0.22‡ -0.09† 0.10† -0.28‡ 
RR       1 0.07* -0.08* 0.17‡ 0.07* -0.08* 0.05 0.04 0.06 -0.03 0.10† 0.01 0.06 -0.06 0.08* 
Temp        1 -0.10† -0.13‡ -0.11† -0.07* -0.13‡ -0.06 -0.01 0.01 0.06 -0.02 0.24‡ -0.17‡ 0.24‡ 
SpO2         1 -0.09† 0.37‡ -0.13‡ -0.02 -0.12‡ -0.01 0.15‡ -0.10† 0.05 -0.09† 0.13‡ -0.15‡ 
H+          1 0.10† -0.21‡ 0.42‡ 0.12† 0.03 0.08* 0.19‡ 0.08* -0.09† 0.04 -0.09† 
paO2           1 -0.08* 0.01 -0.01 0.03 0.08* 0.02 -0.06 -0.05 0.04 -0.04 
HCO3
-            1 0.04 -0.10† -0.32‡ -0.03 0.07* 0.03 -0.07* -0.02 -0.05 
K+             1 0.21‡ 0.14‡ -0.01 0.04 -0.02 0.05 0.02 0.00 
Urea              1 0.67‡ -0.31‡ 0.12† -0.24‡ 0.18‡ -0.17‡ 0.24‡ 
Creatinine               1 -0.14‡ 0.10† -0.16‡ 0.10† -0.02 0.15‡ 
Albumin                1 0.11† 0.34‡ -0.20‡ 0.17‡ -0.52‡ 
Glucose                 1 -0.01 0.13‡ -0.19‡ 0.03 
Hb                  1 -0.10† 0.00 -0.21‡ 
nØ                   1 -0.24‡ 0.43‡ 
eØ                    1 -0.29‡ 
CRP                     1 
Pearson’s r or Spearman-ρ correlation coefficient used depending on underlying variable distribution; RR – respiratory rate; dBP – diastolic blood pressure; temp – temperature; K
+
 
- potassium; Hb – haemoglobin; nØ – neutrophil count; eØ – eosinophil count; *p<0.05; † p<0.01; ‡p<0.001 
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 APPENDIX E.2. CORRELATION MATRIX OF POTENTIAL CONTINUOUS PROGNOSTIC VARIABLES IN PATIENTS RECEIVING ASSISTED 
VENTILATION 
Table 17.7     Correlations between potential continuous prognostic variables in patients receiving assisted ventilation (n = 199) 
 Age eMRCD BMI Urea Albumin Hb nØ eØ CRP RR* H+~ Time from admission to acidosis 
Age 1 0.29‡ -0.17* 0.42‡ -0.23† -0.31‡ -0.09 -0.12 0.12 0.09 0.09 0.21† 
eMRCD  1 -0.19† 0.08 -0.16* -0.08 0.05 -0.04 0.11 0.11 0.03 0.05 
BMI   1 0.08 0.06 0.13 -0.06 0.11 0.05 -0.06 -0.05 -0.01 
Urea    1 -0.38‡ -0.23† 0.17* -0.27‡ 0.29‡ 0.02 0.19† 0.06 
Albumin     1 0.30‡ -0.16* 0.33‡ -0.41‡ 0.01 0.02 -0.19† 
Hb      1 -0.10 -0.02 -0.08 -0.01 -0.14* -0.12 
nØ       1 -0.23† 0.46‡ 0.09 0.14* -0.01 
eØ        1 -0.35‡ -0.01 -0.05 -0.11 
CRP         1 0.10 -0.02 0.13 
RR~          1 0.21† -0.07 
H+~           1 -0.18† 
Time from admission to acidosis            1 
Pearson’s r or Spearman-ρ correlation coefficient used depending on underlying variable distribution; RR – respiratory rate; Hb – haemoglobin; nØ – neutrophil count; eØ – 
eosinophil count; H
+
 - hydrogen ion concentration; ~ at the time of commencement of assisted ventilation;  *p<0.05; † p<0.01; ‡p<0.001 
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 APPENDIX E.3. CORRELATION MATRIX OF POTENTIAL CONTINUOUS PROGNOSTIC VARIABLES, FOR BOTH SINGLE AND FREQUENT 
READMISSION, IN PATIENTS SURVIVING TO DISCHARGE 
Table 17.8     Correlations between potential continuous prognostic variables in patients surviving to discharge (n = 824) 
 Age 
Previous 
admissions 
Previous 
AECOPD 
Smoking 
load 
FEV1 % pred FVC eMRCD Na
 Urea Albumin Glucose Eosinophils CRP 
Length of 
stay 
Age 1 0.08* -0.09* -0.12† 0.14‡ -0.27‡ 0.30‡ 0.06 0.41‡ -0.30‡ 0.01 -0.04 0.12† 0.19‡ 
Previous admissions  1 0.36‡ 0.07* -0.08* -0.03 0.22‡ 0.02 -0.07 -0.01 -0.04 0.16‡ -0.09† 0.05 
Previous AECOPD   1 0.06 -0.07* -0.09* 0.25‡ 0.04 -0.08* 0.06 -0.07* 0.14‡ -0.05 0.06 
Smoking load    1 -0.06 0.13‡ 0.04 -0.07 -0.07* 0.00 -0.08* 0.05 0.01 -0.02 
FEV1 % pred     1 0.43‡ -0.27‡ -0.07* 0.13‡ -0.04 0.01 -0.03 0.02 -0.12‡ 
FVC      1 0.40‡ -0.10† -0.01 0.10† -0.08* 0.00 -0.06 -0.24‡ 
eMRCD       1 0.03 0.13‡ -0.20‡ 0.01 0.02 0.04 0.25‡ 
Na        1 0.13‡ 0.07* -0.08* 0.17‡ -0.15‡ 0.02 
Urea         1 -0.29‡ 0.10† -0.13‡ 0.21‡ 0.19‡ 
Albumin          1 0.10† 0.14‡ -0.53‡ -0.22‡ 
Glucose           1 -0.21‡ 0.03 0.06 
Eosinophils            1 -0.27‡ -0.12‡ 
CRP             1 0.17‡ 
Length of stay              1 
Pearson’s r or Spearman-ρ correlation coefficient used depending on underlying variable distribution; *p<0.05; † p<0.01; ‡p<0.001 
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 APPENDIX E.4. CORRELATION MATRIX OF POTENTIAL CONTINUOUS PROGNOSTIC VARIABLES FOR POOR QOL IN PATIENTS 
SURVIVING TO DISCHARGE 
Table 17.9     Correlations between potential continuous prognostic variables for poor QoL in patients surviving to discharge (n = 183) 
 Age 
Previous 
admissions 
FEV1 % pred FVC eMRCD BMI Diastolic BP PaCO2 Na K Albumin Hb 
Length of 
stay 
Baseline 
NEADL 
Age 1 0.05 0.10 -0.32‡ 0.20† -0.01 -0.12 0.08 0 0 -0.21† -0.21† 0.17* -0.12 
Previous admissions  1 -0.14 -0.02 0.28‡ -0.05 0.07 0.04 0.04 0.05 0.02 -0.12 0.12 -0.26‡ 
FEV1 % pred   1 0.37‡ -0.34‡ 0.30‡ -0.01 -0.37‡ -0.01 -0.29‡ 0.05 -0.10 -0.19* 0.37‡ 
FVC    1 -0.41‡ 0.13 0.09 -0.39‡ 0.06 -0.07 0.19* 0.17* -0.28‡ 0.47‡ 
eMRCD     1 -0.07 -0.11 0.35‡ -0.08 0.15* -0.09 -0.12 0.28‡ -0.65‡ 
BMI      1 -0.08 -0.04 0.22† -0.08 0.05 0.06 0.03 0.13 
Diastolic BP       1 0.05 0.02 0.01 0.36‡ 0.27‡ 0 0.05 
PaCO2        1 0.05 0.35‡ -0.02 0.05 0.28‡ -0.37‡ 
Na         1 0.03 0.06 0.12 -0.09 0.02 
K          1 0.07 0.11 0.03 -0.15* 
Albumin           1 0.30‡ 0.15* 0.15* 
Hb            1 -0.14 0.18* 
Length of stay             1 -0.30‡ 
Baseline NEADL              1 
Pearson’s r or Spearman-ρ correlation coefficient used depending on underlying variable distribution; *p<0.05; † p<0.01; ‡p<0.001 
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APPENDIX F. ACIDAEMIC RESPIRATORY FAILURE DURING HOSPITAL 
ADMISSION 
Figure 17.1     Development and management of acidaemic respiratory failure 
 
  
Total population, n = 920 
Received NIV, 
n = 68 
Received 
IPPV, n = 1 
Improved / 
ventilation 
inappropriate, 
n = 15 
No respiratory acidaemia on 
admission, n = 747 
Respiratory acidaemia on 
admission, n=173 
Improved / 
ventilation 
inappropriate, n 
= 43 
Received IPPV, 
n = 3 
Received NIV, 
n = 127 
Developed 
acidaemia during 
hospital stay, n = 84 
No acidaemia, n = 
663 
Total requiring assisted 
ventilation, n = 199 
NIV initially, n = 195 
Progressed to IPPV, 
n = 4 
IPPV initially, n = 4 
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APPENDIX G. ATTENDANCE AT FOLLOW-UP ASESSEMENTS FOR PART 2 
Figure 17.2     Flowchart detailing attendance at longitudinal assessments of quality of 
life and health resource use following hospital discharge (Part 2) 
 
 
  
183 Discharge assessments 
performed 
163 6-week assessments 
performed 
155 3-month assessments 
performed 
148 6-month assessments 
performed 
132 12-month assessments 
performed 
8 patients died prior to 
assessment 
4 patients died prior to 
assessment 
8 patients died prior to 
assessment 
15 patients died prior 
to assessment 
12 patients did not attend 
assessment 
14 patients did not attend 
assessment 
12 patients did not attend 
assessment 
13 patients did not attend 
assessment 
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APPENDIX H.  QUESTIONNAIRES 
APPENDIX H.1. THE CHRONIC RESPIRATORY QUESTIONNAIRE 
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APPENDIX H.2. THE ST GEORGE’S RESP IRATORY QUESTIONNAIRE 
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APPENDIX H.3. HOSPITAL ANXIETY AND DEPRESSION SCALE 
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APPENDIX H.4. NOTTINGHAM EXTENDED ACTIVITIES OF DAILY LIVING SCALE 
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APPENDIX I. PATIENT CONSENT FORM AND INFORMATION LEAFLET 
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Survival and quality of life following exacerbations of 
chronic obstructive pulmonary disease. 
 
CONSENT FORM 
       
                     Please initial box 
                   
1. I confirm that I have read and understand the information sheet (version 1.3) for 
the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.  
 
 
2. I understand that my participation in this study is entirely voluntary and I am free 
to withdraw my consent at any time without giving any reason, without my 
medical or legal rights being affected. 
 
 
3. I understand that relevant parts of my medical records will be accessed by the 
individuals within the research team. No other third parties will be granted 
access. 
 
 
4. I agree to being telephoned, or visited, at home if any further details require 
clarification. 
 
 
 
5. I agree to my GP being informed of my participation in the study. 
 
 
 
 
6. I agree to taking part in the study 
 
 
 
 
 
 
 
Name of patient   Date    Signature 
 
 
 
 
 
 
 
 
Name of person taking consent  Date    Signature 
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APPENDIX J. PUBLICATIONS AND PRESENTATIONS 
APPENDIX J.1. PUBLISHED MANUSCRIPTS 
1. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in 
exacerbations of chronic obstructive pulmonary disease. Thorax 2012. 
2. Steer J, Norman EM, Afolabi OA, Gibson GJ, Bourke SC. Dyspnoea severity and 
pneumonia as predictors of in-hospital mortality and early readmission in acute 
exacerbations of COPD. Thorax 2012;67(2):117-21. 
3. Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for 
acute exacerbations of COPD. Qjm 2010;103(11):817-29. 
APPENDIX J.2. PRESENTED ABSTRACTS AND PRESENTATIONS 
1. Effect of hospitalisation for acute exacerbations of COPD on subsequent quality 
of life. Accepted for BTS Winter Meeting 2012 – poster presentation. 
2. Relations of different quality of life tools to subsequent mortality and 
readmission of patients surviving hospitalisation for acute exacerbations of 
COPD. Accepted for BTS Winter Meeting 2012 – poster presentation. 
3. Predicting mortality in patients hospitalised with acute exacerbations of COPD 
(AECOPD) requiring assisted ventilation. ERS Annual Congress: Vienna 2012 – 
oral presentation.  
4. Predicting hospital readmission in patients discharged following acute 
exacerbations of COPD (AECOPD). ERS Annual Congress: Vienna 2012 – poster 
discussion.  
5. The DECAF Score: predicting in-hospital mortality in acute exacerbations of 
COPD. BTS Winter Meeting 2011 – oral presentation. 
6. Late ventilation is associated with high in-hospital mortality in patients 
hospitalised with acute exacerbations of COPD. BTS Winter Meeting 2011 – 
poster presentation 
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7. A novel prognostic score for COPD. Invited speaker at Joint Yorkshire Thoracic 
Society and North of England Thoracic Society Meeting, York 2011. 
8. CURB-65 and mortality in pneumonic and non-pneumonic exacerbations of 
COPD. ERS Annual Congress: Amsterdam 2011 – poster presentation.  
9. Eosinopenia independently predicts in-hospital mortality in patients 
hospitalised with acute exacerbations of COPD. British Association of Lung 
Research Summer Meeting: Newcastle 2011 – poster presentation. 
10. Comparison of indices of nutritional status in prediction of in-hospital mortality 
and early readmission or patients with acute exacerbations of COPD. BTS 
Winter Meeting 2010 – poster presentation. 
11. Evaluation of the MRC dyspnoea scale and a novel extended version in 
prediction of in-hospital death and early readmission in acute exacerbations of 
COPD.  BTS Winter Meeting 2010 – oral presentation. 
12. Comparison of indices of nutritional status in prediction of in-hospital mortality 
and early readmission of patients with acute exacerbations of COPD. Irish 
Thoracic Society Annual Congress 2010 – oral presentation.  
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